id;test_id;test_name;result_id;result;loinc_code;loinc_attribute;updated;method
1;12PTU;Protein, Total, 12 Hour, Urine;TM23;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
2;12PTU;Protein, Total, 12 Hour, Urine;CONC1;Concentration;35663-4;Protein:MCnc:XXX:Urine:Qn:;2012-03-15;Dye Binding (Pyrogallol Red)
3;12PTU;Protein, Total, 12 Hour, Urine;VL21;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
4;12PTU;Protein, Total, 12 Hour, Urine;TPU12;Protein, Total, 12 Hour, U;26801-1;Protein:MRat:12H:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
5;17BFP;Fluticasone 17-Beta-Carboxylic Acid, Urine;89739;Fluticasone 17-B Carboxylic Acid, U;46952-8;Fluticasone propionate:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
6;17OHP;17-Hydroxypregnenolone, Serum;81151;17-Hydroxypregnenolone, S;6765-2;17-Hydroxypregnenolone:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
7;19701;Biliary Tract Malignancy, FISH Only;19428;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
8;19701;Biliary Tract Malignancy, FISH Only;19429;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
9;19701;Biliary Tract Malignancy, FISH Only;19421;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-10-05;Fluorescence In Situ Hybridization (FISH)
10;19701;Biliary Tract Malignancy, FISH Only;19864;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2011-06-21;Fluorescence In Situ Hybridization (FISH)
11;19701;Biliary Tract Malignancy, FISH Only;19424;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
12;19701;Biliary Tract Malignancy, FISH Only;19430;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
13;19701;Biliary Tract Malignancy, FISH Only;19419;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH)
14;19701;Biliary Tract Malignancy, FISH Only;19418;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-05-22;Fluorescence In Situ Hybridization (FISH)
15;19701;Biliary Tract Malignancy, FISH Only;19422;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2014-06-25;Fluorescence In Situ Hybridization (FISH)
16;199PC;Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid;SITE6;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
17;199PC;Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid;199P;CA19-9, Pancreatic Cyst;26924-1;Cancer Ag 19-9:ACnc:Pt:Body fld:Qn:;2012-03-12;Immunoenzymatic Assay
18;199PT;Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid;SITEE;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-04-11;Immunoenzymatic Assay
19;199PT;Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid;199PN;CA 19-9, Peritoneal Fluid;50781-4;Cancer Ag 19-9:ACnc:Pt:Periton fld:Qn:;2013-04-11;Immunoenzymatic Assay
20;1A2;Cytochrome P450 1A2 Genotype;45499;1A2 Phenotype Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) with Allele-Specific Primer Extension (ASPE)/Bead Hybridization with Fluorescence Detection(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
21;1A2O;Cytochrome P450 1A2 Genotype, Saliva;33021;1A2 Phenotype Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) with Allele Specific Primer Extension (ASPE)/Bead Hybridization with Fluorescence Detection(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
22;1STT;First Trimester Maternal Screen;26438;Additional Comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;Immunoenzymatic Assay
23;1STT;First Trimester Maternal Screen;26436;Trisomy 18 Screen Risk Estimate;43994-3;Trisomy 18 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
24;1STT;First Trimester Maternal Screen;26437;Interpretation;59462-2;;2012-04-09;Immunoenzymatic Assay
25;1STT;First Trimester Maternal Screen;B_RCE;Black race;21484-1;Race:Type:Pt:^Mother:Nom:;2012-03-12;Immunoenzymatic Assay
26;1STT;First Trimester Maternal Screen;26435;Down Syndrome Maternal Age Risk;49090-4;Trisomy 21 risk based on maternal age:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
27;1STT;First Trimester Maternal Screen;26434;Down Syndrome Screen Risk Estimate;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
28;1STT;First Trimester Maternal Screen;26426;PAPP-A;32046-5;Pregnancy associated plasma protein A:ACnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoenzymatic Assay
29;1STT;First Trimester Maternal Screen;26427;THCG;19080-1;Choriogonadotropin:ACnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoenzymatic Assay
30;1STT;First Trimester Maternal Screen;NT_;NT;48803-1;Neural tube defect risk:Find:Pt:^Fetus:Qn:;2012-03-15;Immunoenzymatic Assay
31;1STT;First Trimester Maternal Screen;26430;GA on Collection by U/S Scan;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;Immunoenzymatic Assay
32;1STT;First Trimester Maternal Screen;NT_B;NT Twin B;48803-1;Neural tube defect risk:Find:Pt:^Fetus:Qn:;2012-03-15;Immunoenzymatic Assay
33;1STT;First Trimester Maternal Screen;CRL1;CRL Measure 1;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2012-03-15;Immunoenzymatic Assay
34;1STT;First Trimester Maternal Screen;CRL2;CRL Measure 2;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2012-03-15;Immunoenzymatic Assay
35;1STT;First Trimester Maternal Screen;IVF;IVF;47224-1;In vitro fertilization pregnancy:Acnc:Pt:^Patient:Ord:;2012-03-15;Immunoenzymatic Assay
36;1STT;First Trimester Maternal Screen;DT3;Scan Date;34970-4;Date ultrasound:TmStp:Pt:^Patient:Qn:;2012-03-15;Immunoenzymatic Assay
37;1STT;First Trimester Maternal Screen;NUMF;Number of Fetuses;55281-0;Fetuses:Num:Pt:^Patient:Qn:;2012-03-15;Immunoenzymatic Assay
38;1STT;First Trimester Maternal Screen;26880;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
39;1STT;First Trimester Maternal Screen;IDD_;Insulin dependent diabetes;33248-6;Diabetes status:Prid:Pt:^Patient:Nom:;2012-03-15;Immunoenzymatic Assay
40;1STT;First Trimester Maternal Screen;26413;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
41;1STT;First Trimester Maternal Screen;26429;Calculated Age at EDD;43993-5;Age.at delivery:Time:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
42;1STT;First Trimester Maternal Screen;26428;Recalculated Maternal Serum Screen;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
43;1STT;First Trimester Maternal Screen;26412;Maternal Birthdate;21112-8;Birth date:TmStp:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
44;1STT;First Trimester Maternal Screen;26411;Collection Date;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2009-11-13;Immunoenzymatic Assay
45;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20420;Addendum Pathologist:;19139-5;Pathologist name:Pn:Pt:Provider:Nom:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
46;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20418;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
47;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20419;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
48;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20414;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
49;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20413;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
50;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20410;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
51;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20411;Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-08-29;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
52;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20407;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-21;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
53;20405;Barrett's-Associated Neoplasia, Cytology and FISH;20408;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Light Microscopy/Fluorescence In Situ Hybridization (FISH)
54;25HDN;25-Hydroxyvitamin D2 and D3, Serum;2897;25-Hydroxy D2;49054-0;25-Hydroxycalciferol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
55;25HDN;25-Hydroxyvitamin D2 and D3, Serum;2898;25-Hydroxy D3;1989-3;Calcitriol:MCnc:Pt:Ser/Plas:Qn:;2012-02-06;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
56;25HDN;25-Hydroxyvitamin D2 and D3, Serum;83670;25-Hydroxy D Total;62292-8;Calcidiol:MCnc:Pt:Ser/Plas:Qn:;2012-02-06;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
57;4339;DermPath Consultation, Wet Tissue;18277;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
58;4339;DermPath Consultation, Wet Tissue;18269;Diagnostic Impression:;62365-2;Diagnostic impression:Imp:Pt:XXX:Nar:Molgen;2013-12-05;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
59;4339;DermPath Consultation, Wet Tissue;18265;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-05-22;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
60;4339;DermPath Consultation, Wet Tissue;18276;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
61;4339;DermPath Consultation, Wet Tissue;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
62;4339;DermPath Consultation, Wet Tissue;18272;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
63;4339;DermPath Consultation, Wet Tissue;18270;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
64;4339;DermPath Consultation, Wet Tissue;18268;Anatomic Site of Tissue:;39111-0;Body site:Anat:Pt:^Patient:Nom:;2009-11-13;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
65;4339;DermPath Consultation, Wet Tissue;18266;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Formalin-fixed tissues are processed and embedded in paraffin; serial sections are stained with hematoxylin and eosin and examined by light microscopy. Special stains are obtained when indicated.
66;4993;Electron Microscopy;18314;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Electron Microscopy
67;4993;Electron Microscopy;18298;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Electron Microscopy
68;4993;Electron Microscopy;18310;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Electron Microscopy
69;4993;Electron Microscopy;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Electron Microscopy
70;4993;Electron Microscopy;18302;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Electron Microscopy
71;4993;Electron Microscopy;18307;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Electron Microscopy
72;4993;Electron Microscopy;18300;Date and Time of Death:;31211-6;Date of death:TmStp:Pt:^Patient:Qn:;2011-10-05;Electron Microscopy
73;4993;Electron Microscopy;18308;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Electron Microscopy
74;4993;Electron Microscopy;18304;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2009-11-13;Electron Microscopy
75;4993;Electron Microscopy;18999;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Electron Microscopy
76;4993;Electron Microscopy;18297;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Electron Microscopy
77;4993;Electron Microscopy;18299;Place of Death:;21987-3;Geographic place of death:Type:Pt:^Patient:Nom:;2009-11-13;Electron Microscopy
78;4993;Electron Microscopy;18315;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Electron Microscopy
79;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
80;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18461;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
81;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18447;Date and Time of Death:;31211-6;Date of death:TmStp:Pt:^Patient:Qn:;2011-10-05;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
82;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18449;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
83;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18451;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
84;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18444;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
85;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18457;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
86;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18454;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
87;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18446;Place of Death:;21987-3;Geographic place of death:Type:Pt:^Patient:Nom:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
88;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18455;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
89;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18445;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
90;5361;Cardiovascular or Cardiopulmonary Consultation, Autopsy;18462;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Includes hematoxylin-and-eosin and Verhoeff's/Van Gieson's stains.
91;5362;Endomyocardial Biopsy;18481;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
92;5362;Endomyocardial Biopsy;18991;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
93;5362;Endomyocardial Biopsy;18475;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
94;5362;Endomyocardial Biopsy;18477;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
95;5362;Endomyocardial Biopsy;18467;Date and Time of Death:;31211-6;Date of death:TmStp:Pt:^Patient:Qn:;2011-10-05;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
96;5362;Endomyocardial Biopsy;18474;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
97;5362;Endomyocardial Biopsy;18471;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
98;5362;Endomyocardial Biopsy;18469;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
99;5362;Endomyocardial Biopsy;18466;Place of Death:;21987-3;Geographic place of death:Type:Pt:^Patient:Nom:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
100;5362;Endomyocardial Biopsy;18465;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
101;5362;Endomyocardial Biopsy;18464;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
102;5362;Endomyocardial Biopsy;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
103;5362;Endomyocardial Biopsy;18482;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Light MicroscopyIncludes hematoxylin-and-eosin, Gomori's iron, and sulfated alcian blue stains.Electron microscopy, immunoperoxidase, and immunofluorescence are available upon special request. For special studies, call BEFORE the biopsy is performed.
104;5368;Central Nervous System Consultation, Autopsy;18501;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
105;5368;Central Nervous System Consultation, Autopsy;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
106;5368;Central Nervous System Consultation, Autopsy;18497;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
107;5368;Central Nervous System Consultation, Autopsy;18485;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
108;5368;Central Nervous System Consultation, Autopsy;18486;Place of Death:;21987-3;Geographic place of death:Type:Pt:^Patient:Nom:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
109;5368;Central Nervous System Consultation, Autopsy;18495;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
110;5368;Central Nervous System Consultation, Autopsy;18494;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
111;5368;Central Nervous System Consultation, Autopsy;18491;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
112;5368;Central Nervous System Consultation, Autopsy;18489;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
113;5368;Central Nervous System Consultation, Autopsy;18487;Date and Time of Death:;31211-6;Date of death:TmStp:Pt:^Patient:Qn:;2011-10-05;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
114;5368;Central Nervous System Consultation, Autopsy;18502;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
115;5368;Central Nervous System Consultation, Autopsy;18484;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Includes hematoxylin-and-esosin stains. Additional special stains or procedures necessary for diagnosis will be billed separately.
116;5581;Surgical Pathology Consultation, Slides or Blocks to Scottsdale;1112;Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2009-11-13;
117;5581;Surgical Pathology Consultation, Slides or Blocks to Scottsdale;1074;Diagnosis:;29308-4;Diagnosis:Imp:Pt:^Patient:Nom:;2009-11-13;
118;5581;Surgical Pathology Consultation, Slides or Blocks to Scottsdale;1084;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;
119;5581;Surgical Pathology Consultation, Slides or Blocks to Scottsdale;1071;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;
120;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20336;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-06-21;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
121;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20333;Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-08-29;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
122;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20329;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
123;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20337;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-06-21;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
124;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20338;Addendum Pathologist:;19139-5;Pathologist name:Pn:Pt:Provider:Nom:;2011-06-21;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
125;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20331;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2011-06-21;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
126;60198;HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual;20328;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-21;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
127;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20359;Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-08-29;In Situ Hybridization
128;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20364;Addendum Pathologist:;19139-5;Pathologist name:Pn:Pt:Provider:Nom:;2011-06-21;In Situ Hybridization
129;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20362;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-06-21;In Situ Hybridization
130;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20355;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;In Situ Hybridization
131;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20357;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2011-06-21;In Situ Hybridization
132;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20354;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-21;In Situ Hybridization
133;60483;Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization;20363;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-06-21;In Situ Hybridization
134;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20402;Addendum:;35265-8;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
135;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20404;Addendum Pathologist:;19139-5;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
136;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20403;Addendum Comment:;22638-1;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
137;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20398;Signing Pathologist:;19139-5;;2011-06-29;Fluorescence In Situ Hybridization (FISH)
138;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20396;Comment:;22638-1;;2011-08-29;Fluorescence In Situ Hybridization (FISH)
139;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20395;Final Diagnosis:;34574-4;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
140;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20390;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH)
141;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20392;Specimen:;31208-2;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
142;60506;Cutaneous Anaplastic Large Cell Lymphoma, 6p25.3 (IRF4) Rearrangement, FISH, Tissue;20389;Referring Pathologist/Physician;46608-6;;2011-06-21;Fluorescence In Situ Hybridization (FISH)
143;61219;MAML2 (11q21), Mucoepidermoid Carcinoma (MEC);61219;MAML2 (11q21), Mucoepidermoid Carcinoma (MEC);74034-0;MAML2 11q21 gene rearrangements:Prid:Pt:Tiss:Nar:FISH;2013-08-14;Fluorescence In Situ Hybridization (FISH) with DNA probes
144;62512;Small Lymphocytic Lymphoma, FISH, Tissue;70124;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-05-21;Fluorescence In Situ Hybridization (FISH)
145;62512;Small Lymphocytic Lymphoma, FISH, Tissue;70135;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2014-04-30;Fluorescence In Situ Hybridization (FISH)
146;62512;Small Lymphocytic Lymphoma, FISH, Tissue;70123;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
147;62512;Small Lymphocytic Lymphoma, FISH, Tissue;70136;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2014-04-30;Fluorescence In Situ Hybridization (FISH)
148;62512;Small Lymphocytic Lymphoma, FISH, Tissue;70130;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
149;6MAMM;6-Monoacetylmorphine (6-MAM), Confirmation, Meconium;31875;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
150;6MAMM;6-Monoacetylmorphine (6-MAM), Confirmation, Meconium;31874;6-MAM;29345-6;6-Monoacetylmorphine:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
151;6MAMU;6-Monoacetylmorphine (6-MAM) Confirmation, Urine;30983;6-Monoacetylmorphine by GC/MS;10975-1;6-Monoacetylmorphine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
152;6MAMU;6-Monoacetylmorphine (6-MAM) Confirmation, Urine;29898;6-MAM Interpretation;59462-2;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS)
153;70012;Pathology Consultation;70043;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;
154;70012;Pathology Consultation;70044;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;
155;70012;Pathology Consultation;70046;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2014-04-28;
156;70012;Pathology Consultation;70049;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2013-08-07;
157;70012;Pathology Consultation;70048;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2013-08-07;
158;70012;Pathology Consultation;70038;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;
159;70012;Pathology Consultation;70037;Referring Pathologist / Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-08-08;
160;70014;Peripheral T-Cell Lymphoma (PTCL), TP63 (3q28) Rearrangement, FISH, Tissue;70117;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2014-04-30;Fluorescence In Situ Hybridization (FISH)
161;70014;Peripheral T-Cell Lymphoma (PTCL), TP63 (3q28) Rearrangement, FISH, Tissue;70106;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
162;70014;Peripheral T-Cell Lymphoma (PTCL), TP63 (3q28) Rearrangement, FISH, Tissue;70118;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2014-04-30;Fluorescence In Situ Hybridization (FISH)
163;70014;Peripheral T-Cell Lymphoma (PTCL), TP63 (3q28) Rearrangement, FISH, Tissue;70107;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH)
164;70014;Peripheral T-Cell Lymphoma (PTCL), TP63 (3q28) Rearrangement, FISH, Tissue;70113;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
165;70015;Anatomic Pathology Consultation, Wet Tissue;70057;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;
166;70015;Anatomic Pathology Consultation, Wet Tissue;70058;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;
167;70015;Anatomic Pathology Consultation, Wet Tissue;70060;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2014-04-28;
168;70015;Anatomic Pathology Consultation, Wet Tissue;70051;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-08-08;
169;70015;Anatomic Pathology Consultation, Wet Tissue;70063;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2013-08-07;
170;70015;Anatomic Pathology Consultation, Wet Tissue;70052;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;
171;70015;Anatomic Pathology Consultation, Wet Tissue;70062;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2013-08-07;
172;70016;Hematopathology Consultation, Wet Tissue;70024;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;
173;70016;Hematopathology Consultation, Wet Tissue;70027;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;
174;70016;Hematopathology Consultation, Wet Tissue;70028;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;
175;70016;Hematopathology Consultation, Wet Tissue;70035;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2014-04-28;
176;70016;Hematopathology Consultation, Wet Tissue;70033;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2013-08-07;
177;70016;Hematopathology Consultation, Wet Tissue;70032;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2013-08-07;
178;70016;Hematopathology Consultation, Wet Tissue;70023;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-08-08;
179;70064;Renal Pathology Consultation, Wet Tissue;70067;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2013-08-08;Pathology Consultation
180;70064;Renal Pathology Consultation, Wet Tissue;70074;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;Pathology Consultation
181;70064;Renal Pathology Consultation, Wet Tissue;70076;Tissue Description:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2014-04-28;Pathology Consultation
182;70064;Renal Pathology Consultation, Wet Tissue;70068;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Pathology Consultation
183;70064;Renal Pathology Consultation, Wet Tissue;70079;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2013-08-07;Pathology Consultation
184;70064;Renal Pathology Consultation, Wet Tissue;70078;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2013-08-07;Pathology Consultation
185;70064;Renal Pathology Consultation, Wet Tissue;70073;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;Pathology Consultation
186;800039;;FOL;Folate, S;2284-8;Folate:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;
187;800044;;HBIM;HBc IgM Ab, S;31204-1;Hepatitis B virus core Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;
188;800045;;HB_AB;HBs Antibody, S;22322-2;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Ord:;2012-03-15;
189;800045;;HBSQN;HBs Antibody, Quantitative, S;16935-9;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Qn:;2012-03-15;
190;800046;;HCVA;HCV Ab Screen, S;16128-1;Hepatitis C virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;
191;800048;;HAVM;Hepatitis A IgM Ab, S;22314-9;Hepatitis A virus Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;
192;800049;;HBC;HBc Total Ab, S;13952-7;Hepatitis B virus core Ab:ACnc:Pt:Ser/Plas:Ord:EIA;2013-12-18;
193;800050;;H_BAG;HBs Antigen, S;5195-3;Hepatitis B virus surface Ag:ACnc:Pt:Ser:Ord:;2012-10-31;
194;800070;;DEXG2;Rubella IgG Antibody Index;5334-8;Rubella virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;
195;800070;;RBG;Rubella Ab, IgG, S;40667-8;Rubella virus Ab.IgG:ACnc:Pt:Ser/Plas:Ord:EIA;2013-12-18;
196;800083;;B12;Vitamin B12 Assay, S;2132-9;Cobalamins:MCnc:Pt:Ser:Qn:;2012-03-12;
197;800122;;ROG;Measles (Rubeola) Ab, IgG, S;35275-7;Measles virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;
198;800122;;DEXG3;Measles IgG Antibody Index;5244-9;Measles virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;
199;800143;;SS001;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;
200;800143;;34799;HSV type Indeterminate, PCR;20444-6;Herpes simplex virus 1+2 DNA:ACnc:Pt:XXX:Ord:Prob.amp.tar;2013-09-17;
201;800143;;34798;HSV 2, PCR;16131-5;Herpes simplex virus 2 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-07-29;
202;800143;;34797;HSV 1, PCR;16130-7;Herpes simplex virus 1 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-07-29;
203;800146;;TPO;Thyroperoxidase Ab, S;8099-4;Thyroperoxidase Ab:ACnc:Pt:Ser:Qn:;2012-03-12;
204;800147;;HAV;Hepatitis A Total Ab, S;20575-7;Hepatitis A virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;
205;800168;;SRC70;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;
206;800190;;VZG;Varicella-Zoster Ab, IgG, S;15410-4;Varicella zoster virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;
207;800190;;DEXG4;Varicella IgG Antibody Index;5403-1;Varicella zoster virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;
208;800193;;80964;Varicella-Zoster Ab, IgM, S;43588-3;Varicella zoster virus Ab.IgM:ACnc:Pt:Ser:Ord:IF;2012-03-12;
209;800218;;26589;HSV Ab, IgM, S by IFA;44507-2;Herpes simplex virus Ab.IgM:ACnc:Pt:Ser:Ord:IF;2009-11-13;
210;800222;;RNP;RNP Ab, IgG, S;31588-7;Ribonucleoprotein extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;
211;800225;;SSA;SS-A/Ro Ab, IgG, S;33610-7;Sjogrens syndrome-A extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;
212;800227;;SSB;SS-B/La Ab, IgG, S;33613-1;Sjogrens syndrome-B extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;
213;800240;;MUMG;Mumps Ab, IgG, S;6476-6;Mumps virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;
214;800240;;DEXG5;Mumps IgG Antibody Index;25418-5;Mumps virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;
215;80027;B-Cell Lymphoma, FISH, Tissue;19207;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
216;80027;B-Cell Lymphoma, FISH, Tissue;19199;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
217;80027;B-Cell Lymphoma, FISH, Tissue;19200;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Fluorescence In Situ Hybridization (FISH)
218;80027;B-Cell Lymphoma, FISH, Tissue;19206;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
219;80027;B-Cell Lymphoma, FISH, Tissue;19208;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
220;80027;B-Cell Lymphoma, FISH, Tissue;19202;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH)
221;80027;B-Cell Lymphoma, FISH, Tissue;19194;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH)
222;80027;B-Cell Lymphoma, FISH, Tissue;19196;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
223;80027;B-Cell Lymphoma, FISH, Tissue;19193;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH)
224;800354;;TTGA;Tissue Transglutaminase Ab, IgA, S;46128-5;Tissue transglutaminase Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-07;
225;800355;;TTGG;Tissue Transglutaminase Ab, IgG, S;56537-4;Tissue transglutaminase Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-07;
226;800744;;GCLIP;Phospholipid Ab IgG, S;3286-2;Phospholipid Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;
227;800745;;MCLIP;Phospholipid Ab IgM, S;3287-0;Phospholipid Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2012-03-15;
228;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;19218;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization
229;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18761;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization
230;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18954;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;In Situ Hybridization
231;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18953;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;In Situ Hybridization
232;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18755;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;In Situ Hybridization
233;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18756;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;In Situ Hybridization
234;80172;Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization;18762;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;In Situ Hybridization
235;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;18772;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Light Microscopy
236;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Light Microscopy
237;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;18771;Valproic Acid, Tot, S;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Light Microscopy
238;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;Light Microscopy
239;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;18764;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Light Microscopy
240;80184;Cervical Papanicolaou Smear, Diagnostic without Physician Interpretation;18767;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Light Microscopy
241;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Light Microscopy
242;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;18602;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Light Microscopy
243;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;18601;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Light Microscopy
244;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;Light Microscopy
245;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;18597;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Light Microscopy
246;8032;Cervical Papanicolaou Smear, Screening Without Physician Interpretation;18594;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Light Microscopy
247;8041;Cutaneous Immunofluorescence, Biopsy;18607;Clinical Impression:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-12-05;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
248;8041;Cutaneous Immunofluorescence, Biopsy;18604;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
249;8041;Cutaneous Immunofluorescence, Biopsy;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
250;8041;Cutaneous Immunofluorescence, Biopsy;18612;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
251;8041;Cutaneous Immunofluorescence, Biopsy;18608;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
252;8041;Cutaneous Immunofluorescence, Biopsy;18285;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
253;8041;Cutaneous Immunofluorescence, Biopsy;18613;Addendum Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2012-03-05;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
254;8041;Cutaneous Immunofluorescence, Biopsy;18606;Anatomic Site of Tissue:;39111-0;Body site:Anat:Pt:^Patient:Nom:;2009-11-13;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
255;8041;Cutaneous Immunofluorescence, Biopsy;18605;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Direct Immunofluorescence Staining of Cryostat-Prepared Skin Biopsy Sections for IgG, IgM, IgA, C3, and Fibrinogen Deposition
256;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18865;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;In Situ Hybridization Testing
257;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;19214;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization Testing
258;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18864;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization Testing
259;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18962;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;In Situ Hybridization Testing
260;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18961;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;In Situ Hybridization Testing
261;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18859;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;In Situ Hybridization Testing
262;80786;Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization;18858;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;In Situ Hybridization Testing
263;81107;JC Virus (JCV) Detection by In Situ Hybridization;18970;Comment:;48767-8;Service comment 01:Imp:Pt:XXX:Nom:;2012-10-31;In Situ Hybridization with Biotin-Labeled Probes
264;81107;JC Virus (JCV) Detection by In Situ Hybridization;18901; Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization with Biotin-Labeled Probes
265;81107;JC Virus (JCV) Detection by In Situ Hybridization;18895;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;In Situ Hybridization with Biotin-Labeled Probes
266;81107;JC Virus (JCV) Detection by In Situ Hybridization;18969;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;In Situ Hybridization with Biotin-Labeled Probes
267;81107;JC Virus (JCV) Detection by In Situ Hybridization;19222;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;In Situ Hybridization with Biotin-Labeled Probes
268;81107;JC Virus (JCV) Detection by In Situ Hybridization;18902;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;In Situ Hybridization with Biotin-Labeled Probes
269;81107;JC Virus (JCV) Detection by In Situ Hybridization;18896;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;In Situ Hybridization with Biotin-Labeled Probes
270;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;19216;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
271;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18937;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
272;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18978;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
273;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18977;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
274;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18934;Interpretation:;48676-1;HER2:Imp:Pt:Tiss:Nom:;2009-11-13;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
275;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18932;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
276;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18938;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
277;81504;HER2, Breast, Quantitative Immunohistochemistry, Automated;18931;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;US Food and Drug Administration (FDA)-Approved Ventana Pathway Immunoperoxidase Stain
278;82037;ThinPrep Screen, Without Physician Interpretation;19059;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening by Light Microscopy
279;82037;ThinPrep Screen, Without Physician Interpretation;19061;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening by Light Microscopy
280;82037;ThinPrep Screen, Without Physician Interpretation;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
281;82037;ThinPrep Screen, Without Physician Interpretation;19056;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
282;82037;ThinPrep Screen, Without Physician Interpretation;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
283;82039;ThinPrep Diagnostic Without Physician Interpretation;19047;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening by Light Microscopy
284;82039;ThinPrep Diagnostic Without Physician Interpretation;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
285;82039;ThinPrep Diagnostic Without Physician Interpretation;19045;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening by Light Microscopy
286;82039;ThinPrep Diagnostic Without Physician Interpretation;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
287;82039;ThinPrep Diagnostic Without Physician Interpretation;19042;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening by Light Microscopy
288;82091;Amyloid Protein Identification, Paraffin, LC MS/MS;70153;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2014-04-30;82091: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)89054: Histological Stain
289;82091;Amyloid Protein Identification, Paraffin, LC MS/MS;70148;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;82091: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)89054: Histological Stain
290;82091;Amyloid Protein Identification, Paraffin, LC MS/MS;70152;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2014-04-30;82091: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)89054: Histological Stain
291;82091;Amyloid Protein Identification, Paraffin, LC MS/MS;70141;Referring Pathologist / Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2014-04-28;82091: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)89054: Histological Stain
292;82091;Amyloid Protein Identification, Paraffin, LC MS/MS;70142;Ref Path / Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-05-21;82091: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)89054: Histological Stain
293;82526;Amyloid Protein Identification, Fat Aspirate, LC MS/MS;70167;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2014-04-30;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
294;82526;Amyloid Protein Identification, Fat Aspirate, LC MS/MS;70168;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2014-04-30;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
295;82526;Amyloid Protein Identification, Fat Aspirate, LC MS/MS;70163;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
296;82526;Amyloid Protein Identification, Fat Aspirate, LC MS/MS;70156;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2014-04-28;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
297;82526;Amyloid Protein Identification, Fat Aspirate, LC MS/MS;70157;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-05-21;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
298;83342;ThinPrep Screen with Human Papillomavirus (HPV) Reflex;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
299;83342;ThinPrep Screen with Human Papillomavirus (HPV) Reflex;19178;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
300;83342;ThinPrep Screen with Human Papillomavirus (HPV) Reflex;19176;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
301;83342;ThinPrep Screen with Human Papillomavirus (HPV) Reflex;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
302;83342;ThinPrep Screen with Human Papillomavirus (HPV) Reflex;19173;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
303;83343;ThinPrep Diagnostic with Human Papillomavirus (HPV) Reflex;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
304;83343;ThinPrep Diagnostic with Human Papillomavirus (HPV) Reflex;19185;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
305;83343;ThinPrep Diagnostic with Human Papillomavirus (HPV) Reflex;19188;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
306;83343;ThinPrep Diagnostic with Human Papillomavirus (HPV) Reflex;19183;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
307;83343;ThinPrep Diagnostic with Human Papillomavirus (HPV) Reflex;19180;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with HPV High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
308;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19259;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) 
309;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19260;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH) 
310;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19258;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) 
311;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19865;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2011-06-21;Fluorescence In Situ Hybridization (FISH) 
312;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19254;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH) 
313;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19252;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Fluorescence In Situ Hybridization (FISH) 
314;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19248;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH) 
315;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19251;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-10-05;Fluorescence In Situ Hybridization (FISH) 
316;84357;Biliary Tract Malignancy, Cytology and Molecular Testing;19249;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH) 
317;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20290;Addendum Pathologist:;19139-5;Pathologist name:Pn:Pt:Provider:Nom:;2011-06-21;Immunohistochemistry, Automated Quantitation
318;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20288;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-06-21;Immunohistochemistry, Automated Quantitation
319;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20280;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-21;Immunohistochemistry, Automated Quantitation
320;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20281;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunohistochemistry, Automated Quantitation
321;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20285;Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-08-29;Immunohistochemistry, Automated Quantitation
322;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20283;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2011-06-21;Immunohistochemistry, Automated Quantitation
323;89027;Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated;20289;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-06-21;Immunohistochemistry, Automated Quantitation
324;89041;T-Cell Lymphoma, FISH, Tissue;19618;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH) with DNA Probes
325;89041;T-Cell Lymphoma, FISH, Tissue;19615;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-10-05;Fluorescence In Situ Hybridization (FISH) with DNA Probes
326;89041;T-Cell Lymphoma, FISH, Tissue;19622;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
327;89041;T-Cell Lymphoma, FISH, Tissue;19623;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
328;89041;T-Cell Lymphoma, FISH, Tissue;19624;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
329;89041;T-Cell Lymphoma, FISH, Tissue;19616;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Fluorescence In Situ Hybridization (FISH) with DNA Probes
330;89041;T-Cell Lymphoma, FISH, Tissue;19612;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
331;89041;T-Cell Lymphoma, FISH, Tissue;19610;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Fluorescence In Situ Hybridization (FISH) with DNA Probes
332;89041;T-Cell Lymphoma, FISH, Tissue;19609;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Fluorescence In Situ Hybridization (FISH) with DNA Probes
333;89045;BRAF Mutation (T1799A) Analysis by PCR and Sequencing, Thyroid;89045;BRAF Mutation (T1799A) Analysis;53844-7;BRAF gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-08-07;Polymerase Chain Reaction (PCR) and Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
334;89118;ThinPrep Screen with HPV for Women 30 Years and Older;19803;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
335;89118;ThinPrep Screen with HPV for Women 30 Years and Older;19802;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
336;89118;ThinPrep Screen with HPV for Women 30 Years and Older;19800;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
337;89118;ThinPrep Screen with HPV for Women 30 Years and Older;19799;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
338;89118;ThinPrep Screen with HPV for Women 30 Years and Older;19796;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
339;89119;ThinPrep Diagnostic with Human Papillomavirus (HPV) for Women 30 Years and Older;19808;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
340;89119;ThinPrep Diagnostic with Human Papillomavirus (HPV) for Women 30 Years and Older;19809;Specimen Description:;33511-7;Appearance:Aper:Pt:XXX:Nom:;2009-11-13;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
341;89119;ThinPrep Diagnostic with Human Papillomavirus (HPV) for Women 30 Years and Older;19812;Addendum;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
342;89119;ThinPrep Diagnostic with Human Papillomavirus (HPV) for Women 30 Years and Older;19811;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
343;89119;ThinPrep Diagnostic with Human Papillomavirus (HPV) for Women 30 Years and Older;19805;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;ThinPrep Pap Cytology Screening with Human Papillomavirus High-Risk DNA Detection with Genotyping by Real-Time Polymerase Chain Reaction(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
344;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19700;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Immunohistochemical
345;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19698;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Immunohistochemical
346;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19695;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Immunohistochemical
347;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19690;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunohistochemical
348;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19693;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Immunohistochemical
349;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19699;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Immunohistochemical
350;89213;Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual;19691;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunohistochemical
351;89672;PDGFRA, Mutation Analysis, Exon 18;89672;PDGFRA, Mutation Analysis, Ex18;71357-8;PDGFRA gene exon 18 mutation analysis:Prid:Pt:Bld/Tiss:Nar:Sequencing;2013-12-05;Polymerase Chain Reaction (PCR) and Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
352;8973;Congo Red Stain;8973;Congo Red ST;10782-1;Microscopic observation:Prid:Pt:Tiss:Nom:Congo red stain;2009-11-13;
353;8MOP;8-Methoxypsoralen (8-MOP), Serum;80296;8-Methoxypsoralen (8-MOP), S;13625-9;Methoxsalen:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
354;9273;Subcutaneous Fat Aspirate;18948;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31; 
355;9273;Subcutaneous Fat Aspirate;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13; 
356;9273;Subcutaneous Fat Aspirate;18714;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27; 
357;9273;Subcutaneous Fat Aspirate;18720;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13; 
358;9273;Subcutaneous Fat Aspirate;18748;Tissue:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13; 
359;9273;Subcutaneous Fat Aspirate;18713;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29; 
360;9273;Subcutaneous Fat Aspirate;18721;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13; 
361;A1AF;Alpha-1-Antitrypsin, Random, Feces;AAT_F;Alpha-1-Antitrypsin, Random, F;9407-8;Alpha 1 antitrypsin:MCnc:Pt:Stool:Qn:;2012-03-12;Nephelometry
362;A1M24;Alpha-1-Microglobulin, 24 Hour, Urine;CR_C;Creatinine Concentration;20624-3;Creatinine:MCnc:24H:Urine:Qn:;2012-03-15;Immunonephelometry
363;A1M24;Alpha-1-Microglobulin, 24 Hour, Urine;AIM;Alpha-1-Microglobulin, 24-Hour, U;48414-7;Alpha-1-Microglobulin:MRat:24H:Urine:Qn:;2012-03-12;Immunonephelometry
364;A1M24;Alpha-1-Microglobulin, 24 Hour, Urine;VL58;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Immunonephelometry
365;A1M24;Alpha-1-Microglobulin, 24 Hour, Urine;DUR5;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Immunonephelometry
366;A2F;Hemoglobin A2 and F, Blood;2382;Hemoglobin F;4576-5;Hemoglobin F/Hemoglobin.total:MFr:Pt:Bld:Qn:;2009-11-13;Cation Exchange/High-Performance Liquid Chromatography (HPLC)
367;A2F;Hemoglobin A2 and F, Blood;2381;Hemoglobin A2;4551-8;Hemoglobin A2/Hemoglobin.total:MFr:Pt:Bld:Qn:;2009-11-13;Cation Exchange/High-Performance Liquid Chromatography (HPLC)
368;A2M;Alpha-2-Macroglobulin, Serum;A2M;Alpha-2-Macroglobulin, S;1835-8;Alpha-2-Macroglobulin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Nephelometry
369;AACSF;Amino Acids, Quantitative, Spinal Fluid;30129;Arginine;22656-3;Arginine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
370;AACSF;Amino Acids, Quantitative, Spinal Fluid;30124;Tyrosine;22642-3;Tyrosine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
371;AACSF;Amino Acids, Quantitative, Spinal Fluid;50435;Interpretation;59462-2;;2012-04-02;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
372;AACSF;Amino Acids, Quantitative, Spinal Fluid;30125;Phenylalanine;22646-4;Phenylalanine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
373;AACSF;Amino Acids, Quantitative, Spinal Fluid;30121;Methionine;22648-0;Methionine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
374;AACSF;Amino Acids, Quantitative, Spinal Fluid;30123;Leucine;9412-8;Leucine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
375;AACSF;Amino Acids, Quantitative, Spinal Fluid;30122;Isoleucine;22659-7;Isoleucine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
376;AACSF;Amino Acids, Quantitative, Spinal Fluid;30119;Valine;22649-8;Valine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
377;AACSF;Amino Acids, Quantitative, Spinal Fluid;30127;Lysine;22651-4;Lysine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
378;AACSF;Amino Acids, Quantitative, Spinal Fluid;30120;Cystine;22653-0;Cystine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
379;AACSF;Amino Acids, Quantitative, Spinal Fluid;34579;Beta-aminoisobutyric Acid;26590-0;Beta aminoisobutyrate:SCnc:Pt:CSF:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
380;AACSF;Amino Acids, Quantitative, Spinal Fluid;30118;Alpha-amino-n-butyric Acid;26586-8;Alpha aminobutyrate:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
381;AACSF;Amino Acids, Quantitative, Spinal Fluid;30112;Proline;22645-6;Proline:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
382;AACSF;Amino Acids, Quantitative, Spinal Fluid;30126;Ornithine;22647-2;Ornithine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
383;AACSF;Amino Acids, Quantitative, Spinal Fluid;34571;1-Methylhistidine;26584-3;1-Methylhistidine:SCnc:Pt:CSF:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
384;AACSF;Amino Acids, Quantitative, Spinal Fluid;34569;Sarcosine;26598-3;Sarcosine:SCnc:Pt:CSF:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
385;AACSF;Amino Acids, Quantitative, Spinal Fluid;30111;Glutamine;22641-5;Glutamine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
386;AACSF;Amino Acids, Quantitative, Spinal Fluid;34567;Aspartic Acid;22655-5;Aspartate:SCnc:Pt:CSF:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
387;AACSF;Amino Acids, Quantitative, Spinal Fluid;30110;Glutamic Acid;22652-2;Glutamate:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
388;AACSF;Amino Acids, Quantitative, Spinal Fluid;30116;Alanine;22657-1;Alanine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
389;AACSF;Amino Acids, Quantitative, Spinal Fluid;34570;Beta-alanine;26589-2;Beta alanine:SCnc:Pt:CSF:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
390;AACSF;Amino Acids, Quantitative, Spinal Fluid;30117;Citrulline;22654-8;Citrulline:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
391;AACSF;Amino Acids, Quantitative, Spinal Fluid;30107;Threonine;22643-1;Threonine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
392;AACSF;Amino Acids, Quantitative, Spinal Fluid;30128;Histidine;9453-2;Histidine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
393;AACSF;Amino Acids, Quantitative, Spinal Fluid;30115;Glycine;22650-6;Glycine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
394;AACSF;Amino Acids, Quantitative, Spinal Fluid;30108;Serine;22644-9;Serine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
395;AACSF;Amino Acids, Quantitative, Spinal Fluid;30109;Asparagine;26603-1;Asparagine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
396;AACSF;Amino Acids, Quantitative, Spinal Fluid;81934;Taurine;26614-8;Taurine:SCnc:Pt:CSF:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
397;AACSF;Amino Acids, Quantitative, Spinal Fluid;34565;Phosphoethanolamine;26597-5;Phosphoethanolamine:SCnc:Pt:CSF:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
398;AAMSD;Amino Acids, Maple Syrup Urine Disease Panel, Plasma;32450;Interpretation (AAMSD);59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
399;AAMSD;Amino Acids, Maple Syrup Urine Disease Panel, Plasma;32449;Allo-isoleucine;22670-4;Alloisoleucine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
400;AAMSD;Amino Acids, Maple Syrup Urine Disease Panel, Plasma;32448;Leucine;20649-0;Leucine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
401;AAMSD;Amino Acids, Maple Syrup Urine Disease Panel, Plasma;32447;Isoleucine;20648-2;Isoleucine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
402;AAMSD;Amino Acids, Maple Syrup Urine Disease Panel, Plasma;32446;Valine;20661-5;Valine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
403;AAMY;Alpha-Amylase, IgE;AAMY;Alpha-Amylase, IgE;7073-0;Amylase Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
404;AAPD;Amino Acids, Quantitative, Random, Urine;3481;Interpretation (AAPD);12467-7;Amino acids:Prid:Pt:Urine:Nom:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
405;AAPD;Amino Acids, Quantitative, Random, Urine;3452;Taurine;30563-1;Taurine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
406;AAPD;Amino Acids, Quantitative, Random, Urine;3456;Asparagine;27317-7;Asparagine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
407;AAPD;Amino Acids, Quantitative, Random, Urine;3460;Glycine;27325-0;Glycine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
408;AAPD;Amino Acids, Quantitative, Random, Urine;34487;Allo-isoleucine;22699-3;Alloisoleucine/Creatinine:SRto:Pt:Urine:Qn:;2013-08-07;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
409;AAPD;Amino Acids, Quantitative, Random, Urine;34466;Phosphoserine;28600-5;Phosphoserine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
410;AAPD;Amino Acids, Quantitative, Random, Urine;3465;Cystine;26962-1;Cystine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
411;AAPD;Amino Acids, Quantitative, Random, Urine;3462;Alpha-aminoadipic Acid;26725-2;Alpha aminoadipate:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
412;AAPD;Amino Acids, Quantitative, Random, Urine;34467;Phosphoethanolamine;28604-7;Phosphoethanolamine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
413;AAPD;Amino Acids, Quantitative, Random, Urine;3468;Isoleucine;26965-4;Isoleucine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
414;AAPD;Amino Acids, Quantitative, Random, Urine;3469;Leucine;27323-5;Leucine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
415;AAPD;Amino Acids, Quantitative, Random, Urine;3471;Phenylalanine;26967-0;Phenylalanine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
416;AAPD;Amino Acids, Quantitative, Random, Urine;3467;Methionine;26963-9;Methionine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
417;AAPD;Amino Acids, Quantitative, Random, Urine;3463;Alpha-amino-n-butyric Acid;27341-7;Alpha aminobutyrate:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
418;AAPD;Amino Acids, Quantitative, Random, Urine;34485;Hydroxylysine;30050-9;Hydroxylysine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
419;AAPD;Amino Acids, Quantitative, Random, Urine;34479;Ethanolamine;28605-4;Ethanolamine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
420;AAPD;Amino Acids, Quantitative, Random, Urine;34486;Tryptophan;28608-8;Tryptophan/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
421;AAPD;Amino Acids, Quantitative, Random, Urine;3474;Ornithine;27292-2;Ornithine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
422;AAPD;Amino Acids, Quantitative, Random, Urine;3479;Carnosine;27294-8;Carnosine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
423;AAPD;Amino Acids, Quantitative, Random, Urine;3483;Proline;26726-0;Proline:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
424;AAPD;Amino Acids, Quantitative, Random, Urine;3480;Arginine;27296-3;Arginine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
425;AAPD;Amino Acids, Quantitative, Random, Urine;34484;Gamma-amino-n-butyric Acid;28593-2;Gamma aminobutyrate/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
426;AAPD;Amino Acids, Quantitative, Random, Urine;3470;Tyrosine;26966-2;Tyrosine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
427;AAPD;Amino Acids, Quantitative, Random, Urine;3473;Beta-aminoisobutyric Acid;26973-8;Beta aminoisobutyrate:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
428;AAPD;Amino Acids, Quantitative, Random, Urine;3475;Lysine;27304-5;Lysine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
429;AAPD;Amino Acids, Quantitative, Random, Urine;3477;Histidine;27904-2;Histidine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
430;AAPD;Amino Acids, Quantitative, Random, Urine;3455;Serine;26741-9;Serine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
431;AAPD;Amino Acids, Quantitative, Random, Urine;34482;Anserine;28596-5;Anserine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
432;AAPD;Amino Acids, Quantitative, Random, Urine;3464;Valine;26961-3;Valine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
433;AAPD;Amino Acids, Quantitative, Random, Urine;34483;Homocitrulline;32248-7;Homocitrulline/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
434;AAPD;Amino Acids, Quantitative, Random, Urine;3466;Cystathionine;26964-7;Cystathionine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
435;AAPD;Amino Acids, Quantitative, Random, Urine;3472;Beta-alanine;26968-8;Beta alanine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
436;AAPD;Amino Acids, Quantitative, Random, Urine;3461;Alanine;27326-8;Alanine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
437;AAPD;Amino Acids, Quantitative, Random, Urine;3458;Glutamic Acid;30348-7;Glutamate:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
438;AAPD;Amino Acids, Quantitative, Random, Urine;3476;1-Methylhistidine;27044-7;1-Methylhistidine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
439;AAPD;Amino Acids, Quantitative, Random, Urine;3478;3-Methylhistidine;27046-2;3-Methylhistidine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
440;AAPD;Amino Acids, Quantitative, Random, Urine;34481;Argininosuccinic Acid;32229-7;Argininosuccinate/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
441;AAPD;Amino Acids, Quantitative, Random, Urine;34480;Sarcosine;28610-4;Sarcosine/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
442;AAPD;Amino Acids, Quantitative, Random, Urine;3459;Citrulline;27056-1;Citrulline:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
443;AAPD;Amino Acids, Quantitative, Random, Urine;3454;Threonine;27322-7;Threonine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
444;AAPD;Amino Acids, Quantitative, Random, Urine;34477;Hydroxyproline;28601-3;Hydroxyproline/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
445;AAPD;Amino Acids, Quantitative, Random, Urine;34478;Aspartic Acid;30061-6;Aspartate/Creatinine:Ratio:Pt:Urine:Qn:;2013-04-11;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
446;AAPD;Amino Acids, Quantitative, Random, Urine;3457;Glutamine;27043-9;Glutamine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), Quantitative
447;AAQP;Amino Acids, Quantitative, Plasma;34465;Tryptophan;20659-9;Tryptophan:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
448;AAQP;Amino Acids, Quantitative, Plasma;3516;Serine;20656-5;Serine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
449;AAQP;Amino Acids, Quantitative, Plasma;3529;Leucine;20649-0;Leucine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
450;AAQP;Amino Acids, Quantitative, Plasma;3536;Arginine;20637-5;Arginine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
451;AAQP;Amino Acids, Quantitative, Plasma;3528;Isoleucine;20648-2;Isoleucine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
452;AAQP;Amino Acids, Quantitative, Plasma;34450;Alpha-aminoadipic Acid;26600-7;Alpha aminoadipate:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
453;AAQP;Amino Acids, Quantitative, Plasma;34463;Gamma-amino-n-butyric Acid;26609-8;Gamma aminobutyrate:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
454;AAQP;Amino Acids, Quantitative, Plasma;3525;Valine;20661-5;Valine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
455;AAQP;Amino Acids, Quantitative, Plasma;3527;Methionine;20651-6;Methionine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
456;AAQP;Amino Acids, Quantitative, Plasma;3534;Lysine;20650-8;Lysine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
457;AAQP;Amino Acids, Quantitative, Plasma;3526;Cystine;22672-0;Cystine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
458;AAQP;Amino Acids, Quantitative, Plasma;34451;Cystathionine;26607-2;Cystathionine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
459;AAQP;Amino Acids, Quantitative, Plasma;3518;Glutamine;20643-3;Glutamine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
460;AAQP;Amino Acids, Quantitative, Plasma;3519;Proline;20655-7;Proline:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
461;AAQP;Amino Acids, Quantitative, Plasma;3530;Tyrosine;20660-7;Tyrosine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
462;AAQP;Amino Acids, Quantitative, Plasma;3522;Glycine;20644-1;Glycine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
463;AAQP;Amino Acids, Quantitative, Plasma;3533;Ornithine;20652-4;Ornithine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
464;AAQP;Amino Acids, Quantitative, Plasma;3535;Histidine;20645-8;Histidine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
465;AAQP;Amino Acids, Quantitative, Plasma;34452;Beta-aminoisobutyric Acid;26605-6;Beta aminoisobutyrate:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
466;AAQP;Amino Acids, Quantitative, Plasma;3524;Alpha-amino-n-butyric Acid;20634-2;Alpha aminobutyrate:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
467;AAQP;Amino Acids, Quantitative, Plasma;34462;Anserine;26599-1;Anserine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
468;AAQP;Amino Acids, Quantitative, Plasma;34456;Homocitrulline;55876-7;Homocitrulline:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
469;AAQP;Amino Acids, Quantitative, Plasma;32347;Allo-isoleucine;22670-4;Alloisoleucine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
470;AAQP;Amino Acids, Quantitative, Plasma;34453;1-Methylhistidine;20633-4;1-Methylhistidine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
471;AAQP;Amino Acids, Quantitative, Plasma;34455;Carnosine;26606-4;Carnosine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
472;AAQP;Amino Acids, Quantitative, Plasma;34457;Phosphoethanolamine;26612-2;Phosphoethanolamine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
473;AAQP;Amino Acids, Quantitative, Plasma;34464;Hydroxylysine;26610-6;Hydroxylysine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
474;AAQP;Amino Acids, Quantitative, Plasma;34454;3-Methylhistidine;20635-9;3-Methylhistidine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
475;AAQP;Amino Acids, Quantitative, Plasma;3520;Glutamic Acid;20642-5;Glutamate:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
476;AAQP;Amino Acids, Quantitative, Plasma;3532;Beta-Alanine;26604-9;Beta alanine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
477;AAQP;Amino Acids, Quantitative, Plasma;34461;Sarcosine;26613-0;Sarcosine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
478;AAQP;Amino Acids, Quantitative, Plasma;3515;Threonine;20658-1;Threonine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
479;AAQP;Amino Acids, Quantitative, Plasma;3521;Citrulline;20640-9;Citrulline:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
480;AAQP;Amino Acids, Quantitative, Plasma;3523;Alanine;20636-7;Alanine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
481;AAQP;Amino Acids, Quantitative, Plasma;34460;Ethanolamine;26608-0;Ethanolamine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
482;AAQP;Amino Acids, Quantitative, Plasma;3512;Taurine;20657-3;Taurine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
483;AAQP;Amino Acids, Quantitative, Plasma;34449;Phosphoserine;20654-0;Phosphoserine:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
484;AAQP;Amino Acids, Quantitative, Plasma;34458;Hydroxyproline;20647-4;Hydroxyproline:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
485;AAQP;Amino Acids, Quantitative, Plasma;3531;Phenylalanine;14875-9;Phenylalanine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
486;AAQP;Amino Acids, Quantitative, Plasma;3517;Asparagine;20638-3;Asparagine:SCnc:Pt:Ser/Plas:Qn:;2013-08-27;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
487;AAQP;Amino Acids, Quantitative, Plasma;34459;Aspartic Acid;20639-1;Aspartate:SCnc:Pt:Ser/Plas:Qn:;2013-08-07;Quantitative Analysis by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
488;AASCA;Saccharomyces cerevisiae Antibody, IgA, Serum;AASCA;Saccharomyces cerevisiae Ab, IgA, S;47320-7;Saccharomyces cerevisiae Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
489;AAT;Alpha-1-Antitrypsin, Serum;AAT;Alpha-1-Antitrypsin, S;6771-0;Alpha 1 antitrypsin:MCnc:Pt:Ser/Plas:Qn:Nephelometry;2012-03-12;Nephelometry
490;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32445;Interpretation (AAUCD);59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
491;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32444;Ornithine;20652-4;Ornithine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
492;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32443;Arginine;20637-5;Arginine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
493;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32442;Argininosuccinic Acid;32227-1;Argininosuccinate:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
494;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32441;Citrulline;20640-9;Citrulline:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
495;AAUCD;Amino Acids, Urea Cycle Disorders Panel, Plasma;32440;Glutamine;20643-3;Glutamine:SCnc:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
496;AB2GP;Beta-2 Glycoprotein 1 Antibodies, IgA, Serum;AB2GP;Beta 2 GP1 Ab IgA, S;44447-1;Beta 2 glycoprotein 1 Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
497;ABID2;Antibody Identification, Erythrocytes;ABIDW;Antibody Identification, RBC;888-8;Blood group antibodies identified:Prid:Pt:Ser/Plas:Nom:;2012-03-12;ABID2: Ten-Cell PanelABAB, SPAG: Standard Blood Bank TechniquesABEL: Acid-EDTA Elution/Other standard methods may be used in difficult cases.DCTM, MDCG, MDCC3: Direct Antiglobulin Test
498;ABO_M;Grouping and Rh, Blood;ABO_3;Grouping and Rh, B;882-1;ABO+Rh group:Type:Pt:Bld:Nom:;2012-03-12;Standard AABB
499;ABSCM;Antibody Screen, Erythrocytes;ABSCM;Antibody Scrn, RBC;890-4;Blood group antibody screen:ACnc:Pt:Ser/Plas:Ord:;2012-03-12;ABSCM: Two-Cell Panel Antibody ScreenABID2: Ten-Cell PanelABAB, SPAG: Standard Blood Bank TechniquesABEL: Acid-EDTA Elution/Other standard methods may be used in difficult cases.DCTM, MDCG, MDCC3: Direct Antiglobulin Test
500;ABTIH;Antibody Titer, Erythrocytes;TITEP;Titer of Previous Sample;50401-9;Blood group antibody titered:Prid:Pt:Ser/Plas:Nom:;2012-03-12;ABTIH: TitrationABID2: Ten-Cell PanelABA, SPAG: Standard Blood Bank TechniquesABEL: Acid-EDTA Elution/Other standard methods may be used in difficult cases.DCTM, MDCG, MDCC3: Direct Antiglobulin Test
501;ABTIH;Antibody Titer, Erythrocytes;TITE;Titer;50401-9;Blood group antibody titered:Prid:Pt:Ser/Plas:Nom:;2012-03-15;ABTIH: TitrationABID2: Ten-Cell PanelABA, SPAG: Standard Blood Bank TechniquesABEL: Acid-EDTA Elution/Other standard methods may be used in difficult cases.DCTM, MDCG, MDCC3: Direct Antiglobulin Test
502;ACAC;Acacia, IgE;ACAC;Acacia, IgE;6015-2;Acacia longifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
503;ACANT;Acanthamoeba/Naegleria species, Corneal Scraping or Spinal Fluid;ACANT;Acanthamoeba/Naegleria, Corneal/CSF;6594-6;Amoeba identified:Prid:Pt:XXX:Nom:Organism specific culture;2013-12-18;Direct Wet Prep/Culture
504;ACAR;Acarus siro, IgE;ACAR;Acarus Siro, IgE;6254-7;Acarus siro Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
505;ACASM;Pernicious Anemia Cascade;B12PA;Vitamin B12 Assay, S;2132-9;Cobalamins:MCnc:Pt:Ser:Qn:;2012-11-13;Immunoenzymatic Assay
506;ACE;Angiotensin Converting Enzyme, Serum;ACE;Angiotensin Converting Enzyme, S;2742-5;Angiotensin converting enzyme:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Spectrophotometry (SP)
507;ACHE_;Acetylcholinesterase, Amniotic Fluid (AChE-AF), Amniotic Fluid;GACHE;Gestational Age (ACHE);18185-9;Gestational age:Time:Pt:^Fetus:Qn:;2012-03-15;Polyacrylamide Electrophoresis
508;ACHE_;Acetylcholinesterase, Amniotic Fluid (AChE-AF), Amniotic Fluid;9287;Acetylcholinesterase, AF;30106-9;Acetylcholinesterase:ACnc:Pt:Amnio fld:Ord:;2009-11-13;Polyacrylamide Electrophoresis
509;ACHS;Acetylcholinesterase, Erythrocytes;ACHSR;Acetylcholinesterase, RBC;49230-6;Acetylcholinesterase:CCnt:Pt:RBC:Qn:;2012-03-12;Spectrophotometric-Thiocholine Production
510;ACLIP;Phospholipid (Cardiolipin) Antibodies, IgA, Serum;ACLIP;Phospholipid Ab IgA, S;17459-9;Phospholipid Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
511;ACM;Acetaminophen, Serum;8698;Acetaminophen, S;3298-7;Acetaminophen:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
512;ACRN;Acylcarnitines, Quantitative, Plasma;10317;Linoleylcarnitine, C18:2;30534-2;Linoleoylcarnitine (C18:2):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
513;ACRN;Acylcarnitines, Quantitative, Plasma;10301;Decenoylcarnitine, C10:1;30328-9;Decenoylcarnitine (C10:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
514;ACRN;Acylcarnitines, Quantitative, Plasma;10320;3-OH-linoleylcarnitine, C18:2-OH;30237-2;3-Hydroxylinoleoylcarnitine (C18:2-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
515;ACRN;Acylcarnitines, Quantitative, Plasma;10313;Hexadecenoylcarnitine, C16:1;30357-8;Palmitoleylcarnitine (C16:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
516;ACRN;Acylcarnitines, Quantitative, Plasma;10321;3-OH-oleylcarnitine, C18:1-OH;30312-3;3-Hydroxyoleoylcarnitine (C18:1-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
517;ACRN;Acylcarnitines, Quantitative, Plasma;10290;Iso-/Butyrylcarnitine, C4;43243-5;Isobutyrylcarnitine (C4):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
518;ACRN;Acylcarnitines, Quantitative, Plasma;10316;3-OH-hexadecanoylcarnitine, C16-OH;30234-9;3-Hydroxypalmitoylcarnitine (C16-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
519;ACRN;Acylcarnitines, Quantitative, Plasma;10295;Hexanoylcarnitine, C6;30358-6;Hexanoylcarnitine (C6):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
520;ACRN;Acylcarnitines, Quantitative, Plasma;10297;3-OH-hexanoylcarnitine, C6-OH;30236-4;3-Hydroxyhexanoylcarnitine (C6-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
521;ACRN;Acylcarnitines, Quantitative, Plasma;10312;3-OH-tetradecanoylcarnitine, C14-OH;30238-0;3-Hydroxytetradecanoylcarnitine (C14-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
522;ACRN;Acylcarnitines, Quantitative, Plasma;10315;3-OH-hexadecenoylcarnitine,C16:1-OH;30235-6;3-Hydroxypalmitoleylcarnitine (C16:1-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
523;ACRN;Acylcarnitines, Quantitative, Plasma;10318;Oleylcarnitine, C18:1;30542-5;Oleoylcarnitine (C18:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
524;ACRN;Acylcarnitines, Quantitative, Plasma;10304;Glutarylcarnitine, C5-DC;30349-5;Glutarylcarnitine (C5-DC):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
525;ACRN;Acylcarnitines, Quantitative, Plasma;10310;Tetradecanoylcarnitine, C14;30565-6;Tetradecanoylcarnitine (C14):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
526;ACRN;Acylcarnitines, Quantitative, Plasma;10299;Octanoylcarnitine, C8;30540-9;Octanoylcarnitine (C8):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
527;ACRN;Acylcarnitines, Quantitative, Plasma;10308;Tetradecadienoylcarnitine, C14:2;30564-9;Tetradecadienoylcarnitine (C14:2):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
528;ACRN;Acylcarnitines, Quantitative, Plasma;10307;3-OH-dodecanoylcarnitine, C12-OH;30233-1;3-Hydroxydodecanoylcarnitine (C12-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
529;ACRN;Acylcarnitines, Quantitative, Plasma;10306;Dodecanoylcarnitine, C12;30331-3;Dodecanoylcarnitine (C12):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
530;ACRN;Acylcarnitines, Quantitative, Plasma;10305;Dodecenoylcarnitine, C12:1;30332-1;Dodecenoylcarnitine (C12:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
531;ACRN;Acylcarnitines, Quantitative, Plasma;10311;3-OH-tetradecenoylcarnitine C14:1OH;30190-3;3-Hydroxytetradecenoylcarnitine (C14:1-OH):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
532;ACRN;Acylcarnitines, Quantitative, Plasma;10289;Propionylcarnitine, C3;30551-6;Propionylcarnitine (C3):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
533;ACRN;Acylcarnitines, Quantitative, Plasma;10302;Decanoylcarnitine, C10;30327-1;Decanoylcarnitine (C10):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
534;ACRN;Acylcarnitines, Quantitative, Plasma;10309;Tetradecenoylcarnitine, C14:1;30566-4;Tetradecenoylcarnitine (C14:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
535;ACRN;Acylcarnitines, Quantitative, Plasma;10298;Octenoylcarnitine, C8:1;30541-7;Octenoylcarnitine (C8:1):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
536;ACRN;Acylcarnitines, Quantitative, Plasma;10293;Isovaleryl-/2-Methylbutyrylcarn C5;30531-8;Isovalerylcarnitine+Methylbutyrylcarnitine (C5):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
537;ACRN;Acylcarnitines, Quantitative, Plasma;10322;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
538;ACRN;Acylcarnitines, Quantitative, Plasma;10314;Hexadecanoylcarnitine, C16;30356-0;Palmitoylcarnitine (C16):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
539;ACRN;Acylcarnitines, Quantitative, Plasma;10288;Acetylcarnitine, C2;30191-1;Acetylcarnitine (C2):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
540;ACRN;Acylcarnitines, Quantitative, Plasma;82413;Acylcarnitines, Quantitative, P;46252-3;Acylcarnitine pattern:Imp:Pt:Ser/Plas:Nom:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
541;ACRN;Acylcarnitines, Quantitative, Plasma;10319;Stearoylcarnitine, C18;30560-7;Stearoylcarnitine (C18):SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
542;ACTH;Adrenocorticotropic Hormone (ACTH), Plasma;ACTH;Adrenocorticotropic Hormone, P;2141-0;Corticotropin:MCnc:Pt:Plas:Qn:;2012-03-12;Automated Chemiluminescent Immunometric Assay 
543;ACYLG;Acylglycines, Quantitative, Urine;21013;Glutaric acid;13748-9;Glutarate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
544;ACYLG;Acylglycines, Quantitative, Urine;21019;Dodecanedioic acid;13732-3;Dodecanedioate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
545;ACYLG;Acylglycines, Quantitative, Urine;21021;Hexadecanedioic acid;50332-6;Hexadecanedioate/Creatinine:MRto:Pt:Urine:Qn:;2013-08-26;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
546;ACYLG;Acylglycines, Quantitative, Urine;21020;Tetradecanedioic acid;50333-4;Tetradecanedioate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
547;ACYLG;Acylglycines, Quantitative, Urine;21014;Isobutyrylglycine;38360-4;Isobutyrylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
548;ACYLG;Acylglycines, Quantitative, Urine;23387;n-Butyrylglycine;27892-9;Butyrylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
549;ACYLG;Acylglycines, Quantitative, Urine;21017;n-Octanoylglycine;38367-9;N-octanoylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
550;ACYLG;Acylglycines, Quantitative, Urine;21018;trans-Cinnamoylglycine;38417-2;Trans-cinnamoylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
551;ACYLG;Acylglycines, Quantitative, Urine;23390;Suberylglycine;13811-5;Suberylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
552;ACYLG;Acylglycines, Quantitative, Urine;21011;Ethylmalonic Acid;13741-4;Ethylmalonate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
553;ACYLG;Acylglycines, Quantitative, Urine;23389;3-Phenylpropionylglycine;13793-5;Phenylpropionylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
554;ACYLG;Acylglycines, Quantitative, Urine;21012;2-Methylsuccinic acid;13777-8;Methylsuccinate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
555;ACYLG;Acylglycines, Quantitative, Urine;21016;Isovalerylglycine;13766-1;Isovalerylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
556;ACYLG;Acylglycines, Quantitative, Urine;23388;n-Hexanoylglycine;13753-9;Hexanoylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
557;ACYLG;Acylglycines, Quantitative, Urine;21015;2-Methylbutyrylglycine;27097-5;2-Methylbutyrylglycine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
558;ACYLG;Acylglycines, Quantitative, Urine;23414;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
559;ADMA;Asymmetric Dimethylarginine, Plasma;32053;ADMA Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-09-18;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
560;ADNA;DNA Double-Stranded (dsDNA) Antibodies, IgG, Serum;ADNA;DNA Double-Stranded Ab, IgG, S;33800-4;DNA double strand Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
561;ADNAS;Anti-DNase B Titer, Serum;ADNAS;Anti-DNase B Titer, S;5133-4;DNAse B Ab.Streptococcal:ACnc:Pt:Ser:Qn:;2012-03-12;Nephelometry
562;ADULT;Adulterants Survey, Urine;30914;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Spectrophotometry (SP)
563;ADULT;Adulterants Survey, Urine;23510;Nitrites;32710-6;Nitrite:ACnc:Pt:Urine:Ord:;2009-11-13;Spectrophotometry (SP)
564;ADULT;Adulterants Survey, Urine;23509;pH;2756-5;pH:LsCnc:Pt:Urine:Qn:;2009-11-13;Spectrophotometry (SP)
565;ADULT;Adulterants Survey, Urine;22312;Specific Gravity;5811-5;Specific gravity:Rden:Pt:Urine:Qn:Test strip;2009-11-13;Spectrophotometry (SP)
566;AF;Chromosome Analysis, Amniotic Fluid;50460;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
567;AF;Chromosome Analysis, Amniotic Fluid;16044;Amendment;33773-3;Karyotype:Prid:Pt:Amnio fld:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
568;AF;Chromosome Analysis, Amniotic Fluid;16043;Interpretation;69965-2;;2012-04-05;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
569;AF;Chromosome Analysis, Amniotic Fluid;G_750;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
570;AF;Chromosome Analysis, Amniotic Fluid;16040;Method;49549-9; ;2013-07-26;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
571;AF;Chromosome Analysis, Amniotic Fluid;16042;Results;33773-3;Karyotype:Prid:Pt:Amnio fld:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
572;AF;Chromosome Analysis, Amniotic Fluid;G_744;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Includes 2 banded karyograms, analysis of 15 or more metaphases, and other techniques when required. Results are usually confirmed in 15 or more colonies from 3 or more primary cultures.
573;AFBIL;Bilirubin, Amniotic Fluid;GSTN;Gestation;18185-9;Gestational age:Time:Pt:^Fetus:Qn:;2012-03-15;Spectrophotometric Scan
574;AFBIL;Bilirubin, Amniotic Fluid;AMBL;Amniotic Fluid;12476-8;Bilirubin:MCnc:Pt:Amnio fld:Qn:Direct spectrophotometry;2012-03-12;Spectrophotometric Scan
575;AFC;Amniotic Fluid Culture for Genetic Testing;CG132;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Culture
576;AFC;Amniotic Fluid Culture for Genetic Testing;16184;Method;49549-9; ;2013-07-26;Cell Culture
577;AFC;Amniotic Fluid Culture for Genetic Testing;16187;Interpretation;69965-2; ;2014-04-30;Cell Culture
578;AFC;Amniotic Fluid Culture for Genetic Testing;16188;Amendment;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar;2014-04-30;Cell Culture
579;AFC;Amniotic Fluid Culture for Genetic Testing;16793;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Cell Culture
580;AFP;Alpha-Fetoprotein (AFP) Tumor Marker, Serum;AFP;Alpha-Fetoprotein, Tumor Marker, S;53962-7;Alpha-1-Fetoprotein.tumor marker:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Immunoenzymatic Assay
581;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24241;Results;43798-8;Alpha-1-Fetoprotein:ACnc:Pt:Amnio fld:Ord:;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
582;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24235;Interpretation;59462-2;;2012-04-09;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
583;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24236;Additional Comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
584;AFPA;Alpha-Fetoprotein, Amniotic Fluid;9950;Alpha Fetoprotein, AF;43798-8;Alpha-1-Fetoprotein:ACnc:Pt:Amnio fld:Ord:;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
585;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24239;GA at Collection by Scan;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
586;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24240;GA at Collection by Dates;11885-1;Gestational age:Time:Pt:^Fetus:Qn:Estimated from last menstrual period;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
587;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24234;GA Used;21299-3;Gestational age method:Prid:Pt:^Fetus:Nom:*;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
588;AFPA;Alpha-Fetoprotein, Amniotic Fluid;6740;Last Menstrual Period (LMP);8665-2;Date last menstrual period:TmStp:Pt:^Patient:Qn:Reported;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
589;AFPA;Alpha-Fetoprotein, Amniotic Fluid;24233;EDD by LMP;11779-6;Delivery date:TmStp:Pt:^Patient:Qn:Estimated from last menstrual period;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
590;AFPA;Alpha-Fetoprotein, Amniotic Fluid;6739;Collection Date;33882-2;Collection date:TmStp:Pt:XXX:Qn:;2009-11-13;AFPA: Immunoenzymatic AssayACHE_: Polyacrylamide Electrophoresis
591;AFPPT;Alpha-Fetoprotein (AFP), Peritoneal Fluid;SITEF;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
592;AFPSF;Alpha-Fetoprotein (AFP), Spinal Fluid;AFSF;Alpha-Fetoprotein, CSF;1833-3;Alpha-1-Fetoprotein:MCnc:Pt:CSF:Qn:;2012-03-12;Immunoenzymatic Assay
593;AGA;Alpha-Galactosidase, Leukocytes;8785;Alpha-Galactosidase, Leukocytes;24049-9;Alpha galactosidase A:CCnt:Pt:WBC:Qn:;2011-10-05;Fluorometric
594;AGA;Alpha-Galactosidase, Leukocytes;32302;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Fluorometric
595;AGA;Alpha-Galactosidase, Leukocytes;32303;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2011-06-23;Fluorometric
596;AGABS;Alpha-Galactosidase, Blood Spot;50890;Interpretation;59462-2;;2012-04-02;Fluorometric Enzyme Assay
597;AGABS;Alpha-Galactosidase, Blood Spot;50889;Alpha-Galactosidase, BS;55908-8;Alpha galactosidase A:CCnc:Pt:Bld.dot:Qn:;2011-06-23;Fluorometric Enzyme Assay
598;AGABS;Alpha-Galactosidase, Blood Spot;50888;Method;49549-9; ;2013-07-26;Fluorometric Enzyme Assay
599;AGABS;Alpha-Galactosidase, Blood Spot;50891;Amendment;55908-8;Alpha galactosidase A:CCnc:Pt:Bld.dot:Qn:;2014-05-07;Fluorometric Enzyme Assay
600;AGABS;Alpha-Galactosidase, Blood Spot;50887;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Fluorometric Enzyme Assay
601;AGABS;Alpha-Galactosidase, Blood Spot;50885;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorometric Enzyme Assay
602;AGAS;Alpha-Galactosidase, Serum;50583;Method;49549-9; ;2013-07-26;Fluorometric
603;AGAS;Alpha-Galactosidase, Serum;50590;Alpha-Galactosidase,S;1813-5;Alpha galactosidase A:CCnc:Pt:Ser/Plas:Qn:;2009-11-13;Fluorometric
604;AGAS;Alpha-Galactosidase, Serum;50580;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorometric
605;AGAS;Alpha-Galactosidase, Serum;50582;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Fluorometric
606;AGAS;Alpha-Galactosidase, Serum;50584;Interpretation;59462-2;;2012-04-02;Fluorometric
607;AGPB;Alpha-Globin Gene Analysis;16451;Result;21687-9;HBA1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Dosage Analysis by Polymerase Chain Reaction (PCR)/Multiplex Ligation-Dependent Probe Amplification (MLPA)/Luminex Technology(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
608;AGPB;Alpha-Globin Gene Analysis;16450;Method;49549-9; ;2013-07-26;Dosage Analysis by Polymerase Chain Reaction (PCR)/Multiplex Ligation-Dependent Probe Amplification (MLPA)/Luminex Technology(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
609;AGPB;Alpha-Globin Gene Analysis;16452;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Dosage Analysis by Polymerase Chain Reaction (PCR)/Multiplex Ligation-Dependent Probe Amplification (MLPA)/Luminex Technology(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
610;AGPB;Alpha-Globin Gene Analysis;16448;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Dosage Analysis by Polymerase Chain Reaction (PCR)/Multiplex Ligation-Dependent Probe Amplification (MLPA)/Luminex Technology(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
611;AGPB;Alpha-Globin Gene Analysis;16453;Amendment;21687-9;HBA1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Dosage Analysis by Polymerase Chain Reaction (PCR)/Multiplex Ligation-Dependent Probe Amplification (MLPA)/Luminex Technology(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
612;AGS;Silver, Serum;8607;Silver, S;5734-9;Silver:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
613;AGXKM;AGXT Gene, Known Mutation;51094;Amendment;69384-6;AGXT gene mutation analysis limited to known familial mutations:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
614;AGXKM;AGXT Gene, Known Mutation;51091;Result;69384-6;;2012-04-10;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
615;AGXKM;AGXT Gene, Known Mutation;51087;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
616;AGXKM;AGXT Gene, Known Mutation;51090;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
617;AGXKM;AGXT Gene, Known Mutation;51089;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
618;AGXKM;AGXT Gene, Known Mutation;51092;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
619;AGXMS;AGXT Gene, Full Gene Analysis;51082;Amendment;69383-8;AGXT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
620;AGXMS;AGXT Gene, Full Gene Analysis;51075;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
621;AGXMS;AGXT Gene, Full Gene Analysis;51079;Result;69383-8;AGXT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2012-04-10;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
622;AGXMS;AGXT Gene, Full Gene Analysis;51077;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
623;AGXMS;AGXT Gene, Full Gene Analysis;51078;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
624;AGXMS;AGXT Gene, Full Gene Analysis;51080;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
625;AGXT;Alanine:Glyoxylate Aminotransferase (AGXT) Mutation Analysis (G170R), Blood;22648;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
626;AGXT;Alanine:Glyoxylate Aminotransferase (AGXT) Mutation Analysis (G170R), Blood;22653;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
627;AGXT;Alanine:Glyoxylate Aminotransferase (AGXT) Mutation Analysis (G170R), Blood;22650;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
628;AGXT;Alanine:Glyoxylate Aminotransferase (AGXT) Mutation Analysis (G170R), Blood;22651;Method;49549-9; ;2013-07-26;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
629;AIVC;Aldosterone, Inferior Vena Cava, Serum;6503;Aldosterone, IVC;1762-4;Aldosterone:MCnc:Pt:Bld:Qn:;2009-11-13;Liquid Chomatography-Tandem Mass Spectrometry (LC-MS/MS)
630;AJPWO;Ashkenazi Jewish Mutation Analysis Panel Without Cystic Fibrosis (CF);27175;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;AJPWO: Polymerase chain reaction (PCR) analysis is used to test for mutations associated with 8 disorders prevalent in the Ashkenazi Jewish population.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)23425: Heat Inactivation, Fluorometric, Semiautomated
631;AJPWO;Ashkenazi Jewish Mutation Analysis Panel Without Cystic Fibrosis (CF);27178;Method;49549-9; ;2013-07-26;AJPWO: Polymerase chain reaction (PCR) analysis is used to test for mutations associated with 8 disorders prevalent in the Ashkenazi Jewish population.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)23425: Heat Inactivation, Fluorometric, Semiautomated
632;AJPWO;Ashkenazi Jewish Mutation Analysis Panel Without Cystic Fibrosis (CF);27180;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;AJPWO: Polymerase chain reaction (PCR) analysis is used to test for mutations associated with 8 disorders prevalent in the Ashkenazi Jewish population.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)23425: Heat Inactivation, Fluorometric, Semiautomated
633;AJPWO;Ashkenazi Jewish Mutation Analysis Panel Without Cystic Fibrosis (CF);27177;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;AJPWO: Polymerase chain reaction (PCR) analysis is used to test for mutations associated with 8 disorders prevalent in the Ashkenazi Jewish population.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)23425: Heat Inactivation, Fluorometric, Semiautomated
634;AL;Aluminum, Serum;8373;Aluminum, S;5574-9;Aluminum:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
635;ALAD;Aminolevulinic Acid Dehydratase (ALAD), Whole Blood;28399;Interpretation;59462-2;;2012-04-09;Enzymatic End point/Spectrofluorometric
636;ALAD;Aminolevulinic Acid Dehydratase (ALAD), Whole Blood;4021;ALA Dehydratase;2813-4;Porphobilinogen synthase:CCnc:Pt:RBC:Qn:;2009-11-13;Enzymatic End point/Spectrofluorometric
637;ALADW;Aminolevulinic Acid Dehydratase (ALA-D), Washed Erythrocytes;31948;Interpretation;59462-2;;2012-04-09;Enzymatic End point/Spectrofluorometric
638;ALADW;Aminolevulinic Acid Dehydratase (ALA-D), Washed Erythrocytes;31946;ALA Dehydratase;2813-4;Porphobilinogen synthase:CCnc:Pt:RBC:Qn:;2011-06-22;Enzymatic End point/Spectrofluorometric
639;ALAUR;Aminolevulinic Acid (ALA), Urine;61547;Aminolevulinic Acid, U;34284-0;Delta aminolevulinate:SCnc:Pt:Urine:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
640;ALAV;Aldosterone, Left Adrenal Vein, Serum;6349;Aldosterone, LAV;1762-4;Aldosterone:MCnc:Pt:Bld:Qn:;2011-10-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
641;ALB;Albumin, Serum;ALB;Albumin, S;1751-7;Albumin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Photometric, Bromcresol Green
642;ALC;Ethanol, Blood;30908;Ethanol, B;5640-8;Ethanol:MCnc:Pt:Bld:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)
643;ALDR;Grey Alder, IgE;ALDR;Grey Alder, IgE;15284-3;Alnus incana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
644;ALDS;Aldosterone, Serum;8557;Aldosterone, S;1763-2;Aldosterone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
645;ALDU;Aldosterone, 24 Hour, Urine;VL45;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
646;ALDU;Aldosterone, 24 Hour, Urine;8556;Aldosterone, U;1765-7;Aldosterone:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
647;ALDU;Aldosterone, 24 Hour, Urine;TM47;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
648;ALFA;Alpha-Lactoalbumin, IgE;ALFA;Alpha-Lactoalbumin, IgE;7445-0;Lactalbumin alpha Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
649;ALLOI;Allo-isoleucine, Blood Spot;27458;Leucine;20649-0;Leucine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
650;ALLOI;Allo-isoleucine, Blood Spot;27459;Isoleucine;20648-2;Isoleucine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
651;ALLOI;Allo-isoleucine, Blood Spot;27460;Valine;20661-5;Valine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
652;ALLOI;Allo-isoleucine, Blood Spot;27453;Interpretation;59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
653;ALLOI;Allo-isoleucine, Blood Spot;27457;Allo-isoleucine;22670-4;Alloisoleucine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
654;ALLOI;Allo-isoleucine, Blood Spot;27451;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
655;ALLOI;Allo-isoleucine, Blood Spot;27450;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
656;ALLOI;Allo-isoleucine, Blood Spot;27448;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
657;ALM;Almond, IgE;ALM;Almond, IgE;6019-4;Prunus dulcis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
658;ALP;Alkaline Phosphatase, Serum;ALP;Alkaline Phosphatase, S;6768-6;Alkaline phosphatase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Photometric, p-Nitrophenol Phosphate
659;ALPA;Alprazolam, Serum;11236;Alprazolam, S;3312-6;Alprazolam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
660;ALPS;Alpha Beta Double-Negative T Cells for Autoimmune Lymphoproliferative Syndrome;23975;Interpretation;69052-9;;2012-04-09;Flow Cytometry
661;ALPS;Alpha Beta Double-Negative T Cells for Autoimmune Lymphoproliferative Syndrome;23974;alpha/beta-TCR DNT;34963-9;Cells.CD3+TCR alpha beta+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
662;ALPS;Alpha Beta Double-Negative T Cells for Autoimmune Lymphoproliferative Syndrome;23973;%alpha/beta-TCR DNT;34962-1;Cells.CD3+TCR alpha beta+/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
663;ALS;Aldolase, Serum;ALS;Aldolase, S;1761-6;Aldolase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Ultraviolet, Kinetic
664;ALT;Alanine Aminotransferase (ALT) (GPT), Serum;ALT;Alanine Aminotransferase (ALT), S;1742-6;Alanine aminotransferase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Photometric Rate, L-Alanine with Pyridoxal-5-Phosphate
665;ALTN;Alternaria tenuis, IgE;ALTN;Alternaria Tenuis, IgE;6020-2;Alternaria alternata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
666;ALU;Aluminum, 24 Hour, Urine;861;Al Conc;6929-4;Aluminum:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
667;ALU;Aluminum, 24 Hour, Urine;VL13;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
668;ALU;Aluminum, 24 Hour, Urine;8828;Aluminum, 24 Hr, U;26707-0;Aluminum:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
669;ALU;Aluminum, 24 Hour, Urine;TM15;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
670;ALUR;Aluminum, Random, Urine;86377;Aluminum, Random, U;5577-2;Aluminum:MCnc:Pt:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
671;AMA;Mitochondrial Antibodies (M2), Serum;AMA;Mitochondrial Ab, M2, S;49781-8;Mitochondria M2 Ab:ACnc:Pt:Ser:Qn:;2012-03-12;Enzyme Immunoassay (EIA)
672;AMBF;Amylase, Body Fluid;FLD21;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Substrate Kinetic
673;AMBF;Amylase, Body Fluid;AMBFL;Amylase, BF;1795-4;Amylase:CCnc:Pt:Body fld:Qn:;2012-03-12;Substrate Kinetic
674;AMH;Antimullerian Hormone (AMH), Serum;89711;Antimullerian Hormone, S;38476-8;Mullerian inhibiting substance:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;Immunometric Assay
675;AMIKP;Amikacin, Peak, Serum;500042;Amikacin, Peak, S;3319-1;Amikacin^peak:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Enzyme-Multiplied Immunoassay Technique (EMIT)
676;AMIKR;Amikacin, Random, Serum;81752;Amikacin, Random, S;35669-1;Amikacin^random:MCnc:Pt:Ser/Plas:Qn:;2011-04-28;Enzyme-Multiplied Immunoassay Technique (EMIT)
677;AMIKT;Amikacin, Trough, Serum;6774;Amikacin, Trough, S;3321-7;Amikacin^trough:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
678;AMIO;Amiodarone, Serum;2485;Desethylamiodarone;6774-4;Desethylamiodarone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
679;AMIO;Amiodarone, Serum;9247;Amiodarone, S;3330-8;Amiodarone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
680;AMKPK;Amikacin, Peak, Serum;6773;Amikacin, Peak, S;3319-1;Amikacin^peak:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
681;AMLPC;Amylase, Pancreatic Cyst;SITE6;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Substrate Kinetic
682;AMOBS;Amobarbital, Serum;8325;Amobarbital, S;3338-1;Amobarbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
683;AMOXY;Amoxicillin, IgE;AMOXY;Amoxicillin, IgE;6829-6;Amoxicillin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
684;AMP;Ampicillin, IgE;AMP;Ampicillin, IgE;6712-4;Ampicillin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
685;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31882;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
686;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31858;3,4-methylene-dioxyethylamphetamine;27080-1;Methylenedioxyethylamphetamine:MCnt:Pt:Meconium:Qn:;2011-06-16;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
687;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31855;Methamphetamine;27289-8;Methamphetamine:MCnt:Pt:Meconium:Qn:;2011-06-16;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
688;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31856;3,4-methylenedioxyamphetamine;27244-3;Methylenedioxyamphetamine:MCnt:Pt:Meconium:Qn:;2011-06-16;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
689;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31857;3,4-methylene-dioxy-methamphetamine;69025-5;Methylenedioxymethamphetamine:MCnt:Pt:Meconium:Qn:Confirm;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
690;AMPHM;Amphetamine-Type Stimulants, Confirmation, Meconium;31854;Amphetamine;43934-9;Amphetamines:MCnt:Pt:Meconium:Qn:Confirm;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
691;AMPHU;Amphetamines Confirmation, Urine;29280;MDA (Ecstasy metabolite)-by GC/MS;18355-8;Methylenedioxyamphetamine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
692;AMPHU;Amphetamines Confirmation, Urine;29281;MDMA (Ecstasy)-by GC/MS;19570-1;Methylenedioxymethamphetamine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
693;AMPHU;Amphetamines Confirmation, Urine;21197;Amphetamines Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
694;AMPHU;Amphetamines Confirmation, Urine;29278;Phentermine-by GC/MS;3958-6;Phentermine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
695;AMPHU;Amphetamines Confirmation, Urine;2934;Amphetamine-by GC/MS;19346-6;Amphetamine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
696;AMPHU;Amphetamines Confirmation, Urine;2550;Methamphetamine-by GC/MS;3780-4;Methamphetamine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
697;AMPHU;Amphetamines Confirmation, Urine;29279;Pseudoephedrine/Ephedrine-by GC/MS;26785-6;Ephedrine+Pseudoephedrine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
698;AMPHX;Amphetamines Confirmation, Chain of Custody, Urine;6538;Amphetamines Immunoassay Screen;19343-3;Amphetamine:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
699;AMS;Amylase, Total, Serum;AMS;Amylase, Total, S;1798-8;Amylase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Colorimetric Rate Reaction
700;AMSU;Amylase, Timed Collection, Urine;AMYCN;Amylase Concentration;1799-6;Amylase:CCnc:Pt:Urine:Qn:;2012-03-12;Enzymatic Rate
701;AMSU;Amylase, Timed Collection, Urine;VL19;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Enzymatic Rate
702;AMSU;Amylase, Timed Collection, Urine;AMY_U;Amylase, Timed Collection, U;1799-6;Amylase:CCnc:Pt:Urine:Qn:;2012-10-31;Enzymatic Rate
703;AMSU;Amylase, Timed Collection, Urine;TM21;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Enzymatic Rate
704;AMT;Amitriptyline and Nortriptyline, Serum;2451;Amitriptyline and Nortriptyline;3335-7;Amitriptyline+Nortriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
705;AMT;Amitriptyline and Nortriptyline, Serum;2450;Nortriptyline;3872-9;Nortriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
706;AMT;Amitriptyline and Nortriptyline, Serum;8125;Amitriptyline;3333-2;Amitriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
707;AMYKM;Amyloidosis, Transthyretin-Associated Familial, Known Mutation;22773;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
708;AMYKM;Amyloidosis, Transthyretin-Associated Familial, Known Mutation;22771;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
709;AMYKM;Amyloidosis, Transthyretin-Associated Familial, Known Mutation;22770;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
710;AMYKM;Amyloidosis, Transthyretin-Associated Familial, Known Mutation;22768;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
711;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22643;Amendment;21674-7;FGFR2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
712;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22642;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
713;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22641;Result;21674-7;FGFR2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
714;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22640;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
715;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22639;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
716;AMYL;Amyloidosis, Transthyretin-Associated Familial, DNA Sequence, Blood;22637;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing
717;ANA2;Antinuclear Antibodies (ANA), Serum;ANA2;Antinuclear Ab, S;5047-6;Nuclear Ab:ACnc:Pt:Ser:Qn:EIA;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
718;ANAE;Bacterial Culture, Anaerobic;ANAE;Bacterial Culture, Anaerobic;635-3;Bacteria identified:Prid:Pt:XXXX:Mon:Anaerobic culture;2013-09-17;Conventional Culture Techniques
719;ANAH2;Antinuclear Antibodies (ANA), HEp-2 Substrate, Serum;86038;Antinuclear Ab, HEp-2 Substrate, S;8061-4;Nuclear Ab:ACnc:Pt:Ser:Ord:;2012-03-12;Immunofluorescence Assay (IFA)
720;ANAP;Anaplasma phagocytophilum (Human Granulocytic Ehrlichiosis) Antibody, Serum;81157;Anaplasma phagocytophilum Ab, IgG,S;23877-4;Anaplasma phagocytophilum Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
721;ANAS;Alpha-N-Acetylglucosaminidase, Serum;50569;Method;49549-9; ;2013-07-26;Colorimetric
722;ANAS;Alpha-N-Acetylglucosaminidase, Serum;50577;Alpha-N-Acetylglucosaminidase, S;1837-4;Alpha-N-acetylglucosaminidase:CCnc:Pt:Ser/Plas:Qn:;2009-11-13;Colorimetric
723;ANAS;Alpha-N-Acetylglucosaminidase, Serum;50570;Interpretation;59462-2;;2012-04-02;Colorimetric
724;ANAS;Alpha-N-Acetylglucosaminidase, Serum;50566;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Colorimetric
725;ANAS;Alpha-N-Acetylglucosaminidase, Serum;50568;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Colorimetric
726;ANAT;Alpha-N-Acetylglucosaminidase, Fibroblasts;29895;A-N-Acetylglucosaminidase;24091-1;Alpha-N-acetylglucosaminidase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;ANAT: Colorimetric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
727;ANAT;Alpha-N-Acetylglucosaminidase, Fibroblasts;29786;Interpretation (ANAT);59462-2;;2012-04-02;ANAT: Colorimetric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
728;ANCA;Cytoplasmic Neutrophil Antibodies, Serum;3114;c-ANCA;35279-9;Neutrophil cytoplasmic Ab:ACnc:Pt:Ser:Ord:IF;2009-11-13;Indirect Immunofluorescence
729;ANCA;Cytoplasmic Neutrophil Antibodies, Serum;3119;p-ANCA;17357-5;Neutrophil cytoplasmic Ab.perinuclear:ACnc:Pt:Ser:Ord:IF;2009-11-13;Indirect Immunofluorescence
730;ANCH;Anchovy, IgE;ANCH;Anchovy, IgE;7079-7;Engraulis encrasicolus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
731;ANDR;Androstenedione, Serum;500051;Androstenedione, S;1854-9;Androstenedione:MCnc:Pt:Ser/Plas:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
732;ANIDE;Organism Referred for Identification, Anaerobic Bacteria;ANIDE;Organism Ref for ID, Anaerobic Bact;20878-5;Bacteria identified:Prid:Pt:Isolate:Nom:Anaerobic culture;2013-09-17;Dependent on organism submitted, 1 or more of the following methods will be used: Mass Spectrometry or 16S RNA gene sequencing
733;ANISP;Anisakis, Parasite, IgE;ANISP;Anisakis, Parasite, IgE;10919-9;Anisakis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
734;ANSE;Anise, IgE;ANSE;Anise, IgE;7081-3;Pimpinella anisum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
735;ANST;Androstenedione, Serum;7730;Androstenedione, S;1854-9;Androstenedione:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
736;APCRV;Activated Protein C Resistance V (APCRV), Plasma;APCR;APCRV Ratio;13590-5;Activated protein C resistance:TRto:Pt:PPP:Qn:Coag;2012-03-12;Clot-Based Assay
737;APGH;Alpha-Subunit Pituitary Tumor Marker, Serum;9003;AlphaSubunit Pituitary Tumor Marker;14170-5;Pituitary glucoprotein hormone.alpha subunit:MCnc:Pt:Ser:Qn:;2009-11-13;Immunochemiluminescent Assay
738;APIN;Australian Pine, IgE;APIN;Australian Pine, IgE;6032-7;Casuarina equisetifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
739;APLA1;Apolipoprotein A1, Plasma;APLA1;Apolipoprotein A1, P;1869-7;Apolipoprotein A-I:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Automated Turbidimetric Immunoassay
740;APLB;Apolipoprotein B, Plasma;APLB;Apolipoprotein B, P;1884-6;Apolipoprotein B:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Automated Turbidimetric Immunoassay
741;APLBS;Apolipoprotein B, Serum;APLBS;Apolipoprotein B, S;1884-6;Apolipoprotein B:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Only orderable as part of a profile. For more information see LMPP /Lipoprotein Metabolism Profile.
742;APO1K;Apolipoprotein A-I (APOA1) Gene, Known Mutation;33400;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
743;APO1K;Apolipoprotein A-I (APOA1) Gene, Known Mutation;33398;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
744;APO1K;Apolipoprotein A-I (APOA1) Gene, Known Mutation;33397;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
745;APO1K;Apolipoprotein A-I (APOA1) Gene, Known Mutation;33395;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
746;APO1S;Apolipoprotein A-I (APOA1) Gene, Full Gene Analysis;33386;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
747;APO1S;Apolipoprotein A-I (APOA1) Gene, Full Gene Analysis;33384;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
748;APO1S;Apolipoprotein A-I (APOA1) Gene, Full Gene Analysis;33389;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
749;APO1S;Apolipoprotein A-I (APOA1) Gene, Full Gene Analysis;33387;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
750;APO2K;Apolipoprotein A-II (APOA2) Gene, Known Mutation;33422;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
751;APO2K;Apolipoprotein A-II (APOA2) Gene, Known Mutation;33420;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
752;APO2K;Apolipoprotein A-II (APOA2) Gene, Known Mutation;33417;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
753;APO2K;Apolipoprotein A-II (APOA2) Gene, Known Mutation;33419;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
754;APO2S;Apolipoprotein A-II (APOA2) Gene, Full Gene Analysis;33411;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
755;APO2S;Apolipoprotein A-II (APOA2) Gene, Full Gene Analysis;33408;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
756;APO2S;Apolipoprotein A-II (APOA2) Gene, Full Gene Analysis;33409;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
757;APO2S;Apolipoprotein A-II (APOA2) Gene, Full Gene Analysis;33406;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
758;APOB;Apolipoprotein B-100 Molecular Analysis, R3500Q and R3500W;28614;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification with Allele-Specific Primer Extension (ASPE)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
759;APOB;Apolipoprotein B-100 Molecular Analysis, R3500Q and R3500W;89097;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification with Allele-Specific Primer Extension (ASPE)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
760;APOB;Apolipoprotein B-100 Molecular Analysis, R3500Q and R3500W;28613;Result;21619-2;APOE gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Amplification with Allele-Specific Primer Extension (ASPE)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
761;APOB;Apolipoprotein B-100 Molecular Analysis, R3500Q and R3500W;28612;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification with Allele-Specific Primer Extension (ASPE)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
762;APOE;Apolipoprotein E Genotyping, Blood;16627;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR), Including Restriction Digest(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
763;APOE;Apolipoprotein E Genotyping, Blood;29650;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR), Including Restriction Digest(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
764;APOE;Apolipoprotein E Genotyping, Blood;16630;Result;21619-2;APOE gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-04-30;Polymerase Chain Reaction (PCR), Including Restriction Digest(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
765;APOE;Apolipoprotein E Genotyping, Blood;16632;Amendment;21619-2;APOE gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-04-30;Polymerase Chain Reaction (PCR), Including Restriction Digest(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
766;APOE;Apolipoprotein E Genotyping, Blood;16629;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR), Including Restriction Digest(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
767;APPL;Apple, IgE;APPL;Apple, IgE;6021-0;Malus sylvestris Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
768;APR;Apricot, IgE;APR;Apricot, IgE;7091-2;Prunus armeniaca Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
769;APSM;Alpha-2 Plasmin Inhibitor, Plasma;APSM;Alpha-2 Plasmin Inhibitor, P;27810-1;Plasmin inhibitor actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-12;Hydrolysis of Synthetic Chromogenic Substrate, Colorimetric End pointIncludes measurement of the function of antiplasmin, mostly alpha-2-antiplasmin, with slight interferencefrom alpha-2-macroglobulin.
770;APT;Activated Partial Thromboplastin Time (APTT), Plasma;APT;Activated Partial Thrombopl Time, P;14979-9;Coagulation surface induced:Time:Pt:PPP:Qn:Coag;2012-03-12;Electromagnetic Viscosity Detection System
771;ARAV;Aldosterone, Right Adrenal Vein, Serum;6348;Aldosterone, RAV;1762-4;Aldosterone:MCnc:Pt:Bld:Qn:;2011-10-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
772;ARBI;Acetylcholine Receptor (Muscle AChR) Binding Antibody, Serum;8338;ACh Receptor (Muscle) Binding Ab;11034-6;Acetylcholine receptor binding Ab:SCnc:Pt:Ser:Qn:;2009-11-13;Radioimmunoassay (RIA)
773;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27373;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
774;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27370;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
775;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27371;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
776;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27372;Result;48968-2;PKHD1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
777;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27374;Amendment;48968-2;PKHD1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
778;ARPKD;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis;27368;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
779;ARPKM;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation;27379;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
780;ARPKM;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation;27381;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
781;ARPKM;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation;27382;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
782;ARPKM;Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation;27384;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
783;ARSAK;ARSA Gene, Known Mutation;33332;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
784;ARSAK;ARSA Gene, Known Mutation;33331;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
785;ARSAK;ARSA Gene, Known Mutation;33334;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
786;ARSAK;ARSA Gene, Known Mutation;33329;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
787;ARSAS;ARSA Gene, Full Gene Analysis;33318;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
788;ARSAS;ARSA Gene, Full Gene Analysis;33320;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
789;ARSAS;ARSA Gene, Full Gene Analysis;33321;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
790;ARSAS;ARSA Gene, Full Gene Analysis;33322;Result;49706-5;ARSA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
791;ARSAS;ARSA Gene, Full Gene Analysis;33323;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
792;ARSAS;ARSA Gene, Full Gene Analysis;33324;Amendment;49706-5;ARSA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;ARSAS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
793;ARSAW;Arylsulfatase A, Leukocytes;32437;Interpretation;59462-2;;2012-04-02;Colorimetric Enzyme Assay
794;ARSAW;Arylsulfatase A, Leukocytes;32438;Reason for referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Colorimetric Enzyme Assay
795;ARSAW;Arylsulfatase A, Leukocytes;8779;Arylsulfatase A, Leukocytes;24078-8;Cerebroside sulfatase:CCnt:Pt:WBC:Qn:;2011-10-05;Colorimetric Enzyme Assay
796;ARSB;Arylsulfatase B, Fibroblasts;29776;Interpretation (ARSB);59462-2;;2012-04-02;ARSB: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
797;ARSB;Arylsulfatase B, Fibroblasts;29873;Arylsulfatase B, Fibroblasts;24093-7;N-Acetylgalactosamine-4-Sulfatase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;ARSB: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
798;ARST;Arylsulfatase A, Fibroblasts;8778;Arylsulfatase A, Fibroblasts;24077-0;Cerebroside sulfatase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;ARST: Colorimetric Enzyme AssayCRYO: Fibroblast Subculture Followed by Cryopreservation and Storage
799;ARSU;Arylsulfatase A, 24 Hour, Urine;8777;Arylsulfatase A, U;42726-0;Cerebroside sulfatase:CCnc:24H:Urine:Qn:;2009-11-13;Colorimetric, Kinetic
800;ASB;Arsenic, Blood;32190;Arsenic, B;5583-0;Arsenic:MCnc:Pt:Bld:Qn:;2013-09-17;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
801;ASCRI;Ascaris, IgE;ASCRI;Ascaris, IgE;6022-8;Ascaris sp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
802;ASFR;Arsenic Fractionation, 24 Hour, Urine;VL2;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
803;ASFR;Arsenic Fractionation, 24 Hour, Urine;3628;Inorganic Arsenic (Toxic);53838-9;Arsenic.inorganic:MRat:24H:Urine:Qn:;2009-11-13;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
804;ASFR;Arsenic Fractionation, 24 Hour, Urine;3629;Organic Arsenic (Non-Toxic);53839-7;Arsenic.organic:MRat:24H:Urine:Qn:;2009-11-13;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
805;ASFR;Arsenic Fractionation, 24 Hour, Urine;TM4;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
806;ASFRU;Arsenic Fractionation, Random, Urine;32312;Organic Arsenic (Non-Toxic);53778-7;Arsenic.organic:MCnc:Pt:Urine:Qn:;2011-06-23;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
807;ASFRU;Arsenic Fractionation, Random, Urine;32311;Inorganic Arsenic (Toxic);12481-8;Arsenic.inorganic:MCnc:Pt:Urine:Qn:;2011-06-23;Liquid-Liquid Extraction/Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
808;ASHA;Arsenic, Hair;ASHSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
809;ASHA;Arsenic, Hair;31896;Arsenic, Hair;5584-8;Arsenic:MCnt:Pt:Hair:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
810;ASHW;White Ash, IgE;ASHW;White Ash, IgE;6278-6;Fraxinus americana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
811;ASNA;Arsenic, Nails;ASNSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
812;ASNA;Arsenic, Nails;2535;Arsenic, Nails;8157-0;Arsenic:MCnt:Pt:Nail:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
813;ASO;Antistrep-O Titer, Serum;ASO;Antistrep-O Titer, S;5370-2;Streptolysin O Ab:ACnc:Pt:Ser:Qn:;2012-03-12;Nephelometry
814;ASP;Aspergillus fumigatus, IgE;ASP;Aspergillus Fumigatus, IgE;6025-1;Aspergillus fumigatus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
815;ASPAG;Aspergillus (Galactomannan) Antigen, Serum;84356;Aspergillus Ag, S;44357-2;Galactomannan Ag:ACnc:Pt:Ser/Plas:Qn:EIA;2009-11-13;Enzyme Immunoassay (EIA)
816;ASPAR;Asparagus, IgE;ASPAR;Asparagus, IgE;7099-5;Asparagus officinalis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
817;ASPBA;Aspergillus Antigen, Bronchoalveolar Lavage;61009;Aspergillus Ag, BAL;35671-7;Galactomannan Ag:ACnc:Pt:XXX:Qn:;2011-06-16;Enzyme Immunoassay (EIA)
818;ASPG;Aspergillus niger, IgE;ASPG;Aspergillus niger, IgE;6830-4;Aspergillus niger Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
819;ASRU;Arsenic, Random, Urine;89889;Arsenic, Random, U;5586-3;Arsenic:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
820;AST;Aspartate Aminotransferase (AST) (GOT), Serum;AST;Aspartate Aminotransferase (AST), S;1920-8;Aspartate aminotransferase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;Photometric Rate, L-Aspartate with Pyridoxyl-5-Phosphate
821;ASU;Arsenic, 24 Hour, Urine;859;As Concentration;21074-0;Arsenic:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
822;ASU;Arsenic, 24 Hour, Urine;VL14;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
823;ASU;Arsenic, 24 Hour, Urine;31086;Arsenic, 24 Hr, U;5587-1;Arsenic:MRat:24H:Urine:Qn:;2012-03-06;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
824;ASU;Arsenic, 24 Hour, Urine;TIME3;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
825;ATITH;Isoagglutinin Titer, Anti-A, Serum;AT_IT;Isoagglutinin Titer, Anti-A;30314-9;A Ab:Titr:Pt:Ser/Plas:Qn:;2012-03-12;Hemagglutination
826;ATTF;Antithrombin Activity, Plasma;ATTF;Antithrombin Activity, P;27811-9;Antithrombin actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-12;Chromogenic Assay
827;ATTI;Antithrombin Antigen, Plasma;ATTI;Antithrombin Antigen, P;27812-7;Antithrombin Ag actual/Normal:RelMCnc:Pt:PPP:Qn:Imm;2012-03-12;Automated Latex Immunoassay (LIA)
828;AUPU;Aureobasidium pullulans, IgE;AUPU;Aureobasidium Pullulans, IgE;6029-3;Aureobasidium pullulans Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
829;AVOC;Avocado, IgE;AVOC;Avocado, IgE;6033-5;Persea americana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
830;AVP;Arginine Vasopressin, Plasma;80344;Arginine Vasopressin, P;3126-0;Vasopressin:MCnc:Pt:Plas:Qn:;2009-11-13;Radioimmunoassay (RIA)
831;AXINK;AXIN2 Gene, Known Mutation;33949;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-23;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
832;AXINK;AXIN2 Gene, Known Mutation;33946;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
833;AXINK;AXIN2 Gene, Known Mutation;33945;Interpetation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
834;AXINK;AXIN2 Gene, Known Mutation;33943;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
835;AXINS;AXIN2 Gene, Full Gene Analysis;33939;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-23;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
836;AXINS;AXIN2 Gene, Full Gene Analysis;33934;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
837;AXINS;AXIN2 Gene, Full Gene Analysis;33935;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
838;AXINS;AXIN2 Gene, Full Gene Analysis;33932;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
839;B12;Vitamin B12 Assay, Serum;B12;Vitamin B12 Assay, S;2132-9;Cobalamins:MCnc:Pt:Ser:Qn:;2012-03-12;Immunoenzymatic Assay
840;B2M;Beta-2-Microglobulin (Beta-2-M), Serum;B2M;Beta-2-Microglobulin, S;1952-1;Beta-2-Microglobulin:MCnc:Pt:Ser:Qn:;2012-03-12;Nephelometry
841;B2MC;Beta-2-Microglobulin (B-2-M), Spinal Fluid;B2MC;Beta-2-Microglobulin, CSF;1951-3;Beta-2-Microglobulin:MCnc:Pt:CSF:Qn:;2012-03-12;Nephelometry
842;B2MU;Beta-2-Microglobulin (B-2-M), Urine;B2MU;Beta-2-Microglobulin, U;1953-9;Beta-2-Microglobulin:MCnc:Pt:Urine:Qn:;2012-03-12;Automated Chemiluminescent Immunometric Assay
843;B6PA;Pyridoxic Acid (PA), Plasma;61065;Pyridoxic Acid (PA), P;1688-1;4-Pyridoxate:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;Only orderable as part of a profile. For more information see B6PRO / Vitamin B6 Profile (PLP and PA), Plasma.
844;BA190;BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay;MP002;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
845;BA190;BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay;19765;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
846;BABG;Babesia microti IgG Antibodies, Serum;81128;Babesia microti IgG Ab, S;16117-4;Babesia microti Ab.IgG:Titr:Pt:Ser:Qn:;2009-11-13;Immunofluorescence Assay (IFA)
847;BADX;BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay;MP001;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
848;BADX;BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay;19783;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
849;BAHG;Bahia Grass, IgE;BAHG;Bahia Grass, IgE;6034-3;Paspalum notatum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
850;BAKDM;BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen;19824;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis Allele-Specific Primer Extension (ASPE) and Detection by Luminex Bead Array(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
851;BAKDM;BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen;MOFF;BCRABL Fusion Form;55135-8;BCR-ABL1 kinase domain mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-12-05;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis Allele-Specific Primer Extension (ASPE) and Detection by Luminex Bead Array(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
852;BAKDM;BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen;MP004;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis Allele-Specific Primer Extension (ASPE) and Detection by Luminex Bead Array(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
853;BAMB;Bamboo Shoot, IgE;BAMB;Bamboo Shoot, IgE;10920-7;Phyllostachys pubescens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
854;BANA;Banana, IgE;BANA;Banana, IgE;6035-0;Musa spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
855;BAP;Bone Alkaline Phosphatase, Serum;BAP;Bone Alkaline Phosphatase, S;17838-4;Alkaline phosphatase.bone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Immunoenzymatic Assay
856;BARBU;Barbiturates Confirmation, Urine;20651;Barbiturates Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
857;BARBU;Barbiturates Confirmation, Urine;20645;Phenobarbital-by GC/MS;16241-2;Phenobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
858;BARBU;Barbiturates Confirmation, Urine;20644;Secobarbital-by GC/MS;16238-8;Secobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
859;BARBU;Barbiturates Confirmation, Urine;20643;Pentobarbital-by GC/MS;16240-4;Pentobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
860;BARBU;Barbiturates Confirmation, Urine;21442;Butalbital-by GC/MS;16237-0;Butalbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
861;BARBU;Barbiturates Confirmation, Urine;20642;Amobarbital-by GC/MS;16239-6;Amobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
862;BARBX;Barbiturates Confirmation, Chain of Custody, Urine;6668;Barbiturates Immunoassay Screen;19270-8;Barbiturates:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
863;BARRP;Bartonella, Molecular Detection, PCR;SRC51;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
864;BARRP;Bartonella, Molecular Detection, PCR;84440;Bartonella PCR;48864-3;Bartonella sp DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
865;BART;Bartonella Antibody Panel, IgG and IgM, Serum;15661;Bart Quintana IgG;44827-4;Bartonella quintana Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunoflourescence Assay (IFA)
866;BART;Bartonella Antibody Panel, IgG and IgM, Serum;15660;Bart Henselae IgM;6955-9;Bartonella henselae Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunoflourescence Assay (IFA)
867;BART;Bartonella Antibody Panel, IgG and IgM, Serum;15662;Bart Quintana IgM;44825-8;Bartonella quintana Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunoflourescence Assay (IFA)
868;BART;Bartonella Antibody Panel, IgG and IgM, Serum;15659;Bart Henselae IgG;6954-2;Bartonella henselae Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunoflourescence Assay (IFA)
869;BARTB;Bartonella, Molecular Detection, PCR, Blood;56056;Bartonella PCR;16275-0;Bartonella sp DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-23;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
870;BARTB;Bartonella, Molecular Detection, PCR, Blood;SRC98;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
871;BASL;Basil, IgE;BASL;Basil, IgE;7118-3;Ocimum basilicum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
872;BAYL;Bay Leaf, IgE;BAYL;Bay Leaf, IgE;7125-8;Laurus nobilis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
873;BBEET;Berlin Beetle, IgE;BBEET;Berlin Beetle, IgE;15339-5;Trogoderma angustum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
874;BBLD;Bacterial Culture, Blood;BBLD;Bacterial Culture, Blood;17928-3;Bacteria identified:Prid:Pt:Bld:Nom:Aerobic culture;2013-09-17;Automated or Manual Detection of Positive Blood Cultures with Conventional Identification Methods
875;BCARO;Beta-Carotene, Serum;62166;Beta-Carotene, S;2053-7;Carotene:MCnc:Pt:Ser:Qn:;2013-08-07;High-Performance Liquid Chromatography (HPLC)
876;BCGBM;Immunoglobulin Gene Rearrangement, Bone Marrow;19894;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Genomic DNA Extracted Followed by Polymerase Chain Reaction (PCR)(PCR is used pursuant to a license agreement with Roche Molecular Systems, Inc. and InvivoScribe Technologies)
877;BCGR;Immunoglobulin Gene Rearrangement, Blood;18229;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Genomic DNA Extracted Followed by Polymerase Chain Reaction (PCR)(PCR is used pursuant to a license agreement with Roche Molecular Systems, Inc. and InVivoScribe Technologies)
878;BCGRV;Immunoglobulin Gene Rearrangement, Varies;MP017;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Genomic DNA Extracted Followed by Polymerase Chain Reaction (PCR)(PCR is used pursuant to a license agreement with Roche Molecular Systems, Inc. and InvivoScribe Technologies)
879;BCGRV;Immunoglobulin Gene Rearrangement, Varies;19915;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Genomic DNA Extracted Followed by Polymerase Chain Reaction (PCR)(PCR is used pursuant to a license agreement with Roche Molecular Systems, Inc. and InvivoScribe Technologies)
880;BCLL;IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis;19674;Final Diagnosis;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Polymerase Chain Reaction (PCR)/Sequencing/Comparison with IMGT Database for Mutation Status(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
881;BCLL;IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis;MP005;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Polymerase Chain Reaction (PCR)/Sequencing/Comparison with IMGT Database for Mutation Status(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
882;BCRAB;BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML);19598;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) using GeneXpert (Cepheid)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
883;BCRAB;BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML);MP003;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) using GeneXpert (Cepheid)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
884;BCYP;Bald Cypress, IgE;BCYP;Bald Cypress, IgE;7272-8;Taxodium distichum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
885;BDRP;Budgerigar Droppings, IgE;BDRP;Budgerigar Droppings, IgE;6304-0;Budgerigar droppings Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
886;BECH;Beech, IgE;BECH;Beech, IgE;6038-4;Fagus grandifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
887;BEEF;Beef, IgE;BEEF;Beef, IgE;6039-2;Beef Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
888;BEETS;Beets (Beetroot), IgE;BEETS;Beets (Beetroot), IgE;19728-5;Beet Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
889;BENW;White Bean, IgE;BENW;White Bean, IgE;6279-4;Bean white Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
890;BENZU;Benzodiazepines Confirmation, Urine;20663;Benzodiazepines Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
891;BENZU;Benzodiazepines Confirmation, Urine;20660;7-NH-Flunitrazepam-by GC/MS;51777-1;7-Aminoflunitrazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
892;BENZU;Benzodiazepines Confirmation, Urine;20661;Alpha OH-Triazolam-by GC/MS;49876-6;Alpha hydroxytriazolam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
893;BENZU;Benzodiazepines Confirmation, Urine;20659;7-NH-Clonazepam-by GC/MS;51776-3;7-Aminoclonazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
894;BENZU;Benzodiazepines Confirmation, Urine;20670;Alpha OH-Alprazolam-by GC/MS;16348-5;Alpha hydroxyalprazolam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
895;BENZU;Benzodiazepines Confirmation, Urine;20658;OH-Ethyl-Flurazepam-by GC/MS;20532-8;Hydroxyethylflurazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
896;BENZU;Benzodiazepines Confirmation, Urine;20655;Oxazepam-by GC/MS;16201-6;Oxazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
897;BENZU;Benzodiazepines Confirmation, Urine;20657;Temazepam-by GC/MS;20559-1;Temazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
898;BENZU;Benzodiazepines Confirmation, Urine;20656;Lorazepam-by GC/MS;17088-6;Lorazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
899;BENZU;Benzodiazepines Confirmation, Urine;21441;Nordiazepam-by GC/MS;16228-9;Nordiazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
900;BENZX;Benzodiazepines Confirmation, Chain of Custody, Urine;6670;Benzodiazepines Immunoassay Screen;14316-4;Benzodiazepines:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
901;BERG;Bermuda Grass, IgE;BERG;Bermuda Grass, IgE;6041-8;Cynodon dactylon Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
902;BETA2;Beta-2 Transferrin: Detection of Spinal Fluid in Other Body Fluid;80351;Beta-2 Transferrin, BF;13876-8;Beta-2 transferrin:ACnc:Pt:Body fld:Ord:;2009-11-13;Electrophoresis/Immunofixation-Peroxidase Antisera/Dimethylformamide Visualization
903;BFBL;Bilirubin, Body Fluid;FLD14;Fluid Type:;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric, Diazonium Salt
904;BFBL;Bilirubin, Body Fluid;BRNBF;Bilirubin (BF);1974-5;Bilirubin:MCnc:Pt:Body fld:Qn:;2013-12-05;Photometric, Diazonium Salt
905;BFLAC;Lipid Analysis, Body Fluid;BFCMT;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Colorimetry/Spectrophotometry (SP)/ElectrophoresisQuantitates cholesterol and triglycerides. Test includes a consultant interpretation.
906;BFLAC;Lipid Analysis, Body Fluid;BFCHL;Cholesterol (BF);12183-0;Cholesterol:MCnc:Pt:Body fld:Qn:;2013-12-05;Colorimetry/Spectrophotometry (SP)/ElectrophoresisQuantitates cholesterol and triglycerides. Test includes a consultant interpretation.
907;BFTH;Budgerigar Feathers, IgE;BFTH;Budgerigar Feathers, IgE;6030-1;Budgerigar feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
908;BGA;Beta-Galactosidase, Leukocytes;34979;Interpretation (BGA);59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2013-04-11;Fluorometric
909;BGA;Beta-Galactosidase, Leukocytes;8486;Beta-Galactosidase, Leukocytes;24061-4;Beta galactosidase:CCnt:Pt:WBC:Qn:;2009-11-13;Fluorometric
910;BGABS;Beta-Galactosidase, Blood Spot;60986;Beta-Galactosidase, BS;55916-1;Beta galactosidase:CCnc:Pt:Bld.dot:Qn:;2013-12-05;Fluorometric Enzyme Assay
911;BGABS;Beta-Galactosidase, Blood Spot;34430;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Fluorometric Enzyme Assay
912;BGABS;Beta-Galactosidase, Blood Spot;34429;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorometric Enzyme Assay
913;BGAT;Beta-Galactosidase, Fibroblasts;29919;Beta-Galactosidase, Fibroblasts;1942-2;Beta galactosidase:CCnt:Pt:Tiss:Qn:;2009-11-13;BGAT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
914;BGAT;Beta-Galactosidase, Fibroblasts;29826;Interpretation (BGAT);59462-2;;2012-04-02;BGAT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
915;BGAW;Beta-Galactosidase, Blood;60987;Beta-Galactosidase, B;16454-1;Beta galactosidase:CCnc:Pt:Bld:Qn:;2013-12-05;Fluorometric Enzyme Assay
916;BGAW;Beta-Galactosidase, Blood;34428;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Fluorometric Enzyme Assay
917;BGAW;Beta-Galactosidase, Blood;34427;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorometric Enzyme Assay
918;BGL;Beta-Glucosidase, Leukocytes;35636;Beta-Glucosidase, Leukocytes;32540-7;Acid beta glucosidase:CCnt:Pt:WBC:Qn:;2013-12-05;Fluorometric
919;BGLR;Beta-Glucuronidase, Fibroblasts;29913;Beta-Glucuronidase, Fibroblasts;1944-8;Beta glucuronidase:CCnt:Pt:Tiss:Qn:;2009-11-13;BGLR: Fluorometric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
920;BGLR;Beta-Glucuronidase, Fibroblasts;29816;Interpretation (BGLR);59462-2;;2012-04-02;BGLR: Fluorometric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
921;BGLT;Beta-Glucosidase, Fibroblasts;29901;Beta-Glucosidase, Fibroblasts;25829-3;Acid Bbta glucosidase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;BGLT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
922;BGLT;Beta-Glucosidase, Fibroblasts;29796;Interpretation (BGLT);59462-2;;2012-04-02;BGLT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
923;BGRS;Barley Grass, IgE;BGRS;Barley Grass, IgE;6037-6;Hordeum vulgare Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
924;BHCG;Beta-Human Chorionic Gonadotropin, Quantitative, Serum;BHCG;Beta-HCG, Quantitative, S;21198-7;Choriogonadotropin.beta subunit:ACnc:Pt:Ser/Plas:Qn:;2013-08-12;Electrochemiluminescence Immunoassay
925;BHSF;Chorionic Gonadotropin, Beta-Subunit (Quantitative), Spinal Fluid;BHSF;Chorionic Gonad Beta-Subunit QN,CSF;14041-8;Choriogonadotropin.beta subunit:ACnc:Pt:CSF:Qn:;2012-03-15;Immunoenzymatic Assay
926;BHYD;Beta-Hydroxybutyrate, Serum;BHYD;Beta-Hydroxybutyrate, S;6873-4;Beta hydroxybutyrate:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, B-Hydroxybutyrate Dehydrogenase (B-HBDH)
927;BILEA;Bile Acids, Total, Serum;BILEA;Bile Acids, Total, S;14628-2;Bile acid:SCnc:Pt:Ser:Qn:;2012-03-15;Enzymatic
928;BILID;Bilirubin Direct, Serum;BILID;Bilirubin, Direct;1968-7;Bilirubin.glucuronidated+Bilirubin.albumin bound:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Diazotized Sulfanilic Acid
929;BILIT;Bilirubin, Total, Serum;BILIT;Bilirubin Total, S;1975-2;Bilirubin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Diazonium Salt (DPD)
930;BIOTS;Biotinidase, Serum;50673;Interpretation;59462-2;;2012-04-02;Colorimetric
931;BIOTS;Biotinidase, Serum;50672;Biotinidase, S;1982-8;Biotinidase:CCnc:Pt:Ser/Plas:Qn:;2009-11-13;Colorimetric
932;BIOTS;Biotinidase, Serum;50670;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Colorimetric
933;BIOTS;Biotinidase, Serum;50668;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Colorimetric
934;BIOTS;Biotinidase, Serum;50671;Method;49549-9; ;2013-07-26;Colorimetric
935;BIR;Silver Birch, IgE;BIR;Silver Birch, IgE;15283-5;Betula verrucosa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
936;BLAC;Beta-Lactoglobulin, IgE;BLAC;Beta-Lactoglobulin, IgE;41397-1;Beta lactoglobulin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
937;BLACK;Blackberry, IgE;BLACK;Blackberry, IgE;7151-4;Rubus fruticosus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
938;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22989;Amendment;32640-5;BLM gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
939;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22988;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
940;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22985;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
941;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22986;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
942;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22983;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
943;BLM;Bloom Syndrome, Mutation Analysis, 2281del6/ins7;22987;Result;32640-5;BLM gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Bloom syndrome: 2281delATCTGAinsTAGATTC (2281del6/ins7).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
944;BLPEP;Black/White Pepper, IgE;BLPEP;Black/White Pepper, IgE;24159-6;Pepper white+Pepper black Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
945;BLUE;Blueberry, IgE;BLUE;Blueberry, IgE;7152-2;Vaccinium myrtillus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
946;BLW;Walnut-Food, IgE;BLW;Walnut-Food, IgE;6273-7;Juglans spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
947;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;16054;Results;33893-9;Karyotype:Prid:Pt:Bone mar:Nom:;2013-05-22;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
948;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;16055;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
949;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;16056;Amendment;33893-9;Karyotype:Prid:Pt:Bone mar:Nom:;2014-04-30;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
950;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;50462;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2013-07-29;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
951;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;16782;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
952;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;16052;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-07-29;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
953;BM;Chromosome Analysis, Hematologic Disorders, Bone Marrow;G_786;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Culture without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.*In addition to the cell culture without mitogens, a CpG-stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia, small lymphocytic leukemia, lymphocytosis, Waldenstrom macroglobulinemia, or when test FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
954;BMNA;Breast Milk Nutritional Analysis;PTBMA;Proteins;2881-1;Protein:MCnc:Pt:Body fld:Qn:;2012-03-15;Thin-Layer Chromatography (TLC)/Colorimetry/Spectrophotometry (SP)/Other Methodologies as Appropriate
955;BMNA;Breast Milk Nutritional Analysis;TGBMA;Triglycerides;12228-3;Triglyceride:MCnc:Pt:Body fld:Qn:;2012-03-12;Thin-Layer Chromatography (TLC)/Colorimetry/Spectrophotometry (SP)/Other Methodologies as Appropriate
956;BMNA;Breast Milk Nutritional Analysis;GLBMA;Glucose;2344-0;Glucose:MCnc:Pt:Body fld:Qn:;2012-03-15;Thin-Layer Chromatography (TLC)/Colorimetry/Spectrophotometry (SP)/Other Methodologies as Appropriate
957;BMPKM;BMPR1A Gene, Known Mutation;33971;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-10;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the BMPR1A gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
958;BMPKM;BMPR1A Gene, Known Mutation;33968;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the BMPR1A gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
959;BMPKM;BMPR1A Gene, Known Mutation;33967;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the BMPR1A gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
960;BMPKM;BMPR1A Gene, Known Mutation;33965;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the BMPR1A gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
961;BMPMS;BMPR1A Gene, Full Gene Analysis;33954;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
962;BMPMS;BMPR1A Gene, Full Gene Analysis;33956;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
963;BMPMS;BMPR1A Gene, Full Gene Analysis;33957;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
964;BMPMS;BMPR1A Gene, Full Gene Analysis;33961;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-09;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
965;BNP;B-Type Natriuretic Peptide (BNP), Plasma;BNP;B-Type Natriuretic Peptide (BNP);30934-4;Natriuretic peptide.B:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
966;BOAC;Boron, Serum/Plasma;Z1308;Boron;5607-7;Boron:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Inductively Coupled Plasma/Optical Emission Spectrometry (ICP/OES)
967;BOT;Botrytis cinerea, IgE;BOT;Botrytis Cinerea, IgE;6049-1;Botrytis cinerea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
968;BOV;Bovine Serum Albumin, IgE;BOV;Bovine Serum Albumin, IgE;10922-3;Bovine serum albumin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
969;BP;Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum;88874;BP 180, S;53842-1;Basement membrane zone BP180 Ab.IgG:ACnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
970;BP;Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum;28259;BP 230, S;53843-9;Basement membrane zone BP230 Ab.IgG:ACnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
971;BPG2;11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine;VL62;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Enzyme Immunoassay (EIA)
972;BPG2;11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine;TM72;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Enzyme Immunoassay (EIA)
973;BPG2;11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine;81425;11 Beta-Prostaglandin F2 Alpha, U;14007-9;Prostaglandin F2 alpha:MRat:24H:Urine:Qn:;2009-11-13;Enzyme Immunoassay (EIA)
974;BPRP;Bordetella pertussis and Bordetella parapertussis, Molecular Detection, PCR;34995;Bordetella parapertussis PCR;42588-4;Bordetella parapertussis DNA:ACnc:Pt:Nph:Ord:Probe.amp.tar;2013-04-11;Polymerase Chain Reaction (PCR)/DNA Probe Hybridization (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Includes DNA extraction from specimen, PCR amplification, and hybridization
975;BPRP;Bordetella pertussis and Bordetella parapertussis, Molecular Detection, PCR;SRC54;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/DNA Probe Hybridization (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Includes DNA extraction from specimen, PCR amplification, and hybridization
976;BPRP;Bordetella pertussis and Bordetella parapertussis, Molecular Detection, PCR;34994;Bordetella pertussis PCR;43913-3;Bordetella pertussis DNA:ACnc:Pt:Nph:Ord:Probe.amp.tar;2013-04-11;Polymerase Chain Reaction (PCR)/DNA Probe Hybridization (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Includes DNA extraction from specimen, PCR amplification, and hybridization
977;BRAF;BRAF Mutation Analysis (V600E), Tumor;26897;Results;53844-7;BRAF gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
978;BRAF;BRAF Mutation Analysis (V600E), Tumor;26898;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-09;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
979;BRAF;BRAF Mutation Analysis (V600E), Tumor;26896;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
980;BRAF;BRAF Mutation Analysis (V600E), Tumor;26893;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-16;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
981;BRAF;BRAF Mutation Analysis (V600E), Tumor;26899;Amendment;53844-7;BRAF gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-08-08;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
982;BRAF;BRAF Mutation Analysis (V600E), Tumor;26895;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
983;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34666;Result;58415-1;BRAF gene.p.V600E:Arb:Pt:Tiss:Ord:Molgen;2014-05-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
984;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34667;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
985;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34668;Amendment;58415-1;BRAF gene.p.V600E:Arb:Pt:Tiss:Ord:Molgen;2014-05-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
986;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34664;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
987;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34665;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
988;BRAFM;BRAF Mutation Analysis (V600), Melanoma;34662;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-16;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
989;BRAZ;Brazil Nut, IgE;BRAZ;Brazil Nut, IgE;6050-9;Bertholletia excelsa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
990;BREG;Beef Neutral-Regular Insulin, IgE;BREG;Beef Neutral-Regular Insulin, IgE;6147-3;Insulin bovine Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
991;BRLY;Barley, IgE;BRLY;Barley, IgE;6037-6;Hordeum vulgare Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
992;BRM;Bromide, Blood;7731;Bromide, B;25171-0;Bromide:SCnc:Pt:Bld:Qn:;2009-11-13;Colorimetric, Quantitative
993;BRM;Bromide, Blood;8608;Bromide, B;42725-2;Bromide:MCnc:Pt:Bld:Qn:;2009-11-13;Colorimetric, Quantitative
994;BROC;Broccoli, IgE;BROC;Broccoli, IgE;6052-5;Brassica oleracea var italica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
995;BROM;Brome Grass, IgE;BROM;Brome Grass, IgE;6053-3;Bromus inermis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
996;BRUC;Brucella Culture;BRUC;Brucella Culture;552-0;Brucella sp identified:Prid:Pt:XXX:Nom:Organism specific culture;2013-09-17;Conventional Culture Technique
997;BRUCB;Brucella Culture, Blood;BRUCB;Brucella Culture, B;551-2;Brucella sp identified:Prid:Pt:Bld:Nom:Organism specific culture;2013-09-17;Conventional Culture Technique
998;BRUGM;Brucella Antibody Screen, IgG and IgM, Serum;23687;Interpretation;59464-8;;2012-04-09;BRUGM: Enzyme-Linked Immunosorbent Assay (ELISA)BRUTA: Agglutination
999;BRUGM;Brucella Antibody Screen, IgG and IgM, Serum;23685;Brucella Ab Screen, IgG, S;24387-3;Brucella sp Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2009-11-13;BRUGM: Enzyme-Linked Immunosorbent Assay (ELISA)BRUTA: Agglutination
1000;BRUGM;Brucella Antibody Screen, IgG and IgM, Serum;23686;Brucella Ab Screen, IgM, S;24388-1;Brucella sp Ab.IgM:ACnc:Pt:Ser:Ord:EIA;2009-11-13;BRUGM: Enzyme-Linked Immunosorbent Assay (ELISA)BRUTA: Agglutination
1001;BRUTA;Brucella Total Antibody Confirmation, Agglutination, Serum;8112;Brucella Ab, Agglutination, S;19053-8;Brucella sp Ab:Titr:Pt:Ser:Qn:Aggl;2014-04-09;Agglutination
1002;BSPR;Brussel Sprouts, IgE;BSPR;Brussel Sprouts, IgE;7160-5;Brassica oleracea var gemmifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1003;BTDKM;Biotinidase Deficiency, BTD Gene, Known Mutation;27440;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) previously identified in an affected family member in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1004;BTDKM;Biotinidase Deficiency, BTD Gene, Known Mutation;27442;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) previously identified in an affected family member in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1005;BTDKM;Biotinidase Deficiency, BTD Gene, Known Mutation;27439;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) previously identified in an affected family member in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1006;BTDKM;Biotinidase Deficiency, BTD Gene, Known Mutation;27437;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) previously identified in an affected family member in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1007;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27430;Result;53845-4;BTD gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1008;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27431;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1009;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27428;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1010;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27429;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1011;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27426;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1012;BTDMS;Biotinidase Deficiency, BTD Full Gene Analysis;27432;Amendment;53845-4;BTD gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the BTD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1013;BTITH;Isoagglutinin Titer, Anti-B, Serum;BT_IT;Isoagglutinin Titer, Anti-B, B;30201-8;B Ab:Titr:Pt:Ser/Plas:Qn:;2012-03-15;Hemagglutination
1014;BTROP;Blomia tropicalis, IgE;BTROP;Blomia Tropicalis, IgE;10921-5;Blomia tropicalis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1015;BUCW;Buckwheat, IgE;BUCW;Buckwheat, IgE;6054-1;Fagopyrum esculentum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1016;BUN;Blood Urea Nitrogen (BUN), Serum;BUN;Bld Urea Nitrog(BUN), S;3094-0;Urea nitrogen:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Urease Also available as part of an Electrolyte panel.
1017;BUPIS;Bupivacaine, Serum;89548;Bupivacaine, S;3412-4;Bupivacaine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1018;BUPM;Buprenorphine and Norbuprenorphine, Urine;500038;Buprenorphine;3415-7;Buprenorphine:MCnc:Pt:Urine:Qn:;2011-06-27;Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
1019;BUPM;Buprenorphine and Norbuprenorphine, Urine;500040;Norbuprenorphine;49753-7;Norbuprenorphine:MCnc:Pt:Urine:Qn:;2011-06-27;Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
1020;BUTAS;Butalbital, Serum;8427;Butalbital, S;6895-7;Butalbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1021;BWOR;Blood Worm, IgE;BWOR;Blood Worm, IgE;6047-5;Chironomus thummi Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1022;BWSRS;Beckwith-Wiedemann Syndrome (BWS)/Russell-Silver Syndrome (RSS) Molecular Analysis;33516;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification (MLPA) (PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
1023;BWSRS;Beckwith-Wiedemann Syndrome (BWS)/Russell-Silver Syndrome (RSS) Molecular Analysis;33519;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification (MLPA) (PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
1024;BWSRS;Beckwith-Wiedemann Syndrome (BWS)/Russell-Silver Syndrome (RSS) Molecular Analysis;33521;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification (MLPA) (PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
1025;BWSRS;Beckwith-Wiedemann Syndrome (BWS)/Russell-Silver Syndrome (RSS) Molecular Analysis;33518;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification (MLPA) (PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
1026;BXMPL;Box Elder/Maple, IgE;BXMPL;Box Eld/Maple, S, IgE;7155-5;Acer negundo Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1027;BYST;Baker's Yeast, IgE;BYST;Baker's Yeast, IgE;6287-7;Saccharomyces cerevisiae Ab.IgE:ACnc:Pt:Ser:Qn:;2014-04-29;Fluorescence Enzyme Immunoassay (FEIA)
1028;C1ES;C1 Esterase (C1ES) Inhibitor Antigen, Serum;C1ES;C1 Esterase Inhibitor Antigen, S;4477-6;Complement C1 esterase inhibitor:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Nephelometry
1029;C1Q;Complement C1q, Serum;C1Q;Complement C1q, S;4478-4;Complement C1q:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Nephelometry
1030;C2;C2 Complement, Functional, with Reflex, Serum;C2FX;C2 Complement,Functional,S;33408-6;Complement C2:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;C2H(50) Automated Liposome Lysis Assay
1031;C2729;Breast Carcinoma-Associated Antigen (CA 27.29), Serum;C2729;Breast Carcinoma Assoc Ag(CA 27.29);17842-6;Cancer Ag 27-29:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Chemiluminometric Immunoassay
1032;C2AG;C2 Complement, Antigen, Serum;84141;C2 Complement, Antigen, S;4484-2;Complement C2:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Radial Immunodiffusion-Binding Site 
1033;C2FXN;C2 Complement, Functional, Serum;C2FX;C2 Complement,Functional,S;33408-6;Complement C2:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;CH(50) Automated Liposome Lysis Assay
1034;C3;Complement C3, Serum;C3;Complement C3, S;4485-9;Complement C3:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Nephelometry
1035;C4;Complement C4, Serum;C4;Complement C4, S;4498-2;Complement C4:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Nephelometry
1036;C4FX;C4 Complement, Functional, Serum;C4FX;C4 Complement, Functional, S;26931-6;Complement C4:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Turbidimetry
1037;C4U;C4 Acylcarnitine, Quantitative, Urine ;88829;C4 Acylcarnitine, QN, U;53111-1;Butyrylcarnitine (C4)/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1038;C5AG;C5 Complement, Antigen, Serum;C5AG;C5 Complement, Antigen, S;4505-4;Complement C5:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Nephelometry
1039;C5DCU;C5-DC Acylcarnitine, Quantitative, Urine;88831;C5-DC Acylcarnitine, QN, U;54279-5;Glutarylcarnitine (C5-DC)/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1040;C5FX;C5 Complement, Functional, Serum;C5FX;C5 Complement, Functional, S;60472-8;Complement C5.functional:ACnc:Pt:Ser/Plas:Qn:;2014-01-21;Turbidimetry
1041;C5OHU;C5-OH Acylcarnitine, Quantitative, Urine;88830;C5-OH Acylcarnitine, QN, U;50091-8;2-methyl,3-hydroxybutyrylcarnitine (C5-OH)/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1042;C7FX;C7 Complement, Functional, Serum;C7FX;C7 Complement, Functional, S;26996-9;Complement C7:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Turbidimetry
1043;C8FX;C8 Complement, Functional, Serum;C8FX;C8 Complement, Functional, S;50997-6;Complement C8.functional:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Turbidimetry
1044;C9OR;C9orf72 Hexanucleotide Repeat, Molecular Analysis;51777;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;C9OR-Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)C9OFU-Southern Blot
1045;C9OR;C9orf72 Hexanucleotide Repeat, Molecular Analysis;51778;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;C9OR-Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)C9OFU-Southern Blot
1046;C9OR;C9orf72 Hexanucleotide Repeat, Molecular Analysis;51775;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;C9OR-Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)C9OFU-Southern Blot
1047;C9OR;C9orf72 Hexanucleotide Repeat, Molecular Analysis;51781;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;C9OR-Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)C9OFU-Southern Blot
1048;CA153;Cancer Antigen 15-3 (CA 15-3), Serum;CA153;Cancer Ag 15-3, (CA 15-3), S;6875-9;Cancer Ag 15-3:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
1049;CA19;Carbohydrate Antigen 19-9 (CA 19-9), Serum;CA19;Carbohydrate Ag 19-9, S;24108-3;Cancer Ag 19-9:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1050;CA25;Cancer Antigen 125 (CA 125), Serum;CA25;Cancer Ag 125 (CA 125), S;10334-1;Cancer Ag 125:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1051;CABB;Cabbage, IgE;CABB;Cabbage, IgE;7169-6;Brassica oleracea var capitata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1052;CACTK;Carnitine-Acylcarnitine Translocase Deficiency, Known Mutation;33354;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1053;CACTK;Carnitine-Acylcarnitine Translocase Deficiency, Known Mutation;33356;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1054;CACTK;Carnitine-Acylcarnitine Translocase Deficiency, Known Mutation;33353;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1055;CACTK;Carnitine-Acylcarnitine Translocase Deficiency, Known Mutation;33351;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1056;CACTS;Carnitine-Acylcarnitine Translocase Deficiency, Full Gene Analysis;33342;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1057;CACTS;Carnitine-Acylcarnitine Translocase Deficiency, Full Gene Analysis;33345;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1058;CACTS;Carnitine-Acylcarnitine Translocase Deficiency, Full Gene Analysis;33343;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1059;CACTS;Carnitine-Acylcarnitine Translocase Deficiency, Full Gene Analysis;33340;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1060;CAFF;Caffeine, Serum;8754;Caffeine, S;3422-3;Caffeine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
1061;CAGR;Canary Grass, IgE;CAGR;Canary Grass, IgE;6058-2;Phalaris arundinacea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1062;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50549;21-deoxycortisol;53341-4;21-Deoxycortisol:MCnc:Pt:Bld.dot:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1063;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;24053;Interpretation;59462-2;;2012-04-02;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1064;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50551;11-deoxycortisol/Cortisol;45184-9;11-Deoxycortisol/Cortisol:MRto:Pt:Ser/Plas:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1065;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50548;11-deoxycortisol;53338-0;11-Deoxycortisol:MCnc:Pt:Bld.dot:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1066;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50547;Cortisol;53345-5;Cortisol:MCnc:Pt:Bld.dot:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1067;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50546;Androstenedione;53343-0;Androstenedione:MCnc:Pt:Bld.dot:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1068;CAHBS;Congenital Adrenal Hyperplasia (CAH) Newborn Screening, Blood Spot;50545;17-OH Progesterone;38473-5;17-Hydroxyprogesterone:MCnc:Pt:Bld.dot:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1069;CAI;Calcium, Ionized, Serum;CAIS;Calcium, Ionized, S;17863-2;Calcium.ionized:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Ion-Selective Electrode (ISE)
1070;CAI;Calcium, Ionized, Serum;PHCC;pH;2753-2;pH:LsCnc:Pt:Ser/Plas:Qn:;2012-03-15;Ion-Selective Electrode (ISE)
1071;CALFL;Cauliflower, IgE;CALFL;Cauliflower, IgE;6835-3;Brassica oleracea var botrytis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1072;CANCP;Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing;52924;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;PCR-Based Next Generation Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1073;CANCP;Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing;52927;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;PCR-Based Next Generation Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1074;CANCP;Solid Tumor Targeted Cancer Gene Panel by Next Generation Sequencing;52923;Additional Information;8251-1;Service comment:Imp:Pt:XXX:Nom;2014-04-30;PCR-Based Next Generation Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1075;CANW;Canavan Disease, Mutation Analysis, ASPA;16774;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1076;CANW;Canavan Disease, Mutation Analysis, ASPA;16775;Amendment;21081-5;ASPA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-08-09;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1077;CANW;Canavan Disease, Mutation Analysis, ASPA;16772;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1078;CANW;Canavan Disease, Mutation Analysis, ASPA;16773;Results;21081-5;ASPA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1079;CANW;Canavan Disease, Mutation Analysis, ASPA;16771;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1080;CANW;Canavan Disease, Mutation Analysis, ASPA;16769;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Canavan disease: 433(-2)A->G, Y231X(C->A and C->T), E285A, and A305E.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1081;CAR;Carbamazepine, Total, Serum;8654;Carbamazepine, Total, S;3432-2;Carbamazepine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
1082;CARD;Cardamom, IgE;CARD;Cardamom, IgE;15279-3;Elettaria cardamomum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1083;CARN;Carnitine, Plasma;21549;Interpretation;59462-2;;2012-04-05;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1084;CARN;Carnitine, Plasma;21032;AC/FC Ratio;30193-7;Acylcarnitine/Carnitine.free (C0):SRto:Pt:Ser/Plas:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1085;CARN;Carnitine, Plasma;32051;Free (FC);14286-9;Carnitine.free (C0):SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1086;CARN;Carnitine, Plasma;32050;Total;14288-5;Carnitine (C0):SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1087;CARN;Carnitine, Plasma;32052;Acylcarnitine (AC);14282-8;Acylcarnitine:SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1088;CARNP;Carbapenemase Detection-Carba NP Test;CARNP;Carbapenemase-Carba NP Test;74676-8;Carbapenemase:Type:Pt:Isolate:Nom:Carbapenemase Nordmann-Poirel;2014-02-18;Colorimetric Detection of Carbapenem Hydrolysis
1089;CARNS;Carnitine, Serum;32048;AC/FC Ratio;30193-7;Acylcarnitine/Carnitine.free (C0):SRto:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1090;CARNS;Carnitine, Serum;32049;Interpretation;59462-2;;2012-04-05;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1091;CARNS;Carnitine, Serum;32047;Acylcarnitine (AC);14282-8;Acylcarnitine:SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1092;CARNS;Carnitine, Serum;32046;Free (FC);14286-9;Carnitine.free (C0):SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1093;CARNS;Carnitine, Serum;32045;Total;14288-5;Carnitine (C0):SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1094;CARNU;Carnitine, Urine;15789;AC/FC Ratio;43576-8;Acylcarnitine/Carnitine.free (C0):Ratio:Pt:Urine:Qn:;2009-11-13;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1095;CARNU;Carnitine, Urine;21550;Interpretation;59462-2;;2012-04-05;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1096;CARNU;Carnitine, Urine;27122;Free (FC);13718-2;Carnitine.free (C0)/Creatinine:MRto:Pt:Urine:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1097;CARNU;Carnitine, Urine;27121;Total;17866-5;Carnitine/Creatinine:Ratio:Pt:Urine:Qn:;2011-06-22;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
1098;CAROB;Carob, IgE;CAROB;Carob, IgE;7179-5;Ceratonia siliqua Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1099;CAS;Calcium, Total, Serum;CA;Calcium, Total, S;17861-6;Calcium:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, 5-nitro-5'-methyl-BAPTA
1100;CASA;Kidney Stone Analysis;2447;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Infrared Spectrum Analysis
1101;CASA;Kidney Stone Analysis;2439;Weight:;9804-6;Weight:EntMass:Pt:Calculus:Qn:;2009-11-13;Infrared Spectrum Analysis
1102;CASA;Kidney Stone Analysis;SRC1;Source:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Infrared Spectrum Analysis
1103;CASA;Kidney Stone Analysis;8596;Kidney Stone Analysis;40787-4;Calculus analysis:Imp:Pt:Calculus:Nom:Infrared spectroscopy;2009-11-13;Infrared Spectrum Analysis
1104;CASE;Casein, IgE;CASE;Casein, IgE;6062-4;Casein Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1105;CASF;IgG/Albumin Ratio, Spinal Fluid;AIGAC;IgG/Albumin, CSF;2470-3;IgG/Albumin:MCrto:Pt:CSF:Qn:;2012-03-12;Nephelometry
1106;CASF;IgG/Albumin Ratio, Spinal Fluid;ALB_C;Albumin, CSF;1746-7;Albumin:MCnc:Pt:CSF:Qn:;2012-03-12;Nephelometry
1107;CASF;IgG/Albumin Ratio, Spinal Fluid;IGG_C;IgG, CSF;2464-6;IgG:MCnc:Pt:CSF:Qn:;2012-03-15;Nephelometry
1108;CASH;Cashew, IgE;CASH;Cashew, IgE;6718-1;Anacardium occidentale Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1109;CAT;Cat Epithelium, IgE;CAT;Cat Epithelium, IgE;6833-8;Cat dander Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1110;CAT22;22q11.2 Deletion/Duplication, FISH;16256;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1111;CAT22;22q11.2 Deletion/Duplication, FISH;G_760;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1112;CAT22;22q11.2 Deletion/Duplication, FISH;16259;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
1113;CAT22;22q11.2 Deletion/Duplication, FISH;G_757;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1114;CATLN;Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node;SITEB;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
1115;CATN;Calcitonin, Serum;CATN;Calcitonin, S;1992-7;Calcitonin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Immunochemiluminometric Assay (ICMA)
1116;CATP;Catecholamine Fractionation, Plasma, Free;2906;Dopamine;2216-0;Dopamine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated norepinephrine, epinephrine, and dopamine
1117;CATP;Catecholamine Fractionation, Plasma, Free;2901;Epinephrine;2230-1;Epinephrine:MCnc:Pt:Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated norepinephrine, epinephrine, and dopamine
1118;CATP;Catecholamine Fractionation, Plasma, Free;2846;Norepinephrine;2666-6;Norepinephrine:MCnc:Pt:Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated norepinephrine, epinephrine, and dopamine
1119;CATU;Catecholamine Fractionation, Free, 24 Hour, Urine;2108;Dopamine;2218-6;Dopamine:MRat:24H:Urine:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated epinephrine, norepinephrine, and dopamine
1120;CATU;Catecholamine Fractionation, Free, 24 Hour, Urine;2107;Epinephrine;2232-7;Epinephrine:MRat:24H:Urine:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated epinephrine, norepinephrine, and dopamine
1121;CATU;Catecholamine Fractionation, Free, 24 Hour, Urine;2106;Norepinephrine;2668-2;Norepinephrine:MRat:24H:Urine:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Includes unconjugated epinephrine, norepinephrine, and dopamine
1122;CATU;Catecholamine Fractionation, Free, 24 Hour, Urine;VL46;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)Includes unconjugated epinephrine, norepinephrine, and dopamine
1123;CATU;Catecholamine Fractionation, Free, 24 Hour, Urine;TM48;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)Includes unconjugated epinephrine, norepinephrine, and dopamine
1124;CAU;Calcium, 24 Hour, Urine;TM13;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
1125;CAU;Calcium, 24 Hour, Urine;2520;Calcium Concentration;18488-7;Calcium:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
1126;CAU;Calcium, 24 Hour, Urine;VL11;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
1127;CAU;Calcium, 24 Hour, Urine;8594;Calcium, 24 Hr, U;6874-2;Calcium:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
1128;CAUR;Calcium, Random, Urine;60157;Calcium, Random, U;17862-4;Calcium:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
1129;CAVP;California Virus (La Crosse) IgG and IgM, Serum;8764;Calif (LaCrosse) Encep Ab, IgG, S;10904-1;La Crosse virus Ab.IgG:Titr:Pt:Ser:QN:IF;2014-04-09;Immunofluorescence Assay (IFA)
1130;CAVP;California Virus (La Crosse) IgG and IgM, Serum;87280;Calif (LaCrosse) Encep Ab, IgM, S;10905-8;La Crosse virus Ab.IgM:Titr:Pt:Ser:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
1131;CAVPC;California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26366;Calif(LaCrosse) Encep Ab, IgM,CSF;9540-6;La Crosse virus Ab.IgM:titr:Pt:CSF:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
1132;CAVPC;California Virus (La Crosse) Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26365;Calif(LaCrosse) Encep Ab, IgG,CSF;9539-8;La Crosse virus Ab.IgG:Titr:Pt:CSF:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
1133;CBBRP;Coxiella burnetii (Q fever), Molecular Detection, PCR, Blood;35192;Coxiella burnetii PCR;23024-3;Coxiella burnetii DNA:ACnc:Pt:XXX:Ord:Probe amp.tar;2013-09-17;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1134;CBBRP;Coxiella burnetii (Q fever), Molecular Detection, PCR, Blood;35191;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-08-08;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1135;CBC;CBC with Differential, Blood;EOSAA;Eosinophils;711-2;Eosinophils:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1136;CBC;CBC with Differential, Blood;LYMAA;Lymphocytes;731-0;Lymphocytes:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1137;CBC;CBC with Differential, Blood;NEUAA;Neutrophils;751-8;Neutrophils:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1138;CBC;CBC with Differential, Blood;PLTC;Platelet Count;777-3;Platelets:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1139;CBC;CBC with Differential, Blood;BASAA;Basophils;704-7;Basophils:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1140;CBC;CBC with Differential, Blood;MONAA;Monocytes;742-7;Monocytes:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1141;CBC;CBC with Differential, Blood;MCV;MCV;787-2;Mean corpuscular volume:EntVol:Pt:RBC:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1142;CBC;CBC with Differential, Blood;RBC;Erythrocytes;789-8;Erythrocytes:NCnc:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1143;CBC;CBC with Differential, Blood;WBC;Leukocytes;6690-2;Leukocytes:NCnc:Pt:Bld:Qn:Automated count;2012-03-12;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1144;CBC;CBC with Differential, Blood;HGB;Hemoglobin;718-7;Hemoglobin:MCnc:Pt:Bld:Qn:;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1145;CBC;CBC with Differential, Blood;RDW;RBC Distrib Width;788-0;Erythrocyte distribution width:Ratio:Pt:RBC:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1146;CBC;CBC with Differential, Blood;HCT;Hematocrit;4544-3;Hematocrit:VFr:Pt:Bld:Qn:Automated count;2012-03-15;RF/DC (Radio Frequency/Direct Current) detection method Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS (sodium lauryl sulfate) hemoglobin method
1147;CBGC;Galactocerebrosidase, Leukocytes;35585;Interpretation (CBGC);59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2013-08-07;Radioisotopic
1148;CBGC;Galactocerebrosidase, Leukocytes;35584;Galactocerebrosidase, WBC;24084-6;Galactosylceramidase:CCnt:Pt:WBC:Qn:;2013-08-07;Radioisotopic
1149;CBGT;Galactocerebrosidase, Fibroblasts;35587;Galactocerebrosidase, Fibro;24083-8;Galactosylceramidase:CCnt:Pt:Fibroblasts:Qn:;2013-08-07;CBGT: RadioisotopicFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1150;CBGT;Galactocerebrosidase, Fibroblasts;35588;Interpretation (CBGT);59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2013-08-07;CBGT: RadioisotopicFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1151;CBL;Blastomyces Antibody by Immunodiffusion, Spinal Fluid;15134;Blastomyces Immunodiffusion (CSF);51741-7;Blastomyces dermatitidis Ab:ACnc:Pt:CSF:Ord:Immune diffusion;2009-11-13;Immunodiffusion
1152;CBLAS;Blastomyces Antibody by EIA, Spinal Fluid;CBLAS;Blastomyces Ab, EIA, CSF;18197-4;Blastomyces dermatitidis Ab:ACnc:Pt:CSF:Ord:;2012-03-15;Enzyme Immunoassay (EIA)
1153;CBN;Castor Bean, IgE;CBN;Castor Bean, IgE;6063-2;Ricinus communis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1154;CBPA;Cell-Bound Platelet Autoantibody, Solid Phase, Blood;CMT27;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Enzyme-Linked Immunoabsorbent Assay (ELISA)
1155;CBRP;Coxiella burnetii (Q fever), Molecular Detection, PCR;62193;Coxiella burnetii PCR;23024-3;Coxiella burnetii DNA:ACnc:Pt:XXX:Ord:Prope.amp.tar;2013-09-17;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1156;CBRP;Coxiella burnetii (Q fever), Molecular Detection, PCR;SRCQF;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-30;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1157;CBSRP;Coxiella burnetii (Q Fever), Molecular Detection, PCR, Serum;35190;Coxiella burnetii PCR;60261-5;Coxiella burnetii DNA:ACnc:Pt:Ser/Plas:Ord:Probe.amp.tar;2013-12-05;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1158;CBSRP;Coxiella burnetii (Q Fever), Molecular Detection, PCR, Serum;35189;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-08-08;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1159;CBUR;Cocklebur, IgE;CBUR;Cocklebur, IgE;6077-2;Xanthium commune Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1160;CCHZ;Cheese, Cheddar, IgE;CCHZ;Cheese, Cheddar, IgE;6067-3;Cheese cheddar type Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1161;CCNT;Coconut, IgE;CCNT;Coconut, IgE;6081-4;Cocos nucifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1162;CCOC;Coccidioides Antibody, Spinal Fluid;21002;Cocci ID-IgG (CSF);30207-5;Coccidioides immitis Ab.IgG:ACnc:Pt:CSF:Ord;2014-06-19;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
1163;CCOC;Coccidioides Antibody, Spinal Fluid;81542;Cocci Ab, CF (CSF);13917-0;Coccidioides immitis Ab:Titr:Pt:CSF:Qn:Comp fix;2014-07-23;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
1164;CCOC;Coccidioides Antibody, Spinal Fluid;21001;Cocci ID-IgM (CSF);30208-3;Coccidioides immitis Ab.IgM:ACnc:Pt:CSF:Ord;2014-07-23;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
1165;CCP;Cyclic Citrullinated Peptide Antibodies, IgG, Serum;CCP;Cyclic Citrullinated Peptide Ab, S;32218-0;Cyclic citrullinated peptide Ab:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
1166;CD20B;CD20 on B Cells;29581;CD19 Absolute;8116-6;Cells.CD19:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1167;CD20B;CD20 on B Cells;29582;CD20 Absolute;9558-8;Cells.CD20:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1168;CD20B;CD20 on B Cells;29580;%CD20 B-Cells;8119-0;Cells.CD20/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1169;CD20B;CD20 on B Cells;29579;%CD19 B-Cells;8117-4;Cells.CD19/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1170;CD20B;CD20 on B Cells;89584;CD45 Absolute;27071-0;Cells.CD45:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1171;CD20B;CD20 on B Cells;29583;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Flow Cytometry
1172;CD4NY;CD4 Count for Monitoring, New York, Blood;3327;H/S Ratio;54218-3;Cells.CD3+CD4+/Cells.CD3+CD8+:NRto:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1173;CD4NY;CD4 Count for Monitoring, New York, Blood;3319;% CD4 (Helper Cells);8123-2;Cells.CD3+CD4+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1174;CD4NY;CD4 Count for Monitoring, New York, Blood;3322;CD3 (T Cells);8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1175;CD4NY;CD4 Count for Monitoring, New York, Blood;3320;% CD8 (Supp'r Cells);8101-8;Cells.CD3+CD8+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1176;CD4NY;CD4 Count for Monitoring, New York, Blood;3316;% CD3 (T Cells);8124-0;Cells.CD3/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1177;CD4NY;CD4 Count for Monitoring, New York, Blood;3325;CD4 (Helper Cells);24467-3;Cells.CD3+CD4+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1178;CD4NY;CD4 Count for Monitoring, New York, Blood;3326;CD8 (Supp'r Cells);14135-8;Cells.CD3+CD8+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1179;CD4NY;CD4 Count for Monitoring, New York, Blood;3321;CD45 Lymph Count, Flow;27071-0;Cells.CD45:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
1180;CD4RT;CD4 T-Cell Recent Thymic Emigrants (RTE);29178;Interpretation;69052-9; ;2013-08-22;Flow Cytometry
1181;CD4RT;CD4 T-Cell Recent Thymic Emigrants (RTE);89504;CD4 Absolute (cells/uL);24467-3;Cells.CD4:NCnc:Pt:Bld:Qn:;2014-07-23;Flow Cytometry
1182;CDAB;Candida albicans (Monilia), IgE;CDAB;Candida Albicans(Monilia), IgE;6059-0;Candida albicans Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1183;CDAG;Drug Screen, Prescription/OTC, Gastric;500055;Drugs detected:;12287-9;Drugs identified:Prid:Pt:Gast fld:Nom:Screen;2011-06-27;Gas-Liquid Chromatography (GLC)/Mass Spectroscopy
1184;CDAS;Drug Screen, Prescription/OTC, Serum;209034;Drugs detected:;20785-2;Drugs identified:Prid:Pt:Ser/Plas:Nom:Screen;2011-06-27;Gas Chromatography-Mass Spectrometry (GC-MS)
1185;CDAU;Drug Abuse Survey with Confirmation, Urine;30909;Alcohol;42242-8;Ethanol:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1186;CDAU;Drug Abuse Survey with Confirmation, Urine;2577;Opiates;19295-5;Opiates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1187;CDAU;Drug Abuse Survey with Confirmation, Urine;2575;Benzodiazepines;20412-3;Benzodiazepines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1188;CDAU;Drug Abuse Survey with Confirmation, Urine;2578;Phencyclidine;19659-2;Phencyclidine:ACnc:Pt:Urine:Ord:Screen;2013-08-28;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1189;CDAU;Drug Abuse Survey with Confirmation, Urine;21652;Cocaine;20519-5;Cocaine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1190;CDAU;Drug Abuse Survey with Confirmation, Urine;2664;Tetrahydrocannabinol;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1191;CDAU;Drug Abuse Survey with Confirmation, Urine;2573;Amphetamines;20410-7;Amphetamines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1192;CDAU;Drug Abuse Survey with Confirmation, Urine;2574;Barbiturates;19270-8;Barbiturates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Mass Spectrophotometry (GC-MS)
1193;CDAU5;Drug Abuse Survey with Confirmation, Panel 5, Urine;2573;Amphetamines;20410-7;Amphetamines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Screened by Immunoassay
1194;CDAU5;Drug Abuse Survey with Confirmation, Panel 5, Urine;2578;Phencyclidine;19659-2;Phencyclidine:ACnc:Pt:Urine:Ord:Screen;2013-08-28;Screened by Immunoassay
1195;CDAU5;Drug Abuse Survey with Confirmation, Panel 5, Urine;2577;Opiates;19295-5;Opiates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Screened by Immunoassay
1196;CDAU5;Drug Abuse Survey with Confirmation, Panel 5, Urine;2664;Tetrahydrocannabinol;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Screened by Immunoassay
1197;CDAU5;Drug Abuse Survey with Confirmation, Panel 5, Urine;21652;Cocaine;20519-5;Cocaine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Screened by Immunoassay
1198;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;4435;Methadone;16246-1;Methadone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1199;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2577;Opiates;19295-5;Opiates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1200;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2578;Phencyclidine;19659-2;Phencyclidine:ACnc:Pt:Urine:Ord:Screen;2013-08-28;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1201;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2664;Tetrahydrocannabinol;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1202;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;21652;Cocaine;20519-5;Cocaine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1203;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2575;Benzodiazepines;20412-3;Benzodiazepines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1204;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2574;Barbiturates;19270-8;Barbiturates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1205;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;2573;Amphetamines;20410-7;Amphetamines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1206;CDAU7;Drug Abuse Survey with Confirmation, Panel 9, Urine;30909;Alcohol;42242-8;Ethanol:Threshold:Pt:Urine:Ord:Screen;2013-08-26;CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by ImmunoassayETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)
1207;CDAUN;Drug Screen, Prescription/OTC, Urine;500057;Drugs detected:;41270-0;Drugs identified:Prid:Pt:Urine:Nom:;2011-06-27;Gas-Liquid Chromatography (GLC)/Mass Spectroscopy
1208;CDB;Cadmium, Blood;8682;Cadmium, B;5609-3;Cadmium:MCnc:Pt:Bld:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1209;CDFRP;Clostridium difficile Toxin, Molecular Detection, PCR, Feces;83124;Result;54067-4;Clostridium difficile toxin genes:ACnc:Pt:Stool:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1210;CDFRP;Clostridium difficile Toxin, Molecular Detection, PCR, Feces;SRC52;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1211;CDG;Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum;BG160;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Affinity Chromatography-Mass Spectrometry (MS)
1212;CDG;Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum;50820;Interpretation;59462-2;;2012-04-02;Affinity Chromatography-Mass Spectrometry (MS)
1213;CDG;Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum;31720;A-oligo/Di-oligo Ratio;35475-3;A-oligosaccharide/Di-oligosaccharide:MRto:Pt:Ser/Plas:Qn:;2011-06-22;Affinity Chromatography-Mass Spectrometry (MS)
1214;CDG;Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation, Serum;31721;Mono-oligo/Di-oligo Ratio;35469-6;Mono-oligosaccharide/Di-oligosaccharide:MRto:Pt:Ser/Plas:Qn:;2011-06-22;Affinity Chromatography-Mass Spectrometry (MS)
1215;CDH1K;CDH1 Gene, Known Mutation;51619;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1216;CDH1K;CDH1 Gene, Known Mutation;51615;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) amplification followed by DNA sequencing.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1217;CDH1K;CDH1 Gene, Known Mutation;51616;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1218;CDH1K;CDH1 Gene, Known Mutation;51613;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1219;CDH1S;CDH1 Gene, Full Gene Analysis;51609;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH). (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1220;CDH1S;CDH1 Gene, Full Gene Analysis;51604;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH). (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1221;CDH1S;CDH1 Gene, Full Gene Analysis;51605;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH). (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1222;CDH1S;CDH1 Gene, Full Gene Analysis;51602;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH). (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1223;CDIP;Corynebacterium diphtheriae Culture;CDIP;C. diphtheria Culture;16676-9;Corynebacterium diphtheriae:ACnc:Pt:XXX:Ord:Organism specific culture;2013-09-17;Conventional Culture Technique
1224;CDKKM;CDKN1C Gene, Known Mutation;33505;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1225;CDKKM;CDKN1C Gene, Known Mutation;33508;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1226;CDKKM;CDKN1C Gene, Known Mutation;33510;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1227;CDKKM;CDKN1C Gene, Known Mutation;33507;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1228;CDKMS;CDKN1C Gene, Full Gene Analysis;33494;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1229;CDKMS;CDKN1C Gene, Full Gene Analysis;33499;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1230;CDKMS;CDKN1C Gene, Full Gene Analysis;33497;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1231;CDKMS;CDKN1C Gene, Full Gene Analysis;33496;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1232;CDOMB;Cadmium for Occupational Monitoring, Blood;89539;Cadmium Occupational Monitor, B;5609-3;Cadmium:MCnc:Pt:Bld:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1233;CDP;Chlordiazepoxide, Serum;8610;Chlordiazepoxide, S;3457-9;Chlordiazepoxide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
1234;CDROP;Chicken Droppings, IgE;CDROP;Chicken Droppings, IgE;19734-3;Chicken droppings Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1235;CDRU;Cadmium, Random, Urine;60156;Cadmium, Random, U;5611-9;Cadmium:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1236;CDTA;Carbohydrate Deficient Transferrin, Adult, Serum;31714;Mono-oligo/Di-oligo Ratio;35469-6;Mono-oligosaccharide/Di-oligosaccharide:MRto:Pt:Ser/Plas:Qn:;2011-06-22;Affinity Chromatography/Mass Spectrometry (MS) 
1237;CDTA;Carbohydrate Deficient Transferrin, Adult, Serum;31715;Interpretation;59462-2;;2012-04-09;Affinity Chromatography/Mass Spectrometry (MS) 
1238;CDU;Cadmium, 24 Hour, Urine;31075;Cd Concentration;21130-0;Cadmium:MCnc:24H:Urine:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1239;CDU;Cadmium, 24 Hour, Urine;VL83;Total Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1240;CDU;Cadmium, 24 Hour, Urine;31106;Cadmium, 24 Hr, U;5612-7;Cadmium:MRat:24H:Urine:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1241;CDU;Cadmium, 24 Hour, Urine;TIME7;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1242;CEA;Carcinoembryonic Antigen (CEA), Serum;CEA;Carcinoembryonic Ag (CEA), S;2039-6;Carcinoembryonic Ag:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1243;CEAC;Cephalosporium acremonium, IgE;CEAC;Cephalosporium Acremonium, IgE;6066-5;Acremonium sp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1244;CEAPC;Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid;CEAP;CEA, Pancreatic Cyst;12515-3;Carcinoembryonic Ag:MCnc:Pt:Body fld:Qn:;2012-03-15;Immunoenzymatic Assay
1245;CEAPC;Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid;SITE6;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
1246;CEAPT;Carcinoembryonic Antigen (CEA), Peritoneal Fluid;CEAPN;CEA, Peritoneal Fluid;40622-3;Carcinoembryonic Ag:MCnc:Pt:Periton fld:Qn:;2013-12-05;Immunoenzymatic Assay
1247;CEAPT;Carcinoembryonic Antigen (CEA), Peritoneal Fluid;SITED;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
1248;CEASF;Carcinoembryonic Antigen (CEA), Spinal Fluid;CEASF;Carcinoembryonic Ag (CEA), CSF;2037-0;Carcinoembryonic Ag:MCnc:Pt:CSF:Qn:;2012-03-15;Chemiluminometric Immunoassay
1249;CEBPA;CEBPA Mutations, Gene Sequencing;MP019;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Mutation Detection in DNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1250;CED;Mountain Cedar, IgE;CED;Mountain Cedar, IgE;6178-8;Juniperus sabinoides Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1251;CEDR;Cedar, IgE;CEDR;Cedar, IgE;26049-7;Libocedrus decurrens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1252;CELI;Celiac-Associated HLA-DQ Alpha 1 and DQ Beta 1 Medium-High Resolution DNA Typing, Blood;DQB;DQ beta 1;43291-4;HLA-DQB1:ACnc:Pt:Bld:Ord:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probe (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1253;CELI;Celiac-Associated HLA-DQ Alpha 1 and DQ Beta 1 Medium-High Resolution DNA Typing, Blood;DQA;DQ alpha 1;44728-4;HLA-DQA1:ACnc:Pt:Bld:Ord:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probe (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1254;CELY;Celery, IgE;CELY;Celery, IgE;6065-7;Apium graveolens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1255;CENTA;Centromere Antibodies, Serum;11216;Anti-Centromere Antibody;16570-4;Centromere Ab:ACnc:Pt:Ser:Ord:IF;2009-11-13;Immunofluorescence Assay (IFA)
1256;CERE;Ceruloplasmin, Serum;CERE;Ceruloplasmin, S;2064-4;Ceruloplasmin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
1257;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16424;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1258;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16426;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1259;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16427;Method;49549-9; ;2013-07-26;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1260;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16430;Amendment;21654-9;CFTR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1261;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16428;Result;21654-9;CFTR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1262;CFPB;Cystic Fibrosis Mutation Analysis, 106-Mutation Panel;16429;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;The multiplex polymerase chain reaction (PCR)-based assay utilizing the Sequenom Mass ARRAY platform is used to test for mutations associated with cystic fibrosis (106-mutation panel).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1263;CFRC;Bacterial Culture, Cystic Fibrosis, Respiratory;CFRC;Bacterial Culture, Cystic Fibrosis;44798-7;Burkholderia sp identified:Prid:Pt:XXX:Nom:Organism specific culture;2013-09-17;Conventional Culture Technique
1264;CFTH;Canary Feathers, IgE;CFTH;Canary Feathers, IgE;7171-2;Canary feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1265;CFTRK;CFTR Gene, Known Mutation;27255;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR)/DNA sequencing and/or dosage analysis (multiplex ligation-dependent probe amplification: MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1266;CFTRK;CFTR Gene, Known Mutation;27257;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR)/DNA sequencing and/or dosage analysis (multiplex ligation-dependent probe amplification: MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1267;CFTRK;CFTR Gene, Known Mutation;27258;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)/DNA sequencing and/or dosage analysis (multiplex ligation-dependent probe amplification: MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1268;CFTRK;CFTR Gene, Known Mutation;27260;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR)/DNA sequencing and/or dosage analysis (multiplex ligation-dependent probe amplification: MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1269;CFTRM;CFTR Gene, Full Gene Analysis;27246;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1270;CFTRM;CFTR Gene, Full Gene Analysis;27244;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1271;CFTRM;CFTR Gene, Full Gene Analysis;27250;Amendment;21654-9;CFTR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1272;CFTRM;CFTR Gene, Full Gene Analysis;27249;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1273;CFTRM;CFTR Gene, Full Gene Analysis;27248;Result;21654-9;CFTR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1274;CFTRM;CFTR Gene, Full Gene Analysis;27247;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing/Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1275;CFX;Protein C Activity, Plasma;CFX;Protein C Activity, P;27818-4;Protein C actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-15;Amidolysis of Chromogenic Substrate
1276;CGAK;Chromogranin A, Serum;CGAK;Chromogranin A, S;9811-1;Chromogranin A:MCnc:Pt:Ser/Plas:Qn:;2013-07-10;Homogeneous Time-Resolved Fluorescence
1277;CHAG;Trypanosoma cruzi Antibody, IgG, Serum;86159;Trypanosoma cruzi Ab, IgG, S;32725-4;Trypanosoma cruzi Ab.IgG:ACnc:Pt:Ser:Ord:;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
1278;CHCK;Chicken Feathers, IgE;CHCK;Chicken Feathers, IgE;6070-7;Chicken feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1279;CHED;Pseudocholinesterase, Dibucaine Inhibition, Serum;DIB;Dibucaine Inhibition;39354-6;Cholinesterase.dibucaine inhibited/Cholinesterase:CFr:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Acetylthiocholine Substrate with Dibucaine Addition
1280;CHED;Pseudocholinesterase, Dibucaine Inhibition, Serum;PCHE;Pseudocholinesterase;2098-2;Cholinesterase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Acetylthiocholine Substrate with Dibucaine Addition
1281;CHEKK;CHEK2 Gene, Known Mutation;33989;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1282;CHEKK;CHEK2 Gene, Known Mutation;33993;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1283;CHEKK;CHEK2 Gene, Known Mutation;33990;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1284;CHEKK;CHEK2 Gene, Known Mutation;33987;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1285;CHEKS;CHEK2 Gene, Full Gene Analysis;33979;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
1286;CHEKS;CHEK2 Gene, Full Gene Analysis;33983;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
1287;CHEKS;CHEK2 Gene, Full Gene Analysis;33978;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
1288;CHEKS;CHEK2 Gene, Full Gene Analysis;33976;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
1289;CHEP;Chimerism-Recipient Engraftment (Post);MP006;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/Capillary Electrophoresis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems Inc.)
1290;CHEP;Chimerism-Recipient Engraftment (Post);19286;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/Capillary Electrophoresis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems Inc.)
1291;CHER;Cherry, IgE;CHER;Cherry, IgE;6719-9;Prunus avium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1292;CHGL;Chaetomium globosum, IgE;CHGL;Chaetomium Globosum, IgE;7200-9;Chaetomium globosum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1293;CHIC;Chicken, IgE;CHIC;Chicken, IgE;40879-9;Chicken Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1294;CHIDB;Chimerism-Donor;MP015;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/Capillary Electrophoresis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1295;CHILI;Chili Pepper, IgE;CHILI;Chili Pepper, IgE;7591-1;Capsicum frutescens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1296;CHIST;Histoplasma Antibody, Spinal Fluid;15120;Histoplasma Immunodiffusion (CSF);21330-6;Histoplasma capsulatum Ab:ACnc:Pt:CSF:Ord:Immune diffusion;2009-11-13;Complement Fixation (CF)/Immunodiffusion
1297;CHIST;Histoplasma Antibody, Spinal Fluid;15119;Histoplasma Yeast (CSF);27209-6;Histoplasma capsulatum yeast phase Ab:Titr:Pt:CSF:Qn:Comp fix;2013-09-17;Complement Fixation (CF)/Immunodiffusion
1298;CHIST;Histoplasma Antibody, Spinal Fluid;15118;Histoplasma Mycelial (CSF);27220-3;Histoplasma capsulatum mycelial phase Ab:Titr:Pt:CSF:Qn:Comp fix;2013-09-17;Complement Fixation (CF)/Immunodiffusion
1299;CHLBF;Cholesterol, BF;BFCHL;Cholesterol (BF);12183-0;Cholesterol:MCnc:Pt:Body fld:Qn:;2013-12-05;Colorimetry
1300;CHLE;Cholesteryl Esters, Serum;CHLES;Cholesteryl Esters, S;21197-9;Cholesterol esters/Cholesterol.total:MFr:Pt:Ser/Plas:Qn:;2012-03-15;Enzymatic Colorimetric
1301;CHOL;Cholesterol, Total, Serum;CHOL;Cholesterol, Total, S;2093-3;Cholesterol:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Enzymatic Colorimetric
1302;CHOU;Carbohydrate, Urine;9255;Carbohydrate, U;16550-6;Carbohydrates:Prid:Pt:Urine:Nom:;2009-11-13;Thin-Layer Chromatography (TLC), Qualitative
1303;CHRGB;Chimerism-Recipient Germline (Pre);MP014;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/Capillary Electrophoresis (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1304;CHUB;Chub Mackerel, IgE;CHUB;Chub Mackerel, IgE;10925-6;Scomber japonicus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1305;CHXP;Chick Pea, IgE;CHXP;Chick Pea, IgE;7573-9;Cicer arietinus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1306;CHYM;Chymopapain, IgE;CHYM;Chymopapain, IgE;6074-9;Chymopapain Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1307;CI;Inherited Conjugated Hyperbilirubinemias, 24 Hour, Urine;VL57;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2013-08-27;High-Performance Liquid Chromatography (HPLC)
1308;CI;Inherited Conjugated Hyperbilirubinemias, 24 Hour, Urine;30216;Interpretation (CI);59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC)
1309;CI;Inherited Conjugated Hyperbilirubinemias, 24 Hour, Urine;2394;% Copro I;9344-3;Coproporphyrin 1/Coproporphyrin.total:MRto:24H:Urine:Qn:;2013-06-27;High-Performance Liquid Chromatography (HPLC)
1310;CI;Inherited Conjugated Hyperbilirubinemias, 24 Hour, Urine;TM74;Collection Duration;30211-7;Collection duration:Time:*:XXX:Qn:;2013-06-27;High-Performance Liquid Chromatography (HPLC)
1311;CI;Inherited Conjugated Hyperbilirubinemias, 24 Hour, Urine;8652;Copro I + III;2137-8;Coproporphyrin:MRat:24H:Urine:Qn:;2013-06-27;High-Performance Liquid Chromatography (HPLC)
1312;CIFS;Cutaneous Immunofluorescence Antibodies (IgG), Serum;21540;Basement Membrane IgG;29994-1;Basement membrane Ab.IgG:ACnc:Pt:Ser:Ord:IF;2009-11-13;Detection of IgG Anti-Intercellular Substance (ICS) and Anti-Basement Membrane Zone (BMZ) Antibodies by Indirect Immunofluorescence Technique Using Rhesus Monkey Esophagus Substrate and Human NaCl Split-Skin Substrate
1313;CIFS;Cutaneous Immunofluorescence Antibodies (IgG), Serum;21541;Monkey Esophagus IgG;66881-4;Skin Ab.IgG:ACnc:Pt:Ser:Ord:Monkey esophagus substrate;2014-01-21;Detection of IgG Anti-Intercellular Substance (ICS) and Anti-Basement Membrane Zone (BMZ) Antibodies by Indirect Immunofluorescence Technique Using Rhesus Monkey Esophagus Substrate and Human NaCl Split-Skin Substrate
1314;CIFS;Cutaneous Immunofluorescence Antibodies (IgG), Serum;21542;Human Split Skin IgG;45178-1;Basement membrane zone Ab.IgG:ACnc:Pt:Ser:Ord:IF;2009-11-13;Detection of IgG Anti-Intercellular Substance (ICS) and Anti-Basement Membrane Zone (BMZ) Antibodies by Indirect Immunofluorescence Technique Using Rhesus Monkey Esophagus Substrate and Human NaCl Split-Skin Substrate
1315;CIMRP;Coccidioides immitis/posadasii, Molecular Detection, PCR;28288;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1316;CIMRP;Coccidioides immitis/posadasii, Molecular Detection, PCR;SRC64;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1317;CIMRP;Coccidioides immitis/posadasii, Molecular Detection, PCR;88804;Result;48588-8;Coccidioides sp rRNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1318;CINN;Cinnamon, IgE;CINN;Cinnamon, IgE;6837-9;Cinnamomum spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1319;CINP;Cortisol, Serum, LC-MS/MS;23607;PM Cortisol;9812-9;Cortisol^evening:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1320;CINP;Cortisol, Serum, LC-MS/MS;23606;AM Cortisol;9813-7;Cortisol^morning:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1321;CINP;Cortisol, Serum, LC-MS/MS;84279;Cortisol, S, LC-MS/MS;2143-6;Cortisol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1322;CITAL;Citalopram, Serum;83730;Citalopram, S;34635-3;Citalopram:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1323;CITR;Citrate Excretion, 24 Hour, Urine;CITC1;Citrate Concentration;21203-5;Citrate:MCnc:24H:Urine:Qn:;2012-03-15;Enzymatic
1324;CITR;Citrate Excretion, 24 Hour, Urine;VL49;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Enzymatic
1325;CITR;Citrate Excretion, 24 Hour, Urine;CITRT;Citrate Excretion, U;6687-8;Citrate:MRat:24H:Urine:Qn:;2012-03-15;Enzymatic
1326;CITR;Citrate Excretion, 24 Hour, Urine;TM51;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Enzymatic
1327;CK;Creatine Kinase (CK), Serum;CK;Creatine Kinase (CK), S;2157-6;Creatine kinase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Creatine Phosphate + ADP
1328;CKMB;Creatine Kinase (CK) MB Isoenzyme, Serum;CKMB;Creatine Kinase(CK) MB Isoenzyme, S;13969-1;Creatine kinase.MB:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay
1329;CL;Chloride, Serum;CL;Chloride, S;2075-0;Chloride:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective ElectrodeAlso available as part of an electrolyte panel.
1330;CLAD;Cladosporium, IgE;CLAD;Cladosporium, IgE;53760-5;Cladosporium sp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1331;CLAM;Clam, IgE;CLAM;Clam, IgE;6076-4;Ruditapes spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1332;CLBF;Chloride, Body Fluid;FLD22;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Indirect Ion-Selective Electrode (ISE)/Coulometric
1333;CLBF;Chloride, Body Fluid;CL_BF;Chloride, BF;2072-7;Chloride:SCnc:Pt:Body fld:Qn:;2012-03-15;Indirect Ion-Selective Electrode (ISE)/Coulometric
1334;CLLM;CLL Monitoring, MRD Detection, Blood;20436;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2011-07-07;Immunophenotyping
1335;CLLM;CLL Monitoring, MRD Detection, Blood;20435;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;Immunophenotyping
1336;CLLM;CLL Monitoring, MRD Detection, Blood;20433;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
1337;CLLM;CLL Monitoring, MRD Detection, Blood;20425;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
1338;CLLM;CLL Monitoring, MRD Detection, Blood;20426;Ref. Path Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunophenotyping
1339;CLLM;CLL Monitoring, MRD Detection, Blood;20428;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-05-21;Immunophenotyping
1340;CLONS;Clonazepam, Serum;500108;Clonazepam, S;3494-2;Clonazepam:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)
1341;CLOV;Clove, IgE;CLOV;Clove, IgE;7234-8;Syzygium aromaticum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1342;CLSF;Chloride, Spinal Fluid;CLSF;Chloride, CSF;2070-1;Chloride:SCnc:Pt:CSF:Qn:;2012-03-15;Indirect Ion-Selective Electrode (ISE)
1343;CLU;Chloride, 24 Hour, Urine;VL28;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode (ISE)
1344;CLU;Chloride, 24 Hour, Urine;CL_C1;Chloride Concentration;21194-6;Chloride:SCnc:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode (ISE)
1345;CLU;Chloride, 24 Hour, Urine;CL24H;Chloride, 24 Hr, U;2079-2;Chloride:SRat:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode (ISE)
1346;CLU;Chloride, 24 Hour, Urine;TM30;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode (ISE)
1347;CLYME;Lyme Disease Serology, Spinal Fluid;CLYME;Lyme Disease Serology, CSF;16475-6;Borrelia burgdorferi Ab:ACnc:Pt:CSF:Ord:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
1348;CLYWB;Lyme Disease Antibody, Immunoblot, Spinal Fluid;29599;IgM Band(s);23985-5;Borrelia burgdorferi Ab.IgM band pattern:Imp:Pt:CSF:Nom:IB;2011-06-22;Immunoblot
1349;CLYWB;Lyme Disease Antibody, Immunoblot, Spinal Fluid;26363;IgM Immunoblot;43573-5;Borrelia burgdorferi Ab.IgM:ACnc:Pt:CSF:Qn:IB;2014-05-19;Immunoblot
1350;CLYWB;Lyme Disease Antibody, Immunoblot, Spinal Fluid;83857;IgG Immunoblot;22126-7;Borrelia burgdorferi Ab.IgG:ACnc:Pt:CSF:Qn;2014-04-09;Immunoblot
1351;CLYWB;Lyme Disease Antibody, Immunoblot, Spinal Fluid;29598;IgG Band(s);23979-8;Borrelia burgdorferi Ab.IgG band pattern:Imp:Pt:CSF:Nom:IB;2011-06-22;Immunoblot
1352;CLZ;Clozapine, Serum;33841;Norclozapine;10992-6;Norclozapine:MCnc:Pt:Ser/Plas:Qn:;2013-08-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1353;CLZ;Clozapine, Serum;33842;Clozapine+Norclozapine Total;12375-2;Clozapine+Norclozapine:MCnc:Pt:Ser/Plas:Qn:;2013-08-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1354;CLZ;Clozapine, Serum;33840;Clozapine;6896-5;Clozapine:MCnc:Pt:Ser/Plas:Qn:;2013-08-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1355;CMA;Centromere Antibodies, IgG, Serum;CMA;Centromere Ab, IgG, S;31290-0;Centromere Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
1356;CMAC;Chromosomal Microarray, Congenital, Blood;51484;Amendment;62378-5;Chromosome copy number change:Type:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Chromosomal Microarray (CMA)
1357;CMAC;Chromosomal Microarray, Congenital, Blood;51483;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Chromosomal Microarray (CMA)
1358;CMAC;Chromosomal Microarray, Congenital, Blood;CG633;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Chromosomal Microarray (CMA)
1359;CMAC;Chromosomal Microarray, Congenital, Blood;51482;Results;62378-5;Chromosome copy number change:Type:Pt:Bld/Tiss:Nom:Molgen;2013-07-29;Chromosomal Microarray (CMA)
1360;CMAC;Chromosomal Microarray, Congenital, Blood;51481;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Chromosomal Microarray (CMA)
1361;CMAC;Chromosomal Microarray, Congenital, Blood;CG632;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Chromosomal Microarray (CMA)
1362;CMAPD;Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling;52973;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Chromosomal Microarray (CMA)
1363;CMAPD;Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling;52971;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Chromosomal Microarray (CMA)
1364;CMAPD;Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling;CG911;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Chromosomal Microarray (CMA)
1365;CMAPD;Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling;CG910;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Chromosomal Microarray (CMA)
1366;CMIL;Common Millet, IgE;CMIL;Common Millet, IgE;6175-4;Panicum milliaceum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1367;CMS;Chromosome Analysis, for Congenital Disorders, Blood;50463;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1368;CMS;Chromosome Analysis, for Congenital Disorders, Blood;16090;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1369;CMS;Chromosome Analysis, for Congenital Disorders, Blood;16091;Interpretation;69965-2;;2012-04-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1370;CMS;Chromosome Analysis, for Congenital Disorders, Blood;16092;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1371;CMS;Chromosome Analysis, for Congenital Disorders, Blood;16088;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1372;CMS;Chromosome Analysis, for Congenital Disorders, Blood;G_37;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1373;CMS;Chromosome Analysis, for Congenital Disorders, Blood;16785;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1374;CMUMP;Mumps Virus Antibodies, IgG and IgM (Separate Determinations), Spinal Fluid;1415;Mumps Virus Ab, IgM;21402-3;Mumps virus Ab.IgM:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence
1375;CMUMP;Mumps Virus Antibodies, IgG and IgM (Separate Determinations), Spinal Fluid;1414;Mumps Virus Ab, IgG;21401-5;Mumps virus Ab.IgG:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence
1376;CMVC8;Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry;28163;Interpretation;69052-9; ;2013-08-22;Flow Cytometry
1377;CMVC8;Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry;28144;Total CD8 T cells;14135-8;Cells.CD8:NCnc:Pt:Bld:Qn:;2014-07-23;Flow Cytometry
1378;CMVC8;Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry;28143;Total CD3 T cells;8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
1379;CMVQU;Cytomegalovirus DNA Detection and Quantification, Plasma;61861;CMV DNA Detect/Quant, P;72494-8;Cytomegalovirus DNA:LaCnc:Pt:Plas:Qn:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction with TaqMan Probe Hybridization (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1380;CNUT;Chestnut, Sweet, IgE;CNUT;Chestnut, Sweet, IgE;6259-6;Castanea sativa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1381;COCOA;Cacao/Cocoa, IgE;COCOA;Cacao/Cocoa, IgE;6073-1;Chocolate Ab.IgE:ACnc:Pt:Ser:Qn:;2012-10-31;Fluorescence Enzyme Immunoassay (FEIA)
1382;COCOU;Cortisol/Cortisone, Free, 24 Hour, Urine;TM93;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1383;COCOU;Cortisol/Cortisone, Free, 24 Hour, Urine;10327;Cortisone, U;14044-2;Cortisone:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1384;COCOU;Cortisol/Cortisone, Free, 24 Hour, Urine;VL47;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1385;COCOU;Cortisol/Cortisone, Free, 24 Hour, Urine;8546;Cortisol, U;14158-0;Cortisol:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1386;COCR;Cockroach, IgE;COCR;Cockroach, IgE;30170-5;Periplaneta americana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1387;COD;Codfish, IgE;COD;Codfish, IgE;6082-2;Gadus morhua Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1388;COHBB;Carbon Monoxide, Blood;8649;Carbon Monoxide, B;20563-3;Carboxyhemoglobin/Hemoglobin.total:MFr:Pt:Bld:Qn:;2009-11-13;Carboxyhemoglobin-Co-oximetry
1389;COKEM;Cocaine and Metabolites Confirmation, Meconium;31864;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1390;COKEM;Cocaine and Metabolites Confirmation, Meconium;31860;Benzoylecgonine;27026-4;Benzoylecgonine:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1391;COKEM;Cocaine and Metabolites Confirmation, Meconium;31861;Cocaethylene;26815-1;Cocaethylene:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1392;COKEM;Cocaine and Metabolites Confirmation, Meconium;31859;Cocaine;26956-3;Cocaine:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1393;COKEU;Cocaine and Metabolite Confirmation, Urine;20671;Cocaine Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
1394;COKEU;Cocaine and Metabolite Confirmation, Urine;2902;Benzoylecgonine-by GC/MS;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
1395;COKEU;Cocaine and Metabolite Confirmation, Urine;2922;Cocaine-by GC/MS;3398-5;Cocaine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
1396;COKEX;Cocaine and Metabolite Confirmation, Chain of Custody, Urine;2903;Cocaine Immunoassay Screen;3393-6; ;2014-01-21;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
1397;COM;Complement, Total, Serum;COM;Complement, Total, S;4532-8;Complement total hemolytic CH50:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Liposome Lysis Assay
1398;COR;Cortisol, Serum, LC-MS/MS;400008;PM Cortisol;9812-9;Cortisol^evening specimen:MCnc:Pt:Ser/Plas:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1399;COR;Cortisol, Serum, LC-MS/MS;400007;AM Cortisol;9813-7;Cortisol^morning specimen:MCnc:Pt:Ser/Plas:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1400;COR;Cortisol, Serum, LC-MS/MS;500052;Cortisol, S, LC-MS/MS;2143-6;Cortisol:MCnc:Pt:Ser/Plas:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1401;CORAB;Hepatitis B Core Total Antibodies, with Reflex to Hepatitis B Core Antibody, IgM, Serum;CORAB;HBc Total Ab, w/Reflex, S;16933-4;Hepatitis B virus core Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay (CIA)
1402;CORAB;Hepatitis B Core Total Antibodies, with Reflex to Hepatitis B Core Antibody, IgM, Serum;CORAB;HBc Total Ab, w/Reflex, S;16933-4;Hepatitis B virus core Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
1403;CORI;Coriander, IgE;CORI;Coriander, IgE;16650-4;Coriandrum sativum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1404;CORN;Corn-Food, IgE;CORN;Corn-Food, IgE;6087-1;Zea mays Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1405;CORT;Cortisol, Serum;CAM;AM Result;9813-7;Cortisol^morning:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1406;CORT;Cortisol, Serum;CPM;PM Result;9812-9;Cortisol^evening specimen:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1407;CORT;Cortisol, Serum;CORTP;Cortisol, S;2143-6;Cortisol:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1408;CORTC;Corticosterone, Serum;88221;Corticosterone, S;2139-4;Corticosterone:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1409;CORTU;Cortisol, Free, 24 Hour, Urine;VL47;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1410;CORTU;Cortisol, Free, 24 Hour, Urine;TM93;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1411;CORTU;Cortisol, Free, 24 Hour, Urine;8546;Cortisol, U;14158-0;Cortisol:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1412;CORU;Cobalt, Random, Urine;60354;Cobalt, Random, U;5628-3;Cobalt:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1413;COS;Cobalt, Serum;80084;Cobalt, S;5627-5;Cobalt:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1414;COTT;Cotton Fiber, IgE;COTT;Cotton Fiber, IgE;19737-6;Cotton fibers Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1415;COU;Cobalt, 24 Hour, Urine;VL64;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1416;COU;Cobalt, 24 Hour, Urine;21705;Co Conc;21208-4;Cobalt:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1417;COU;Cobalt, 24 Hour, Urine;80083;Cobalt, 24 Hr, U;29916-4;Cobalt:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1418;COU;Cobalt, 24 Hour, Urine;TM75;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
1419;COW;Cow Epithelium, IgE;COW;Cow Epithelium, IgE;7257-9;Cow epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1420;CPG;Chromosome Analysis, CpG Mitogen Study for B-Cell Disorder;CG140;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Cultures with CpG Mitogen without mitogensIncludes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.
1421;CPG;Chromosome Analysis, CpG Mitogen Study for B-Cell Disorder;50465;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Cell Cultures with CpG Mitogen without mitogensIncludes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.
1422;CPG;Chromosome Analysis, CpG Mitogen Study for B-Cell Disorder;29642;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Cell Cultures with CpG Mitogen without mitogensIncludes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.
1423;CPG;Chromosome Analysis, CpG Mitogen Study for B-Cell Disorder;CG138;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Cell Cultures with CpG Mitogen without mitogensIncludes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.
1424;CPOXK;CPOX Gene, Known Mutation;33827;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the CPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1425;CPOXK;CPOX Gene, Known Mutation;33829;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the CPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1426;CPOXK;CPOX Gene, Known Mutation;33830;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the CPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1427;CPOXK;CPOX Gene, Known Mutation;33833;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the CPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1428;CPOXS;CPOX Gene, Full Gene Analysis;33822;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1429;CPOXS;CPOX Gene, Full Gene Analysis;33818;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1430;CPOXS;CPOX Gene, Full Gene Analysis;33816;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1431;CPOXS;CPOX Gene, Full Gene Analysis;33819;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1432;CPR;C-Peptide, Serum;CRPN;C-Peptide, S;1986-9;C peptide:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
1433;CPTKM;Carnitine Palmitoyltransferase II Deficiency, Known Mutation;33606;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the CPT2 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1434;CPTKM;Carnitine Palmitoyltransferase II Deficiency, Known Mutation;33609;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the CPT2 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1435;CPTKM;Carnitine Palmitoyltransferase II Deficiency, Known Mutation;33607;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the CPT2 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1436;CPTKM;Carnitine Palmitoyltransferase II Deficiency, Known Mutation;33604;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the CPT2 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1437;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33593;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1438;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33596;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1439;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33597;Result;49678-6;CPT2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1440;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33598;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1441;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33599;Amendment;49678-6;CPT2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1442;CPTMS;Carnitine Palmitoyltransferase II Deficiency, Full Gene Analysis;33595;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
1443;CR;Chromium, Random, Urine;31078;Chromium, Random, U;5623-4;Chromium:MCnc:Pt:Urine:Qn:;2011-06-22;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectometry (DRC-ICP-MS)
1444;CRAB;Crab, IgE;CRAB;Crab, IgE;6092-1;Cancer pagurus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1445;CRANB;Cranberry, IgE;CRANB;Cranberry, IgE;7262-9;Vaccinium oxycoccos Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1446;CRAY;Crayfish, IgE;CRAY;Crayfish, IgE;7265-2;Astacus astacus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1447;CRBF;Creatinine, Body Fluid;FLD13;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Enzymatic Colorimetric Assay
1448;CRBF;Creatinine, Body Fluid;CR_BF;Creatinine, BF;12190-5;Creatinine:MCnc:Pt:Body fld:Qn:;2012-03-15;Enzymatic Colorimetric Assay
1449;CRDPU;Creatine Disorders Panel, Urine;23384;Creatinine;14683-7;Creatinine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectometry (LC-MS/MS)
1450;CRDPU;Creatine Disorders Panel, Urine;23268;Creatine/Creatinine Ratio;13484-1;Creatine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectometry (LC-MS/MS)
1451;CRDPU;Creatine Disorders Panel, Urine;23270;Creatine Disorders Panel Interp;59462-2;;2012-04-02;Liquid Chromatography-Tandem Mass Spectometry (LC-MS/MS)
1452;CRDPU;Creatine Disorders Panel, Urine;23383;Creatine;15046-6;Creatine:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectometry (LC-MS/MS)
1453;CREAZ;Creatinine with Estimated GFR (MDRD), Serum;CREAC;Creatinine, S;2160-0;Creatinine:MCnc:Pt:Ser/Plas:Qn:;2012-11-13;Enzymatic Colorimetric AssayAlso available as part of an electrolyte panel.
1454;CREAZ;Creatinine with Estimated GFR (MDRD), Serum;EGFA;eGFR-African American;48643-1;Glomerular filtration rate/1.73 sq M.predicted.black:ArVRat:Pt:Ser/Plas:Qn:Creatinine-based formula (MDRD);2012-03-15;Enzymatic Colorimetric AssayAlso available as part of an electrolyte panel.
1455;CREAZ;Creatinine with Estimated GFR (MDRD), Serum;EGFN;eGFR-Non African American;48642-3;Glomerular filtration rate/1.73 sq M.predicted.non black:VRat:Pt:Ser/Plas:Qn:Creatinine-based formula (MDRD);2012-03-15;Enzymatic Colorimetric AssayAlso available as part of an electrolyte panel.
1456;CRNP;Corn Pollen, IgE;CRNP;Corn Pollen, IgE;7248-8;Zea mays pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1457;CROT;Carrot, IgE;CROT;Carrot, IgE;6061-6;Daucus carota Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1458;CRP;C-Reactive Protein (CRP), Serum;CRP;C-Reactive Protein (CRP), S;1988-5;C reactive protein:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Latex Particle-Enhanced Immunoturbidimetric Assay
1459;CRP;C-Reactive Protein (CRP), Serum;CRP;C-Reactive Protein (CRP), S;1988-5;C reactive protein:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
1460;CRS;Chromium, Serum;8638;Chromium, S;5622-6;Chromium:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectometry (DRC-ICP-MS)
1461;CRU;Chromium, 24 Hour, Urine;VL42;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1462;CRU;Chromium, 24 Hour, Urine;45492;Chromium Concentration;21201-9;Chromium:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1463;CRU;Chromium, 24 Hour, Urine;8593;Chromium, 24 Hr, U;5624-2;Chromium:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1464;CRU;Chromium, 24 Hour, Urine;TM44;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1465;CRYE;Cultivated Rye, IgE;CRYE;Cultivated Rye, IgE;6236-4;Secale cereale pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1466;CRYPF;Cryptococcus Antigen, Pleural Fluid;60320;Cryptococcus Ag, Pleural Fluid;43228-6;Cryptococcus sp Ag:ACnc:Pt:XXX:Ord:LA;2011-06-24;Latex Agglutination
1467;CRYPS;Cryptosporidium Antigen, Feces;24086;Cryptosporidium Ag, F;6371-9;Cryptosporidium sp Ag:ACnc:Pt:Stool:Ord:EIA;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
1468;CRYPU;Cryptococcus Antigen, Urine;60319;Cryptococcus Ag, Urine;43228-6;Cryptococcus sp Ag:ACnc:Pt:XXX:Ord:LA;2011-06-24;Latex Agglutination
1469;CRY_S;Cryoglobulin, Serum;2684;Cryoglobulin, S;15174-6;Cryoglobulin/Serum.total:VFr:Pt:Ser:Qn:Spun Westergren tube;2013-09-18;CRY_S: Quantitation and Qualitative Typing Precipitation at 1 Degree C.Orderable as part of a panel or as a stand alone test. For further information see CRGSP / Cryoglobulin and Cryofibrinogen Panel, Serum and Plasma.IMFXC: Immunofixation
1470;CSED;Cottonseed, IgE;CSED;Cottonseed, IgE;6089-7;Cottonseed Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1471;CSPR;Chicken Serum Proteins, IgE;CSPR;Chicken Serum Proteins, IgE;6836-1;Chicken serum proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1472;CSRMK;Calcium Sensing Receptor (CASR) Gene, Known Mutation;34683;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Only orderable as part of a profile. For more information see CSRMK / Calcium Sensing Receptor (CASR) Gene, Known Mutation.
1473;CSRMK;Calcium Sensing Receptor (CASR) Gene, Known Mutation;34682;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Only orderable as part of a profile. For more information see CSRMK / Calcium Sensing Receptor (CASR) Gene, Known Mutation.
1474;CSRMK;Calcium Sensing Receptor (CASR) Gene, Known Mutation;34685;Interpretation;69053-7;Endocrinologist review:Imp:Pt:XXX:Nar:;2014-05-07;Only orderable as part of a profile. For more information see CSRMK / Calcium Sensing Receptor (CASR) Gene, Known Mutation.
1475;CSRSM;Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis;34676;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Only orderable as part of a profile. For more information see CSRSM / Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis.
1476;CSRSM;Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis;34677;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Only orderable as part of a profile. For more information see CSRSM / Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis.
1477;CSRSM;Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis;34679;Interpretation;69053-7;Endocrinologist review:Imp:Pt:XXX:Nar:;2014-05-07;Only orderable as part of a profile. For more information see CSRSM / Calcium Sensing Receptor (CASR) Gene, Full Gene Analysis.
1478;CSU;Chyluria Screen;CHOLU;Cholesterol;14444-4;Cholesterol:MCnc:Pt:Urine:Qn:;2012-03-15;Enzymatic Colorimetric/Electrophoresis/Spectrophotometry (SP)
1479;CSU;Chyluria Screen;CMTCS;Interpretive Comment;59462-2;;2012-04-09;Enzymatic Colorimetric/Electrophoresis/Spectrophotometry (SP)
1480;CSU;Chyluria Screen;TRIGU;Triglycerides;14450-1;Triglyceride:MCnc:Pt:Urine:Qn:;2012-03-12;Enzymatic Colorimetric/Electrophoresis/Spectrophotometry (SP)
1481;CTB;Mycobacterial Culture;CTB;Mycobacterial Culture;50941-4;Mycobacterium sp:ACnc:Pt:XXX:Ord:Organism sp culture;2014-04-09;Automated Detection of Positive Cultures Followed by Organism Identification with Rapid Methods, Which May Include Nucleic Acid Probes, DNA Sequencing, and Real-Time Polymerase Chain Reaction (PCR) When Appropriate(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1482;CTBBL;Mycobacterial Culture, Blood;CTBBL;Mycobacterial Culture, B;13956-8;Mycobacterium tuberculosis DNA:ACnc:Pt:XXX:Ord:Prob.amp.tar;2013-09-17;Continuously Monitored Automated Broth Culture Instrument with Conventional Methods for Identification of Mycobacteria
1483;CTBID;Culture Referred for Identification, Mycobacterium;CTBID;Culture Refer for ID, Mycobacterium;13956-8;Mycobacterium tuberculosis DNA:ACnc:Pt:XXX:Ord:Prob.amp.tar;2013-09-17;Nucleic Acid Probe/16S rDNA SequencingNucleic acid probes used for identification, when applicable, include those for Mycobacterium avium-intracellulare complex, Mycobacterium gordonae, and Mycobacterium tuberculosis complex. 16S rDNA sequencing is used for identification, when applicable, for slowly and rapidly growing Mycobacterium species and aerobic actinomycetes (including Nocardia species and Streptomyces species).
1484;CTCB;Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood;50641;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;CellSearch System
1485;CTCB;Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood;50639;Interpretation;59465-5;;2012-04-02;CellSearch System
1486;CTCB;Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood;50640;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;CellSearch System
1487;CTCB;Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood;50636;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;CellSearch System
1488;CTCC;Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood;50808;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;CellSearch System
1489;CTCC;Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood;50807;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;CellSearch System
1490;CTCC;Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood;50810;Interpretation;59465-5;;2012-04-02;CellSearch System
1491;CTCC;Circulating Tumor Cells (CTC) for Colorectal Cancer by CellSearch, Blood;50805;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;CellSearch System
1492;CTCP;Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood;50981;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2011-06-23;CellSearch System
1493;CTCP;Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood;50984;Interpretation;59465-5;;2012-04-02;CellSearch System
1494;CTCP;Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood;50985;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;CellSearch System
1495;CTCP;Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood;50986;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2011-06-23;CellSearch System
1496;CTCP;Circulating Tumor Cells (CTC) for Prostate Cancer by CellSearch, Blood;50983;Result;68123-9;Circulating tumor cells.prostate:NCnc:Pt:Bld:Qn:;2013-12-05;CellSearch System
1497;CTF;Colorado Tick Fever Antibody, IFA;Z0583;Colorado Tick Fever IgG Ab;16121-6;Colorado tick fever virus Ab.IgG:Titr:Pt:Ser;Qn:;2014-05-13;Immunofluorescence Assay (IFA)
1498;CTF;Colorado Tick Fever Antibody, IFA;Z0306;Colorado Tick Fever IgM Ab;16122-4;Colorado tick fever virus Ab.IgM:Titr:Pt:Ser:Qn:;2014-05-13;Immunofluorescence Assay (IFA)
1499;CTI;Chromosome Analysis, Skin Biopsy;16028;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1500;CTI;Chromosome Analysis, Skin Biopsy;16780;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1501;CTI;Chromosome Analysis, Skin Biopsy;16030;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1502;CTI;Chromosome Analysis, Skin Biopsy;16031;Interpretation;69965-2;;2012-04-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1503;CTI;Chromosome Analysis, Skin Biopsy;50475;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1504;CTI;Chromosome Analysis, Skin Biopsy;16032;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1505;CTI;Chromosome Analysis, Skin Biopsy;G_12;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1506;CTRE;Chestnut Tree, IgE;CTRE;Chestnut Tree, IgE;6069-9;Castanea sativa pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1507;CTRNA;Chlamydia trachomatis by Nucleic Acid Amplification (GEN-PROBE);SRC14;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Transcription Mediated Amplification
1508;CTRNA;Chlamydia trachomatis by Nucleic Acid Amplification (GEN-PROBE);34874;Chlamydia trachomatis amplified RNA;43304-5;Chlamydia trachomatis rRNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-04-11;Transcription Mediated Amplification
1509;CTSA;Ceramide Trihexoside/Sulfatide Accumulation in Urine Sediment, Urine;81979;Interpretive Comment;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2014-05-21;Thin-Layer Chromatography (TLC)
1510;CTU;Creatinine, 24 Hour, Urine;VL8;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Enzymatic Colorimetric Assay
1511;CTU;Creatinine, 24 Hour, Urine;NCTU_;Creatinine Conc;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Enzymatic Colorimetric Assay
1512;CTU;Creatinine, 24 Hour, Urine;TM10;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Enzymatic Colorimetric Assay
1513;CTU;Creatinine, 24 Hour, Urine;CRE_A;Creatinine, U;2162-6;Creatinine:MRat:24H:Urine:Qn:;2012-10-31;Enzymatic Colorimetric Assay
1514;CTWD;Cottonwood, IgE;CTWD;Cottonwood, IgE;6090-5;Populus deltoides Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1515;CTX;Beta-CrossLaps (Beta-CTx), Serum;CTX;Beta-CrossLaps (B-CTx), S;41171-0;Collagen crosslinked C-telopeptide:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
1516;CUKE;Cucumber, IgE;CUKE;Cucumber, IgE;6724-9;Cucumis sativus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1517;CURL;Curvularia lunata, IgE;CURL;Curvularia Lunata, IgE;6094-7;Curvularia lunata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1518;CURR;Curry, IgE;CURR;Curry, IgE;7270-2;Curry Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1519;CURU;Copper, Random, Urine;60426;Copper, Random, U;5632-5;Copper:MCnc:Pt:Urine:Qn:;2011-06-24;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1520;CUS;Copper, Serum;8612;Copper, S;5631-7;Copper:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1521;CUT;Copper, Liver Tissue;8687;Copper, Liver Ts;8198-4;Copper:MCnt:Pt:Tiss:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1522;CUU;Copper, 24 Hour, Urine;TM7;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1523;CUU;Copper, 24 Hour, Urine;8590;Copper, 24 Hr, U;5633-3;Copper:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1524;CUU;Copper, 24 Hour, Urine;855;Cu Concentration;21219-1;Copper:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1525;CUU;Copper, 24 Hour, Urine;VL4;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
1526;CVID;Common Variable Immunodeficiency Confirmation Flow Panel;28124;Interpretation;69052-9;;2012-04-09;Fluorescent Flow Cytometry
1527;CVS;Chromosome Analysis, Chorionic Villus Sampling;16151;Interpretation;69965-2;;2012-04-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1528;CVS;Chromosome Analysis, Chorionic Villus Sampling;16150;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1529;CVS;Chromosome Analysis, Chorionic Villus Sampling;16152;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1530;CVS;Chromosome Analysis, Chorionic Villus Sampling;16148;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-07-29;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1531;CVS;Chromosome Analysis, Chorionic Villus Sampling;50465;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1532;CVS;Chromosome Analysis, Chorionic Villus Sampling;G_737;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1533;CVS;Chromosome Analysis, Chorionic Villus Sampling;16790;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
1534;CWAY;Caraway, IgE;CWAY;Caraway, IgE;7178-7;Carum carvi Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1535;CYAN;Cyanide, Blood;8691;Cyanide, B;5634-1;Cyanide:MCnc:Pt:Bld:Qn:;2009-11-13;Colorimetric
1536;CYCL;Cyclospora Stain;CYCL;Cyclospora Stain;50313-6;Cyclospora sp identified:Prid:Pr:Stool:Nom:Safranin stain;2013-09-17;Safranin Stain of Stool
1537;CYCMS;21-Hydroxylase Gene (CYP21A2), Full Gene Analysis, Prenatal;35014;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing and Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1538;CYCMS;21-Hydroxylase Gene (CYP21A2), Full Gene Analysis, Prenatal;35015;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing and Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1539;CYSPR;Cyclosporine, Blood;35143;Cyclosporine, B;3520-4;Cyclosporine:MCnc:Pt:Bld:Qn:;2013-12-05;High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS)
1540;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;50441;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1541;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;3591;Arginine;25322-9;Arginine:SRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1542;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;VL36;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1543;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;3590;Ornithine;25491-2;Ornithine:SRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1544;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;TM38;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1545;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;50444;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1546;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;3589;Lysine;25464-9;Lysine:SRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1547;CYSQN;Cystinuria Profile, Quantitative, 24 Hour, Urine;3583;Cystine;13966-7;Cystine:SRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1548;CYSR;Cystinuria Profile, Quantitative, Random, Urine;23515;Lysine;13769-5;Lysine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1549;CYSR;Cystinuria Profile, Quantitative, Random, Urine;23514;Cystine;13725-7;Cystine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1550;CYSR;Cystinuria Profile, Quantitative, Random, Urine;23517;Arginine;13708-3;Arginine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1551;CYSR;Cystinuria Profile, Quantitative, Random, Urine;23516;Ornithine;13786-9;Ornithine/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1552;CYSTC;Cystatin C with Estimated GFR, Serum;EGFRC;eGFR by Cystatin C;50210-4;Glomerular filtration rate/1.73 sq M.predicted:ArVRat:Pt:Ser/Plas:Qn:Cystatin-based formula;2013-12-05;Immunoturbidimetric
1553;CYSTC;Cystatin C with Estimated GFR, Serum;CYSC;Cystatin C, S;33863-2;Cystatin C:MCnc:Pt:Ser/Plas:Qn:;2013-12-05;Immunoturbidimetric
1554;CYSWB;Cysticercosis, IgG Antibody, Western Blot Assay, Serum;81354;Cysticercosis, IgG Ab, West Blot, S;6374-3;Taenia solium larva Ab.IgG band pattern:ACnc:Pt:Ser:Ord:IB;2013-09-17;Western Blot Assay
1555;DAAMP;Drug of Abuse, Amphetamine Screen with GC-MS Confirmation, Urine;11164;Amphetamines;8150-5;Amphetamines:MCnc:Pt:Urine:Qn:;2009-11-13;DAAMP: Enzyme-Multiplied Immunoassay Technique (EMIT)DAUAM: Gas Chromatography-Mass Spectrometry (GC-MS)
1556;DABAR;Drug of Abuse, Barbiturate Screen with GC-MS Confirmation, Urine;11301;Barbiturates;9426-8;Barbiturates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1557;DABZO;Drug of Abuse, Benzodiazepine Screen with GC-MS Confirmation, Urine;11572;Benzodiazepines;9428-4;Benzodiazepines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1558;DAGL;Gliadin (Deamidated) Antibody, IgA, Serum;DAGL;Gliadin(Deamidated) Ab, IgA, S;20495-8;Gliadin Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
1559;DAND;Dandelion, IgE;DAND;Dandelion, IgE;6097-0;Taraxacum vulgare Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1560;DASM4;Drugs of Abuse Screen, Meconium 4;32080;Methamphetamine;27289-8;Methamphetamine:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1561;DASM4;Drugs of Abuse Screen, Meconium 4;32082;Cocaine;26956-3;Cocaine:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1562;DASM4;Drugs of Abuse Screen, Meconium 4;32084;Opiate;26744-3;Opiates:MCnt:Pt:Meconium:Qn:Screen;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1563;DASM4;Drugs of Abuse Screen, Meconium 4;32078;Amphetamine;26895-3;Amphetamines:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1564;DASM5;Drugs of Abuse Screen, Meconium 5;32199;Methamphetamine;27289-8;Methamphetamine:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1565;DASM5;Drugs of Abuse Screen, Meconium 5;32197;Amphetamine;26895-3;Amphetamines:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1566;DASM5;Drugs of Abuse Screen, Meconium 5;32201;Cocaine;26956-3;Cocaine:MCnt:Pt:Meconium:Qn:;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1567;DASM5;Drugs of Abuse Screen, Meconium 5;32203;Opiate;26744-3;Opiates:MCnt:Pt:Meconium:Qn:Screen;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1568;DASM5;Drugs of Abuse Screen, Meconium 5;32205;Phencyclidine;26829-2;Phencyclidine:MCnt:Pt:Meconium:Qn:Screen;2011-06-22;Enzyme-Linked Immunosorbent Assay (ELISA)
1569;DATE;Date, Fruit, IgE;DATE;Date, Fruit, IgE;7275-1;Phoenix canariensis pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1570;DATRE;Date, Tree, IgE;DATRE;Date, Tree, IgE;31002-9;Phoenix dactylifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1571;DAU;Drug of Abuse Screen, DAU10, Urine;11570;Opiates;8220-6;Opiates:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1572;DAU;Drug of Abuse Screen, DAU10, Urine;11165;Methadone;3774-7;Methadone:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1573;DAU;Drug of Abuse Screen, DAU10, Urine;11573;Phencyclidine;3937-0;Phencyclidine:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1574;DAU;Drug of Abuse Screen, DAU10, Urine;501206;Ethanol;5645-7;Ethanol:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1575;DAU;Drug of Abuse Screen, DAU10, Urine;200209;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-05-22;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1576;DAU;Drug of Abuse Screen, DAU10, Urine;11161;Cocaine Metabolite;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1577;DAU;Drug of Abuse Screen, DAU10, Urine;11572;Benzodiazepines;9428-4;Benzodiazepines:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1578;DAU;Drug of Abuse Screen, DAU10, Urine;11301;Barbiturates;9426-8;Barbiturates:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1579;DAU;Drug of Abuse Screen, DAU10, Urine;11162;Tetrahydrocannabinols;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1580;DAU;Drug of Abuse Screen, DAU10, Urine;11164;Amphetamines;8150-5;Amphetamines:MCnc:Pt:Urine:Qn:;2009-11-13;Ethanol, DAU9: Enzyme-Multiplied Immunoassay Technique (EMIT)
1581;DAU7;Drugs of Abuse Screen, DAU7, Urine;11570;Opiates;8220-6;Opiates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1582;DAU7;Drugs of Abuse Screen, DAU7, Urine;11573;Phencyclidine;3937-0;Phencyclidine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1583;DAU7;Drugs of Abuse Screen, DAU7, Urine;11572;Benzodiazepines;9428-4;Benzodiazepines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1584;DAU7;Drugs of Abuse Screen, DAU7, Urine;11161;Cocaine Metabolite;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1585;DAU7;Drugs of Abuse Screen, DAU7, Urine;200209;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-05-22;Enzyme-Multiplied Immunoassay Technique (EMIT)
1586;DAU7;Drugs of Abuse Screen, DAU7, Urine;11301;Barbiturates;9426-8;Barbiturates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1587;DAU7;Drugs of Abuse Screen, DAU7, Urine;11162;Tetrahydrocannabinols;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1588;DAU7;Drugs of Abuse Screen, DAU7, Urine;11164;Amphetamines;8150-5;Amphetamines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1589;DAU8;Drugs of Abuse Screen, DAU8, Urine;11572;Benzodiazepines;9428-4;Benzodiazepines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1590;DAU8;Drugs of Abuse Screen, DAU8, Urine;11164;Amphetamines;8150-5;Amphetamines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1591;DAU8;Drugs of Abuse Screen, DAU8, Urine;11570;Opiates;8220-6;Opiates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1592;DAU8;Drugs of Abuse Screen, DAU8, Urine;200209;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-05-22;Enzyme-Multiplied Immunoassay Technique (EMIT)
1593;DAU8;Drugs of Abuse Screen, DAU8, Urine;11162;Tetrahydrocannabinols;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1594;DAU8;Drugs of Abuse Screen, DAU8, Urine;11161;Cocaine Metabolite;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1595;DAU8;Drugs of Abuse Screen, DAU8, Urine;501206;Ethanol;5645-7;Ethanol:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1596;DAU8;Drugs of Abuse Screen, DAU8, Urine;11573;Phencyclidine;3937-0;Phencyclidine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1597;DAU8;Drugs of Abuse Screen, DAU8, Urine;11301;Barbiturates;9426-8;Barbiturates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1598;DAU9;Drugs of Abuse Screen, DAU9, Urine;11164;Amphetamines;8150-5;Amphetamines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1599;DAU9;Drugs of Abuse Screen, DAU9, Urine;11301;Barbiturates;9426-8;Barbiturates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1600;DAU9;Drugs of Abuse Screen, DAU9, Urine;11572;Benzodiazepines;9428-4;Benzodiazepines:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1601;DAU9;Drugs of Abuse Screen, DAU9, Urine;11165;Methadone;3774-7;Methadone:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1602;DAU9;Drugs of Abuse Screen, DAU9, Urine;200209;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-05-22;Enzyme-Multiplied Immunoassay Technique (EMIT)
1603;DAU9;Drugs of Abuse Screen, DAU9, Urine;11161;Cocaine Metabolite;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1604;DAU9;Drugs of Abuse Screen, DAU9, Urine;11162;Tetrahydrocannabinols;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1605;DAU9;Drugs of Abuse Screen, DAU9, Urine;11570;Opiates;8220-6;Opiates:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1606;DAU9;Drugs of Abuse Screen, DAU9, Urine;11573;Phencyclidine;3937-0;Phencyclidine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1607;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501214;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
1608;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501213;Phenylpropanolamine;17443-3;Phenylpropanolamine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1609;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501212;Pseudoephedrine/Ephedrine;26785-6;Ephedrine+Pseudoephedrine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1610;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501211;Phentermine;20557-5;Phentermine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1611;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501210;MDA (Ecstasy Metabolite);27409-2;Methylenedianiline:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1612;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;500197;MDMA (Ecstasy);18358-2;Methylenedioxymethamphetamine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1613;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501209;Methamphetamine;16235-4;Methamphetamine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1614;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501208;Amphetamine;16234-7;Amphetamine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1615;DAUAM;Drug of Abuse, Amphetamines GC-MS Confirmation, Urine;501207;GC/MS Confirmation - Amphetamine;16234-7;Amphetamine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1616;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501225;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
1617;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501224;Alpha-OH-Triazolam;49876-6;Alpha hydroxytriazolam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1618;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501223;Alpha OH-Alprazolam;16348-5;Alpha hydroxyalprazolam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1619;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501222;7-NH-Flunitrazepam;51777-1;7-Aminoflunitrazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1620;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501221;7-NH-Clonazepam;51776-3;7-Aminoclonazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1621;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501220;OH-Ethyl-Flurazepam;20532-8;Hydroxyethylflurazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1622;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501219;Temazepam;20559-1;Temazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1623;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501218;Oxazepam;16201-6;Oxazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1624;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501215;GC/MS Confirmation - Benzodiazepine;20412-3;Benzodiazepines:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1625;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501216;Lorazepam;17088-6;Lorazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1626;DAUBZ;Drug of Abuse, Benzodiazepines GC-MS Confirmation, Urine;501217;Nordiazepam;16228-9;Nordiazepam:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
1627;DAUCO;Drug of Abuse, Cocaine Screen with GC-MS Confirmation, Urine;11161;Cocaine Metabolite;3394-4;Benzoylecgonine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1628;DCP;Des-Gamma-Carboxy Prothrombin (DCP), Serum;DCP;Des-Gamma-Carboxy Prothrombin, S;34444-0;Acarboxyprothrombin:MCnc:Pt:Ser/Plas:Qn:;2013-08-07;Isotachophoresis with Laser-Induced Fluorescence
1629;DCRN;11-Deoxycorticosterone, Serum;31964;11-Deoxycorticosterone, S;1656-8;11-Deoxycorticosterone:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1630;DCTM;Direct Coombs, Blood;DCTM;Direct Coombs, B;1007-4;Direct antiglobulin test.poly specific reagent:ACnc:Pt:RBC:Ord:;2012-03-15;Direct Antiglobulin TestStandard AABB.
1631;DDI;D-Dimer, Plasma;DDIRC;Fibrinogen Equivalent Units (FEU);48065-7;Fibrin D-dimer FEU:MCnc:Pt:PPP:Qn:;2012-04-09;Immunoassay Turbidimetric
1632;DEEP;Deer Epithelium, IgE;DEEP;Deer Epithelium, IgE;10926-4;Deer epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1633;DESIP;Desipramine, Serum;81854;Desipramine, S;3531-1;Desipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
1634;DF;House Dust Mites/Dermatophagoides farinae, IgE;DF;House Dust Mites/D.F., IgE;6095-4;Dermatophagoides farinae Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1635;DFIR;Douglas Fir, IgE;DFIR;Douglas Fir, IgE;7310-6;Pseudotsuga taxifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1636;DGGL;Gliadin (Deamidated) Antibody, IgG, Serum;DGGL;Gliadin(Deamidated) Ab, IgG, S;63459-2;Gliadin peptide Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
1637;DHEA_;Dehydroepiandrosterone (DHEA), Serum;81405;Dehydroepiandrosterone, S;2193-1;Dehydroepiandrosterone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1638;DHES;Dehydroepiandrosterone Sulfate (DHEA-S), Serum;DHES;Dehydroepiandrosterone Sulfate, S;2191-5;Dehydroepiandrosterone sulfate:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Chemiluminescent Immunometric Assay
1639;DHTS;Dihydrotestosterone, Serum;81479;Dihydrotestosterone, S;1848-1;Androstanolone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1640;DIA;Diazepam and Nordiazepam, Serum;2459;Diazepam and Nordiazepam;16757-7;Diazepam+Nordiazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)   (Separate determinations are performed.)
1641;DIA;Diazepam and Nordiazepam, Serum;2475;Nordiazepam;3537-8;Nordiazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)   (Separate determinations are performed.)
1642;DIA;Diazepam and Nordiazepam, Serum;8629;Diazepam, S;3548-5;Diazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)   (Separate determinations are performed.)
1643;DIA;Diazepam and Nordiazepam, Serum;2459;Diazepam and Nordiazepam;16757-7;Diazepam+Nordiazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)(Separate determinations are performed.)
1644;DIA;Diazepam and Nordiazepam, Serum;8629;Diazepam, S;3548-5;Diazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)(Separate determinations are performed.)
1645;DIA;Diazepam and Nordiazepam, Serum;2475;Nordiazepam;3537-8;Nordiazepam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)(Separate determinations are performed.)
1646;DIG;Digoxin, Serum;DIG;Digoxin, S;10535-3;Digoxin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay
1647;DILL;Dill, IgE;DILL;Dill, IgE;7280-1;Anethum graveolens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1648;DIP;Diphtheria Toxoid IgG Antibody Assay, Serum;DIP;Diphtheria Toxoid IgG Ab, S;48654-8;Corynebacterium diphtheriae toxin Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme Immunoassay (EIA)
1649;DIS2;HLA Class II Molecular Typing Disease Association;DQ;DQ Locus Serology;34143-8;HLA-DQ Ag.locus 2:Type:Pt:WBC:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1650;DIS2;HLA Class II Molecular Typing Disease Association;DR;DR Locus Serology;21341-3;HLA-DR Ag.locus:Type:Pt:WBC:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1651;DIS2;HLA Class II Molecular Typing Disease Association;DR1;DRB1 Locus Molecular;21341-3;HLA-DR Ag.locus:Type:Pt:WBC:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1652;DIS2;HLA Class II Molecular Typing Disease Association;DRB3M;DRB3 Locus Molecular;59022-4;HLA-DRB3:Type:Pt:Bld:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1653;DIS2;HLA Class II Molecular Typing Disease Association;DP3;DPB1 Locus Molecular;59017-4;HLA-DPB1:Type:Pt:Bld:Nom:High resolution;2013-08-07;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1654;DIS2;HLA Class II Molecular Typing Disease Association;DQ2;DQA1 Locus Molecular;44728-4;HLA-DQA1:ACnc:Pt:Bld:Ord:;2013-08-07;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1655;DIS2;HLA Class II Molecular Typing Disease Association;DP2;DPA1 Locus Molecular;59018-2;HLA-DPA1:Type:Pt:Bld:Nom:High resolution;2013-08-07;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1656;DIS2;HLA Class II Molecular Typing Disease Association;DRB5M;DRB5 Locus Molecular;59020-8;HLA-DRB5:Type:Pt:Bld:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1657;DIS2;HLA Class II Molecular Typing Disease Association;DQ1;DQB1 Locus Molecular;13305-8;HLA-DQ:Type:Pt:Bld:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1658;DIS2;HLA Class II Molecular Typing Disease Association;DRB4M;DRB4 Locus Molecular;59021-6;HLA-DRB4:Type:Pt:Bld:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1659;DISI;HLA Class I Molecular Typing Disease Association;BW1;Bw Locus Serology;38549-2;HLA-B W locus:Type:Pt:Bld:Nom:;2013-04-11;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1660;DISI;HLA Class I Molecular Typing Disease Association;CLOC3;C Locus Molecular;38547-6;HLA-C locus:Type:Pt:Bld:Nom:;2013-04-11;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1661;DISI;HLA Class I Molecular Typing Disease Association;CLOC1;Cw Locus Serology;38547-6;HLA-C Ag.locus:Type:Pt:WBC:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1662;DISI;HLA Class I Molecular Typing Disease Association;BLOC3;B Locus Molecular;38546-8;HLA-B Ag.locus:Type:Pt:WBC:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1663;DISI;HLA Class I Molecular Typing Disease Association;ALOC3;A Locus Molecular;38548-4;HLA-A locus:Type:Pt:Bld:Nom:;2013-04-11;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1664;DISI;HLA Class I Molecular Typing Disease Association;BLOC1;B Locus Serology;38546-8;HLA-B locus:Type:Pt:Bld:Nom:;2013-04-11;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1665;DISI;HLA Class I Molecular Typing Disease Association;ALOC1;A Locus Serology;38548-4;HLA-A locus:Type:Pt:Bld:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1666;DLAC;D-Lactate, Plasma;8878;D-Lactate, P;14045-9;D-lactate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzymatic
1667;DLAU;D-Lactate, Urine;8873;D-Lactate, U;14046-7;D-lactate:SCnc:Pt:Urine:Qn:;2009-11-13;Enzymatic
1668;DLDL;Direct LDL, Serum;DLDL;Direct LDL, S;18262-6;Cholesterol.in LDL:MCnc:Pt:Ser/Plas:Qn:Direct assay;2012-03-15;Enzymatic Colorimetric
1669;DMETH;Drug of Abuse, Methadone Screen with GC-MS Confirmation, Urine;11165;Methadone;3774-7;Methadone:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1670;DMIC;Dermatophagoides microceras, IgE;DMIC;D. Microceras, IgE;14036-8;Dermatophagoides microceras Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1671;DOC;11-Deoxycortisol, Serum;8547;11-Deoxycortisol, S;1657-6;11-Deoxycortisol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1672;DOGD;Dog Dander, IgE;DOGD;Dog Dander, IgE;6098-8;Dog dander Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1673;DOXA;Oxalate Analysis in Hemodialysate;DOXA;Oxalate, Dialysate Fluid;47715-8;Oxalate:SCnc:Pt:Dial fld:Qn:;2013-04-11;Enzymatic Oxalate Oxidase
1674;DOXP;Doxepin and Nordoxepin, Serum;2470;Doxepin and Nordoxepin;3582-4;Doxepin+Nordoxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
1675;DOXP;Doxepin and Nordoxepin, Serum;9301;Doxepin;3579-0;Doxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
1676;DOXP;Doxepin and Nordoxepin, Serum;2464;Nordoxepin;3862-0;Nordoxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
1677;DP;House Dust Mites/Dermatophagoides pteronyssinus, IgE;DP;House Dust Mites/D.P., IgE;6096-2;Dermatophagoides pteronyssinus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1678;DPCP;Drug of Abuse, Phencyclidine Screen With GC-MS Confirmation, Urine;11573;Phencyclidine;3937-0;Phencyclidine:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1679;DRD4;Dopamine Receptor D4 Genotype (DRD4), Blood;29115;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by Sizing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1680;DRD4O;Dopamine Receptor D4 Genotype (DRD4), Saliva;32984;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-09;Polymerase Chain Reaction (PCR) Followed by Sizing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1681;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16893;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1682;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16896;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1683;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16897;Amendment;21756-2;ATN1 gene.CAG repeats:Arb:Pt:Bld/Tiss:Ord:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1684;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16894;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1685;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16895;Result;21756-2;ATN1 gene.CAG repeats:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1686;DRPLA;Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis;16891;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1687;DSG13;Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3), Serum;24027;DSG 3;43312-8;Desmoglein 3 Ab:ACnc:Pt:Ser:Qn:;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
1688;DSG13;Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3), Serum;83680;DSG 1;43311-0;Desmoglein 1 Ab:ACnc:Pt:Ser:Qn:;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
1689;DSP;Disopyramide, Serum;8220;Disopyramide, S;3576-6;Disopyramide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
1690;DSS;Drug Screen, Prescription/OTC, Serum;31072;Drugs detected:;20785-2;Drugs identified:Prid:Pt:Ser/Plas:Nom:Screen;2011-06-22;Gas Chromatography-Mass Spectrometry (GC-MS)
1691;DTHC;Drug of Abuse, Tetrahydrocannabinol Screen with GC-MS Confirmation, Urine;11162;Tetrahydrocannabinols;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1692;DUCK;Duck Feathers, IgE;DUCK;Duck Feathers, IgE;6100-2;Duck feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1693;DULOX;Duloxetine, Serum;89305;Duloxetine, S;46227-5;Duloxetine:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
1694;DUP15;15q11.2 Duplication, FISH;30138;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1695;DUP15;15q11.2 Duplication, FISH;30136;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
1696;DUP15;15q11.2 Duplication, FISH;G_481;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1697;DUP15;15q11.2 Duplication, FISH;G_478;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1698;E1;Estrone, Serum;81418;Estrone, S;2258-2;Estrone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1699;EAG;Hepatitis Be Antigen, Serum;EAG;Hepatitis Be Ag, S;13954-3;Hepatitis B virus little e Ag:ACnc:Pt:Ser:Ord:EIA;2013-09-17;Chemiluminescence Immunoassay (CIA)
1700;EBVB;Epstein-Barr Virus (EBV), Molecular Detection, PCR, Blood;56096;Result;5002-1;Epstein Barr virus DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1701;EBVE;Epstein-Barr Virus (EBV), IgG Antibody to Early Antigen, Serum;EBVE;EBV EA IgG Ab, S;22295-0;Epstein Barr virus early Ab.IgG:ACnc:Pt:Ser:Ord:;2012-03-15;Multiplex Flow Immunoassay
1702;ECHO;Echovirus Antibody Panel, CF (Serum);Z0320;Echovirus 30 Ab;6392-5;Echovirus 30 Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1703;ECHO;Echovirus Antibody Panel, CF (Serum);Z0319;Echovirus 11 Ab;6708-2;Echovirus 11 Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1704;ECHO;Echovirus Antibody Panel, CF (Serum);Z0573;Echovirus 4 Ab;5143-3;Echovirus 4 Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1705;ECHO;Echovirus Antibody Panel, CF (Serum);Z0312;Echovirus 7 Ab;6922-9;Echovirus 7 Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1706;ECHO;Echovirus Antibody Panel, CF (Serum);Z0318;Echovirus 9 Ab;5147-4;Echovirus 9 Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1707;EEEP;Eastern Equine Encephalitis Antibody, IgG and IgM, Serum;83355;East Equine Enceph Ab, IgM, S;10898-5;Eastern equine encephalitis virus Ab.IgM3/25/2014Titr:Pt:Ser:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
1708;EEEP;Eastern Equine Encephalitis Antibody, IgG and IgM, Serum;83354;East Equine Enceph Ab, IgG, S;10896-9;Eastern equine encephalitis virus Ab.IgG:Titr:Pt:Ser:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
1709;EEPC;Eastern Equine Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26369;East Equine Enceph Ab, IgG, CSF;10897-7;Eastern equine encephalitis virus Ab.IgG:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
1710;EEPC;Eastern Equine Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26370;East Equine Enceph Ab, IgM, CSF;10899-3;Eastern equine encephalitis virus Ab.IgM:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
1711;EEST;Estradiol, Serum;81816;Estradiol, S;2243-4;Estradiol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1712;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33313;Amendment;21665-5;EGFR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1713;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33312;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-09;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1714;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33307;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-20;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1715;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33309;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1716;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33310;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1717;EGFR;EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor;33311;Result;21665-5;EGFR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1718;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51464;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1719;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51469;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1720;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51467;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1721;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51466;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1722;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51470;Amendment;21665-5;EGFR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-08-23;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1723;EGFRX;Lung Cancer, EGFR with ALK Reflex, Tumor;51468;Result;21665-5;EGFR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-08-23;Polymerase Chain Reaction (PCR) and Fluorescence In Situ Hybridization (FISH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1724;EGG;Egg White, IgE;EGG;Egg White, IgE;6106-9;Egg white Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1725;EGGP;Eggplant, IgE;EGGP;Eggplant, IgE;7296-7;Solanum melongena Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1726;EGPL;English Plantain, IgE;EGPL;English Plantain, IgE;6110-1;Plantago lanceolata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1727;EHOR;European Hornet, IgE;EHOR;European Hornet, IgE;15342-9;Vespa crabro Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1728;EHRC;Ehrlichia chaffeensis (HME) Antibody, IgG, Serum;81478;Ehrlichia Chaffeensis (HME) Ab, IgG;47405-6;Ehrlichia chaffeensis Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
1729;EHRL;Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood;32010;Ehrlichia muris-like;48866-8;Ehrlichia sp DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-12-05;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1730;EHRL;Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood;23663;Ehrlichia chaffeensis;27994-3;Ehrlichia chaffeensis DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1731;EHRL;Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood;23664;Ehrlichia ewingii/canis;48866-8;Ehrlichia sp DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1732;EHRL;Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood;84319;Anaplasma phagocytophilum;30039-2;Anaplasma phagocytophilum DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1733;ELDR;Elder, IgE;ELDR;Elder, IgE;6108-5;Sambucus nigra Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1734;ELM;Elm, IgE;ELM;Elm, IgE;6109-3;Ulmus americana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1735;EMA;Endomysial Antibodies (IgA), Serum;9360;Endomysial Ab;27038-9;Endomysium Ab.IgA:Titr:Pt:Ser:Qn:IF;2014-02-26;Staining of Rhesus Monkey Esophagus Substrate by Indirect Immunofluorescence Assay (IFA) for IgA Endomysial Antibodies (EMA)
1736;EMAY;Euroglyphus maynei, IgE;EMAY;Euroglyphus Maynei, IgE;6114-3;Euroglyphus maynei Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1737;ENTP;Enterovirus, Molecular Detection, PCR, Plasma;56068;Enterovirus PCR, P;29591-5;Enterovirus RNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-09-17;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1738;EOSU;Eosinophils, Urine;EOSU;Eosinophils, U;32014-3;Eosinophils/100 leukocytes:NFr:Pt:Urine:Qn:Manual count;2012-03-15;Hansel Stain
1739;EOXD;Ethylene Oxide, IgE;EOXD;Ethylene Oxide, IgE;6112-7;Ethylene oxide Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1740;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;34987;Shiga Toxin PCR;53947-8;Escherichia coli shiga-like toxin (stx1+stx2)+H7 flagellar (fliC) genes:Prid:Pt:XXX:Nom:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1741;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;34984;Salmonella PCR;49612-5;Salmonella sp DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1742;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;34985;Shigella PCR;46455-2;Shigella sp DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1743;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;34986;Yersinia PCR;48646-4;Yersinia sp DNA:Prid:Pt:XXX:Nom:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1744;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;34983;Campylobacter jejuni/coli PCR;71429-5;Campylobacter sp DNA.diarrheagenic:Pr:Pt:Stool:Ord:Probe.amp.tar;2014-08-20;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1745;EPFRP;Bacterial Enteric Pathogens, Molecular Detection, PCR, Feces;SRC61;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1746;EPIP1;Epithelia Panel # 1;EPIP1;Epithelia Panel # 1;30185-3;(Cat dander+Cow dander+Dog dander+Horse dander) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1747;EPO;Erythropoietin (EPO), Serum;EPO;Erythropoietin (EPO), S;15061-5;Erythropoietin:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay (ICMA)
1748;EPO;Erythropoietin (EPO), Serum;EPO;Erythropoietin (EPO), S;15061-5;Erythropoietin:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
1749;EPUR;Epicoccum purpurascens, IgE;EPUR;Epicoccum Purpurascens, IgE;6111-9;Epicoccum purpurascens Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1750;ESYC;Eastern Sycamore, IgE;ESYC;Eastern Sycamore, IgE;6263-8;Platanus occidentalis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1751;ETGL;Ethylene Glycol, Serum;8749;Ethylene Glycol, S;14721-5;Ethylene glycol:SCnc:Pt:Ser/Plas:Qn:;2014-04-15;Gas-Liquid Chromatography (GLC)
1752;ETGL;Ethylene Glycol, Serum;8749;Ethylene Glycol, S;14721-5;Ethylene glycol:SCnc:Pt:Ser/Plas:Qn:;2014-04-15;Gas Chromatography-Flame Ionization Detection (GC-FID)
1753;ETOHB;Ethanol, Blood;11811;Ethanol, B;5640-8;Ethanol:MCnc:Pt:Bld:Qn:;2009-11-13;Gas-Liquid Chromatography (GLC)
1754;ETOHS;Ethanol, Serum;11511;Ethanol, S;5643-2;Ethanol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas-Liquid Chromatography (GLC)
1755;ETOHU;Ethanol, Urine;11137;Ethanol, U;5645-7;Ethanol:MCnc:Pt:Urine:Qn:;2009-11-13;Gas-Liquid Chromatography (GLC)
1756;ETX;Ethosuximide, Serum;8769;Ethosuximide, S;3616-0;Ethosuximide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
1757;EUCL;Eucalyptus, IgE;EUCL;Eucalyptus, IgE;6113-5;Eucalyptus spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1758;EVROL;Everolimus, Blood;35146;Everolimus, B;50544-6;Everolimus:MCnc:Pt:Bld:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
1759;F17HP;17-Hydroxy Progesterone, Urine;Z0931;17-Hydroxy Progesterone, U;9616-4;;2012-03-12;Radioimmunoassay (RIA)
1760;F3AAG;Androstanediol Glucuronide;Z2250;Androstanediol Glucuronide;1680-8;3-Alpha-Androstanediol glucuronide:MCnc:Pt:Ser:Qn:;2012-03-12;High Pressure Liquid Chromatography and Tandem Mass Spectrometry (HPLC/MS-MS)
1761;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;22901;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1762;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;CG020;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1763;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;22902;Amendment;21816-4;t(5,12)(PDGFRB,ETV6) gene translocation:Arb:Pt:Bld/Tiss:Ord:Molgen;2013-07-30;Fluorescence In Situ Hybridization (FISH)
1764;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;22900;Result;21816-4;t(5,12)(PDGFRB,ETV6) gene translocation:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
1765;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;22899;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1766;F512;PDGFRB/TEL Translocation (5;12) for Chronic Myelomonocytic Leukemia, FISH;CG022;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1767;F5DNA;Factor V Leiden (R506Q) Mutation, Blood;21838;Factor V Leiden (R506Q) Mutation, B;21667-1;F5 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Direct Mutation Analysis
1768;F5DNA;Factor V Leiden (R506Q) Mutation, Blood;21839;F5DNA Interpretation;69049-5;;2012-04-05;Direct Mutation Analysis
1769;F5HAR;5-HIAA (5-Hydroxyindoleacetic Acid), Random Urine;Z2672;5-HIAA;11145-0;5-Hydroxyindoleacetate/Creatinine:MRto:Pt:Urine:Qn;2014-04-03;High Performance Liquid Chromatography
1770;F5HAR;5-HIAA (5-Hydroxyindoleacetic Acid), Random Urine;Z2673;Creatinine, Random Urine;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2014-04-03;High Performance Liquid Chromatography
1771;F5M;5-Methyltetrahydrofolate;Z2241;5-Methyltetrahydrofolate;57547-5;5-Methyltetrahydrofolate:SCnc:Pt:CSF:Qn:;2012-03-12;High Performance Liquid Chromatography-Electrochemistry
1772;F8A;Coagulation Factor VIII Activity Assay, Plasma;F8A;Coag Factor VIII Activity Assay, P;3209-4;Coagulation factor VIII activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Activated Partial Thromboplastin Clot-Based Assay
1773;FA1GP;Alpha-1-Acid Glycoprotein;FA1GP;Alpha-1-Acid Glycoprotein;2685-6;Alpha-1-Acid glycoprotein:MCnc:Pt:Ser/Plas:Qn:;2013-12-05;Fixed Rate Time Nephelometry
1774;FAAST;Adenovirus Antigen Detection, Gastroenteritis, EIA;Z2275;Adenovirus Ag, EIA;5825-5; ;2013-08-19;Enzyme immunoassay (EIA)
1775;FABKM;Fabry Disease, Known Mutation;27277;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation in the GLA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1776;FABKM;Fabry Disease, Known Mutation;27279;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation in the GLA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1777;FABKM;Fabry Disease, Known Mutation;27280;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation in the GLA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1778;FABKM;Fabry Disease, Known Mutation;27282;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation in the GLA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1779;FABMS;Fabry Disease, Full Gene Analysis;27294;Amendment;34515-7;GLA gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1780;FABMS;Fabry Disease, Full Gene Analysis;27291;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1781;FABMS;Fabry Disease, Full Gene Analysis;27292;Result;34515-7;GLA gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1782;FABMS;Fabry Disease, Full Gene Analysis;27293;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1783;FABMS;Fabry Disease, Full Gene Analysis;27288;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1784;FABMS;Fabry Disease, Full Gene Analysis;27290;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in all 7 exons of the GLA gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1785;FACEC;Angiotensin Converting Enzyme, CSF;FACEC;Angiotensin Convert Enzyme CSF;12480-0;Angiotensin converting enzyme:CCnc:Pt:CSF:Qn:;2013-11-15;Quantitative Spectrophotometry
1786;FACTV;Coagulation Factor V Activity Assay, Plasma;FACTV;Coag Factor V Assay, P;3193-0;Coagulation factor V activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Prothrombin Clot-Based Assay
1787;FACY;Acyclovir, Serum/Plasma;Z1440;Acyclovir;9416-9;;2013-12-18;High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
1788;FADDB;Adenosine Deaminase, Blood;FADDB;Adenosine Deaminase, Blood;1722-8;Adenosine deaminase:CCnc:Pt:Bld:Qn:;2014-05-12;Colorimetric (C), Kinetic
1789;FADIP;Adiponectin;Z1569;Adiponectin;47828-9;Adiponectin:MCnc:Pt:Ser/Plas:Qn;2014-03-27;Enyzme-Linked Immunosorbent Assay (ELISA)
1790;FADV;Adenovirus Antibody, Serum;Z0737;Adenovirus Ab;5041-9;Adenovirus Ab:Titr:Pt:Ser:Qn:Comp fix;2014-05-13;Complement Fixation (CF)
1791;FAFE;Aspergillus flavus IgE;Z3858;Aspergillus flavus IgE;6024-4;Aspergillus flavus Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-20;Radioimmunoassay (RIA)
1792;FAGPP;Aspergillus IgG Precipitins Panel;Z3834;Aspergillus niger;10894-4;Aspergillus niger Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-07-01;Gel Diffusion
1793;FAGPP;Aspergillus IgG Precipitins Panel;Z3837;Aspergillus flavus;23820-4;Aspergillus flavus Ab:Acnc:Pt:Ser:Ord:Immune diffusion;2014-07-01;Gel Diffusion
1794;FAGPP;Aspergillus IgG Precipitins Panel;Z3836;Aspergillus fumigatus Mix;23821-2;Aspergillus fumigatus Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-07-01;Gel Diffusion
1795;FAGPP;Aspergillus IgG Precipitins Panel;Z3835;Aspergillus nidulans;24508-4;Aspergillus nidulans Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-07-01;Gel Diffusion
1796;FAGPP;Aspergillus IgG Precipitins Panel;Z3833;Aspergillus terreus;24509-2;Aspergillus terreus Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-07-01;Gel Diffusion
1797;FALBU;Albuterol, Serum/Plasma;Z1441;Albuterol;9311-2;;2013-12-18;High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
1798;FALG;Alpha Lactalbumin IgG;FALG;Alpha Lactalbumin IgG;63418-8;Lactalbumin alpha Ab.IgG:MCnc:Pt:Ser:Qn:;2013-12-05;Enzyme Immunoassay (FEIA)
1799;FAMCE;Cheese American IgE;Z3867;CLASS;15622-4;Cheese American Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-04;Radioimmunoassay (RIA)
1800;FAMCE;Cheese American IgE;Z3866;Cheese American IgE;7201-7;Cheese American Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-04;Radioimmunoassay (RIA)
1801;FAML;Acute Myeloid Leukemia (AML), FISH;23314;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1802;FAML;Acute Myeloid Leukemia (AML), FISH;23312;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1803;FAML;Acute Myeloid Leukemia (AML), FISH;G_713;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1804;FAML;Acute Myeloid Leukemia (AML), FISH;G_711;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1805;FANBF;Anti-Nuclear Ab (FANA), Body Fluid;Z2413;ANA Titer;14613-4;Nuclear Ab:Titr:Pt:Body fld:Qn:;2013-11-01;Immunofluorescence Assay (IFA)
1806;FANBF;Anti-Nuclear Ab (FANA), Body Fluid;Z2414;ANA Pattern;13067-4;Nuclear Ab pattern:Imp:Pt:Body fld:Nom:IF;2013-11-01;Immunofluorescence Assay (IFA)
1807;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22975;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1808;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22976;Result;32639-7;FANCC gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1809;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22972;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1810;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22974;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1811;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22978;Amendment;32639-7;FANCC gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1812;FANCA;Fanconi Anemia C Mutation Analysis, IVS4(+4)A->T and 322delG;22977;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) analysis is used to test for the following mutations associated with Fanconi anemia: 322delG and IVS4(+4)A->T.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1813;FANG;Angiotensin II, Plasma;Z0938;Angiotensin II, P;1860-6;;2012-03-12;Direct Radioimmunoassay (RIA)
1814;FANGI;Angiotensin I, Plasma;Z0939;Angiotensin I, P;1858-0;;2012-03-12;Direct Radioimmunoassay (RIA)
1815;FANT;Fire Ant, IgE;FANT;Fire Ant, IgE;6117-6;Solenopsis invicta Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1816;FAO;Fatty Acid Oxidation Probe Assay, Fibroblast Culture;23484;Method;49549-9; ;2013-07-26;FAO: Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry (MS/MS) for AcylcarnitinesFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1817;FAO;Fatty Acid Oxidation Probe Assay, Fibroblast Culture;23486;Results;35574-3;Fatty acid oxidation:Prid:Pt:Fibroblasts:Nom:;2009-11-13;FAO: Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry (MS/MS) for AcylcarnitinesFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1818;FAO;Fatty Acid Oxidation Probe Assay, Fibroblast Culture;23487;Interpretation;59462-2;;2012-04-02;FAO: Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry (MS/MS) for AcylcarnitinesFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1819;FAO;Fatty Acid Oxidation Probe Assay, Fibroblast Culture;23483;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;FAO: Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry (MS/MS) for AcylcarnitinesFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1820;FAO;Fatty Acid Oxidation Probe Assay, Fibroblast Culture;23481;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;FAO: Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry (MS/MS) for AcylcarnitinesFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
1821;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16979;Linoleic Acid, C18:2w6;35165-0;Linoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1822;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16992;Docosenoic Acid, C22:1;35160-1;Docosenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1823;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17006;Total Fatty Acids;24461-6;Fatty acids:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1824;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16999;Phytanic Acid, C16:0(CH3)4;22671-2;Phytanate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1825;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17000;Triene Tetraene Ratio;35411-8;Trienoate/Arachidonate:SRto:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1826;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17001;Total Saturated;35175-9;Fatty acids.saturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1827;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17002;Total Monounsaturated;35176-7;Fatty acids.monounsaturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1828;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16998;Pristanic Acid, C15:0(CH3)4;22761-1;Pristanate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1829;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17004;Total w3;35178-3;Fatty acids.omega 3:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1830;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16968;Lauroleic Acid, C12:1;35151-0;Lauroleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1831;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17056;Interpretation;59462-2;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1832;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16982;Stearic Acid, C18:0;35149-4;Octadecanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1833;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16997;Hexacosanoic Acid, C26:0;30197-8;Fatty acids.very long chain.C26:0:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1834;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16984;Arachidonic Acid, C20:4w6;35168-4;Arachidonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1835;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16985;Mead Acid, C20:3w9;35172-6;Mead acid:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1836;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16986;h-g-Linolenic Acid, C20:3w6;35171-8;Homo-gamma linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1837;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16987;Arachidic Acid, C20:0;35169-2;Arachidate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1838;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16994;Nervonic Acid, C24:1w9;35170-0;Nervonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1839;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16995;Tetracosanoic Acid, C24:0;30195-2;Fatty acids.very long chain.C24:0:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1840;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16991;DTA, C22:4w6;35182-5;Docosatetraenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1841;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16990;DPA, C22:5w3;35180-9;Docosapentaenate w3:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1842;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16989;DPA, C22:5w6;35181-7;Docosapentaenate w6:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1843;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16996;Hexacosenoic Acid, C26:1;33036-5;Fatty acids.very long chain.C26:1:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1844;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16988;DHA, C22:6w3;35174-2;Docosahexaenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1845;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16983;EPA, C20:5w3;35173-4;Eicosapentaenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1846;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16971;Myristoleic Acid, C14:1;35158-5;Myristoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1847;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16972;Myristic Acid, C14:0;35157-7;Myristate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1848;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17005;Total w6;35179-1;Fatty acids.omega 6:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1849;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16973;Hexadecadienoic Acid, C16:2;35154-4;Hexadecadienoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1850;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16974;Hexadecenoic Acid, C16:1w9;35155-1;Hexadecenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1851;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16975;Palmitoleic Acid, C16:1w7;35162-7;Palmitoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1852;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16976;Palmitic Acid, C16:0;35161-9;Palmitate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1853;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16977;g-Linolenic Acid, C18:3w6;35163-5;Gamma linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1854;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16978;a-Linolenic Acid, C18:3w3;35164-3;Alpha linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1855;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16981;Vaccenic Acid, C18:1w7;35167-6;Vaccenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1856;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16980;Oleic Acid, C18:1w9;35166-8;Oleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1857;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16966;Decenoic Acid, C10:1;35147-8;Decenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1858;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16967;Decanoic Acid, C10:0;35146-0;Decanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1859;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16970;Tetradecadienoic Acid, C14:2;35148-6;Tetradecadienoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1860;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16969;Lauric Acid, C12:0;35150-2;Laurate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1861;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;16965;Octanoic Acid, C8:0;35145-2;Octanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1862;FAPCP;Fatty Acid Profile, Comprehensive (C8-C26), Serum;17003;Total Polyunsaturated;35177-5;Fatty acids.polyunsaturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1863;FAPEP;Fatty Acid Profile, Essential, Serum;17054;Interpretation;59462-2;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1864;FAPEP;Fatty Acid Profile, Essential, Serum;17048;Total w6;35179-1;Fatty acids.omega 6:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1865;FAPEP;Fatty Acid Profile, Essential, Serum;17046;Total Polyunsaturated Acid;35177-5;Fatty acids.polyunsaturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1866;FAPEP;Fatty Acid Profile, Essential, Serum;17039;DPA, C22:5w3;35180-9;Docosapentaenate w3:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1867;FAPEP;Fatty Acid Profile, Essential, Serum;17033;Arachidonic Acid, C20:4w6;35168-4;Arachidonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1868;FAPEP;Fatty Acid Profile, Essential, Serum;17045;Total Monounsaturated Acid;35176-7;Fatty acids.monounsaturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1869;FAPEP;Fatty Acid Profile, Essential, Serum;17044;Total Saturated Acid;35175-9;Fatty acids.saturated:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1870;FAPEP;Fatty Acid Profile, Essential, Serum;17042;Nervonic Acid, C24:1w9;35170-0;Nervonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1871;FAPEP;Fatty Acid Profile, Essential, Serum;17043;Triene Tetraene Ratio;35411-8;Trienoate/Arachidonate:SRto:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1872;FAPEP;Fatty Acid Profile, Essential, Serum;17040;DTA, C22:4w6;35182-5;Docosatetraenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1873;FAPEP;Fatty Acid Profile, Essential, Serum;17041;Docosenoic Acid, C22:1;35160-1;Docosenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1874;FAPEP;Fatty Acid Profile, Essential, Serum;17036;Arachidic Acid, C20:0;35169-2;Arachidate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1875;FAPEP;Fatty Acid Profile, Essential, Serum;17037;DHA, C22:6w3;35174-2;Docosahexaenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1876;FAPEP;Fatty Acid Profile, Essential, Serum;17032;EPA, C20:5w3;35173-4;Eicosapentaenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1877;FAPEP;Fatty Acid Profile, Essential, Serum;17021;Lauric Acid, C12:0;35150-2;Laurate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1878;FAPEP;Fatty Acid Profile, Essential, Serum;17022;Myristic Acid, C14:0;35157-7;Myristate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1879;FAPEP;Fatty Acid Profile, Essential, Serum;17035;h-g-Linolenic, C20:3w6;35171-8;Homo-gamma linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1880;FAPEP;Fatty Acid Profile, Essential, Serum;17034;Mead Acid, C20:3w9;35172-6;Mead acid:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1881;FAPEP;Fatty Acid Profile, Essential, Serum;17047;Total w3;35178-3;Fatty acids.omega 3:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1882;FAPEP;Fatty Acid Profile, Essential, Serum;17049;Total Fatty Acids;24461-6;Fatty acids:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1883;FAPEP;Fatty Acid Profile, Essential, Serum;17028;Linoleic Acid, C18:2w6;35165-0;Linoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1884;FAPEP;Fatty Acid Profile, Essential, Serum;17029;Oleic Acid, C18:1w9;35166-8;Oleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1885;FAPEP;Fatty Acid Profile, Essential, Serum;17030;Vaccenic Acid, C18:1w7;35167-6;Vaccenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1886;FAPEP;Fatty Acid Profile, Essential, Serum;17031;Stearic Acid, C18:0;35149-4;Octadecanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1887;FAPEP;Fatty Acid Profile, Essential, Serum;17027;a-Linolenic Acid, C18:3w3;35164-3;Alpha linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1888;FAPEP;Fatty Acid Profile, Essential, Serum;17024;Palmitoleic Acid, C16:1w7;35162-7;Palmitoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1889;FAPEP;Fatty Acid Profile, Essential, Serum;17025;Palmitic Acid, C16:0;35161-9;Palmitate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1890;FAPEP;Fatty Acid Profile, Essential, Serum;17026;g-Linolenic Acid, C18:3w6;35163-5;Gamma linolenate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1891;FAPEP;Fatty Acid Profile, Essential, Serum;17023;Hexadecenoic Acid, C16:1w9;35155-1;Hexadecenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1892;FAPEP;Fatty Acid Profile, Essential, Serum;17038;DPA, C22:5w6;35181-7;Docosapentaenate w6:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1893;FAPKM;Familial Adenomatous Polyposis (FAP) Known Mutation;17251;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;DNA Sequencing or Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) (Test is used for detecting the presence of a specific mutation previously identified in an affected family member.)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1894;FAPKM;Familial Adenomatous Polyposis (FAP) Known Mutation;17254;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;DNA Sequencing or Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) (Test is used for detecting the presence of a specific mutation previously identified in an affected family member.)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1895;FAPKM;Familial Adenomatous Polyposis (FAP) Known Mutation;17252;Method;49549-9; ;2013-07-26;DNA Sequencing or Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) (Test is used for detecting the presence of a specific mutation previously identified in an affected family member.)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1896;FAPKM;Familial Adenomatous Polyposis (FAP) Known Mutation;17249;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;DNA Sequencing or Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) (Test is used for detecting the presence of a specific mutation previously identified in an affected family member.)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1897;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17007;Octanoic Acid, C8:0;35145-2;Octanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1898;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17055;Interpretation;59462-2;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1899;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17012;Tetradecadienoic Acid, C14:2;35148-6;Tetradecadienoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1900;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17016;Palmitoleic Acid, C16:1w7;35162-7;Palmitoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1901;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17014;Myristic Acid, C14:0;35157-7;Myristate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1902;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17013;Myristoleic Acid, C14:1;35158-5;Myristoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1903;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17020;Stearic Acid, C18:0;35149-4;Octadecanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1904;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17009;Decanoic Acid, C10:0;35146-0;Decanoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1905;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17017;Palmitic Acid, C16:0;35161-9;Palmitate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1906;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17015;Hexadecadienoic Acid, C16:2;35154-4;Hexadecadienoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1907;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17010;Lauroleic Acid, C12:1;35151-0;Lauroleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1908;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17008;Decenoic Acid, C10:1;35147-8;Decenoate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1909;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17011;Lauric Acid, C12:0;35150-2;Laurate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1910;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17018;Linoleic Acid, C18:2w6;35165-0;Linoleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1911;FAPM;Fatty Acid Profile, Mitochondrial (C8-C18), Serum;17019;Oleic Acid, C18:1w9;35166-8;Oleate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
1912;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17266;Amendment;20990-8;APC gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1913;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17265;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1914;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17264;Result;20990-8;APC gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1915;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17263;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1916;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17262;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1917;FAPMS;Familial Adenomatous Polyposis (FAP) Mutation Screen;17260;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis/Protein Truncation Test with Follow-up sequencing when appropriateGene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)Direct Mutation Analysis Utilizing Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1918;FART;Artichoke (Cynara scolymus) IgE;Z3865;CLASS;15543-2;Cynara scolymus Ab.IgE.RAST class:Threshold:Pt:Ser:Ord;2014-07-25;Radioimmunoassay (RIA)
1919;FART;Artichoke (Cynara scolymus) IgE;Z3864;Artichoke;7094-6;Cynara scolymus Ab.IgE:ACnc:Pt:Ser:Qn;2014-07-25;Radioimmunoassay (RIA)
1920;FASP;Aspergillus Antibodies, Immunodiffusion, Serum;Z0519;Aspergillus fumigatus Ab;6808-0;Aspergillus fumigatus 1 Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-05-13;Immunodiffusion (ID)
1921;FASP;Aspergillus Antibodies, Immunodiffusion, Serum;Z0717;Aspergillus flavus Ab;9490-4;Aspergillus flavus Ab:ACnc:Pt:Ser:Ord:;2014-05-13;Immunodiffusion (ID)
1922;FASP;Aspergillus Antibodies, Immunodiffusion, Serum;Z0518;Aspergillus niger Ab;10894-4;Aspergillus niger Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2014-05-13;Immunodiffusion (ID)
1923;FASPE;Aspen (Populus tremuloides) IgE;Z4012;Aspen (Populus tremuloides) IgE;7101-9;Populus tremula Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;Radioimmunoassay (RIA)
1924;FASPE;Aspen (Populus tremuloides) IgE;Z4013;CLASS;15548-1;Populus tremula Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-21;Radioimmunoassay (RIA)
1925;FATF;Fat, Feces;TFAT;Total Fat/24 Hr;16142-2;Fat:MRat:24H:Stool:Qn:;2012-03-15;Nuclear Magnetic Resonance (NMR) Spectroscopy
1926;FATF;Fat, Feces;DUR2;Duration;13363-7;Collection duration:Time:*:Stool:Qn:;2012-03-15;Nuclear Magnetic Resonance (NMR) Spectroscopy
1927;FATF;Fat, Feces;STWT;Total Weight;30078-0;Specimen weight:Mass:Pt:Stool:Qn:;2012-03-15;Nuclear Magnetic Resonance (NMR) Spectroscopy
1928;FBALL;B-Cell Acute Lymphoblastic Leukemia (ALL), FISH;G_723;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1929;FBALL;B-Cell Acute Lymphoblastic Leukemia (ALL), FISH;G_721;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1930;FBALL;B-Cell Acute Lymphoblastic Leukemia (ALL), FISH;22921;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1931;FBALL;B-Cell Acute Lymphoblastic Leukemia (ALL), FISH;22923;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1932;FBC;Fibroblast Culture for Genetic Testing;16175;Interpretation;69965-2; ;2013-08-09;Cell Culture
1933;FBC;Fibroblast Culture for Genetic Testing;16176;Amendment;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar;2014-04-30;Cell Culture
1934;FBC;Fibroblast Culture for Genetic Testing;16172;Method;49549-9; ;2013-07-26;Cell Culture
1935;FBC;Fibroblast Culture for Genetic Testing;CG033;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Culture
1936;FBC;Fibroblast Culture for Genetic Testing;CG030;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Cell Culture
1937;FBIOT;Vitamin B7, H (Biotin);Z2042;Biotin (Vitamin B7);34398-8;;2013-12-19;Microbiological Assay
1938;FBIU;Bicarbonate, Urine;Z1447;Bicarbonate;1964-6;Bicarbonate:SCnc:Pt:Urine:Qn:;2013-12-18;Enzymatic Assay (EZA)
1939;FBL;Fungal Culture, Blood;FBL;Fungal Culture, Blood;601-5;Fungus identified:Pt:Bld:Nom:Culture;2013-09-17;Conventional broth culture technique with identification by macroscopic and microscopic morphology, nucleic acid hybridization probes, D2 rDNA gene sequencing, real-time polymerase chain reaction (rtPCR), or MALDI-TOF mass spectrometry. Dimorphic pathogen identification is confirmed using molecular methods (ie, nucleic acid hybridization probes, D2 rDNA gene sequencing, rtPCR or MALDI-TOF mass spectrometry).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
1940;FBLP;B-Cell Lymphoma, FISH, Blood or Bone Marrow;27192;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1941;FBLP;B-Cell Lymphoma, FISH, Blood or Bone Marrow;G_703;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1942;FBLP;B-Cell Lymphoma, FISH, Blood or Bone Marrow;27190;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
1943;FBLP;B-Cell Lymphoma, FISH, Blood or Bone Marrow;G_701;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1944;FBMT;XX/XY in Opposite Sex Bone Marrow Transplantation, FISH;16214;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1945;FBMT;XX/XY in Opposite Sex Bone Marrow Transplantation, FISH;16211;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1946;FBMT;XX/XY in Opposite Sex Bone Marrow Transplantation, FISH;G_694;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1947;FBMT;XX/XY in Opposite Sex Bone Marrow Transplantation, FISH;G_691;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1948;FBORE;Bordetella pertussis Antibodies, IgG and IgM by ELISA with Reflex to Immunoblot;Z2615;B. pertussis Ab, IgM;42329-3;Bordetella pertussis Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2013-08-21;Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
1949;FBORE;Bordetella pertussis Antibodies, IgG and IgM by ELISA with Reflex to Immunoblot;Z2614;B. pertussis Ab, IgG;42330-1;Bordetella pertussis Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-08-21;Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
1950;FBP1;15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH;23361;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1951;FBP1;15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH;23368;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1952;FBP1;15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH;CG041;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1953;FBP1;15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH;CG039;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
1954;FBPTS;Bordetella pertussis Antibodies, IgA, IgG and IgM by ELISA with Reflex to Immunoblot;Z2618;B. pertussis Ab, IgM;42329-3;Bordetella pertussis Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2013-08-21;Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
1955;FBPTS;Bordetella pertussis Antibodies, IgA, IgG and IgM by ELISA with Reflex to Immunoblot;Z2616;B. pertussis Ab, IgA;42328-5;Bordetella pertussis Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2013-08-21;Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
1956;FBPTS;Bordetella pertussis Antibodies, IgA, IgG and IgM by ELISA with Reflex to Immunoblot;Z2617;B. pertussis Ab, IgG;42330-1;Bordetella pertussis Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-08-21;Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Immunoblot
1957;FBSH;Firebush (Kochia), IgE;FBSH;Firebush (Kochia), IgE;6118-4;Kochia scoparia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
1958;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;16784;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
1959;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;16080;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Fluorescence In Situ Hybridization (FISH)
1960;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;16079;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1961;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;16078;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Fluorescence In Situ Hybridization (FISH)
1962;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;16076;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1963;FBUCC;X and Y Aneuploidy Detection, Buccal Smear, FISH;G_23;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1964;FC1EQ;C1 Esterase Inhibitor, Functional Assay, Serum;81493;C1 Esterase Inhib, Functional, QN;48494-9;Complement C1 esterase inhibitor actual/Normal:RelCCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme Immunoassay (EIA)
1965;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0219;Testosterone, Serum (Total);2986-8;;2013-05-23;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1966;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0224;Androstenedione;1854-9;Androstenedione:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1967;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0221;17-Alpha-Hydroxyprogesterone;1668-3;17-Hydroxyprogesterone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1968;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0222;Progesterone;2839-9;Progesterone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1969;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0218;Cortisol;2143-6;Cortisol:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1970;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0223;Dehydroepiandrosterone (DHEA);2193-1;Dehydroepiandrosterone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1971;FCAH;CAH  Pediatric Profile 5: 17,20 Desmolase Deficiency (Androstene-dione, Cortisol, DHEA, 17-OH-Prenenolone, Progesterone, 17-Alpha-Hydroxyprogesterone, Testosterone);Z0220;17-OH Pregnenolone;6765-2;17-Hydroxypregnenolone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)High Performance Liquid Chromatography/Tandem Mass Spectrometry(LC-MS/MS)
1972;FCALP;Calprotectin;Z0843;Calprotectin;38445-3;;2012-03-12;Enzyme Linked Immunosorbent Assay (ELISA)
1973;FCAMP;Campylobacter jejuni Antibody, ELISA;Z0668;Campylobacter Jejuni Antibody,ELISA;26818-5;Campylobacter jejuni Ab:ACnc:Pt:Ser:Qn:EIA;2014-05-06;Enzyme-Linked Immunosorbent Assay (ELISA)
1974;FCANA;Candida albicans Antibodies (IgG, IgA, IgM);Z2317;C. Albicans IgG;51539-5; ;2013-08-19;Enzyme-Linked Immunosorbent Assay (ELISA)
1975;FCART;Chikungunya Antibodies with Reflex(es) to Titer;Z4121;Chikungunya IgM Screen;56131-6;Chikungunya virus Ab.IgM:ACnc:Pt:Ser/Plas:Ord:IF;2014-07-25;Immunofluorescence Assay (IFA)
1976;FCART;Chikungunya Antibodies with Reflex(es) to Titer;Z4120;Chikungunya IgG Screen;56129-0;Chikungunya virus Ab.IgG:ACnc:Pt:Ser/Plas:Ord:IF;2014-07-25;Immunofluorescence Assay (IFA)
1977;FCAS;Citric Acid, Serum;FCAS;Citric Acid, Serum;2127-9;Citrate:MCnc:Pt:Ser/Plas:Qn:;2014-01-10;Spectrophotometry (SP) Enzymatic
1978;FCCEV;Complete CADASIL Evaluation;FCCEV;Complete Cadasil Evaluation;41077-9;NOTCH3 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-12-05;Next Generation Sequencing
1979;FCDC;Cri-du-chat Syndrome, 5p15.2 Deletion, FISH;23261;Interpretation;69965-2;;2012-04-09;Flourescence In Situ Hybridization (FISH)
1980;FCDC;Cri-du-chat Syndrome, 5p15.2 Deletion, FISH;23259;Method;49549-9; ;2013-07-26;Flourescence In Situ Hybridization (FISH)
1981;FCDC;Cri-du-chat Syndrome, 5p15.2 Deletion, FISH;CG049;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Flourescence In Situ Hybridization (FISH)
1982;FCDC;Cri-du-chat Syndrome, 5p15.2 Deletion, FISH;CG051;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Flourescence In Situ Hybridization (FISH)
1983;FCEPH;Cephalosporin IgE;Z4058;Cephalosporin IgE;50033-0;Cephalosporin Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;Radioimmunoassay (RIA)
1984;FCFT;Cortisol, Free and Total;Z3616;Cortisol, Free;2145-1;Cortisol.free:MCnc:Pt:Ser/Plas:Qn:;2014-01-07;Liquid Chromatography Tandem Mass Spectrometry (LS/MS/MS), Equilibrium Dialysis
1985;FCFT;Cortisol, Free and Total;Z3615;Cortisol, Total;2143-6;Cortisol:MCnc:Pt:Ser/Plas:Qn:;2014-01-07;Liquid Chromatography Tandem Mass Spectrometry (LS/MS/MS), Equilibrium Dialysis
1986;FCGHP;Array Comparative Genomic Hybridization (aCGH) Parental Testing, FISH;50992;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
1987;FCGHP;Array Comparative Genomic Hybridization (aCGH) Parental Testing, FISH;50997;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1988;FCGHP;Array Comparative Genomic Hybridization (aCGH) Parental Testing, FISH;50995;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1989;FCGHP;Array Comparative Genomic Hybridization (aCGH) Parental Testing, FISH;CG528;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1990;FCHIC;CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH;22467;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
1991;FCHIC;CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH;G_681;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
1992;FCHIC;CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH;22466;Results;41749-3;CHIC2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
1993;FCHIC;CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH;22465;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
1994;FCHIC;CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH;G_683;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
1995;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1462;Heptachlorepoxide;9473-0;;2013-12-18;Gas Chromatography (GC)
1996;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1466;Gamma-Chlordane;11096-5;;2013-12-18;Gas Chromatography (GC)
1997;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1463;Oxychlordane;21437-9;;2013-12-18;Gas Chromatography (GC)
1998;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1464;Heptachlor;9472-2;;2013-12-18;Gas Chromatography (GC)
1999;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1461;Trans-Nonachlor;23937-6;;2013-12-18;Gas Chromatography (GC)
2000;FCHLM;Chlordane and Metabolites, Serum/Plasma;Z1445;Alpha-Chlordane;11091-6;;2013-12-18;Gas Chromatography (GC)
2001;FCHO;Cholestanol;Z0949;Cholestanol;2082-6;;2012-03-12;Gas Chromatography/Mass Spectrometry (GC/MS)
2002;FCHOP;Myxoid/Round Cell Liposarcoma 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue;27395;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
2003;FCHOP;Myxoid/Round Cell Liposarcoma 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue;27393;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2004;FCHOP;Myxoid/Round Cell Liposarcoma 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue;CG061;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2005;FCHOP;Myxoid/Round Cell Liposarcoma 12q13 (DDIT3 or CHOP) Rearrangement, FISH, Tissue;27390;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH)
2006;FCHYS;Chymotrypsin, Stool;FCHYS;Chymotrypsin, Stool;25375-7;Chymotrypsin:CCnt:Pt:Stool:Qn:;2014-01-03;Enzymatic/Spectrophotometric
2007;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;17297;Result;35506-5;CLL gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2008;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;17296;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2009;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;G_671;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2010;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;17298;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
2011;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;17299;Amendment;35506-5;CLL gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Fluorescence In Situ Hybridization (FISH)
2012;FCLL;Chronic Lymphocytic Leukemia (CLL), FISH;G_673;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2013;FCLNE;Anti-Phosphatidylcholine Ab;Z0140;Anti-Phosphatidylcholine IgM;13077-3;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2014;FCLNE;Anti-Phosphatidylcholine Ab;Z0149;Anti-phosphatidylcholine IgG;13076-5;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2015;FCLNE;Anti-Phosphatidylcholine Ab;Z0141;Anti-Phosphatidylcholine IgA;13078-1;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2016;FCLPS;Cathartic Laxatives Profile, Stool;Z1336;Magnesium;29911-5;;2012-03-12;Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES)
2017;FCMG;Cytomegalovirus (CMV) Genotype;Z3695;UL97 Mutation;72833-7;Cytomegalovirus UL97 gene mutations detected:Prid:Pt:Isolate:Nom:;2014-04-16;Polymerase Chain Reaction (PCR)DNA Sequencing
2018;FCMG;Cytomegalovirus (CMV) Genotype;Z3696;UL54 Mutation;33631-3;Cytomegalovirus UL54 gene mutations detected:Prid:Pt:Isolate:Nom:;2014-04-16;Polymerase Chain Reaction (PCR)DNA Sequencing
2019;FCNAB;Chromatin (Nucleosomal) Antibody;FCNAB;Chromatin (Nucleosomal) Ab;34416-8;Nucleosome Ab:ACnc:Pt:Ser:Qn:EIA;2014-01-23;Immunoassay
2020;FCORT;Cortisol, Free, LC/MS/MS;Z1572;Cortisol, Free, LC/MS/MS;2145-1;Cortisol.free:MCnc:Pt:Ser/Plas:Qn:;2014-04-17;Liquid Chromatography Tandem Mass Spectrometry, Equilibrium Dialysis
2021;FCP12;Cytokine Panel 12;Z2729;Interleukin 6;26881-3;Interleukin 6:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2022;FCP12;Cytokine Panel 12;Z2730;Interleukin 8;33211-4;Interleukin 8:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2023;FCP12;Cytokine Panel 12;Z2731;Tumor Necrosis Factor - alpha;3074-2;Tumor necrosis factor.alpha:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2024;FCP12;Cytokine Panel 12;Z2727;Interleukin 13;33822-8;Interleukin 13:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2025;FCP12;Cytokine Panel 12;Z2726;Interleukin 10;26848-2;Interleukin 10:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2026;FCP12;Cytokine Panel 12;Z2728;Interleukin 1 beta;13629-1;Interleukin 1 beta:MCnc:Pt:Ser/Plas:Qn;2014-05-19;Quantitative Multiplex Bead Assay
2027;FCP12;Cytokine Panel 12;Z2724;Interleukin 4;27161-9;Interleukin 4:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2028;FCP12;Cytokine Panel 12;Z2732;Interleukin 2;33939-0;Interleukin 2:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2029;FCP12;Cytokine Panel 12;Z2721;Interleukin 2 Receptor CD25 Soluble;33939-0;Interleukin 2:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2030;FCP12;Cytokine Panel 12;Z2722;Interleukin 12;41760-0;Interleukin 12:MCnc:Pt:Ser/Plas:Qn:;2014-05-19;Quantitative Multiplex Bead Assay
2031;FCPC;Chlamydophila pneumoniae Culture;Z2086;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;
2032;FCPC;Chlamydophila pneumoniae Culture;Z0656;C. Pneumoniae Culture;21184-7;Chlamydophila pneumoniae:ACnc:Pt:XXX:Ord:Organism specific culture;2014-04-28;
2033;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;G_661;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2034;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;16224;Amendment;50619-6;Karyotype:Prid:Pt:Bld/Tiss:Nar:;2013-08-09;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2035;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;16222;Results;50619-6;Karyotype:Prid:Pt:Bld/Tiss:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2036;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;G_664;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2037;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;16223;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2038;FCSP;Chromosome Anomalies, Unspecified Miscellaneous with Chromosome-Specific FISH Probes;16220;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2039;FD;Familial Dysautonomia, Mutation Analysis, IVS20(+6T->C) and R696P;23032;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with familial dysautonomia: R696P and IVS20(+6)T->C.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2040;FD;Familial Dysautonomia, Mutation Analysis, IVS20(+6T->C) and R696P;23029;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with familial dysautonomia: R696P and IVS20(+6)T->C.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2041;FD;Familial Dysautonomia, Mutation Analysis, IVS20(+6T->C) and R696P;23030;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with familial dysautonomia: R696P and IVS20(+6)T->C.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2042;FD;Familial Dysautonomia, Mutation Analysis, IVS20(+6T->C) and R696P;23031;Results;46992-4;DYS gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with familial dysautonomia: R696P and IVS20(+6)T->C.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2043;FD;Familial Dysautonomia, Mutation Analysis, IVS20(+6T->C) and R696P;23027;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with familial dysautonomia: R696P and IVS20(+6)T->C.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2044;FDANT;Dantrolene, Serum/Plasma;Z1449;Dantrolene;9746-9;;2013-12-18;Spectrofluorometry (SF)
2045;FDFA;Dengue Fever Antibodies (IgG, IgM);Z1720;Interpretation;51785-4; ;2013-08-19;Enzyme-Linked Immunosorbent Assay (ELISA)
2046;FDFA;Dengue Fever Antibodies (IgG, IgM);Z1719;Dengue Fever IgM;29663-2; ;2013-08-19;Enzyme-Linked Immunosorbent Assay (ELISA)
2047;FDFA;Dengue Fever Antibodies (IgG, IgM);Z1718;Dengue Fever IgG;29661-6; ;2013-08-19;Enzyme-Linked Immunosorbent Assay (ELISA)
2048;FDIGS;Digitoxin, Serum or Plasma;Z1479;Digitoxin;3559-2;;2013-12-18;Immunoassay (IA)
2049;FDIPY;Dipyridamole;Z1451;Dipyridamole;10536-1;;2013-12-18;High-Performance Liquid Chromatography (HPLC) 
2050;FDOC;Deoxycorticosterone (DOC), Serum;Z0253;Deoxycorticosterone (DOC), Serum;1656-8;11-Deoxycorticosterone:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;HPLC Tandem Mass Spectrometry
2051;FDPDG;Dihydropyrimidine Dehydrogenase (DPD) Gene Mutation Analysis;Z3701;DPD Gene Mutation;45284-7;DPYD gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-04-16;Polymerase Chain Reaction (PCR), Single Nucleotide Primer Extension
2052;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2968;Drug Screen Comments, S/P;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2053;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2962;Cannabinoids, S/P;8172-9;Cannabinoids:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2054;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2966;Phencyclidine, S/P;8236-2;Phencyclidine:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2055;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2967;Propoxyphene, S/P;59734-4;Propoxyphene:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2056;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z3007;Oxycodone, S/P;13576-4;Oxycodone:Threshold:Pt:Ser/Plas:Ord;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2057;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2965;Opiates, S/P;8219-8;Opiates:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2058;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2964;Methadone, S/P;59705-4;Mathadone:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2059;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2963;Cocaine, S/P;8191-9;Cocaine:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2060;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2960;Barbiturates, S/P;20421-4;Barbituates:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2061;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2961;Benzodiazepines, S/P;46976-7;Benzodiazepines:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2062;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z3006;Methamphetamine, S/P;3777-0;Methamphetamine:Threshold:Pt:Ser/Plas:Ord;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2063;FDS9R;Drug Screen 9 Panel, Serum or Plasma-Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation;Z2959;Amphetamines, S/P;8149-7;Amphetamines:Threshold:Pt:Ser/Plas:Ord:Screen;2014-06-09;Qualitative Enzyme-Linked Immunosorbent AssayQuantitative Gas Chromatography-Mass SpectrometryQuantitative Liquid Chromatography-Tandem Mass Spectrometry
2064;FDSOX;11-Desoxycortisol (Specific Compound S);Z0271;11-Desoxycortisol, Mass Spectrometry;1657-6;11-Deoxycortisol:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;HPLC Tandem Mass Spectrometry
2065;FEC;Iron and Total Iron-Binding Capacity, Serum;TIBC;Total Iron Binding Capacity;2500-7;Iron binding capacity:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
2066;FEC;Iron and Total Iron-Binding Capacity, Serum;SAT;Percent Saturation;14801-5;Iron saturation:ScRto:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
2067;FEC;Iron and Total Iron-Binding Capacity, Serum;IRON;Iron;2498-4;Iron:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
2068;FECHA;Ehrlichia chaffeensis Antibodies (IgG, IgM);Z0546;E. chaffeensis Ab IgM;9784-0;Ehrlichia chaffeensis Ab.IgM:Titr:Pt:Ser:Qn:;2014-05-07;Immunofluorescence Assay (IFA)
2069;FECHA;Ehrlichia chaffeensis Antibodies (IgG, IgM);Z0545;E. chaffeensis Ab IgG;9783-2;Ehrlichia chaffeensis Ab.IgG:Titr:Pt:Ser:Qn:;2014-05-07;Immunofluorescence Assay (IFA)
2070;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51054;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2071;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51058;Amendment;57962-3;FECH gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2072;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51056;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2073;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51055;Result;57962-3;FECH gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:;2011-06-16;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2074;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51051;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2075;FECHK;Ferrochelatase (FECH) Gene, Known Mutation;51053;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2076;FECHS;Ferrochelatase (FECH) Gene, Full Gene Analysis;51063;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2077;FECHS;Ferrochelatase (FECH) Gene, Full Gene Analysis;51065;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2078;FECHS;Ferrochelatase (FECH) Gene, Full Gene Analysis;51066;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2079;FECHS;Ferrochelatase (FECH) Gene, Full Gene Analysis;51068;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2080;FECLT;Euglobulin Clot Lysis Time;FECLT;Euglobulin Clot Lysis Time;3244-1;Coagulum lysis:Time:Pt:PPP:Qn:Coag;2014-01-10;Clot Dissolution
2081;FECP;Eosinophil Cationic Protein (ECP);Z3617;Eosinophil Cationic Prot.;25638-8;Eosinophil cationic protein:MCnc:Pt:Ser:Qn:;2014-01-07;Fluoroenzyme Immunoassay (UNICAP)
2082;FEEP;Ferret Epithelium, IgE;FEEP;Ferret Epithelium, IgE;11172-4;Ferret epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2083;FEHA;Entamoeba histolytica Antigen, EIA;Z2070;E histolytica Antigen;6398-2;Entamoeba histolytica Ag:ACnc:Pt:Stool:Qn:EIA;2014-02-24;Enzyme Immunoassay (EIA)
2084;FELAS;Elastase, Pancreatic, Serum;Z0925;Elastase;14048-3;;2012-03-12;Direct Radioimmunoassay (RIA)
2085;FELBA;Felbamate (Felbatol), Serum;80782;Felbamate (Felbatol), S;6899-9;Felbamate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
2086;FENTA;Fentanyl Confirmation, Urine;200189;Interpretation;59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2087;FENTA;Fentanyl Confirmation, Urine;200188;Fentanyl;3637-6;Fentanyl:MCnc:Pt:Urine:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2088;FENTA;Fentanyl Confirmation, Urine;200187;Norfentanyl;11075-9;Norfentanyl:MCnc:Pt:Urine:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2089;FENTS;Fentanyl, Serum;31830;Fentanyl;3636-8;Fentanyl:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2090;FENTS;Fentanyl, Serum;31829;Norfentanyl;11074-2;Norfentanyl:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2091;FENTU;Fentanyl with Metabolite Confirmation, Urine;45532;Fentanyl Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2092;FENTU;Fentanyl with Metabolite Confirmation, Urine;45530;Fentanyl;3637-6;Fentanyl:MCnc:Pt:Urine:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2093;FENTU;Fentanyl with Metabolite Confirmation, Urine;45531;Norfentanyl;11075-9;Norfentanyl:MCnc:Pt:Urine:Qn:;2011-06-23;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2094;FER;Semen Analysis;FRCT;Fructose;13943-6;Fructose:ACnc:Pt:Semen:Ord:;2012-03-15;Manual
2095;FER;Semen Analysis;AGGLU;Agglutination;33217-1;Spermatozoa.agglutinated:ACnc:Pt:Semen:Ord:;2012-03-12;Manual
2096;FER;Semen Analysis;VISC;Viscosity;32789-0;Viscosity:Visc:Pt:Semen:Ord:;2012-03-12;Manual
2097;FER;Semen Analysis;CMT45;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Manual
2098;FER;Semen Analysis;MOTY;Motility;6800-7;Spermatozoa.motile/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Manual
2099;FER;Semen Analysis;SPML;Sperm/mL;9780-8;Spermatozoa:NCnc:Pt:Semen:Qn:;2012-03-15;Manual
2100;FER;Semen Analysis;MOTML;Motile/mL;42531-4;Spermatozoa.motile:NCnc:Pt:Semen:Qn:;2012-03-15;Manual
2101;FER;Semen Analysis;VL53;Semen Volume;3160-9;Specimen volume:Vol:Pt:Semen:Qn:;2012-03-12;Manual
2102;FER;Semen Analysis;PH1;pH;2752-4;pH:LsCnc:Pt:Semen:Qn:;2012-03-15;Manual
2103;FER;Semen Analysis;ABSTN;Abstinence;10587-4;Sexual abstinence duration:Time:Pt:^Patient:Qn:;2012-03-12;Manual
2104;FER;Semen Analysis;APP3;Appearance;13359-5;Character:Aper:Pt:Semen:Nom:;2012-03-12;Manual
2105;FER2;WHO Morphology;CMT24;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Includes concentration, World Health Organization morphology, and presence of other cellular elements.
2106;FER2;WHO Morphology;WBC5;WBC/mL;10579-1;Leukocytes:NCnc:Pt:Semen:Qn:;2012-03-12;Includes concentration, World Health Organization morphology, and presence of other cellular elements.
2107;FERR;Ferritin, Serum;FERR;Ferritin, S;2276-4;Ferritin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
2108;FESE;Fennel Seed, IgE;FESE;Fennel Seed, IgE;10929-8;Foeniculum vulgare seed Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2109;FEST;Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue;51540;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2110;FEST;Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue;51538;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2111;FEST;Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue;CG636;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2112;FEST;Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue;51535;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-28;Fluorescence In Situ Hybridization (FISH)
2113;FET;Iron, Liver Tissue;7770;Hepatic Iron Index;49061-5;Hepatic iron index:Ratio:Pt:Liver:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
2114;FET;Iron, Liver Tissue;8350;Iron, Liver Ts;15357-7;Iron:MCnt:Pt:Tiss:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
2115;FEU;Iron, 24 Hour, Urine;854;Fe Concentration;30030-1;Iron:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
2116;FEU;Iron, 24 Hour, Urine;VL20;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
2117;FEU;Iron, 24 Hour, Urine;TM22;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
2118;FEU;Iron, 24 Hour, Urine;8571;Iron, 24 Hr, U;2499-2;Iron:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
2119;FEUR;Iron, Random, Urine;88970;Iron, Random, U;2504-9;Iron:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
2120;FEWS;Ewing Sarcoma (EWS) 22q12 Rearrangement, FISH, Tissue;22664;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
2121;FEWS;Ewing Sarcoma (EWS) 22q12 Rearrangement, FISH, Tissue;CG072;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2122;FEWS;Ewing Sarcoma (EWS) 22q12 Rearrangement, FISH, Tissue;22661;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2123;FEWS;Ewing Sarcoma (EWS) 22q12 Rearrangement, FISH, Tissue;22663;Results;21783-6;Cells.t(12,22)(ATF1,EWSR1)/Cells.total:NFr:Pt:Bld/Tiss:Qn:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2124;FEWS;Ewing Sarcoma (EWS) 22q12 Rearrangement, FISH, Tissue;22659;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH)
2125;FEYE;Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue;CG081;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2126;FEYE;Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue;29679;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2127;FEYE;Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue;29676;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH)
2128;FEYE;Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue;29681;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
2129;FFAG4;Filaria IgG4 Antibody, ELISA;FFAG4;Filaria IgG4 Antibody;14208-3;Filaria Ab.IgG4:ACnc:Pt:Ser:Qn;2014-05-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2130;FFES;Estradiol Free, Serum (includes Estradiol and SHBG);Z0229;Free Estradiol, Serum;2240-0;;2012-03-12;Mass Spectrometry
2131;FFES;Estradiol Free, Serum (includes Estradiol and SHBG);Z0259;Estradiol, Serum;35384-7;;2012-03-12;Mass Spectrometry
2132;FFES;Estradiol Free, Serum (includes Estradiol and SHBG);Z0230;Sex Hormone Binding Globulin (SHBG);13967-5;Sex hormone binding globulin:SCnc:Pt:Ser/Plas:Qn:;2012-03-12;Mass Spectrometry
2133;FFES;Estradiol Free, Serum (includes Estradiol and SHBG);Z0228;Free Estradiol, Percent;14960-9;;2012-03-12;Mass Spectrometry
2134;FFOAB;Formic Acid, Serum/Plasma;Z1439;Formic Acid;2292-1;;2013-12-18;Ion Chromatography (IC)
2135;FFPII;Food Panel II IgG;Z3705;Chicken IgG;35532-1;Chicken Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2136;FFPII;Food Panel II IgG;Z3706;Chocolate/Cacao IgG;35554-5;Chocolate Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2137;FFPII;Food Panel II IgG;Z3707;Codfish/Scrod IgG;49099-5;Gadus morhua Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2138;FFPII;Food Panel II IgG;Z3720;Yeast Saccharomyces cerevisiae IgG;35538-8;Saccharomyces cerevisiae Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2139;FFPII;Food Panel II IgG;Z3719;Wheat IgG;35537-0;Triticum aestivum Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2140;FFPII;Food Panel II IgG;Z3718;Tomato IgG;35547-9;Lycopersicon lycopersicum Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2141;FFPII;Food Panel II IgG;Z3717;Soybean IgG;35546-1;Glycine max Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2142;FFPII;Food Panel II IgG;Z3714;Pork IgG;35543-8;Pork Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2143;FFPII;Food Panel II IgG;Z3715;Potato White IgG;35544-6;Solanum tuberosum Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2144;FFPII;Food Panel II IgG;Z3716;Rye Food IgG;51933-0;Secale cereale Ab.IgG:Mcnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2145;FFPII;Food Panel II IgG;Z3709;Egg White IgG;35535-4;Egg white Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2146;FFPII;Food Panel II IgG;Z3710;Malt IgG;51922-3;Malt Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2147;FFPII;Food Panel II IgG;Z3711;Oat IgG;51901-7;Avena sativa Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2148;FFPII;Food Panel II IgG;Z3712;Orange IgG;51904-1;Citrus sinensis Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2149;FFPII;Food Panel II IgG;Z3708;Corn IgG;35534-7;Zea mays Ab.IgG:MCnc:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2150;FFPII;Food Panel II IgG;Z3702;Barley IgG;51917-3;Hordeum vulgare Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2151;FFPII;Food Panel II IgG;Z3703;Beef IgG;35529-7;Beef Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2152;FFPII;Food Panel II IgG;Z3704;Casein IgG;53829-8;Casein Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2153;FFPII;Food Panel II IgG;Z3713;Peanut IgG;35542-0;Arachis hypogaea Ab.IgG:MCnc:Pt:Ser:Qn:;2014-01-16;Enzyme Immunoassay (FEIA)
2154;FFRBS;Friedreich Ataxia, Frataxin, Quantitative, Blood Spot;32252;Interpretation;59462-2;;2012-04-09;Luminex Immunoassay
2155;FFRBS;Friedreich Ataxia, Frataxin, Quantitative, Blood Spot;32250;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2011-06-22;Luminex Immunoassay
2156;FFRBS;Friedreich Ataxia, Frataxin, Quantitative, Blood Spot;32249;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-22;Luminex Immunoassay
2157;FFRM;Formic Acid, Urine;Z1465;Formic Acid (Creatinine corrected);13742-2;;2013-12-18;Colorimetry (C)/Gas Chromatography (GC)
2158;FFRM;Formic Acid, Urine;Z1438;Formic Acid, U;14052-5;;2013-12-18;Colorimetry (C)/Gas Chromatography (GC)
2159;FFRM;Formic Acid, Urine;Z1460;Creatinine, U;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2013-12-18;Colorimetry (C)/Gas Chromatography (GC)
2160;FFRWB;Friedreich Ataxia, Frataxin, Quantitative, Whole Blood;32256;Interpretation;59462-2;;2012-04-09;Luminex Immunoassay
2161;FFRWB;Friedreich Ataxia, Frataxin, Quantitative, Whole Blood;32254;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2011-06-22;Luminex Immunoassay
2162;FFRWB;Friedreich Ataxia, Frataxin, Quantitative, Whole Blood;32253;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-22;Luminex Immunoassay
2163;FFTAT;Thrombin-Antithrombin Complex;Z0209;Thrombin Antithrombin Complex;14182-0;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2164;FFTEN;Tetrahydrobiopterin & Neopterin Profile (BH4, N);Z2235;Tetrahydrobiopterin;59247-7;;2013-05-23;Electrochemistry and Fluorescences
2165;FFTEN;Tetrahydrobiopterin & Neopterin Profile (BH4, N);Z2234;Neopterin;34146-1;Neopterin:SCnc:Pt:CSF:Qn:;2012-03-12;Electrochemistry and Fluorescences
2166;FFTHM;Thiopental and Metabolite, Serum/Plasma;Z1457;Pentobarbital;3924-8;Pentobarbital:MCnc:Pt:Ser/Plas:Qn:;2013-12-18;Gas Chromatography (GC)
2167;FFTHM;Thiopental and Metabolite, Serum/Plasma;Z1446;Thiopental;4050-1;;2013-12-18;Gas Chromatography (GC)
2168;FFTHO;Thiosulfate, Urine;Z1472;Thiosulfate;12420-6;;2013-12-18;Colorimetry (C), Ion Chromatography (IC)
2169;FFTHO;Thiosulfate, Urine;Z1452;Creatinine;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2013-12-18;Colorimetry (C), Ion Chromatography (IC)
2170;FFTIC;Ticlopidine, Serum/Plasma;Z1475;Ticlopidine;11003-1;;2013-12-18;Gas Chromatography (GC)
2171;FFTOX;Toxocara Antibody, ELISA (Serum);Z1721;Toxocara Antibody, Serum, ELISA;5386-8;;2012-03-20;Enzyme Linked Immunosorbent Assay (ELISA)
2172;FFTPO;Thrombopoietin (TPO);FFTPO;Thrombopoietin (TPO);43237-7;Thrombopoietin:MCnc:Pt:PPP:Qn:EIA;2014-01-16;Immunoassay
2173;FFTRO;Trofile DNA Co-Receptor Tropism Assay;Z2283;Tropotype Result;53923-9;HIV 1 tropism:Prid:Pt:Bld:Nar:::Micro;2012-03-12;CD4 cell culture assay for phenotypic recombinant-virus co-receptor tropism.
2174;FFTRP;Trofile Co-Receptor Tropism Assay;Z1038;Tropotype Result;57182-8;;2012-03-12;CD4 cell culture assay for phenotypic recombinant-virus co-receptor tropism.
2175;FFTUM;Tumor Necrosis Factor-Alpha, Highly Sensitive;Z1550;TNF-Alpha, Highly Sensitive;3074-2; ;2014-03-28;Immunoassay
2176;FFTXM;Toxoplasma IgM, ELISA, Serum;Z1491;Toxoplasma IgM, ELISA, Serum;8040-8;;2013-11-01;ELISA
2177;FFTZU;Flunitrazepam (Rohypnol) Confirmation, Urine;Z3293;7-Aminoflunitrazepam;51777-1;7-Aminoflunitrazepam:MCnc:Pt:Urine:Qn:Confirm;2014-09-04;Gas Chromatography/Mass Spectrometry (GC/MS)Only orderable as a reflex from FSED
2178;FFTZU;Flunitrazepam (Rohypnol) Confirmation, Urine;Z3292;Flunitrazepam;20528-6;Flunitrazepam:MCnc:Pt:Urine:Qn:Confirm;2014-09-04;Gas Chromatography/Mass Spectrometry (GC/MS)Only orderable as a reflex from FSED
2179;FG4FI;IgG4 Food Panel I;Z3728;Potato White IgG4;56429-4;Solanum tuberosum Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2180;FG4FI;IgG4 Food Panel I;Z3730;Wheat IgG4;56417-9;Triticum aestivum Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2181;FG4FI;IgG4 Food Panel I;Z3729;Soybean IgG4;56390-8;Glycine max Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2182;FG4FI;IgG4 Food Panel I;Z3723;Casein IgG4;56207-4;Casein Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2183;FG4FI;IgG4 Food Panel I;Z3724;Chicken IgG4;56218-1;Chicken Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2184;FG4FI;IgG4 Food Panel I;Z3725;Corn IgG4;56231-4;Zea mays Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2185;FG4FI;IgG4 Food Panel I;Z3727;Milk Cow IgG4;56234-8;Cow milk Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2186;FG4FI;IgG4 Food Panel I;Z3726;Egg Whole IgG4;56255-3;Egg whole Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2187;FG4FI;IgG4 Food Panel I;Z3721;Alpha Lactalbumin IgG4;56301-5;Lactalbumin alpha Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2188;FG4FI;IgG4 Food Panel I;Z3722;Beef IgG4;56438-5;Beef Ab.IgG4:MCnc:Pt:Ser:Qn:;2014-02-24;Enzyme Immunoassay (FEIA)
2189;FGAKM;Fibrinogen Alpha-Chain (FGA) Gene, Known Mutation;33483;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2190;FGAKM;Fibrinogen Alpha-Chain (FGA) Gene, Known Mutation;33486;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2191;FGAKM;Fibrinogen Alpha-Chain (FGA) Gene, Known Mutation;33485;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2192;FGAKM;Fibrinogen Alpha-Chain (FGA) Gene, Known Mutation;33488;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2193;FGAMS;Fibrinogen Alpha-Chain (FGA) Gene, Full Gene Analysis;33477;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2194;FGAMS;Fibrinogen Alpha-Chain (FGA) Gene, Full Gene Analysis;33472;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2195;FGAMS;Fibrinogen Alpha-Chain (FGA) Gene, Full Gene Analysis;33475;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2196;FGAMS;Fibrinogen Alpha-Chain (FGA) Gene, Full Gene Analysis;33474;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2197;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;50850;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2198;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;50855;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2199;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;50856;Amendment;42635-3;Chromosome 12p tetrasomy:Arb:Pt:Tiss fixed:Ord:Molgen;2013-07-30;Fluorescence In Situ Hybridization (FISH)
2200;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;CG291;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2201;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;50853;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2202;FGCT;Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue;50854;Result;42635-3;Chromosome 12p tetrasomy:Arb:Pt:Tiss fixed:Ord:Molgen;2011-06-16;Fluorescence In Situ Hybridization (FISH)
2203;FGEN;Fungal Culture, Routine;FGEN;Fungal Culture, Routine;42805-2;Fungus identified:Prid:Pt:XXX:Nom:;2013-09-17;Conventional agar culture technique with identification by macroscopy and microscopic morphology, nucleic acid hybridization probes, D2 rDNA gene sequencing, real-time polymerase chain reaction (rtPCR), or MALDI-TOF mass spectrometry. Dimorphic pathogen identification is confirmed using molecular methods (ie, nucleic acid hybridization probes, D2 rDNA gene sequencing, rtPCR or MALDI-TOF mass spectrometry).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2204;FGF23;Fibroblast Growth Factor 23 (FGF23), Plasma;88662;Fibroblast Growth Factor 23, P;46699-5;Fibroblast growth factor 23:ACnc:Pt:Plas:Qn:;2009-11-13;Immunometric Enzyme Assay
2205;FGFR1;FGFR1, 8p11.2 Rearrangement, FISH;CG605;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Fluorescence In Situ Hybridization (FISH)
2206;FGFR1;FGFR1, 8p11.2 Rearrangement, FISH;34396;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2207;FGFR1;FGFR1, 8p11.2 Rearrangement, FISH;CG606;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Fluorescence In Situ Hybridization (FISH)
2208;FGHBP;Growth Hormone Binding Protein (GHBP);Z1749;Growth Hormone Binding Protein;11015-5;;2012-03-12;Ligand binding immunoprecipitation assay
2209;FGLIO;1p/19q Deletion in Gliomas, FISH, Tissue;CG092;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2210;FGLIO;1p/19q Deletion in Gliomas, FISH, Tissue;17396;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2211;FGLIO;1p/19q Deletion in Gliomas, FISH, Tissue;17399;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2212;FGLIO;1p/19q Deletion in Gliomas, FISH, Tissue;17398;Results;42634-6;Del(1p,19q) gene deletion:Arb:Pt:Tiss fixed:Ord:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2213;FGLIO;1p/19q Deletion in Gliomas, FISH, Tissue;17394;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2214;FGLMA;GlycoMark;Z0275;GlycoMark;53835-5;;2012-03-12;Enzymatic, Colorimetric Assay
2215;FGNRH;Gonadotropin Releasing Hormone (Gn-RH);Z0929;Gonadotropin Releasing Hormone;13660-6;;2012-03-12;Direct Radioimmunoassay (RIA)
2216;FGQ1B;Ganglioside GQ1b Antibody (IgG), EIA;Z2521;GQ1b Ab (IgG);14254-7;Ganglioside GQ1b Ab.IgG:Titr:Pt:Ser:Qn;2014-03-28;Enzyme Immunoassay (EIA)
2217;FH24U;Histamine, 24-Hour Urine;Z3693;Histamine, 24 hr Urine;13756-2;Histamine/Creatinine:MRto:24H:Urine:Qn:;2014-04-16;Immunoassay
2218;FH24U;Histamine, 24-Hour Urine;Z3694;Creatinine, 24-Hour Urine;2162-6;Creatinine:MRat:24H:Urine:Qn:;2014-04-16;Immunoassay
2219;FH24U;Histamine, 24-Hour Urine;Z3686;Total Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2014-04-16;Immunoassay
2220;FH2GE;HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue;51125;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH) 
2221;FH2GE;HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue;51123;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) 
2222;FH2GE;HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue;51119;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH) 
2223;FH2GE;HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue;CG555;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) 
2224;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;51137;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2225;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;51138;Amendment;31150-6;HER2:ACnc:Pt:Tiss:Ord:FISH;2013-07-30;Fluorescence In Situ Hybridization (FISH)
2226;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;51135;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2227;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;51131;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2228;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;51136;Result;31150-6;HER2:ACnc:Pt:Tiss:Ord:FISH;2011-06-23;Fluorescence In Situ Hybridization (FISH)
2229;FH2MT;HER2 Amplification, Miscellaneous Tumor, FISH, Tissue;CG566;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2230;FH2UR;HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue;51722;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2231;FH2UR;HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue;51720;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2232;FH2UR;HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue;CG644;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2233;FH2UR;HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue;51716;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-23;Fluorescence In Situ Hybridization (FISH)
2234;FHAM;Human Anti-mouse Antibody (HAMA);FHAM;Human Anti-mouse AB (HAMA);14975-7;Human antimouse Ab:MCnc:Pt:Ser:Qn:;2014-04-14;Enzyme Linked Immunosorbent Assay (ELISA)
2235;FHAN;Hantavirus Antibodies (IgG, IgM) with Reflex to Confirmation;Z1943;Hantavirus IgM;26650-2;Hantavirus sin nombre Ab.IgM:ACnc:Pt:Ser:Ord:;2014-05-21;ELISA
2236;FHAN;Hantavirus Antibodies (IgG, IgM) with Reflex to Confirmation;Z1942;Hantavirus IgG;26620-5;Hantavirus Ab.IgG:ACnc:Pt:Ser:Ord:;2014-05-21;ELISA
2237;FHDLS;HDL Cholesterol Subclasses;Z1556;HDL-2 Cholesterol;9832-7;Cholesterol.in HDL 2:MCnc:Pt:Ser/Plas:Qn;2014-03-28;Precipitation, Colorimetric, Enzymatic
2238;FHDLS;HDL Cholesterol Subclasses;Z1560;HDL-3 Cholesterol;9833-5;Cholesterol.in HDL 3:MCnc:Pt:Ser/Plas:Qn;2014-03-28;Precipitation, Colorimetric, Enzymatic
2239;FHER;HER-2/neu, Quantitative, ELISA;Z0985;HER-2/neu Quantitative;32996-1; ;2012-03-12;Enzyme Linked Immunosorbent Assay (ELISA)
2240;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;16882;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2241;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;G_652;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2242;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;16885;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2243;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;16884;Results;31150-6;HER2:ACnc:Pt:Tiss:Ord:FISH;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2244;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;16880;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2245;FHER2;HER2 Amplification Associated with Breast Cancer, FISH, Tissue;16886;Amendment;31150-6;HER2:ACnc:Pt:Tiss:Ord:FISH;2013-08-09;Fluorescence In Situ Hybridization (FISH)
2246;FHEXA;Hexagonal Phospholipid Neutralization;Z0210;Hexagonal Phospholipid Neutral;3282-1;;2012-03-12;Clot
2247;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0980;ALT (SGPT);1743-4;;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2248;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0978;Bilirubin, Total;1975-2;Bilirubin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2249;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0979;GGT;2324-2;Gamma glutamyl transferase:CCnc:Pt:Ser/Plas:Qn:;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2250;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0975;Alpha 2 Macroglobulins, Qn;1835-8;Alpha-2-Macroglobulin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2251;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0977;Apolipoprotein A-1;1869-7;Apolipoprotein A-I:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2252;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0976;Haptoglobin;4542-7;Haptoglobin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2253;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0973;Necroinflammat Activity Score;48792-6;;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2254;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0971;Fibrosis Score;48795-9;;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2255;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0972;Fibrosis Stage;48794-2;;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2256;FHFIB;Hepatitis C Virus (HCV) FibroSURE;Z0974;Necroinflammat Activity Grade;48793-4;;2012-03-12;ImmunologicColorimetricKinetic - colorimetricNephelometry
2257;FHPCF;Heparin Cofactor II;Z0213;Heparin Cofactor II;3268-0;;2012-03-12;Chromogenic
2258;FHPL;Human Placental Lactogen (HPL);Z0146;Human Placental Lactogen;2104-8;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2259;FHSTW;Histamine, Whole Blood;Z2753;Histamine, Whole Blood;46436-2;Histamine:SCnc:Pt:Bld:Qn:;2013-12-05;Quantitative Enzyme-Linked Immunosorbent Assay
2260;FHTL;HTLV I/II DNA, Qualitative Real-Time  PCR;Z0501;HTLV-II DNA;16980-5;HTLV 2 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-08-20;Real-Time PCR
2261;FHTL;HTLV I/II DNA, Qualitative Real-Time  PCR;Z0500;HTLV-I DNA;16981-3;HTLV 1 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-08-20;Real-Time PCR
2262;FHVP;Hepatitis A (HAV) SuperQual by PCR;Z1262;HAV RNA;7904-6;;2012-03-12;Polymerase Chain Reaction (PCR)
2263;FHYDC;Hydroxychloroquine, Serum/Plasma;Z1437;Hydroxychloroquine;3684-8;;2013-12-18;High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
2264;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3349;Allergen Interp Immunocap Score IgE;33536-4; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2265;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3347;Allergen, Food, Pork IgE;6219-0; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2266;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3335;A. pullulans Ab, Precipitin;6810-6; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2267;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3340;A. fumigatus 2 Ab, Precipitin;29334-0; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2268;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3346;Allergen, Food, Beef IgE;6039-2; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2269;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3345;Allergen, Animal, Feather Mix IgE;31161-3; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2270;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3344;T. sacchari Ab, Precipitin;21561-6; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2271;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3341;A. fumigatus 3 Ab, Precipitin;15151-4; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2272;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3342;S. viridis Ab, Precipitin;22572-2; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2273;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3343;T. candidus Ab, Precipitin;21560-8; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2274;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3348;Allergen Fungi/Mold, Phoma betae IgE;6216-6; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2275;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3339;A. flavus Ab, Precipitin;23820-4; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2276;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3338;T. vulgaris 1 Ab, Precipitin;6821-3; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2277;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3336;Pigeon Serum Ab, Precipitin;6733-0; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2278;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3334;A. fumigatus 6 Ab, Precipitin;6809-8; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2279;FHYPP;Hypersensitivity Pneumonitis Extended Panel (Farmer's Lung Panel);Z3333;A. fumigatus 1 Ab, Precipitin;6808-0; ;2013-12-19;Qualitative Immunodiffusion/Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay
2280;FIB;Fibrinogen, Plasma;FIB;Fibrinogen, P;3255-7;Fibrinogen:MCnc:Pt:PPP:Qn:Coag;2012-03-15;Electromagnetic End point Detection: STA-R Evolution
2281;FIGBP;IGF Binding Protein-1 (IGFBP-1);Z2268;IGFBP-1;12722-5;Insulin-Like growth factor binding protein 1:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay (RIA)
2282;FIL1S;Interleukin-10 (IL-10) Serum;FIL1S;IL-10, Serum;26848-2;Interleukin 10:MCnc:Pt:Ser/Plas:Qn:;2014-08-21;Multiplex array Electrochemiluminescence
2283;FIL2M;Interleukin 2;FIL2M;Interleukin 2;33939-0;Interleukin 2:MCnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Multiplex Bead Assay
2284;FIL2S;Interleukin 2 Receptor (CD25), Soluble;FIL2S;IL 2 Receptor (CD25), Soluble;33939-0;Interleukin 2:MCnc:Pt:Ser/Plas:Qn:;2014-02-18;Quantitative Multiplex Bead Assay
2285;FIL4S;Interleukin-4 (IL-4) Serum;FIL4S;IL-4, Serum;27161-9;Interleukin 4:MCnc:Pt:Ser/Plas:Qn:;2014-08-21;Multiplex array electrochemiluminescence
2286;FIL5P;Interleukin - 5 (IL 5) Plasma;FIL5P;IL-5, Plasma;33938-2;Interleukin 5:MCnc:Pt:Ser/Plas:Qn:;2014-08-21;Multiplex array electrochemiluminescence
2287;FIL6H;Interleukin-6, Highly Sensitive;FIL6H;IL-6, Highly Sensitive;26881-3;Interleukin 6:MCnc:Pt:Ser/Plas:Qn:;2013-12-20;Enzyme Linked Immunosorbent Immunoassay
2288;FILK6;Interleukin 6;FILK6;Interleukin 6;26881-3;Interleukin 6:MCnc:Pt:Ser/Plas:Qn;2014-07-01;Quantitative Multiplex Bead Assay
2289;FIMM;Immunofixation, CSF;Z1570;Interpretation:;13174-8;Interpretation:Imp:Pt:CSF:Nom:Immunofixation;2012-03-20;Immunofixation
2290;FIMRG;Imatinib Mesylate Responsive Genes, Locus Anomalies, FISH;G_A02;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2291;FIMRG;Imatinib Mesylate Responsive Genes, Locus Anomalies, FISH;27113;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2292;FIMRG;Imatinib Mesylate Responsive Genes, Locus Anomalies, FISH;G_A04;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2293;FIMRG;Imatinib Mesylate Responsive Genes, Locus Anomalies, FISH;27115;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2294;FIMT;Inflammatory Myofibroblastic Tumors (IMT), 2p23 Rearrangement, FISH, Tissue;29607;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2295;FIMT;Inflammatory Myofibroblastic Tumors (IMT), 2p23 Rearrangement, FISH, Tissue;29605;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2296;FIMT;Inflammatory Myofibroblastic Tumors (IMT), 2p23 Rearrangement, FISH, Tissue;CG101;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2297;FIMT;Inflammatory Myofibroblastic Tumors (IMT), 2p23 Rearrangement, FISH, Tissue;29602;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2298;FINCH;Finch Feathers, IgE;FINCH;Finch Feathers, IgE;13833-9;Finch feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2299;FINS;Insulin, Free, Serum;FINS;Free Insulin, S;6901-3;Insulin.free:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Chemiluminescent Immunoenzymatic Assay System
2300;FINTA;Interleukin 1a;Z0942;Interleukin 1-Alpha;33821-0;Interleukin 1 alpha:MCnc:Pt:Ser/Plas:Qn;2012-03-12;Enzyme Immunoassay (EIA)
2301;FINTB;Interleukin 1b;Z0943;Interleukin 1-Beta;13629-1;Interleukin 1 beta:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Enzyme Immunoassay (EIA)
2302;FIXKM;Hemophilia B, Factor IX Gene Known Mutation Screening;23766;Factor IX Known Mutation Interp;69049-5;;2012-04-05;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2303;FIXKM;Hemophilia B, Factor IX Gene Known Mutation Screening;23765;Factor IX Known Mutation  Result;69483-6;;2012-04-10;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2304;FIXKM;Hemophilia B, Factor IX Gene Known Mutation Screening;23763;F IX Know Mut Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2305;FIXMS;Hemophilia B, Factor IX Gene Mutation Screening;23778;Factor IX Mutation Screen Result;38896-7;F9 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2306;FIXMS;Hemophilia B, Factor IX Gene Mutation Screening;23776;FIX Mut Screen Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2307;FIXMS;Hemophilia B, Factor IX Gene Mutation Screening;23779;Factor IX Mutation Screen Interp;69049-5;;2012-04-05;Polymerase Chain Reaction (PCR)/Fluorescent DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2308;FJCV;JC Polyoma Virus DNA, Quantitative Real-Time PCR, Plasma;Z0559;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-08-09;Real-Time PCR
2309;FJPE;Jalapeno/Chipotle (Capsicum annuum) IgE;Z3880;Jalapeno/Chipotle IgE;11189-8;Pepper jalapeno Ab.IgE:ACnc:Pt:Ser:Qn;2014-07-25;Radioimmunoassay (RIA)
2310;FJPE;Jalapeno/Chipotle (Capsicum annuum) IgE;Z3881;CLASS;21453-6;Pepper jalapeno Ab.IgE.RAST class:Threshold:Pt:Ser:Ord;2014-07-25;Radioimmunoassay (RIA)
2311;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;CG111;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2312;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;23279;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2313;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;23280;Result;21700-0;Kallman syndrome gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2314;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;23281;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2315;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;23282;Amendment;21700-0;Kallman syndrome gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Fluorescence In Situ Hybridization (FISH)
2316;FKAL;Kallmann Syndrome, Xp22.3 Deletion, FISH;CG109;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2317;FKETO;Ketoconazole, Serum/Plasma;Z1443;Ketoconazole;10990-0;;2013-12-18;High-Performance Liquid Chromatography/Tandem MassSpectrometry (LC-MS/MS)
2318;FKHR;Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue;27349;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2319;FKHR;Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue;27346;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2320;FKHR;Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue;27351;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2321;FKHR;Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue;CG121;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2322;FL;Fluoride, Plasma;8641;Fluoride, P;14726-4;Fluoride:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Ion-Selective Electrode (ISE)
2323;FLACF;Lactoferrin, Fecal by ELISA;FLACF;Lactoferrin, Fecal by ELISA;40703-1; ;2013-10-31;Qualitative Enzyme-Linked Immunosorbent Assay
2324;FLCA;Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue;51146;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2325;FLCA;Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue;CG583;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2326;FLCA;Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue;51143;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2011-03-09;Fluorescence In Situ Hybridization (FISH)
2327;FLEC;Flecainide, Serum;9243;Flecainide, S;3638-4;Flecainide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
2328;FLEP;Leptin;Z0262;Leptin;21365-2;Leptin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2329;FLEVO;Levodopa, Serum/Plasma;Z1444;Levodopa;9385-6;;2013-12-18;High-Performance Liquid Chromatography (HPLC)
2330;FLGA;FLG Gene, Mutation Analysis;55016;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2331;FLGA;FLG Gene, Mutation Analysis;55019;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2332;FLGA;FLG Gene, Mutation Analysis;55015;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2333;FLGA;FLG Gene, Mutation Analysis;55013;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2334;FLIPR;Lipase, Random Urine;Z1559;Lipase, Urine;10888-6;Triacylglycerol lipase:CCnc:Pt:Urine:Qn;2013-12-18;Enzymatic Colorimetric
2335;FLNDR;Flounder (Bothidae/Pleuronectidae Fam) IgE;Z3816;CLASS;15715-6;Flounder Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-21;ImmunoCAP FEIA
2336;FLNDR;Flounder (Bothidae/Pleuronectidae Fam) IgE;Z3815;Flounder IgE;7316-3;Flounder Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;ImmunoCAP FEIA
2337;FLP;Fetal Lung Profile, Amniotic Fluid;2405;L/S Ratio;14976-5;Lecithin/Sphingomyelin:Ratio:Pt:Amnio fld:Qn:;2009-11-13;Thin-Layer Chromatography (TLC) with Quantitation by Densitometry Includes lecithin/sphingomyelin (L/S) ratio, and phosphatidylglycerol (PG), semiquantitative on amniotic fluid.
2338;FLP;Fetal Lung Profile, Amniotic Fluid;2408;Result;47226-6;Fetal lung maturity:Imp:Pt:Amnio fld:Nom:;2009-11-13;Thin-Layer Chromatography (TLC) with Quantitation by Densitometry Includes lecithin/sphingomyelin (L/S) ratio, and phosphatidylglycerol (PG), semiquantitative on amniotic fluid.
2339;FLP;Fetal Lung Profile, Amniotic Fluid;2407;Phospglycerol;2785-4;Phosphatidylglycerol:ACnc:Pt:Amnio fld:Ord:;2009-11-13;Thin-Layer Chromatography (TLC) with Quantitation by Densitometry Includes lecithin/sphingomyelin (L/S) ratio, and phosphatidylglycerol (PG), semiquantitative on amniotic fluid.
2340;FLP;Fetal Lung Profile, Amniotic Fluid;8929;Fetal Lung Profile, AF;47226-6;Fetal lung maturity:Imp:Pt:Amnio fld:Nom:;2009-11-13;Thin-Layer Chromatography (TLC) with Quantitation by Densitometry Includes lecithin/sphingomyelin (L/S) ratio, and phosphatidylglycerol (PG), semiquantitative on amniotic fluid.
2341;FLPA2;Lipoprotein Associated Phospholipase A2 (PLAC);Z2707;Lipoprotein Assoc Phospholipase A2;39804-0;Lipoprotein associated phospholipase A2:MCnc:Pt:PSer/Plas:Qn:;2014-02-18;Quantitative Enzyme-Linked Immunosorbent Assay
2342;FLRET;Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue;51753;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2343;FLRET;Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue;CG650;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2344;FLRET;Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue;51750;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-18;Fluorescence In Situ Hybridization (FISH)
2345;FLUC;5-Flucytosine, Serum;82741;5-Flucytosine, S;3639-2;5-Fluorocytosine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2346;FLUCO;Fluconazole, Serum;82522;Fluconazole, S;10987-6;Fluconazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2347;FLUOX;Fluoxetine, Serum;251;Norfluoxetine, S;3868-7;Norfluoxetine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
2348;FLUOX;Fluoxetine, Serum;252;Fluoxetine+Norfluoxetine;10339-0;Fluoxetine+Norfluoxetine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
2349;FLUOX;Fluoxetine, Serum;80228;Fluoxetine, S;3644-2;Fluoxetine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
2350;FLUPV;Lupus Anticoagulant Evaluation with Reflex;Z0735;DRVVT Screen;6303-2;Coagulation dilute Russell viper venom induced:Time:Pt:PPP:Qn:Coag;2014-04-17;Photo Optical Clot Detection
2351;FLUPV;Lupus Anticoagulant Evaluation with Reflex;Z0734;Lupus Anticoagulant;3281-3;Lupus anticoagulant:Imp:Pt:PPP:Nom:;2014-04-17;Photo Optical Clot Detection
2352;FLUPV;Lupus Anticoagulant Evaluation with Reflex;Z0544;PTT-LA Screen;34571-0;Coagulation surface induced.lupus sensitive:Time:Pt:PPP:Qn:Coag;2014-04-18;Photo Optical Clot Detection
2353;FMACR;Macroamylase;FMACR;Macroamylase;15358-5;Macroamylase:ACnc:Pt:Ser/Plas:Ord:;2013-12-18;Polyethylene Glycol Precipitation
2354;FMAS;Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue;53801;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2355;FMAS;Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue;CG873;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2356;FMAS;Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue;53799;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2357;FMAS;Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue;53796;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2358;FMB;Fetomaternal Bleed, Flow Cytometry, Blood;4058;Remarks;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-08-08;Flow Cytometry
2359;FMB;Fetomaternal Bleed, Flow Cytometry, Blood;28203;Rh Immune Globulin;55731-4;Inject Rh immune globulin:Mass:Pt:Dose:Qn:;2009-11-13;Flow Cytometry
2360;FMB;Fetomaternal Bleed, Flow Cytometry, Blood;28202;Fetal-Maternal Bleed;55730-6;Fetal blood:Vol:Pt:Bld:Qn:;2011-10-05;Flow Cytometry
2361;FMB;Fetomaternal Bleed, Flow Cytometry, Blood;28204;Mother's Rh;10331-7;Rh:Type:Pt:Bld:Nom:;2009-11-13;Flow Cytometry
2362;FMBNY;Fetomaternal Bleed, New York;28203;Rh Immune Globulin;55731-4;Inject Rh immune globulin:Mass:Pt:Dose:Qn:;2009-11-13;Flow Cytometry
2363;FMBNY;Fetomaternal Bleed, New York;28246;Remarks;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-08-08;Flow Cytometry
2364;FMBNY;Fetomaternal Bleed, New York;28204;Mother's Rh;10331-7;Rh:Type:Pt:Bld:Nom:;2009-11-13;Flow Cytometry
2365;FMBNY;Fetomaternal Bleed, New York;28202;Fetal-Maternal Bleed;55730-6;Fetal blood:Vol:Pt:Bld:Qn:;2011-10-05;Flow Cytometry
2366;FMDL;Miller-Dieker Syndrome, 17p13.3 Deletion, FISH;23328;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2367;FMDL;Miller-Dieker Syndrome, 17p13.3 Deletion, FISH;CG169;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-21;Fluorescence In Situ Hybridization (FISH)
2368;FMDL;Miller-Dieker Syndrome, 17p13.3 Deletion, FISH;23327;Results;48974-0;MDCR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2369;FMDL;Miller-Dieker Syndrome, 17p13.3 Deletion, FISH;23326;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2370;FMDL;Miller-Dieker Syndrome, 17p13.3 Deletion, FISH;CG171;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2371;FMDS;Myelodysplastic Syndrome (MDS), FISH;G_579;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2372;FMDS;Myelodysplastic Syndrome (MDS), FISH;23292;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2373;FMDS;Myelodysplastic Syndrome (MDS), FISH;23290;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2374;FMDS;Myelodysplastic Syndrome (MDS), FISH;G_577;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2375;FMEL;Melanoma, FISH, Tissue;51335;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2376;FMEL;Melanoma, FISH, Tissue;51333;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-15;Fluorescence In Situ Hybridization (FISH)
2377;FMEL;Melanoma, FISH, Tissue;51332;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2378;FMEL;Melanoma, FISH, Tissue;51330;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-08-15;Fluorescence In Situ Hybridization (FISH)
2379;FMELT;Melatonin;Z2261;Melatonin;11055-1;;2012-03-12;Quantitative Radioimmunoassay
2380;FMETF;Metformin,  Serum/Plasma;Z1476;Metformin;35698-0;;2013-12-18;High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
2381;FMFC;Myeloma, FISH, Fixed Cells;51018;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2382;FMFC;Myeloma, FISH, Fixed Cells;CG408;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2383;FMFC;Myeloma, FISH, Fixed Cells;51015;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2384;FMFC;Myeloma, FISH, Fixed Cells;51020;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
2385;FMGA;Myelin Assoc. Glycoprotein (MAG) Antibody w/Reflex to MAG-SGPG & MAG, EIA;Z2522;MAG Ab (IgM), Western Blot;31023-5;Myelin associated glycoprotein Ab.IgM:ACnc:Pt:Ser:Ord:IB;2014-04-01;Western Blot (WB)Enzyme Immunoassay (EIA) (if appropriate)
2386;FMI2;MI-2;Z2421;MI-2;18485-3;Mi-2 Ab:ACnc:Pt:Ser:Ord:;2013-11-01;Immunoprecipitation (IPP)
2387;FMIL;Foxtail Millet, IgE;FMIL;Foxtail Millet, IgE;11186-4;Setaria italica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2388;FMINT;Mint (Mentha Piperita) IgE;Z3801;CLASS;15853-5;Mentha piperita Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-20;ImmunoCAP FEIA
2389;FMINT;Mint (Mentha Piperita) IgE;Z3800;Mint IgE;11190-6;Mentha piperita Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-20;ImmunoCAP FEIA
2390;FMNB;Neuroblastoma, 2p24 (MYCN) Amplification, FISH, Blood or Bone Marrow;34385;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2391;FMNB;Neuroblastoma, 2p24 (MYCN) Amplification, FISH, Blood or Bone Marrow;CG602;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Fluorescence In Situ Hybridization (FISH)
2392;FMNB;Neuroblastoma, 2p24 (MYCN) Amplification, FISH, Blood or Bone Marrow;CG603;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Fluorescence In Situ Hybridization (FISH)
2393;FMOT;Motilin, Plasma or Serum;Z0924;Motilin (Plasma);13891-7;;2012-03-12;Direct Radioimmunoassay (RIA)
2394;FMPNC;Mycoplasma pneumoniae Culture;Z3756;M Pneumoniae Culture;19054-6;Mycoplasma pneumoniae:ACnc:Pt:XXX:Ord:Organism specific culture;2014-05-19;
2395;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3575;Maternal Race;21484-1;Race:Type:Pt:^Mother:Nom:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2396;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3565;Patient's PAPP-A;32046-5;Pregnancy associated plasma protein A:ACnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2397;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3569;Maternal Screen Interpretation;49586-1;First & Second trimester integrated maternal screen:Imp:Pt:^Patient:Nom:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2398;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3570;Maternal Age At Delivery;21612-7;Age:Time:Pt:^Patient:Qn:Reported;2013-11-15;Quantitative Chemiluminescent Immunoassay
2399;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3571;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2400;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3572;Estimated Due Date;11778-8;Delivery date:TmStp:Pt:^Patient:Qn:Clinical.estimate;2013-11-15;Quantitative Chemiluminescent Immunoassay
2401;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3577;Crown Rump Length;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2013-11-15;Quantitative Chemiluminescent Immunoassay
2402;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3574;Number of Fetuses;11878-6;Fetuses:Num:Pt:^Patient:Qn:US;2013-11-15;Quantitative Chemiluminescent Immunoassay
2403;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3566;MoM for PAPP-A;32123-2;Pregnancy associated plasma protein A:MoM:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2404;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3567;Nuchal Translucency (NT);12146-7;Thickness:Len:Pt:Nuchal fold^fetus:Qn:US.measured:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2405;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3568;MoM for NT;49035-9;Thickness:MoM:Pt:Nuchal fold^fetus:Qn:US.measured:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2406;FMSI1;Maternal Serum Screening, Integrated, Specimen #1;Z3573;Gestational Age (Exact);18185-9;Gestational age:Time:Pt:^Fetus:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2407;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3601;Family Hx Neural Tube Defect;8670-2;History of family member diseases:Fiond:Pt:Family:Nom:Reported;2013-11-15;Quantitative Chemiluminescent Immunoassay
2408;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3583;Patient's AFP;1834-1;Alpha-1-Fetoprotein:MCnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2409;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3603;Maternal Race;21484-1;Race:Type:Pt:^Mother:Nom:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2410;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3592;MoM for PAPP-A;32123-2;Pregnancy associated plasma protein A:MoM:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2411;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3605;Crown Rump Length;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2013-11-15;Quantitative Chemiluminescent Immunoassay
2412;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3604;Number of Fetuses;11878-6;Fetuses:Num:Pt:^Patient:Qn:US;2013-11-15;Quantitative Chemiluminescent Immunoassay
2413;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3599;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2414;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3600;Insulin Req Maternal Diabetes;44877-9;Insulin dependent diabetes mellitus:ACnc:Pt:^Patient:Ord:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2415;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3589;Patient's DIA;23883-2;Inhibin A:MCnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2416;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3587;Patient's uE3;2250-9;Estriol.unconjugated:MCnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2417;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3588;MoM for uE3;20466-9;Estriol.unconjugated:MoM:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2418;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3590;MoM for DIA;35738-4;Inhibin A:MoM:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2419;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3597;Estimated Due Date;11778-8;Delivery date:TmStp:Pt:^Patient:Qn:Clinical.estimate;2013-11-15;Quantitative Chemiluminescent Immunoassay
2420;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3596;Maternal Age At Delivery;21612-7;Age:Time:Pt:^Patient:Qn:Reported;2013-11-15;Quantitative Chemiluminescent Immunoassay
2421;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3595;Maternal Screen Interpretation;49586-1;First & Second trimester integrated maternal screen:Imp:Pt:^Patient:Nom:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2422;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3594;MoM for NT;49035-9;Thickness:MoM:Pt:Nuchal fold^fetus:Qn:US.measured:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2423;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3598;Gestational Age (Exact);18185-9;Gestational age:Time:Pt:^Fetus:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2424;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3591;Patient's PAPP-A;32046-5;Pregnancy associated plasma protein A:ACnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2425;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3593;Nuchal Translucency (NT);12146-7;Thickness:Len:Pt:Nuchal fold^fetus:Qn:US.measured:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2426;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3586;MoM for hCG;20465-1;Choriogonadotropin:Mom:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2427;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3585;Patient's hCG;19080-1;Choriogonadotropin:ACnc:Pt:Ser/Plas:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2428;FMSI2;Maternal Serum Screening, Integrated, Specimen #2;Z3584;MoM for AFP;29253-2;Alpha-1-Fetoprotein^^adjusted:MoM:Pt:Amnio fld:Qn:;2013-11-15;Quantitative Chemiluminescent Immunoassay
2429;FMST;Myeloid Sarcoma, FISH, Tissue;51576;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2430;FMST;Myeloid Sarcoma, FISH, Tissue;CG642;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2431;FMST;Myeloid Sarcoma, FISH, Tissue;CG641;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-28;Fluorescence In Situ Hybridization (FISH)
2432;FMST;Myeloid Sarcoma, FISH, Tissue;51574;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2433;FMTCP;Mycobacterium tuberculosis Complex, PCR, Non-Respiratory;Z3691;MTB Complex, PCR;38379-4;Mycobacterium tuberculosis complex DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-04-14;Polymerase Chain Reaction (PCR)
2434;FMTCP;Mycobacterium tuberculosis Complex, PCR, Non-Respiratory;Z3690;Non-Respiratory Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-14;Polymerase Chain Reaction (PCR)
2435;FMYPN;Mycoplasma pneumoniae IgA;Z0147;MP IgA;26684-1;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2436;FNAD;Nadolol, Serum/Plasma;Z1430;Nadolol;12406-5;;2013-12-18;High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
2437;FNALO;Naloxone Screen, Total (Conjugated/Unconjugated), Urine;Z1488;Naloxone Screen, Total, U;42618-9;;2013-12-18;High Performance Liquid Chromatography/Tandem MassSpectrometry (LC-MS/MS)
2438;FNEA;Neurokinin A (Substance K);Z2259;Neurokinin A;49728-9;Neurokinin A:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay
2439;FNECT;Nectarine (Prunus spp) IgE;Z4001;CLASS;15871-7;Prunus persica var nucipersica Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-21;Radioimmunoassay (RIA)
2440;FNECT;Nectarine (Prunus spp) IgE;Z4000;Nectarine IgE;7523-4;Prunus persica var nucipersica Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;Radioimmunoassay (RIA)
2441;FNEOP;Neopterin;Z1568;Neopterin, Serum;9740-2;Neopterin:SCnc:Pt:Ser/Plas:Qn;2013-12-18;Radioimmunoassay (RIA)
2442;FNEU;Neurotransmitter Metabolites/Amines;Z0850;3-O-methyldopa;3496-7;;2012-03-12;HPLC-Electrochemistry
2443;FNEU;Neurotransmitter Metabolites/Amines;Z0849;Homovanillic acid;40846-8;;2012-03-12;HPLC-Electrochemistry
2444;FNEU;Neurotransmitter Metabolites/Amines;Z0852;5-Hydroxyindoleacetic acid;47544-2;;2012-03-12;HPLC-Electrochemistry
2445;FNIAC;Niacin (Vitamin B3);Z0144;Niacin;34342-6;;2012-03-12;High Performance Liquid Chromatography (HPLC)
2446;FNIFE;Nifedipine, Serum/Plasma;Z1403;Nifedipine;9386-4;;2012-03-12;Higher Performance Liquid Chromatography (HPLC)
2447;FNLV;Norovirus, EIA (Stool);Z0526;Norovirus Antigen;49117-5;Norovirus Ag:ACnc:Pt:Stool:Ord:;2012-03-15;Enzyme Immunoassay (EIA)
2448;FNMYC;Neuroblastoma, 2p24 (MYCN) Amplification, FISH;CG191;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2449;FNMYC;Neuroblastoma, 2p24 (MYCN) Amplification, FISH;23043;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2450;FNMYC;Neuroblastoma, 2p24 (MYCN) Amplification, FISH;CG189;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2451;FNMYC;Neuroblastoma, 2p24 (MYCN) Amplification, FISH;23041;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2452;FOAKE;Oak Live (Quercus virginiana) IgE;Z4119;CLASS;15880-8;Quercus virginiana Ab.IgE.rast class:ACnc:Pt:Ser:Ord:;2014-07-25;ImmunoCAP FEIA
2453;FOAKE;Oak Live (Quercus virginiana) IgE;Z4118;Oak Live (Quercus virginiana) IgE;6164-8;Quercus virginiana Ab.IgE:ACnc:Pt:Ser:Q;2014-07-25;ImmunoCAP FEIA
2454;FOGT;False Oat Grass, IgE;FOGT;False Oatgrass, IgE;6726-4;Arrhenatherum elatius Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2455;FOL;Folate, Serum;FOL;Folate, S;2284-8;Folate:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
2456;FOL;Folate, Serum;FOL;Folate, S;2284-8;Folate:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Competitive Binding Receptor Assay
2457;FOOD1;Food-Nut Panel # 2;FOOD1;Food-Nut Panel # 2;46707-6;(Anacardium occidentale+Carya illinoinensis+Juglans spp+Pistacia vera) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2458;FOOD2;Food-Fruit Panel;FOOD2;Food-Fruit Panel;46714-2;(Malus sylvestris+Musa spp+Prunus persica+Pyrus communis) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2459;FOOD3;Food-Vegetable Panel;FOOD3;Food-Vegetable Panel;46711-8;(Brassica oleracea var italica+Daucus carota+Phaseolus vulgaris+Pisum sativum+Zea mays) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2460;FOOD4;Food-Grain Panel;FOOD4;Food-Grain Panel;46713-4;(Hordeum vulgare+Oryza sativa+Secale cereale+Triticum aestivum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2461;FOOD5;Food-Meat Panel;FOOD5;Food-Meat Panel;46710-0;(Beef+Chicken meat+Pork+Turkey meat) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2462;FOOD6;Food Panel;FOOD6;Food Panel;30187-9;(Arachis hypogaea+Cow milk+Egg white+Gadus morhua+Glycine max+Triticum aestivum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2463;FOOD7;Food-Seafood Panel;FOOD7;Food-Seafood Panel;46712-6;(Gadus morhua+Mytilus edulis+Pandalus borealis+Salmo salar+Thunnus albacares) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2464;FOOD8;Food-Nut Panel # 1;FOOD8;Food-Nut Panel # 1;46708-4;(Arachis hypogaea+Bertholletia excelsa+Cocos nucifera+Corylus avellana+Prunus dulcis) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2465;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3765;Opiates, S/P, Oxymorphone;60467-8;Oxymorphone:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2466;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3763;Opiates, S/P, Hydromorphone;3683-0;Hydromorphone:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2467;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3764;Opiates, S/P, Oxycodone;3893-5;Oxycodone:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2468;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3762;Opiates, S/P, Hydrocodone;3680-6;Hydrocodone:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2469;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3761;Opiates, S/P, Morphine;3827-3;Morphine:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2470;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3760;Opiates, S/P, Codeine;3506-3;Codeine:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2471;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3759;Opiates, S/P, 6_AM;12788-6;6-Monoacetylmorphine:MCnc:Pt:Ser/Plas:Qn:;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2472;FOPCQ;Opiates - Confirmation/Quantitation, Serum or Plasma;Z3758;Opiates, S/P Interpretation;8218-0;Opiates:Threshold:Pt:Ser/Plas:Ord:Confirm;2014-04-28;Quantitative Liquid Chromatography-Tandem Mass Spectrometry
2473;FP73;1p36.3 Microdeletion Syndrome, FISH;23209;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2474;FP73;1p36.3 Microdeletion Syndrome, FISH;23211;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2475;FP73;1p36.3 Microdeletion Syndrome, FISH;CG201;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2476;FP73;1p36.3 Microdeletion Syndrome, FISH;CG199;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2477;FPAB;Vitamin B5 (Pantothenic Acid) Bioassay;FPAB;Pantothenic Acid (B-5) Bioassay;2722-7;Pantothenate:MCnc:Pt:Ser/Plas/Bld:Qn:;2013-04-11;Microbiological Assay
2478;FPANS;Pancreastatin;Z2267;Pancreastatin;49013-6;Pancreastatin:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Radioimmunoassay
2479;FPCPD;Plasma Cell Proliferative Disorder (PCPD), FISH;22620;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Cytoplasmic Immunoglobulin (cIg) Staining Followed by Fluorescence In Situ Hybridization (FISH)
2480;FPCPD;Plasma Cell Proliferative Disorder (PCPD), FISH;22618;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-07-29;Cytoplasmic Immunoglobulin (cIg) Staining Followed by Fluorescence In Situ Hybridization (FISH)
2481;FPCPD;Plasma Cell Proliferative Disorder (PCPD), FISH;G_569;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cytoplasmic Immunoglobulin (cIg) Staining Followed by Fluorescence In Situ Hybridization (FISH)
2482;FPCPD;Plasma Cell Proliferative Disorder (PCPD), FISH;22615;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Cytoplasmic Immunoglobulin (cIg) Staining Followed by Fluorescence In Situ Hybridization (FISH)
2483;FPEPS;Pepsinogen I;Z0941;Pepsinogen I;2736-7;;2012-03-12;Direct Radioimmunoassay (Direct RIA)
2484;FPFRG;Prothrombin Fragment 1+2;Z0212;Prothrombin Fragment 1+2;27824-2;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2485;FPFUZ;Phenosense Entry HIV Drug Resistance Assay;Z1041;Phenosense Entry Fuzeon;45182-3;;2012-03-12;CD4 cell culture assay for phenotypic recombinant virus entry
2486;FPGE2;Prostaglandin E2 (PG E2), Urine;Z0930;Prostaglandin E2 (PGE2), U;2853-0;;2012-03-12;Direct Radioimmunoassay (RIA)
2487;FPGO;Anaplasma phagocytophilum Antibodies (IgG, IgM);Z2276;A. phagocytophilum IgG;9783-2;Ehrlichia chaffeensis Ab.IgG:Titr:Pt:Ser:Qn;2014-07-16;Immunofluorescence Assay (IFA)
2488;FPGO;Anaplasma phagocytophilum Antibodies (IgG, IgM);Z2277;A. phagocytophilum IgM;9784-0;Ehrlichia chaffeensis Ab.IgM:Titr:Pt:Ser:Qn;2014-07-16;Immunofluorescence Assay (IFA)
2489;FPHET;Anti-Phosphatidylethanolamine Panel;Z0142;Anti-Phosphatidylethanolamine IgM;13077-3;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2490;FPHET;Anti-Phosphatidylethanolamine Panel;Z0150;Anti-Phosphatidylethanolamine IgG;13076-5;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2491;FPHET;Anti-Phosphatidylethanolamine Panel;Z0143;Anti-Phosphatidylethanolamine IgA;13078-1;;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
2492;FPHIV;Phenosense HIV Drug Resistance Replication Capacity;Z1042;Phenosense HIV;49665-3;;2012-03-12;CD4 cell culture assay for phenotypic recombinant virus resistance
2493;FPHNZ;Phenelzine, Serum/Plasma;Z1450;Phenelzine;9778-2;;2013-12-18;Gas Chromatography (GC)
2494;FPLAS;Plasma Cell Proliferative Disorder, FISH, Tissue;51386;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-12-21;Fluorescence In Situ Hybridization (FISH)
2495;FPLAS;Plasma Cell Proliferative Disorder, FISH, Tissue;51389;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2496;FPLAS;Plasma Cell Proliferative Disorder, FISH, Tissue;CG630;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2497;FPMSA;PM-Scl Antibody;FPMSA;PM-Scl Antibody;14131-7;PM-1 ACnc:Pt:Ser:Ord:;2014-01-23;Immunodiffusion (ID)
2498;FPOC;Aneuploidy Detection, Products of Conception (POC), FISH;22370;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2499;FPOC;Aneuploidy Detection, Products of Conception (POC), FISH;CG239;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2500;FPOC;Aneuploidy Detection, Products of Conception (POC), FISH;22367;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2501;FPOC;Aneuploidy Detection, Products of Conception (POC), FISH;CG241;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2502;FPOLE;Pollock White (Pollachius virens) IgE;Z4003;CLASS;21470-0;Pollachius virens Ab.IgE.rast class:ACnc:Pt:Ser:Ord:;2014-07-25;ImmunoCAP FEIA
2503;FPOLE;Pollock White (Pollachius virens) IgE;Z4002;Pollock White IgE;11191-4;Pollachius virens Ab.IgE:ACnc:Pt:Ser:Qn:;2014-07-25;ImmunoCAP FEIA
2504;FPOM;Pomegranate (Punica granatum) IgE;Z3874;Pomegranate IgE;21471-8;Punica granatum Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-20;Radioimmunoassay (RIA)
2505;FPOM;Pomegranate (Punica granatum) IgE;Z3875;CLASS;21472-6;Punica granatum Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-20;Radioimmunoassay (RIA)
2506;FPORC;Serotonin Release Assay, Unfractionated Heparin;Z0125;unfractionated heparin Result;50734-3;Serotonin release.heparin.porcine interpretation:Imp:Pt:Ser:Nom;2014-05-01;Serotonin Release Assay (SRA)
2507;FPORC;Serotonin Release Assay, Unfractionated Heparin;Z0124;unfractionated heparin High Dose;50729-3;Serotonin release 100 U/mL heparin.porcine:ACnc:Pt:Ser:Qn;2014-05-01;Serotonin Release Assay (SRA)
2508;FPORC;Serotonin Release Assay, Unfractionated Heparin;Z0123;unfractionated heparin Low Dose;50730-1;Serotonin release 0.1 U/mL heparin.porcine:ACnc:Pt:Ser:Qn:;2014-05-01;Serotonin Release Assay (SRA)
2509;FPROP;Propofol, Serum/Plasma;Z1448;Propofol;34673-4;;2013-12-18;Gas Chromatography (GC)
2510;FPRSG;Prostaglandin D2 (PG D2), Urine;Z2325;Prostaglandins (PG D2), U;14054-1;Prostaglandin D2:MRat:24H:Urine:Qn:;2013-12-19;Direct Immunoassay (RIA)
2511;FPRSG;Prostaglandin D2 (PG D2), Urine;Z2565;Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2013-08-18;Direct Immunoassay (RIA)
2512;FPRTF;Parrot Australian (Budgerigar) Feathers IgE;Z4052;Parrot Australian Feathers IgE;6030-1;Budgerigar feather Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-29;ImmunoCAP FEIA
2513;FPRTF;Parrot Australian (Budgerigar) Feathers IgE;Z4053;CLASS;15592-9;Budgerigar feather Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-29;ImmunoCAP FEIA
2514;FPSAU;Prostate-Specific Antigen, Ultrasensitive;Z0983;PSA, Ultrasensitive;35741-8;;2012-03-12;Electrochemiluminescence immunoassay (ECLIA)
2515;FPYD;Pyridostigmine, Serum/Plasma;Z1435;Pyridostigmine;9390-6;;2013-12-18;Gas Chromatography (GC)
2516;FQPPS;Porphyrins, Feces;15530;Isocoproporphyrin;33625-5;Isocoproporphyrin:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2517;FQPPS;Porphyrins, Feces;15534;Protoporphyrin;2891-0;Protoporphyrin:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2518;FQPPS;Porphyrins, Feces;15529;Coproporphyrin III;23846-9;Coproporphyrin 3:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2519;FQPPS;Porphyrins, Feces;15520;Heptacarboxyl III;49901-2;Heptacarboxylporphyrin III:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2520;FQPPS;Porphyrins, Feces;TM70;Collection Duration;13363-7;Collection duration:Time:*:Stool:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2521;FQPPS;Porphyrins, Feces;15521;Isoheptacarboxyl;23885-7;Isoheptacarboxylporphyrin:MRat:XXX:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2522;FQPPS;Porphyrins, Feces;15545;CoproIII/CoproI ratio;33618-0;Coproporphyrin 3/Coproporphyrin 1:MRto:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2523;FQPPS;Porphyrins, Feces;15522;Hexacarboxyl I;23874-1;Hexacarboxylporphyrin I:MRat:XXX:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2524;FQPPS;Porphyrins, Feces;15523;Hexacarboxyl III;23875-8;Hexacarboxylporphyrin III:MRat:XXX:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2525;FQPPS;Porphyrins, Feces;15519;Heptacarboxyl I;49900-4;Heptacarboxylporphyrin I:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2526;FQPPS;Porphyrins, Feces;15524;Isohexacarboxyl;23886-5;Isohexacarboxylporphyrin:MRat:XXX:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2527;FQPPS;Porphyrins, Feces;15527;Isopentacarboxyl;23887-3;Isopentacarboxylporphyrin:MRat:XXX:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2528;FQPPS;Porphyrins, Feces;81652;Interpretation (FQPPS);59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2529;FQPPS;Porphyrins, Feces;15525;Pentacarboxyl  I;33623-0;Pentacarboxylporphyrin 1:MRat:24H:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2530;FQPPS;Porphyrins, Feces;15518;Uroporphyrin III;33585-1;Uroporphyrin 3 isomer:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2531;FQPPS;Porphyrins, Feces;W6;Total weight;30078-0;Specimen weight:Mass:Pt:Stool:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2532;FQPPS;Porphyrins, Feces;15517;Uroporphyrin I;26691-6;Uroporphyrin 1 isomer:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2533;FQPPS;Porphyrins, Feces;15526;Pentacarboxyl III;33624-8;Pentacarboxylporphyrin 3:MRat:24H:Stool:Qn:;2011-10-05;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2534;FQPPS;Porphyrins, Feces;15528;Coproporphyrin I;23845-1;Coproporphyrin 1:MRat:24H:Stool:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)Porphyrins are quantified by fluorescence.
2535;FRAJI;Raji Cell Immune Complex Assay;FRAJI;Raji Cell Immune Complex Assay;10864-7;Immune complex:ACnc:Pt:Ser/Plas:Qn:Raji cell assay;2014-04-30;Quantitative Flow Cytometry
2536;FRANC;Francisella Tularensis Antibody;Z0713;Francisella tularensis Ab;5167-2;Francisella tularensis Ab:Titr:Pt:Ser:Qn:LA;2014-07-07;Direct Aggulation (DA)
2537;FRCE;Cedar Red (Juniperus virginiana) IgE;Z4022;Cedar Red IgE;7195-1;Juniperus virginiana Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-20;ImmunoCAP FEIA
2538;FRCE;Cedar Red (Juniperus virginiana) IgE;Z4023;CLASS;15616-6;Juniperus virginiana Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-20;ImmunoCAP FEIA
2539;FRDIG;Digoxin, Free, Serum;FRDIG;Digoxin, Free, S;3562-6;Digoxin.free:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Ultrafiltration Followed by Electrochemiluminescent Immunoassay
2540;FREB;Retinol Binding Protein;Z1558;Retinol Binding Protein;1836-6;Alpha-2-Retinol binding protein:MCnc:Pt:Ser/Plas:Qn;2013-12-18;Fixed Rate Time Nephelometry
2541;FRFIT;Rabies Antibody Endpoint;Z2071;Rabies Titer-Response;6524-3;Rabies virus Ab:ACnc:Pt:Ser:Qn:Neut;2014-02-21;Serum Neutralization Fluorescent Antibody
2542;FRHFG;Rheumatoid Factor (IgG,IgA,IgM);Z3625;Rheumatoid Factor (IgM);11573-3;Rheumatoid factor.IgM:ACnc:Pt:Ser:Qn:;2014-01-10;Enzyme Linked Immunosorbent Immunoassay
2543;FRHFG;Rheumatoid Factor (IgG,IgA,IgM);Z3624;Rheumatoid Factor (IgA);33313-8;Rheumatoid factor.IgA:ACnc:Pt:Ser:Qn:;2014-01-10;Enzyme Linked Immunosorbent Immunoassay
2544;FRHFG;Rheumatoid Factor (IgG,IgA,IgM);Z3623;Rheumatoid Factor (IgG);33314-6;Rheumatoid factor.IgG:ACnc:Pt:Ser:Qn:;2014-01-10;Enzyme Linked Immunosorbent Immunoassay
2545;FRMH;Formaldehyde, IgE;FRMH;Formaldehyde, IgE;6119-2;Formaldehyde Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2546;FROE;Oak Red (Quercus rubra) IgE;Z3853;CLASS;15881-6;Quercus rubra Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-21;Radioimmunoassay (RIA)
2547;FROE;Oak Red (Quercus rubra) IgE;Z3852;Oak Red (Quercus rubra) IgE;7534-1;Quercus rubra Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;Radioimmunoassay (RIA)
2548;FROPI;Ropivacaine, Serum/Plasma;Z2296;Ropivacaine;51203-8;Ropivacaine:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Gas Chromatography (GC)
2549;FROS;Fructose, Semen or Seminal Plasma;CMT49;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;A Qualitative Method Using Resorcinol
2550;FROS;Fructose, Semen or Seminal Plasma;VOLSM;Semen Volume;3160-9;Specimen volume:Vol:Pt:Semen:Qn:;2012-03-12;A Qualitative Method Using Resorcinol
2551;FROS;Fructose, Semen or Seminal Plasma;FRUCS;Fructose, Semen/Seminal P;13943-6;Fructose:ACnc:Pt:Semen:Ord:;2012-03-15;A Qualitative Method Using Resorcinol
2552;FROS;Fructose, Semen or Seminal Plasma;ABSSM;Abstinence;10587-4;Sexual abstinence duration:Time:Pt:^Patient:Qn:;2012-03-12;A Qualitative Method Using Resorcinol
2553;FROS1;Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue;51739;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-18;Fluorescence In Situ Hybridization (FISH)
2554;FROS1;Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue;51744;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2555;FROS1;Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue;51742;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2556;FROS1;Lung Cancer, ROS1 (6q22) Rearrangement, FISH, Tissue;CG648;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2557;FROSE;Rosemary (Rosmarinus officinalis) IgE;Z3798;Rosemary IgE;30043-4;Rosmarinus officinalis Ab.IgE: ACnc: Pt:Ser:Qn:;2014-06-16;Radioimmunoassay (RIA)
2558;FRSE;Red Snapper (Lutjanus spp) IgE;Z3997;CLASS;16025-9;Snapper red Ab.IgE.RAST class:Threshold:Pt:Ser:Ord;2014-07-16;ImmunoCAP FEIA
2559;FRSE;Red Snapper (Lutjanus spp) IgE;Z3996;Red Snapper IgE;7661-2;Snapper red Ab.IgE:Acnc:Pt:Ser:Qn;2014-07-16;ImmunoCAP FEIA
2560;FRT3;T3 (Triiodothyronine), Free, Serum;FRT3C;T3 (Triiodothyronine), Free, S;3051-0;Triiodothyronine.free:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
2561;FRT4;T4 (Thyroxine), Free, Serum;FRT4;T4 (Thyroxine), Free, S;3024-7;Thyroxine.free:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Chemiluminometric Immunoassay
2562;FRT4D;T4 (Thyroxine), Free by Dialysis, Serum;8859;T4 (Thyroxine), Free by Dialysis, S;6892-4;Thyroxine.free:MCnc:Pt:Ser/Plas:Qn:Dialysis;2009-11-13;Equilibrium Dialysis/Tandem Mass Spectrometry (MS/MS)
2563;FRTAL;T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH;27573;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2564;FRTAL;T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH;G_557;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2565;FRTAL;T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH;G_559;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2566;FRTAL;T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH;27571;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2567;FRTEL;Subtelomeric Region Anomalies, FISH;G_547;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2568;FRTEL;Subtelomeric Region Anomalies, FISH;G_549;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2569;FRTEL;Subtelomeric Region Anomalies, FISH;17188;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2570;FRTEL;Subtelomeric Region Anomalies, FISH;17191;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH) with DNA Probes
2571;FRTIX;Free Thyroxine Index (FTI), Serum;TUP;T3 (Triiodothyronine), Uptake, S;3050-2;Triiodothyronine resin uptake (T3RU):NFr:Pt:Ser/Plas:Qn:;2012-03-12;Chemiluminometric Immunoassay
2572;FRTIX;Free Thyroxine Index (FTI), Serum;FRTI;Free Thyroxine Index;32215-6;Thyroxine free index:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Chemiluminometric Immunoassay
2573;FRTIX;Free Thyroxine Index (FTI), Serum;T4S;Thyroxine, Total, S;3026-2;Thyroxine:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Chemiluminometric Immunoassay
2574;FRTLP;T-Cell Lymphoma, FISH, Blood or Bone Marrow;27592;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2575;FRTLP;T-Cell Lymphoma, FISH, Blood or Bone Marrow;G_953;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2576;FRTLP;T-Cell Lymphoma, FISH, Blood or Bone Marrow;G_955;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2577;FRTLP;T-Cell Lymphoma, FISH, Blood or Bone Marrow;27594;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2578;FRUCT;Fructosamine, Serum;FRUCT;Fructosamine, S;15069-8;Fructosamine:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Colorimetric Rate Reaction
2579;FRVMP;Respiratory Virus Mini Panel by PCR;Z3741;Respiratory Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-02-06;Qualitative Reverse Transcription Polymerase Chain Reaction
2580;FRVMP;Respiratory Virus Mini Panel by PCR;Z3744;RSV by PCR;40988-8;Respiratory syncytial virus RNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-02-06;Qualitative Reverse Transcription Polymerase Chain Reaction
2581;FRVMP;Respiratory Virus Mini Panel by PCR;Z3743;Influenza B by PCR;40982-1;Influenza virus B RNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-02-06;Qualitative Reverse Transcription Polymerase Chain Reaction
2582;FRVMP;Respiratory Virus Mini Panel by PCR;Z3742;Influenza A by PCR;34487-9;Influenza virus A RNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-02-06;Qualitative Reverse Transcription Polymerase Chain Reaction
2583;FRW;False Ragweed, IgE;FRW;False Ragweed, IgE;6115-0;Franseria acanthicarpa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2584;FSCT;Sex Chromosome Determination, FISH, Tissue;51565;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2585;FSCT;Sex Chromosome Determination, FISH, Tissue;CG639;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Fluorescence In Situ Hybridization (FISH)
2586;FSCT;Sex Chromosome Determination, FISH, Tissue;51563;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
2587;FSCT;Sex Chromosome Determination, FISH, Tissue;CG638;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-28;Fluorescence In Situ Hybridization (FISH)
2588;FSEC;Secretin;Z0934;Secretin;2933-0;;2012-03-12;Direct Radioimmunoassay (RIA)
2589;FSGT;Salivary Gland Tumor, MYB (6q23) Rearrangement FISH, Tissue;CG875;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2590;FSGT;Salivary Gland Tumor, MYB (6q23) Rearrangement FISH, Tissue;53812;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Fluorescence In Situ Hybridization (FISH)
2591;FSGT;Salivary Gland Tumor, MYB (6q23) Rearrangement FISH, Tissue;53810;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2592;FSGT;Salivary Gland Tumor, MYB (6q23) Rearrangement FISH, Tissue;53807;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Fluorescence In Situ Hybridization (FISH)
2593;FSH;Follicle-Stimulating Hormone (FSH), Serum;FSH;FSH, S;15067-2;Follitropin:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
2594;FSHOX;SHOX-DNA-DxTM;Z2269;SHOXDNAdx;34500-9;SHOX gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2012-10-31;Mutation analysis by PCR, DHPLC and sequencing as needed
2595;FSIL;Silicon, Serum/Plasma;Z1431;Silicon;10829-0;;2013-12-18;Inductively Coupled Plasma/ Optical Emission Spectrometry (ICP/OES)
2596;FSINE;Sinemet , Serum/Plasma;Z1456;Carbidopa;9328-6;;2013-12-18;High-Performance Liquid Chromatography (HPLC)
2597;FSINE;Sinemet , Serum/Plasma;Z1436;Levodopa;9385-6;;2013-12-18;High-Performance Liquid Chromatography (HPLC)
2598;FSLAA;Soluble Liver Antigen (SLA) Autoantibody;FSLAA;SLA Autoantibody;32219-8;Cytokeratin Ab:ACnc:Pt:Ser:Qn:EIA;2014-04-03;Enzyme Linked Immunosorbent Immunoassay (ELISA)
2599;FSMS;Smith-Magenis/Potocki-Lupski Syndromes, 17p11.2 Deletion/Duplication, FISH;23238;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2600;FSMS;Smith-Magenis/Potocki-Lupski Syndromes, 17p11.2 Deletion/Duplication, FISH;CG209;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2601;FSMS;Smith-Magenis/Potocki-Lupski Syndromes, 17p11.2 Deletion/Duplication, FISH;23236;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2602;FSMS;Smith-Magenis/Potocki-Lupski Syndromes, 17p11.2 Deletion/Duplication, FISH;CG211;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2603;FSMTX;Sulfamethoxazole IgE;Z4061;CLASS;21544-2;ulfamethoxazole Ab.IgE.RAST class:Threshold:Pt:Ser:Ord;2014-07-10;Radioimmunoassay (RIA)
2604;FSMTX;Sulfamethoxazole IgE;Z4060;Sulfamethoxazole IgE;50031-4;Sulfamethoxazole Ab.IgE:ACnc:Pt:Ser:Qn;2014-07-10;Radioimmunoassay (RIA)
2605;FSRA;Serotonin Release Assay (SRA), LMWH;Z3626;LMWH SRA Result;50735-0;Serotonin release.heparin.low molecular weight interpretation:Imp:Pt:Ser:Nom:;2014-01-02;Radiobinding 14C Serotonin Radiolabel
2606;FSRA;Serotonin Release Assay (SRA), LMWH;Z3627;LMWH Low Dose, 0.1 U/mL;50732-7;Serotonin release 0.1 U/mL heparin.low molecular weight:ACnc:Pt:Ser:Qn:;2014-01-02;Radiobinding 14C Serotonin Radiolabel
2607;FSRAU;Serotonin Release Assay, Unfractionated Heparin;Z3633;UFH High Dose, 100 IU/mL;50727-7;Serotonin release 100 U/mL heparin.unfractionated:ACnc:Pt:Ser:Qn:;2014-04-09;Radiobinding 14C Serotonin Radiolabel
2608;FSRAU;Serotonin Release Assay, Unfractionated Heparin;Z3631;UFH Low Dose, 0.1 IU/mL;50728-5;Serotonin release 0.1 U/mL heparin.unfractionated:ACnc:Pt:Ser:Qn:;2014-04-09;Radiobinding 14C Serotonin Radiolabel
2609;FSRAU;Serotonin Release Assay, Unfractionated Heparin;Z3630;UFH SRA Result;50733-5;Serotonin release interpretation:Imp:Pt:Ser:Nom:;2014-04-09;Radiobinding 14C Serotonin Radiolabel
2610;FSRP;SRP;Z2422;SRP;33921-8;Signal recognition particle Ab:ACnc:Pt:Ser/Plas:Ord:;2013-11-01;Immunoprecipitation (IPP)
2611;FSRY;Sex-Determining Region Y, Yp11.3 Deletion, FISH;CG251;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2612;FSRY;Sex-Determining Region Y, Yp11.3 Deletion, FISH;23303;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2613;FSRY;Sex-Determining Region Y, Yp11.3 Deletion, FISH;CG249;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2614;FSRY;Sex-Determining Region Y, Yp11.3 Deletion, FISH;23301;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2615;FSTS;Steroid Sulfatase Deficiency, Xp22.3 Deletion, FISH;23248;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2616;FSTS;Steroid Sulfatase Deficiency, Xp22.3 Deletion, FISH;23250;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2617;FSTS;Steroid Sulfatase Deficiency, Xp22.3 Deletion, FISH;CG219;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2618;FSTS;Steroid Sulfatase Deficiency, Xp22.3 Deletion, FISH;CG221;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2619;FSYT;Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue;CG261;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2620;FSYT;Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue;22912;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2621;FSYT;Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue;22911;Results;21825-5;t(X,18)(SSXT,SSX1) gene translocation:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH)
2622;FSYT;Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue;22910;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2623;FSYT;Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue;22907;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH)
2624;FUCT;Alpha-Fucosidase, Fibroblasts;29885;Alpha-Fucosidase, Fibroblasts;24046-5;Alpha fucosidase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;FUCT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
2625;FUCT;Alpha-Fucosidase, Fibroblasts;29756;Interpretation (FUCT);59462-2;;2012-04-02;FUCT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
2626;FUCW;Alpha-Fucosidase, Leukocytes;8814;Alpha-Fucosidase, Leukocytes;24047-3;Alpha fucosidase:CCnt:Pt:WBC:Qn:;2009-11-13;Fluorometric
2627;FUNID;Culture Referred for Identification, Fungus;FUNID;Culture Referred for ID, Fungus;42805-2;Fungus identified:Prid:Pt:XXX:Nom:;2013-09-17;Fungi are identified using macroscopic and microscopic morphology, nucleic acid hybridization probes, D2 rDNA gene sequencing, real-time polymerase chain reaction (rtPCR), or MALDI-TOF mass spectrometry. Dimorphic pathogen identification is confirmed using molecular methods (ie, nucleic acid hybridization probe, D2 rDNA gene sequencing, rtPCR or MALDI-TOF mass spectrometry).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2628;FURA;Uranium, Urine;Z1442;Uranium;5752-1;;2013-12-18;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2629;FURO;UroVysion for Detection of Bladder Cancer;16874;Interpretation;59465-5;Pathologist review:Imp:Pt:XXX:Nom:;2014-04-30;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2630;FURO;UroVysion for Detection of Bladder Cancer;16869;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2631;FURO;UroVysion for Detection of Bladder Cancer;16872;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2632;FURO;UroVysion for Detection of Bladder Cancer;16871;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) Using DNA Probes
2633;FUS;Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11 (FUS or TLS) Rearrangement, FISH, Tissue;CG323;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2634;FUS;Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11 (FUS or TLS) Rearrangement, FISH, Tissue;50787;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2635;FUS;Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11 (FUS or TLS) Rearrangement, FISH, Tissue;50785;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2636;FUS;Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11 (FUS or TLS) Rearrangement, FISH, Tissue;50782;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorescence In Situ Hybridization (FISH)
2637;FUSM;Fusarium moniliforme, IgE;FUSM;Fusarium Moniliforme, IgE;6121-8;Fusarium moniliforme Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2638;FVEGF;Vascular Endothelial Growth Factor (VEGF), ELISA;Z1575;VEGF;34694-0;Vascular endothelial growth factor:Pt:Ser/Plas:Qn:;2014-04-03;Enzyme Immunoassay (ELISA)
2639;FVITB;Vitamin B12 Binding Capacity;Z2657;Vitamin B12 Binding Capacity;2171-7;Cobalamins.unsaturated binding capacity:MCnc:Pt:Ser/Plas:Qn:;2013-07-29;Quantitative Radioimmunoassay
2640;FWHS;Wolf-Hirschhorn Syndrome, 4p16.3 Deletion, FISH;CG271;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2641;FWHS;Wolf-Hirschhorn Syndrome, 4p16.3 Deletion, FISH;23222;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2642;FWHS;Wolf-Hirschhorn Syndrome, 4p16.3 Deletion, FISH;CG269;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2643;FWHS;Wolf-Hirschhorn Syndrome, 4p16.3 Deletion, FISH;23220;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2644;FWHTS;Smut Wheat (Ustilago tritici) IgE;Z4048;Smut Wheat (Ustilago tritici) IgE;7708-1;Ustilago tritici Ab.IgE:ACnc:Pt:Ser:Qn;2014-08-04;Radioimmunoassay (RIA)
2645;FXCH;Coagulation Factor X Chromogenic Activity Assay, Plasma;FXCH;Factor X Chromogenic Activity Assay;33984-6;Coagulation factor X activity actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-15;Chromogenic
2646;FXIST;X-Inactivation (XIST), Xq13.2 Deletion, FISH;23200;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2647;FXIST;X-Inactivation (XIST), Xq13.2 Deletion, FISH;CG281;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2648;FXIST;X-Inactivation (XIST), Xq13.2 Deletion, FISH;23198;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2649;FXIST;X-Inactivation (XIST), Xq13.2 Deletion, FISH;CG279;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
2650;FXPB;Fragile X Syndrome, Molecular Analysis;16474;Result;36913-2;FMR1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2651;FXPB;Fragile X Syndrome, Molecular Analysis;16475;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2652;FXPB;Fragile X Syndrome, Molecular Analysis;16473;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2653;FXPB;Fragile X Syndrome, Molecular Analysis;16476;Amendment;36913-2;FMR1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2654;FXPB;Fragile X Syndrome, Molecular Analysis;16472;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2655;FXPB;Fragile X Syndrome, Molecular Analysis;16470;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)-Based Assays (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2656;FXYLP;Xylene Exposure Panel, Urine;Z1459;Methylhippuric Acid (Creat correct);13774-5;;2013-12-18;Ion Chromatography (IC), Colorimetry (C)
2657;FXYLP;Xylene Exposure Panel, Urine;Z1458;Methylhippuric Acid;21387-6;;2013-12-18;Ion Chromatography (IC), Colorimetry (C)
2658;FXYLP;Xylene Exposure Panel, Urine;Z1299;Creatinine;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Ion Chromatography (IC), Colorimetry (C)
2659;FXYM;Known 45,X, Mosaicism Reflex Analysis, FISH;22931;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
2660;FXYM;Known 45,X, Mosaicism Reflex Analysis, FISH;22934;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
2661;FXYM;Known 45,X, Mosaicism Reflex Analysis, FISH;CG314;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
2662;FXYM;Known 45,X, Mosaicism Reflex Analysis, FISH;22929;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
2663;FYABS;Yo Antibody Screen with Reflex to Titer and Western Blot;Z3692;Yo Ab, IFA;14249-7;Purkinje cells Ab:ACnc:Pt:Ser:Ord:IF;2014-04-14;Immunofluorescence Assay (IFA)Western Blot (WB)
2664;FYOG;Yogurt (Lactobacillus bulgaricus) IgE;Z3868;Yogurt IgE;7787-5;Yogurt Ab.IgE:ACnc:Pt:Ser:Qn:;2014-08-21;Radioimmunoassay (RIA)
2665;FYOG;Yogurt (Lactobacillus bulgaricus) IgE;Z3869;CLASS;21609-3;Yogurt Ab.IgE.RAST class:Threshold:Pt:Ser:Ord:;2014-08-21;Radioimmunoassay (RIA)
2666;FZ003;Lyme Disease Antibody Index;Z0358;Control Ab Index;23833-7;Borrelia burgdorferi Ab index:ACnc:Pt:Ser+CSF:Ord:;2014-08-01;Only orderable as part of a profile. For further information see FBBAB "Lyme Disease Ab for CNS Infection"
2667;FZ003;Lyme Disease Antibody Index;Z0677;Lyme Disease Ab Index;23833-7;Borrelia burgdorferi Ab index:ACnc:Pt:Ser+CSF:Ord:;2014-08-01;Only orderable as part of a profile. For further information see FBBAB "Lyme Disease Ab for CNS Infection"
2668;FZ004;Albumin Ratio;Z0359;Albumin Ratio;14117-6;IgG index:RelRto:Pt:Ser+CSF:Qn:;2014-08-01;Only orderable as part of a profile. For further information see FBBAB "Lyme Disease Ab for CNS Infection"
2669;F_10;Coagulation Factor X Activity Assay, Plasma;F_10;Coag Factor X Assay, P;3218-5;Coagulation factor X activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Prothrombin Clot-Based Assay
2670;F_11;Coagulation Factor XI Activity Assay, Plasma;F_11;Coag Factor XI Assay, P;3226-8;Coagulation factor XI activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Activated Partial Thromboplastin Clot-Based Assay
2671;F_12;Coagulation Factor XII Activity Assay, Plasma;F_12;Coag Factor XII Assay, P;3232-6;Coagulation factor XII activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Activated Partial Thromboplastin Clot-Based Assay
2672;F_2;Coagulation Factor II Activity Assay, Plasma;F_2;Coag Factor II Assay, P;3289-6;Prothrombin.activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Prothrombin Clot-Based Assay
2673;F_7;Coagulation Factor VII Activity Assay, Plasma;F_7;Coag Factor VII Assay, P;3198-9;Coagulation factor VII activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Prothrombin Clot-Based Assay
2674;F_9;Coagulation Factor IX Activity Assay, Plasma;F_9;Coag Factor IX Assay, P;3187-2;Coagulation factor IX activity actual/Normal:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Activated Partial Thromboplastin Clot-Based Assay
2675;G6PD;Glucose-6-Phosphate Dehydrogenase (G-6-PD), Quantitative, Erythrocytes;G6PD_;G-6-PD, QN, RBC;32546-4;Glucose-6-Phosphate dehydrogenase:CCnt:Pt:RBC:Qn:;2012-03-15;Kinetic Spectrophotometry (KS)
2676;G6ST;N-Acetylgalactosamine-6-Sulfate Sulfatase, Fibroblasts;29726;Interpretation (G6ST);59462-2;;2012-04-02;G6ST: FluorometricFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
2677;G6ST;N-Acetylgalactosamine-6-Sulfate Sulfatase, Fibroblasts;35766;N-Acetylgalactosamine 6 Slft, Fibro;2647-6;N-Acetylgalactosamine-4-Sulfatase:CCnt:Pt:Tiss:Qn;2014-07-10;G6ST: FluorometricFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
2678;GAABS;Acid Alpha-Glucosidase, Blood Spot ;30102;Interpretation;59462-2;;2012-04-02;Fluorometric Enzyme Assay
2679;GAABS;Acid Alpha-Glucosidase, Blood Spot ;30149;Acid alpha-glucosidase;55827-0;Alpha glucosidase A:CCnc:Pt:Bld.dot:Qn:;2011-10-03;Fluorometric Enzyme Assay
2680;GAABS;Acid Alpha-Glucosidase, Blood Spot ;30098;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorometric Enzyme Assay
2681;GAABS;Acid Alpha-Glucosidase, Blood Spot ;30101;Method;49549-9; ;2013-07-26;Fluorometric Enzyme Assay
2682;GAABS;Acid Alpha-Glucosidase, Blood Spot ;30100;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Fluorometric Enzyme Assay
2683;GAAKM;Pompe Disease, Known Mutation;50961;Result;53864-5;GAA gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2011-06-16;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2684;GAAKM;Pompe Disease, Known Mutation;50962;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2685;GAAKM;Pompe Disease, Known Mutation;50964;Amendment;53864-5;GAA gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2686;GAAKM;Pompe Disease, Known Mutation;50960;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2687;GAAKM;Pompe Disease, Known Mutation;50959;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2688;GAAKM;Pompe Disease, Known Mutation;50957;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2689;GAAMS;Pompe Disease, Full Gene Sequencing;50971;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2690;GAAMS;Pompe Disease, Full Gene Sequencing;50972;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2691;GAAMS;Pompe Disease, Full Gene Sequencing;50974;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2692;GAAMS;Pompe Disease, Full Gene Sequencing;50969;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2693;GABA;Gabapentin, Serum;80826;Gabapentin, S;9738-6;Gabapentin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
2694;GAL1P;Galactose-1-Phosphate (Gal-1-P), Erythrocytes;24101;Galactose-1-Phosphate Conversion;2312-7;Galactose 1 phosphate:MCnc:Pt:RBC:Qn:;2009-11-13;Ultraviolet, Enzymatic
2695;GAL1P;Galactose-1-Phosphate (Gal-1-P), Erythrocytes;80337;Galactose-1-Phosphate, RBC;33360-9;Galactose 1 phosphate:MCnt:Pt:RBC:Qn:;2009-11-13;Ultraviolet, Enzymatic
2696;GAL3;Galectin-3, Serum;86202;Galectin-3, S;62419-7;Galectin 3:MCnc:Pt:Ser/Plas:Qn:;2013-11-11;Enzyme-Linked Immunosorbent Assay (ELISA)
2697;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22588;Amendment;42318-6;GALT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2698;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22587;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2699;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22586;Result;42318-6;GALT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2700;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22585;Method;49549-9; ;2013-07-26;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2701;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22584;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2702;GAL6;Galactosemia Gene Analysis (6-Mutation Panel);22582;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;A real-time polymerase chain reaction (PCR)-based assay is utilized to examine DNA for 6 alterations: Q188R, S135L, L195P, K285N, N314D (Duarte), and L218L (Los Angeles).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2703;GALCK;Krabbe Disease, Known Mutation;33582;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis and/or Follow up PCR is utilized to test for the presence of mutations previously identified in an affected family member. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2704;GALCK;Krabbe Disease, Known Mutation;33584;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis and/or Follow up PCR is utilized to test for the presence of mutations previously identified in an affected family member. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2705;GALCK;Krabbe Disease, Known Mutation;33585;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis and/or Follow up PCR is utilized to test for the presence of mutations previously identified in an affected family member. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2706;GALCK;Krabbe Disease, Known Mutation;33587;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis and/or Follow up PCR is utilized to test for the presence of mutations previously identified in an affected family member. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2707;GALCS;Krabbe Disease, Full Gene Analysis and Large (30 kb) Deletion, PCR;33576;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2708;GALCS;Krabbe Disease, Full Gene Analysis and Large (30 kb) Deletion, PCR;33571;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2709;GALCS;Krabbe Disease, Full Gene Analysis and Large (30 kb) Deletion, PCR;33574;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2710;GALCS;Krabbe Disease, Full Gene Analysis and Large (30 kb) Deletion, PCR;33573;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2711;GALP;Galactose, Quantitative, Plasma;83638;Galactose, QN, P;2308-5;Galactose:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Spectrophotometric, Kinetic
2712;GALT;Galactose-1-Phosphate Uridyltransferase (GALT), Blood;2296;Interpretation (GALT);48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Enzyme Reaction Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2713;GALT;Galactose-1-Phosphate Uridyltransferase (GALT), Blood;8333;Gal-1-P Uridyltransferase, RBC;24082-0;Galactose 1 phosphate uridyl transferase:CCnt:Pt:RBC:Qn:;2009-11-13;Enzyme Reaction Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2714;GALTK;Galactosemia Gene Analysis, Known Mutation;22593;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR)-based assay is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2715;GALTK;Galactosemia Gene Analysis, Known Mutation;22595;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR)-based assay is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2716;GALTK;Galactosemia Gene Analysis, Known Mutation;22596;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)-based assay is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2717;GALTK;Galactosemia Gene Analysis, Known Mutation;22598;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR)-based assay is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2718;GALTM;GALT Gene, Full Gene Analysis;27421;Amendment;42318-6;GALT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2719;GALTM;GALT Gene, Full Gene Analysis;27419;Result;42318-6;GALT gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2720;GALTM;GALT Gene, Full Gene Analysis;27420;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2721;GALTM;GALT Gene, Full Gene Analysis;27415;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2722;GALTM;GALT Gene, Full Gene Analysis;27417;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2723;GALTM;GALT Gene, Full Gene Analysis;27418;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing is utilized to test for the presence of a mutation in all 11 exons of the GALT gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2724;GALTP;Galactose-1-Phosphate Uridyltransferase Biochemical Phenotyping, Erythrocytes;80341;Gal-1-Phos Urdyltrns Phenotype,RBC;33780-8;Galactose 1 phosphate uridyl transferase phenotype:Type:Pt:Bld:Nom:;2009-11-13;GALTP: Isoelectric FocusingGALT: Ultraviolet, Kinetic
2725;GALU;Galactose, Quantitative, Urine;8765;Galactose, QN, U;2310-1;Galactose:MCnc:Pt:Urine:Qn:;2009-11-13;Spectrophotometric, Kinetic
2726;GANC;Ganciclovir, Serum;80140;Ganciclovir, S;15367-6;Ganciclovir:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
2727;GARL;Garlic, IgE;GARL;Garlic, IgE;6122-6;Allium sativum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2728;GASCA;Saccharomyces cerevisiae Antibody, IgG, Serum;GASCA;Saccharomyces cerevisiae Ab, IgG, S;47321-5;Saccharomyces cerevisiae Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
2729;GAST;Gastrin, Serum;GAST;Gastrin, S;2333-3;Gastrin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Chemiluminescent Immunometric Assay
2730;GAUW;Gaucher Disease, Mutation Analysis, GBA;16676;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2731;GAUW;Gaucher Disease, Mutation Analysis, GBA;16679;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2732;GAUW;Gaucher Disease, Mutation Analysis, GBA;16680;Amendment;21729-9;PSAP gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2733;GAUW;Gaucher Disease, Mutation Analysis, GBA;16677;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2734;GAUW;Gaucher Disease, Mutation Analysis, GBA;16678;Result;21729-9;PSAP gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2735;GAUW;Gaucher Disease, Mutation Analysis, GBA;16674;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Gaucher disease: 84G->GG, IVS2(+1)G->A, N370S, delta 55bp, V394L, D409H, L444P, and R496H.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2736;GB2GP;Beta-2 Glycoprotein 1 Antibodies, IgG, Serum;GB2GP;Beta 2 GP1 Ab IgG, S;44448-9;Beta 2 glycoprotein 1 Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
2737;GBAKM;Gaucher Disease, Known Mutation;33562;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2738;GBAKM;Gaucher Disease, Known Mutation;33563;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2012-06-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2739;GBAKM;Gaucher Disease, Known Mutation;33565;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2740;GBAKM;Gaucher Disease, Known Mutation;33560;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2741;GBAMS;Gaucher Disease, Full Gene Analysis;33555;Amendment;41104-1;GBA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2742;GBAMS;Gaucher Disease, Full Gene Analysis;33551;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2743;GBAMS;Gaucher Disease, Full Gene Analysis;33552;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2744;GBAMS;Gaucher Disease, Full Gene Analysis;33553;Result;41104-1;GBA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2745;GBAMS;Gaucher Disease, Full Gene Analysis;33554;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2746;GBAMS;Gaucher Disease, Full Gene Analysis;33549;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-20;GBAMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2747;GBM;Glomerular Basement Membrane Antibodies, IgG, Serum;GBM;Glomerular Basement Membrane IgG Ab;31254-6;Basement membrane Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
2748;GCBN;Green Coffee Bean, IgE;GCBN;Green Coffee Bean, IgE;6132-5;Coffee bean green Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2749;GCC;Gallstone Cholesterol Content;GCC_;Cholesterol;54438-7;Cholesterol:MCnt:Pt:Calculus:Qn:;2012-03-15;Spectrophotometry (SP)/Other Methodologies as Appropriate
2750;GCLIP;Phospholipid (Cardiolipin) Antibodies, IgG, Serum;GCLIP;Phospholipid Ab IgG, S;3286-2;Phospholipid Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
2751;GCRNA;Neisseria gonorrhoeae by Nucleic Acid Amplification (GEN-PROBE);34875;Neisseria gonorrhoeae amplified RNA;43305-2;Neisseria gonorrhoeae rRNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-04-11;Transcription Mediated Amplification
2752;GCRNA;Neisseria gonorrhoeae by Nucleic Acid Amplification (GEN-PROBE);SRC17;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Transcription Mediated Amplification
2753;GCT;Galactosemia Reflex, Blood;8333;Gal-1-P Uridyltransferase, RBC;24082-0;Galactose 1 phosphate uridyl transferase:CCnt:Pt:RBC:Qn:;2009-11-13;Enzyme Reaction Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2754;GCT;Galactosemia Reflex, Blood;2296;Interpretation (GALT);48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Enzyme Reaction Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2755;GD65C;Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid;21702;GAD65 Ab Assay, CSF;53708-4;Glutamate decarboxylase 65 Ab:SCnc:Pt:CSF:Qn:;2009-11-13;Immunoprecipitation Assay
2756;GD65S;Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum;81596;GAD65 Ab Assay, S;30347-9;Glutamate decarboxylase 65 Ab:SCnc:Pt:Ser:Qn:;2009-11-13;Radioimmunoassay (RIA)
2757;GDOM;Glycyphagus domesticus, IgE;GDOM;Glycyphagus Domesticus, IgE;6126-7;Glycophagus domesticus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2758;GDU;Gadolinium, 24 Hour, Urine;29248;Gd Conc;8200-8;Gadolinium:MCnc:Pt:Urine:Qn:;2011-10-05;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2759;GDU;Gadolinium, 24 Hour, Urine;29252;Gadolinium, 24 Hr, U;8201-6;Gadolinium:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2760;GDU;Gadolinium, 24 Hour, Urine;VL82;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2761;GDU;Gadolinium, 24 Hour, Urine;TM101;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2762;GDUR;Gadolinium, Random, Urine;29276;Gadolinium, Random, U;8200-8;Gadolinium:MCnc:Pt:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2763;GELA;Gelatin, IgE;GELA;Gelatin, IgE;7332-0;Gelatin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2764;GEN;Bacterial Culture, Aerobic;GEN;Bacterial Culture, Aerobic;634-6;Bacteria identified:Prid:Pt:XXX:Nom:Aerobic culture;2013-09-17;Conventional Culture Technique
2765;GENPK;Gentamicin, Peak, Serum;6775;Gentamicin, Peak, S;3663-2;Gentamicin^peak:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
2766;GENT;Gentamicin, Random, Serum;81750;Gentamicin, Random, S;35668-3;Gentamicin^random:MCnc:Pt:Ser/Plas:Qn:;2011-04-28;Enzyme-Multiplied Immunoassay Technique (EMIT)
2767;GENTT;Gentamicin, Trough, Serum;6795;Gentamicin, Trough, S;3665-7;Gentamicin^trough:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
2768;GERB;Gerbil Epithelium, IgE;GERB;Gerbil Epithelium, IgE;7334-6;Gerbil epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2769;GFDKM;FTCD Gene, Known Mutation;33543;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;GFDKM: Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2770;GFDKM;FTCD Gene, Known Mutation;33541;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;GFDKM: Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2771;GFDKM;FTCD Gene, Known Mutation;33540;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;GFDKM: Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2772;GFDKM;FTCD Gene, Known Mutation;33538;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;GFDKM: Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2773;GFDMS;FTCD Gene, Full Gene Analysis;33527;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;GFDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2774;GFDMS;FTCD Gene, Full Gene Analysis;33529;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;GFDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2775;GFDMS;FTCD Gene, Full Gene Analysis;33530;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;GFDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2776;GFDMS;FTCD Gene, Full Gene Analysis;33532;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;GFDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)FBC: Cell Culture
2777;GGT;Gamma-Glutamyltransferase (GGT), Serum;GGT;Gamma Glutamyltransferase (GGT), S;2324-2;Gamma glutamyl transferase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric
2778;GGT;Gamma-Glutamyltransferase (GGT), Serum;GGT;Gamma Glutamyltransferase (GGT), S;2324-2;Gamma glutamyl transferase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric Rate
2779;GGUM;Guar Gum, IgE;GGUM;Guar Gum, IgE;10933-0;Cyamopsis tetragonoloba Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2780;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21416;Nelfinavir;30294-3;Nelfinavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2781;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;34917;Rilpivirine;68463-9;Rilpivirine:Susc:Pt:Isolate:OrdQn:Genotyping;2013-08-07;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2782;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21406;Didanosine;30284-4;Didanosine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2783;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;26732;Fosamprenavir;43736-8;Fosamprenavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2784;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;28201;Tipranavir with Ritonavir;49622-4;Tipranavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2785;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;26735;Saquinavir with Ritonavir;49621-6;Saquinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2786;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21412;Lamivudine/Emtricitabine;30283-6;Lamivudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2787;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21410;Nevirapine;30289-3;Nevirapine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2788;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21532;Lopinavir with Ritonavir;42000-0;Lopinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2789;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;26734;Indinavir with Ritonavir;49619-0;Indinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2790;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;26733;Fosamprenavir with Ritonavir;51409-1;Fosamprenavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2791;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21415;Indinavir;30292-7;Indinavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2792;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;23624;Atazanavir;41403-7;Atazanavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2793;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;28076;Atazanavir with Ritonavir;49618-2;Atazanavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2794;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;82340;HIV-1 Genotypic Drug Resistance, P;30554-0;HIV reverse transcriptase gene mutations detected:Prid:Pt:Isolate:Nom:;2013-09-17;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2795;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;26784;Darunavir with Ritonavir;49630-7;Darunavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2796;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21395;Reverse Transcriptase Mutations;30554-0;HIV reverse transcriptase gene mutations detected:Prid:Pt:Isolate:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2797;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21408;Stavudine;30286-9;Stavudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2798;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21530;Tenofovir;41396-3;Tenofovir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2799;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21405;Zidovudine;30282-8;Zidovudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2800;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21414;Efavirenz;30291-9;Efavirenz:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2801;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;31267;Etravirine;52749-9;Etravirine:Susc:Pt:Isolate:OrdQn:Genotyping;2011-06-22;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2802;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21400;Protease Mutations;33630-5;HIV protease gene mutations detected:Prid:Pt:Isolate:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2803;GHIV;HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;21411;Abacavir;30287-7;Abacavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2804;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;28201;Tipranavir with Ritonavir;49622-4;Tipranavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2805;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;26735;Saquinavir with Ritonavir;49621-6;Saquinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2806;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21406;Didanosine;30284-4;Didanosine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2807;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;23624;Atazanavir;41403-7;Atazanavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2808;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21532;Lopinavir with Ritonavir;42000-0;Lopinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2809;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21415;Indinavir;30292-7;Indinavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2810;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;26734;Indinavir with Ritonavir;49619-0;Indinavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2811;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21405;Zidovudine;30282-8;Zidovudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2812;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;26733;Fosamprenavir with Ritonavir;51409-1;Fosamprenavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2813;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21395;Reverse Transcriptase Mutations;30554-0;HIV reverse transcriptase gene mutations detected:Prid:Pt:Isolate:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2814;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21408;Stavudine;30286-9;Stavudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2815;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;26732;Fosamprenavir;43736-8;Fosamprenavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2816;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;28076;Atazanavir with Ritonavir;49618-2;Atazanavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2817;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21410;Nevirapine;30289-3;Nevirapine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2818;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;34917;Rilpivirine;68463-9;Rilpivirine:Susc:Pt:Isolate:OrdQn:Genotyping;2013-08-07;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2819;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;31267;Etravirine;52749-9;Etravirine:Susc:Pt:Isolate:OrdQn:Genotyping;2011-06-22;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2820;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21414;Efavirenz;30291-9;Efavirenz:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2821;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;26784;Darunavir with Ritonavir;49630-7;Darunavir+Ritonavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2822;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21530;Tenofovir;41396-3;Tenofovir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2823;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21412;Lamivudine/Emtricitabine;30283-6;Lamivudine:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2824;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21400;Protease Mutations;33630-5;HIV protease gene mutations detected:Prid:Pt:Isolate:Nom:;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2825;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21411;Abacavir;30287-7;Abacavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2826;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;82340;HIV-1 Genotypic Drug Resistance, P;30554-0;HIV reverse transcriptase gene mutations detected:Prid:Pt:Isolate:Nom:;2013-09-17;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2827;GHIVS;HIV-1 Ultrasensitive Genotypic Drug Resistance Mutation Analysis, Plasma;21416;Nelfinavir;30294-3;Nelfinavir:Susc:Pt:Isolate:OrdQn:Genotyping;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Followed by DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2828;GIAR;Giardia Antigen, Feces;24085;Giardia Ag, F;6412-1;Giardia lamblia Ag:ACnc:Pt:Stool:Ord:EIA;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
2829;GING;Ginger, IgE;GING;Ginger, IgE;7335-3;Zingiber officinale Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2830;GLBF;Glucose, Body Fluid;FLD12;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric, Hexokinase
2831;GLBF;Glucose, Body Fluid;GL_BF;Glucose, BF;2344-0;Glucose:MCnc:Pt:Body fld:Qn:;2012-03-15;Photometric, Hexokinase
2832;GLDR;Goldenrod, IgE;GLDR;Goldenrod, IgE;6128-3;Solidago virgaurea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2833;GLIC;CD8 T-Cell Immune Competence, Global, Blood;30645;Interpretation;69052-9; ;2013-08-22;Flow Cytometry
2834;GLP;Glucagon, Plasma;9358;Glucagon, P;2338-2;Glucagon:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay Following Extraction
2835;GLSF;Glucose, Spinal Fluid;GLSF;Glucose, CSF;2342-4;Glucose:MCnc:Pt:CSF:Qn:;2012-03-15;Photometric, Glucose Oxidase/Peroxidase (VITROS Dry Slide)
2836;GLT;Gluten, IgE;GLT;Gluten, IgE;6125-9;Gluten Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2837;GLUR;Glucose, 24 Hour, Urine;VL7;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Glucose Hexokinase
2838;GLUR;Glucose, 24 Hour, Urine;GLUCN;Glucose Concentration;21305-8;Glucose:MCnc:24H:Urine:Qn:;2012-03-15;Glucose Hexokinase
2839;GLUR;Glucose, 24 Hour, Urine;TM9;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Glucose Hexokinase
2840;GLUR;Glucose, 24 Hour, Urine;GLUU;Glucose, U;2351-5;Glucose:MRat:24H:Urine:Qn:;2012-10-31;Glucose Hexokinase
2841;GLURA;Glucose, Random, Serum;GLURA;Glucose, Random, S;2345-7;Glucose:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Hexokinase
2842;GMILK;Goat's Milk, IgE;GMILK;Goat's Milk, IgE;7340-3;Goat milk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2843;GNEM;Green Nemitti, IgE;GNEM;Green Nemitti, IgE;6133-3;Cladotanytarsus lewisi Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2844;GOAT;Goat Epithelium, IgE;GOAT;Goat Epithelium, IgE;6127-5;Goat epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2845;GOOS;Goose Feathers, IgE;GOOS;Goose Feathers, IgE;6129-1;Goose feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2846;GPEA;Green Pea, IgE;GPEA;Green Pea, IgE;6204-2;Pisum sativum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2847;GPEP;Green Pepper, IgE;GPEP;Green Pepper, IgE;6852-8;Pepper green Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2848;GPI;Glucose Phosphate Isomerase, Erythrocytes;GPI_;Glucose Phosphate Isomerase, B;44050-3;Glucose phosphate isomerase:CCnt:Pt:RBC:Qn:;2012-03-15;Kinetic Spectrophotometry (KS)
2849;GRAP;Grape, IgE;GRAP;Grape, IgE;6841-1;Vitis vinifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2850;GRAS1;Grass Panel # 1;GRAS1;Grass Panel # 1;30189-5;((Dactylis glomerata+Festuca elatior+Lolium perenne+Phleum pratense+Poa pratensis) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2851;GRAS2;Grass Panel # 2;GRAS2;Grass Panel # 2;30188-7;(Cynodon dactylon+Lolium perenne+Phleum pratense+Poa pratensis+Sorghum halepense+Paspalum notatum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2852;GRAS3;Grass Panel # 3;GRAS3;Grass Panel # 3;50654-3;(Anthoxanthum odoratum+Lolium perenne+Phleum pratense+Secale cereale+Holcus lanatus) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2853;GRFE;Greek Fennel, IgE;GRFE;Greek Fennel, IgE;19739-2;Trigonella foenum-graecum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2854;GRFR;Grapefruit, IgE;GRFR;Grapefruit, IgE;6131-7;Citrus paradisis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2855;GRHKM;GRHPR Gene, Known Mutation;33781;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase chain reaction (PCR)/DNA sequence analysis or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc).
2856;GRHKM;GRHPR Gene, Known Mutation;33778;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase chain reaction (PCR)/DNA sequence analysis or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc).
2857;GRHKM;GRHPR Gene, Known Mutation;33777;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase chain reaction (PCR)/DNA sequence analysis or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc).
2858;GRHKM;GRHPR Gene, Known Mutation;33775;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase chain reaction (PCR)/DNA sequence analysis or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc).
2859;GRHMS;GRHPR Gene, Full Gene Analysis;33769;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2860;GRHMS;GRHPR Gene, Full Gene Analysis;33766;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2861;GRHMS;GRHPR Gene, Full Gene Analysis;33763;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2862;GRHMS;GRHPR Gene, Full Gene Analysis;33765;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2863;GRNKM;Progranulin Gene (GRN), Known Mutation;29669;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2864;GRNKM;Progranulin Gene (GRN), Known Mutation;29667;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2865;GRNKM;Progranulin Gene (GRN), Known Mutation;29664;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2866;GRNKM;Progranulin Gene (GRN), Known Mutation;29666;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2867;GRNMS;Progranulin Gene (GRN), Full Gene Analysis;29655;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2868;GRNMS;Progranulin Gene (GRN), Full Gene Analysis;29653;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2869;GRNMS;Progranulin Gene (GRN), Full Gene Analysis;29658;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2870;GRNMS;Progranulin Gene (GRN), Full Gene Analysis;29656;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2871;GRW;Giant Ragweed, IgE;GRW;Giant Ragweed, IgE;6124-2;Ambrosia trifida Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2872;GSNKM;Gelsolin (GSN) Gene, Known Mutation;51347;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar;2014-05-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2873;GSNKM;Gelsolin (GSN) Gene, Known Mutation;51345;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2874;GSNKM;Gelsolin (GSN) Gene, Known Mutation;51342;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2875;GSNKM;Gelsolin (GSN) Gene, Known Mutation;51344;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
2876;GSNMS;Gelsolin (GSN) Gene, Full Gene Analysis;33453;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2877;GSNMS;Gelsolin (GSN) Gene, Full Gene Analysis;33455;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2878;GSNMS;Gelsolin (GSN) Gene, Full Gene Analysis;33450;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2879;GSNMS;Gelsolin (GSN) Gene, Full Gene Analysis;33452;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2880;GSTB;Green String Bean, IgE;GSTB;Green String Bean, IgE;6831-2;Bean green Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2881;GUAV;Guava, IgE;GUAV;Guava, IgE;10934-8;Psidium guajava Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2882;GUIN;Guinea Pig Epithelium, IgE;GUIN;Guinea Pig Epithelium, IgE;6134-1;Guinea pig epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2883;GUM;Gum Arabic, IgE;GUM;Gum Arabic, IgE;7382-5;Gum arabic Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2884;GWEE;Grain Weevil, IgE;GWEE;Grain Weevil, IgE;11174-0;Sitophilus granarius Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2885;HAKE;Hake, Fish, IgE;HAKE;Hake, Fish, IgE;19741-8;Merluccius merluccius Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2886;HALI;Halibut, IgE;HALI;Halibut, IgE;6842-9;Hippoglossus hippoglossus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2887;HALO;Haloperidol, Serum;80339;Haloperidol, S;3669-9;Haloperidol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2888;HALO;Haloperidol, Serum;169;Reduced Haloperidol;38364-6;Haloperidol.reduced:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2889;HAPT;Haptoglobin, Serum;HAPT;Haptoglobin, S;46127-7;Haptoglobin:MCnc:Pt:Ser/Plas:Qn:Nephelometry;2012-03-15;Nephelometry
2890;HAV;Hepatitis A Total Antibodies, Serum;HAV;Hepatitis A Total Ab, S;20575-7;Hepatitis A virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
2891;HAVAB;Hepatitis A Total Antibodies, with Reflex to Hepatitis A IgM Antibody, Serum;HAVAB;Hepatitis A Total Ab, w/Reflex, S;20575-7;Hepatitis A virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay (CIA)
2892;HAVAB;Hepatitis A Total Antibodies, with Reflex to Hepatitis A IgM Antibody, Serum;HAVAB;Hepatitis A Total Ab, w/Reflex, S;20575-7;Hepatitis A virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
2893;HAVM;Hepatitis A IgM Antibody, Serum;HAVM;Hepatitis A IgM Ab, S;22314-9;Hepatitis A virus Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay (CIA)
2894;HAVM;Hepatitis A IgM Antibody, Serum;HAVM;Hepatitis A IgM Ab, S;22314-9;Hepatitis A virus Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
2895;HAZ;Hazelnut-Tree, IgE;HAZ;Hazelnut-Tree, IgE;6137-4;Corylus avellana pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2896;HBA1C;Hemoglobin A1c, Blood;HBA1C;Hemoglobin A1c, B;4548-4;Hemoglobin A1c/Hemoglobin.total:MFr:Pt:Bld:Qn:;2012-03-15;Ion-Exchange Chromatography Quantitative
2897;HBAB;Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum;HBSQN;HBs Antibody, Quantitative, S;16935-9;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Qn:;2012-03-15;Chemiluminometric Immunoassay
2898;HBAB;Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum;HB_AB;HBs Antibody, S;22322-2;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminometric Immunoassay
2899;HBAB;Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum;HB_AB;HBs Antibody, S;22322-2;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescent Immunoassay (CIA)
2900;HBAB;Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum;HBSQN;HBs Antibody, Quantitative, S;16935-9;Hepatitis B virus surface Ab:ACnc:Pt:Ser:Qn:;2012-03-15;Chemiluminescent Immunoassay (CIA)
2901;HBABT;Hepatitis B Surface Antibody Monitor, Post-Transplant, Serum;HBABT;HBs Ab Monitor, Post-transplant, S;32019-2;Hepatitis B virus surface Ab:Titr:Pt:Ser:Qn:;2012-03-15;Chemiluminescent Immunoassay (CIA)
2902;HBAG;Hepatitis B Surface Antigen, Serum;H_BAG;HBs Antigen, S;5195-3;Hepatitis B virus surface Ag:ACnc:Pt:Ser:Ord:;2012-10-31;Chemiluminescence Immunoassay (CIA)
2903;HBAG;Hepatitis B Surface Antigen, Serum;H_BAG;HBs Antigen, S;5195-3;Hepatitis B virus surface Ag:ACnc:Pt:Ser:Ord:;2012-10-31;Chemiluminesence Immunoassay
2904;HBAGP;Hepatitis B Surface Antigen Prenatal, Serum;HBSAP;HBs Antigen Prenatal, S;5195-3;Hepatitis B virus surface Ag:ACnc:Pt:Ser:Ord:;2012-10-31;Chemiluminescence Immunoassay (CIA)
2905;HBC;Hepatitis B Core Total Antibodies, Serum;HBC;HBc Total Ab, S;13952-7;Hepatitis B virus core Ab:ACnc:Pt:Ser/Plas:Ord:EIA;2013-12-18;Chemiluminescence Immunoassay (CIA)
2906;HBC;Hepatitis B Core Total Antibodies, Serum;HBC;HBc Total Ab, S;13952-7;Hepatitis B virus core Ab:ACnc:Pt:Ser/Plas:Ord:EIA;2013-12-18;Chemiluminescence Immunoassay
2907;HBEA;Hornbeam, IgE;HBEA;Horn Beam, IgE;7416-1;Carpinus betulus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2908;HBF;Hemoglobin F, Blood;6812;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2009-11-13;Ion-Exchange/High-Performance Liquid Chromatography (HPLC)
2909;HBF;Hemoglobin F, Blood;8269;Hemoglobin F, B;42246-9;Hemoglobin F/Hemoglobin.total:MFr:Pt:Bld:Qn:HPLC;2009-11-13;Ion-Exchange/High-Performance Liquid Chromatography (HPLC)
2910;HBGCD;Hepatitis Bs Antigen (HBsAg) for Cadaveric or Hemolyzed Specimens, Serum;83626;HBsAg Cadaver/Hemolyzed, S;5196-1;Hepatitis B virus surface Ag:ACnc:Pt:Ser:Ord:EIA;2009-11-13;Enzyme Immunoassay (EIA)
2911;HBIM;Hepatitis B Core Antibody, IgM, Serum;HBIM;HBc IgM Ab, S;31204-1;Hepatitis B virus core Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay (CIA)
2912;HBIM;Hepatitis B Core Antibody, IgM, Serum;HBIM;HBc IgM Ab, S;31204-1;Hepatitis B virus core Ab.IgM:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
2913;HBL;Chromosome Analysis, Hematologic Disorders, Blood;16068;Amendment;29770-5;Karyotype:Prid:Pt:Bld/Tiss:Nom:;2013-08-09;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2914;HBL;Chromosome Analysis, Hematologic Disorders, Blood;16064;Method;49549-9; ;2013-07-26;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2915;HBL;Chromosome Analysis, Hematologic Disorders, Blood;16067;Interpretation;69965-2;;2012-04-05;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2916;HBL;Chromosome Analysis, Hematologic Disorders, Blood;16066;Results;29770-5;Karyotype:Prid:Pt:Bld/Tiss:Nom:;2009-11-13;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2917;HBL;Chromosome Analysis, Hematologic Disorders, Blood;50467;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2918;HBL;Chromosome Analysis, Hematologic Disorders, Blood;G_540;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2919;HBL;Chromosome Analysis, Hematologic Disorders, Blood;16783;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Cell Culture Without Mitogens*Includes 2 banded karyograms, analysis of 20 or more metaphases, and other banding techniques when required.*In addition to the cell culture without mitogens,a CpG stimulated culture will be added and 10 additional cells will be analyzed for any specimen received from a patient age 30 or older with a reason for referral of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphocytosis, Waldenstrom's macroglobulinemia, or when FCLL / Chronic Lymphocytic Leukemia (CLL), FISH is ordered concurrently.
2920;HBRP;Histoplasma capsulatum/Blastomyces dermatitidis, Molecular Detection, PCR;SRC78;Histo/Blasto Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2921;HBRP;Histoplasma capsulatum/Blastomyces dermatitidis, Molecular Detection, PCR;32458;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2922;HBRPB;Histoplasma capsulatum/Blastomyces dermatitidis, Molecular Detection, PCR, Blood;SRC79;Histo/Blasto Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2923;HBV;Honeybee Venom, IgE;HBV;Honeybee Venom, IgE;6844-5;Apis mellifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2924;HBVQU;Hepatitis B Virus (HBV) DNA Detection and Quantification by Real-Time PCR, Serum;88634;HBV DNA Detect/Quant, S;42595-9;Hepatitis B virus DNA:ACnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2925;HCCAD;Hepatitis C Virus Antibody Screen for Cadaveric or Hemolyzed Specimens, Serum;87858;HCV Ab Cadaver/Hemolyzed Screen, S;13955-0;Hepatitis C virus Ab:ACnc:Pt:Ser:Ord:EIA;2009-11-13;HCCAD: Enzyme Immunoassay (EIA)
2926;HCCD;Hereditary Colon Cancer Multi-Gene Large Deletion and Duplication Analysis;51425;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Polymerase Chain Reaction (PCR) followed by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2927;HCCD;Hereditary Colon Cancer Multi-Gene Large Deletion and Duplication Analysis;51422;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Polymerase Chain Reaction (PCR) followed by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2928;HCCD;Hereditary Colon Cancer Multi-Gene Large Deletion and Duplication Analysis;51420;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Polymerase Chain Reaction (PCR) followed by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2929;HCCD;Hereditary Colon Cancer Multi-Gene Large Deletion and Duplication Analysis;51418;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Polymerase Chain Reaction (PCR) followed by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2930;HCCP;Hereditary Colon Cancer Multi-Gene Panel;51403;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2931;HCCP;Hereditary Colon Cancer Multi-Gene Panel;51399;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2932;HCCP;Hereditary Colon Cancer Multi-Gene Panel;51400;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2933;HCCP;Hereditary Colon Cancer Multi-Gene Panel;51397;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2934;HCH;Hematologic Disorders, Chromosome Hold, Bone Marrow or /Peripheral Blood;51355;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Direct preparation of specimen
2935;HCH;Hematologic Disorders, Chromosome Hold, Bone Marrow or /Peripheral Blood;51358;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Direct preparation of specimen
2936;HCH;Hematologic Disorders, Chromosome Hold, Bone Marrow or /Peripheral Blood;51356;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Direct preparation of specimen
2937;HCH;Hematologic Disorders, Chromosome Hold, Bone Marrow or /Peripheral Blood;51353;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Direct preparation of specimen
2938;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50255;Interpretation;59462-2;;2012-04-02;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2939;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50254;Methylcitric Acid;26904-3;2-Methylcitrate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2940;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50250;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2941;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50252;Homocysteine;13965-9;Homocysteine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2942;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50253;Methylmalonic Acid;13964-2;Methylmalonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2943;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50251;Method;49549-9; ;2013-07-26;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2944;HCMM;Homocysteine (Total), Methylmalonic Acid, and Methylcitric Acid, Blood Spots;50248;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
2945;HCO3;Bicarbonate, Serum;HCO3;Bicarbonate, S;1963-8;Bicarbonate:SCnc:Pt:Ser:Qn:;2012-03-15;Photometric, Enzymatic
2946;HCPCR;Hepatitis C Antibody Screen with Reflex to HCV RNA by PCR, Serum;HCVA2;HCV Ab Screen, S;16128-1;Hepatitis C virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;HCPCR: Chemiluminescence ImmunoassayHCVQU: Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2947;HCV;Hepatitis C Antibody Screen, Serum;HCVA;HCV Ab Screen, S;16128-1;Hepatitis C virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescense Immunoassay (CIA)
2948;HCV;Hepatitis C Antibody Screen, Serum;HCVA;HCV Ab Screen, S;16128-1;Hepatitis C virus Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Chemiluminescence Immunoassay
2949;HCVG;Hepatitis C Virus Genotype, Serum;81618;HCV Genotype, S;32286-7;Hepatitis C virus genotype:Prid:Pt:Ser/Plas:Nom:Probe.amp.tar;2009-11-13;Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Followed by Hybridization with Sequence-Specific, Fluorescent-Labeled Oligonucleotide Probes(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
2950;HCVQU;Hepatitis C Virus (HCV) RNA Detection and Quantification by Real-Time Reverse Transcription-PCR (RT-PCR), Serum;83142;HCV RNA Detect/Quant, S;11011-4;Hepatitis C virus RNA:ACnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2009-11-13;Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2951;HCYSP;Homocysteine, Total, Plasma;80379;Homocysteine, Total, P;13965-9;Homocysteine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
2952;HCYSU;Homocysteine, Total, Urine;80378;Homocysteine, Total, U;26582-7;Homocysteine/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
2953;HD;Huntington Disease, Molecular Analysis;51205;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2954;HD;Huntington Disease, Molecular Analysis;51208;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2955;HD;Huntington Disease, Molecular Analysis;51206;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2956;HD;Huntington Disease, Molecular Analysis;51203;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2957;HD1;House Dust Panel;HD1;House Dust Panel;37987-5;(Blatella germanica+Dermatophagoides farinae+Dermatophagoides pteronyssinus+House dust Hollister Stier) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2958;HDCH;Cholesterol, HDL, Serum;HDCH;Cholesterol, HDL, S;2085-9;Cholesterol.in HDL:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Enzymatic Colorimetric
2959;HDG;House Dust/Greer Lab, IgE;HDG;House Dust/Greer Lab, IgE;9828-5;House dust Greer Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2960;HDHS;House Dust/H-S Lab, IgE;HDHS;House Dust/H-S Lab, IgE;7425-2;House dust Hollister Stier Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2961;HELIG;Helicobacter pylori Antibody, IgG, Serum;110325;Helicobacter Pylori IgG, EIA;17859-0;Helicobacter pylori Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2012-03-12;Enzyme Immunoassay (EIA)
2962;HELM;Helminthosporium halodes, IgE;HELM;Helminthosporium Halodes, IgE;6138-2;Helminthosporium halodes Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2963;HEPI;Hamster Epithelium, IgE;HEPI;Hamster Epithelium, IgE;6135-8;Hamster epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2964;HERR;Herring, IgE;HERR;Herring, IgE;6139-0;Clupea harengus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2965;HEVG;Hepatitis E Virus IgG Antibody, Serum;86211;HEV IgG Ab, S;49693-5;Hepatitis E virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA ;2014-03-12;Enzyme Immunoassay (EIA)-Screening Procedure
2966;HEVM;Hepatitis E Virus IgM Antibody Screen with Reflex to Confirmation, Serum;86212;HEV IgM Ab Screen, S;14212-5;Hepatitis E virus Ab.IgM:ACnc:Pt:Ser:Ord:  ;2014-03-10;Enzyme Immunoassay (EIA)-Screening Procedure
2967;HEVML;Hepatitis E Virus IgM Antibody Confirmation, Serum;61903;HEV IgM Ab Confirmation, S;14212-5;Hepatitis E virus Ab.IgM:ACnc:Pt:Ser:Ord:   ;2013-08-22;Line Immunoassay (LIA)
2968;HEXAI;Hexahydrophtalic Anhydride, IgE;HEXAI;Hexahydrophtalic Anhydride, IgE;19742-6;Hexahydrophthalic anhydride Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2969;HEXKM;Tay-Sachs Disease, HEXA Gene, Known Mutation;30254;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) in the HEXA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems. Inc.)
2970;HEXKM;Tay-Sachs Disease, HEXA Gene, Known Mutation;30257;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) in the HEXA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems. Inc.)
2971;HEXKM;Tay-Sachs Disease, HEXA Gene, Known Mutation;30258;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) in the HEXA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems. Inc.)
2972;HEXKM;Tay-Sachs Disease, HEXA Gene, Known Mutation;30260;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a specific mutation(s) in the HEXA gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems. Inc.)
2973;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30268;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2974;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30269;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2975;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30266;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2976;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30272;Amendment;32632-2;HEXA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2977;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30271;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2978;HEXMS;Tay-Sachs Disease, HEXA Gene, Full Gene Analysis;30270;Result;32632-2;HEXA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the HEXA gene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2979;HFH;Hematologic Disorders, Fluorescence In Situ Hybridization (FISH) Hold, Bone Marrow or Peripheral Blood;51378;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Direct preparation of specimen
2980;HFH;Hematologic Disorders, Fluorescence In Situ Hybridization (FISH) Hold, Bone Marrow or Peripheral Blood;51375;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Direct preparation of specimen
2981;HFH;Hematologic Disorders, Fluorescence In Situ Hybridization (FISH) Hold, Bone Marrow or Peripheral Blood;51380;Interpretations;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Direct preparation of specimen
2982;HFH;Hematologic Disorders, Fluorescence In Situ Hybridization (FISH) Hold, Bone Marrow or Peripheral Blood;51377;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Direct preparation of specimen
2983;HFSF;Horsefly/Stablefly, IgE;HFSF;Horsefly/Stablefly, IgE;6144-0;Tabanus spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
2984;HG;Mercury, Blood;8618;Mercury, B;5685-3;Mercury:MCnc:Pt:Bld:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2985;HGB_Q;Hemoglobin, Qualitative, Urine;HGBQL;Hemoglobin, QL;5794-3;Hemoglobin:ACnc:Pt:Urine:Ord:Test strip;2012-03-15;Dipstick
2986;HGB_Q;Hemoglobin, Qualitative, Urine;RBC3;RBC;13945-1;Erythrocytes:Naric:Pt:Urine sed:Qn:Microscopy.light.HPF;2012-03-15;Dipstick
2987;HGB_Q;Hemoglobin, Qualitative, Urine;APP4;Appearance;5767-9;Appearance:Aper:Pt:Urine:Nom:;2012-03-12;Dipstick
2988;HGH;Growth Hormone, Serum;HGH;Growth Hormone, S;2963-7;Somatotropin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
2989;HGHAR;Mercury, Hair;31900;Mercury, Hair;5686-1;Mercury:MCnt:Pt:Hair:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2990;HGHAR;Mercury, Hair;HGHSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2991;HGNA;Mercury, Nails;HGNSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2992;HGNA;Mercury, Nails;2509;Mercury, Nails;8204-0;Mercury:MCnt:Pt:Nail:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2993;HGRU;Mercury, Random, Urine;60248;Mercury, Random, U;5689-5;Mercury:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2994;HGU;Mercury, 24 Hour, Urine;VL3;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2995;HGU;Mercury, 24 Hour, Urine;856;Hg Concentration;21383-5;Mercury:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2996;HGU;Mercury, 24 Hour, Urine;TM5;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2997;HGU;Mercury, 24 Hour, Urine;8592;Mercury, 24 Hr, U;6693-6;Mercury:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
2998;HHEMO;Hemochromatosis HFE Gene Analysis, Blood;16186;Amendment;21694-5;HFE gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-08-09;Polymerase chain reaction (PCR)-based assay (using LightCycler technology) is used to test for 3 mutations in the HFE gene: C282Y, H63D, and S65C. The S65C mutation is only reported when it is found with the C282Y mutation.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
2999;HHEMO;Hemochromatosis HFE Gene Analysis, Blood;16182;Results;21694-5;HFE gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR)-based assay (using LightCycler technology) is used to test for 3 mutations in the HFE gene: C282Y, H63D, and S65C. The S65C mutation is only reported when it is found with the C282Y mutation.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3000;HHEMO;Hemochromatosis HFE Gene Analysis, Blood;16183;Interpretation;69047-9; ;2014-04-30;Polymerase chain reaction (PCR)-based assay (using LightCycler technology) is used to test for 3 mutations in the HFE gene: C282Y, H63D, and S65C. The S65C mutation is only reported when it is found with the C282Y mutation.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3001;HHEMO;Hemochromatosis HFE Gene Analysis, Blood;16181;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)-based assay (using LightCycler technology) is used to test for 3 mutations in the HFE gene: C282Y, H63D, and S65C. The S65C mutation is only reported when it is found with the C282Y mutation.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3002;HHEMO;Hemochromatosis HFE Gene Analysis, Blood;16171;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR)-based assay (using LightCycler technology) is used to test for 3 mutations in the HFE gene: C282Y, H63D, and S65C. The S65C mutation is only reported when it is found with the C282Y mutation.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3003;HHTM;Hereditary Hemorrhagic Telangiectasia, ENG and ACVRL1 Large Deletion/Duplication, Molecular Analysis;45500;ENG-ACVRL1, Large Del/Dup Interp;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3004;HHTM;Hereditary Hemorrhagic Telangiectasia, ENG and ACVRL1 Large Deletion/Duplication, Molecular Analysis;31068;ENG-ACVRL1, Large Del/Dup Result;69481-0;;2012-04-10;Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3005;HHV6;Human Herpesvirus-6, Molecular Detection, PCR, Plasma;87532;Result;43244-3;Herpes virus 6 DNA:ACnc:Pt:Ser:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3006;HHV6;Human Herpesvirus-6, Molecular Detection, PCR, Plasma;30064;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3007;HHV6;Human Herpesvirus-6, Molecular Detection, PCR, Plasma;SS011;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3008;HHV6V;Human Herpesvirus-6, Molecular Detection, PCR, Varies;56093;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3009;HHV6V;Human Herpesvirus-6, Molecular Detection, PCR, Varies;56092;Result;33941-6;Herpes virus 6 DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3010;HHV6V;Human Herpesvirus-6, Molecular Detection, PCR, Varies;SS012;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3011;HHV8;Human Herpesvirus-8 Antibody, IgG, Serum;81971;Human Herpesvirus-8, Ab, IgG, S;40834-4;Herpes virus 8 Ab.IgG:ACnc:Pt:Ser:Ord:IF;2009-11-13;Immunofluorescence Assay (IFA)
3012;HIAA;5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine;VL33;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3013;HIAA;5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine;TM35;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3014;HIAA;5-Hydroxyindoleacetic Acid (5-HIAA), 24 Hour, Urine;9248;5-Hydroxyindoleacetic Acid, U;1695-6;5-Hydroxyindoleacetate:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3015;HIBS;Haemophilus influenzae Type B Antibody, IgG, Serum;83261;Haemophilus influenzae B Ab, IgG, S;11257-3;Haemophilus influenzae B Ab.IgG:MCnc:Pt:Ser:Qn:EIA;2009-11-13;Enzyme Immunoassay (EIA)
3016;HIPA;Hippuric Acid, Urine;Z1306;Hippuric Acid(Creatinine corrected);13754-7;Hippurate/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-12;Ion Chromatography (IC), Colorimetry (C)
3017;HIPA;Hippuric Acid, Urine;Z2513;Specific Gravity Confirmation;2965-2;Specific gravity:Rden:Pt:Urine:Qn:;2012-03-12;Ion Chromatography (IC), Colorimetry (C)
3018;HIPA;Hippuric Acid, Urine;Z1305;Creatinine;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Ion Chromatography (IC), Colorimetry (C)
3019;HIPA;Hippuric Acid, Urine;Z1309;Hippuric Acid;6709-0;Hippurate:MCnc:Pt:Urine:Qn:;2012-03-12;Ion Chromatography (IC), Colorimetry (C)
3020;HIS;Histone Autoantibodies, Serum;HIS;Histone Autoantibodies, S;43231-0;Histone Ab:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3021;HISTO;Histoplasma capsulatum Antibody Screen, Serum;HISTO;Histoplasma Ab Screen, S;44522-1;Histoplasma capsulatum Ab:ACnc:Pt:Ser:Ord:EIA;2012-03-15;HISTO: Enzyme-Linked Immunosorbent Assay (ELISA)SHSTO: Complement Fixation (CF)/Immunodiffusion
3022;HIT;Heparin-PF4 Antibody (HIT), Serum;21469;Interpretation;69049-5;;2012-04-09;Enzyme-Linked Immunosorbent Assay (ELISA)
3023;HIT;Heparin-PF4 Antibody (HIT), Serum;21470;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Enzyme-Linked Immunosorbent Assay (ELISA)
3024;HIV2;HIV-2 Antibody Evaluation, Serum;86702;HIV-2 Ab Eval, S;30361-0;HIV 2 Ab:ACnc:Pt:Ser:Ord:EIA;2009-11-13;Enzyme Immunoassay (EIA)
3025;HIV2L;HIV-2 Antibody Confirmation, Serum;61785;HIV-2 Ab Confirmation, S;7919-4;HIV 2 Ab:ACnc:Pt:Ser:Ord:;2013-08-07;Line Immunoassay (LIA)
3026;HIV2M;HIV-2 Antibody Screen, Serum;60356;HIV-2 Ab Screen, S;30361-0;HIV 2 Ab:ACnc:Pt:Ser:Ord:EIA;2011-06-24;Enzyme Immunoassay (EIA)
3027;HIVCO;HIV-1 and HIV-2 Antigen and Antibody Evaluation, Serum;HIVC1;HIV-1/-2 Ag and Ab Screen, S;56888-1;HIV 1+2 Ab+HIV1 p24 Ag:ACnc:Pt:Ser:Ord:EIA;2014-08-07;Chemiluminescent Microparticle Immunoassay
3028;HIVDI;HIV-1 and HIV-2 Antibody Differentiation, Serum;36112;HIV-1 Ab Differentiation, S;29893-5;HIV 1 Ab:ACnc:Pt:Ser:Ord:EIA;2014-08-07;Membrane Immunoconcentration
3029;HIVDI;HIV-1 and HIV-2 Antibody Differentiation, Serum;36113;HIV-2 Ab Differentiation, S;30361-0;HIV 2 Ab:ACnc:Pt:Ser:Ord:EIA;2014-08-07;Membrane Immunoconcentration
3030;HIVFA;HIV-1 Antibody Confirmation by Immunofluorescence, Serum;81758;HIV-1 Ab Confirm by IFA, S;14092-1;HIV 1 Ab:ACnc:Pt:Ser:Ord:IF;2009-11-13;Indirect Immunofluorescence Assay
3031;HIVQR;HIV-1 RNA Quantification with Reflex to HIV-1 Genotypic Drug Resistance Mutation Analysis, Plasma;81958;HIV-1 RNA Quantification, P;20447-9;HIV 1 RNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2009-11-13;HIVQR: Reverse Transcription-Polymerase Chain Reaction (RT-PCR)GHIV: Reverse Transcription-Polymerase Chain Reaction (RT-PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3032;HIVQU;HIV-1 RNA Quantification, Plasma;81958;HIV-1 RNA Quantification, P;20447-9;HIV 1 RNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2009-11-13;Reverse Transcription-Polymerase Chain Reaction (RT-PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3033;HL15O;HLA-B 1502 Genotype, Carbamazepine Hypersensitivity, Saliva;33054;HLA-B 1502 Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3034;HL57O;HLA-B 5701 Genotype, Abacavir Hypersensitivity, Saliva;33024;HLA-B 5701 Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3035;HL58O;HLA-B*5801 Genotype, Allopurinol Hypersensitivity, Saliva;35105;HLA-B 5801 Saliva Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Qualitative allele-specific real-time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3036;HLA15;HLA-B 1502 Genotype, Carbamazepine Hypersensitivity, Blood;29317;HLA-B 1502 Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3037;HLA15;HLA-B 1502 Genotype, Carbamazepine Hypersensitivity, Blood;89347;HLA-B 1502 Result;57979-7;HLA-B*1502:ACnc:Pt:Bld:Ord:;2011-10-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3038;HLA57;HLA-B 5701 Genotype, Abacavir Hypersensitivity, Blood;29316;HLA-B 5701 Reviewed by;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3039;HLA57;HLA-B 5701 Genotype, Abacavir Hypersensitivity, Blood;29315;HLA-B 5701 Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3040;HLA57;HLA-B 5701 Genotype, Abacavir Hypersensitivity, Blood;89346;HLA-B 5701 Result;42358-2;HLA-B5701:ACnc:Pt:XXX:Ord:;2009-11-13;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3041;HLA58;HLA-B*5801 Genotype, Allopurinol Hypersensitivity, Blood;35102;HLA-B 5801 Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3042;HLLFH;Hematologic Disorders, Leukemia/Lymphoma; Flow Hold Varies;CK075;Final Diagnosis;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2013-04-11;Immunophenotyping
3043;HLLFH;Hematologic Disorders, Leukemia/Lymphoma; Flow Hold Varies;CK077;Microscopic Description;22635-7;Path report.microscopic observation:Prid:Pt:Specimen:Nar:XXX stain;2013-04-11;Immunophenotyping
3044;HMBSK;HMBS Gene, Known Mutation;33679;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3045;HMBSK;HMBS Gene, Known Mutation;33682;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3046;HMBSK;HMBS Gene, Known Mutation;33681;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3047;HMBSK;HMBS Gene, Known Mutation;33684;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3048;HMBSS;HMBS Gene, Full Gene Analysis;33673;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3049;HMBSS;HMBS Gene, Full Gene Analysis;33671;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3050;HMBSS;HMBS Gene, Full Gene Analysis;33670;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3051;HMBSS;HMBS Gene, Full Gene Analysis;33668;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3052;HOP;Hop Fruit, IgE;HOP;Hop Fruit, IgE;6141-6;Humulus lupus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3053;HORM;Horse Meat, IgE;HORM;Horse Meat, IgE;19743-4;Horse meat Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3054;HORS;Horse Dander, IgE;HORS;Horse Dander, IgE;6143-2;Horse dander Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3055;HOXB1;HOXB13 Mutation Analysis (G84E);52778;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3056;HOXB1;HOXB13 Mutation Analysis (G84E);52775;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3057;HOXB1;HOXB13 Mutation Analysis (G84E);52772;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3058;HP;Hereditary Pancreatitis, Mutation Screen;17362;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3059;HP;Hereditary Pancreatitis, Mutation Screen;17364;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3060;HP;Hereditary Pancreatitis, Mutation Screen;17363;Result;22070-7;Hereditary pancreatitis gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3061;HP;Hereditary Pancreatitis, Mutation Screen;17365;Amendment;22070-7;Hereditary pancreatitis gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3062;HP;Hereditary Pancreatitis, Mutation Screen;17359;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3063;HP;Hereditary Pancreatitis, Mutation Screen;17361;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3064;HPFH;Hemoglobin F, Red Cell Distribution, Blood;8270;Hemoglobin F, Red Cell Distrib, B;4579-9;Hemoglobin F:ACnc:Pt:Bld:Ord:;2009-11-13;Flow Cytometry
3065;HPFH;Hemoglobin F, Red Cell Distribution, Blood;2104;Interpretation;59466-3; ;2013-08-22;Flow Cytometry
3066;HPKM;Hereditary Pancreatitis, Known Mutation;23434;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3067;HPKM;Hereditary Pancreatitis, Known Mutation;23437;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3068;HPKM;Hereditary Pancreatitis, Known Mutation;23439;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3069;HPKM;Hereditary Pancreatitis, Known Mutation;23436;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3070;HPP;Pancreatic Polypeptide, Plasma;8014;Pancreatic Polypeptide, P;2721-9;Pancreatic polypeptide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Radioimmunoassay (RIA)
3071;HPSA;Helicobacter pylori Antigen, Feces;24088;Helicobacter pylori Ag, F;17780-8;Helicobacter pylori Ag:ACnc:Pt:Stool:Ord:EIA;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
3072;HPV;Human Papillomavirus (HPV) DNA Detection with Genotyping, High-Risk Types by PCR, ThinPrep;SS017;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3073;HPYA;Helicobacter pylori Antibody, IgA, Serum;DEXHA;Index Value;6420-4;Helicobacter pylori Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3074;HPYM;Helicobacter pylori Antibody, IgM, Serum;DEXHM;Index Value;5177-1;Helicobacter pylori Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3075;HQ;HemoQuant, Feces;2413;Dietary Status;11320-9;Feeding and dietary status:Find:Pt:^Patient:Nar:Reported;2009-11-13;Fluorescence Quantitation
3076;HQ;HemoQuant, Feces;2410;Fecal Hemoglobin;27396-1;Hemoglobin.gastrointestinal:MCnt:Pt:Stool:Qn:;2009-11-13;Fluorescence Quantitation
3077;HQ;HemoQuant, Feces;9220;Hemoquant, F;27396-1;Hemoglobin.gastrointestinal:MCnt:Pt:Stool:Qn:;2009-11-13;Fluorescence Quantitation
3078;HSCRP;C-Reactive Protein, High Sensitivity, Serum;HSCRP;C-Reactive Protein, High Sens, S;30522-7;C reactive protein:MCnc:Pt:Ser/Plas:Qn:High sensitivity;2012-03-15;Latex Particle Enhanced Immunoturbidimetric Assay
3079;HSCRP;C-Reactive Protein, High Sensitivity, Serum;HSCRP;C-Reactive Protein, High Sens, S;30522-7;C reactive protein:MCnc:Pt:Ser/Plas:Qn:High sensitivity;2012-03-15;Immunoturbidimetry
3080;HSMR;Herpes Simplex Virus (HSV) Antibody, IgM, by Immunofluorescence Assay (IFA), Serum;26589;HSV Ab, IgM, S by IFA;44507-2;Herpes simplex virus Ab.IgM:ACnc:Pt:Ser:Ord:IF;2009-11-13;Immunofluorescence Assay (IFA)
3081;HSMR;Herpes Simplex Virus (HSV) Antibody, IgM, by Immunofluorescence Assay (IFA), Serum;26589;HSV Ab, IgM, S by IFA;44507-2;Herpes simplex virus Ab.IgM:ACnc:Pt:Ser:Ord:IF;2009-11-13;
3082;HSPR;Horse Serum Proteins, IgE;HSPR;Horse Serum Proteins, IgE;10935-5;Horse serum proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3083;HTGFN;Thyroglobulin, Tumor Marker, Fine-Needle Aspiration (FNA)-Needle Wash, Lymph Node;SITEJ;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-04-11;Immunoenzymatic Assay
3084;HTGFN;Thyroglobulin, Tumor Marker, Fine-Needle Aspiration (FNA)-Needle Wash, Lymph Node;TGFN;Thyroglobulin, FNA, Lymph Node;53920-5;Thyroglobulin:MCnc:Pt:Lymph node.FNA:Qn:;2013-04-11;Immunoenzymatic Assay
3085;HTLVI;Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II) Antibody Screen with Confirmation, Serum;9539;HTLV-I/-II Ab Screen, S;29901-6;HTLV 1+2 Ab:ACnc:Pt:Ser:Ord:EIA;2009-11-13;Enzyme Immunoassay (EIA)
3086;HTLVL;Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II) Antibody Confirmation, Serum;83277;HTLV-I/-II Ab Confirmation, S;22362-8;HTLV 1+2 Ab:ACnc:Pt:Ser:Ord:;2009-11-13;Line Immunoassay (LIA)
3087;HTT;Serotonin Transporter Genotype, Blood;83302;Serotonin Transporter Genotype;50330-0;SLC6A4 gene mutation analysis:Prid:Pt:Bld:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by Sizing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3088;HUNTK;Hunter Syndrome, Known Mutation;33924;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the IDS gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3089;HUNTK;Hunter Syndrome, Known Mutation;33921;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the IDS gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3090;HUNTK;Hunter Syndrome, Known Mutation;33927;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-25;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the IDS gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3091;HUNTK;Hunter Syndrome, Known Mutation;33923;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the IDS gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3092;HUNTS;Hunter Syndrome, Full Gene Analysis;33916;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-25;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the IDS gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3093;HUNTS;Hunter Syndrome, Full Gene Analysis;33913;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the IDS gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3094;HUNTS;Hunter Syndrome, Full Gene Analysis;33912;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-01;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the IDS gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3095;HUNTS;Hunter Syndrome, Full Gene Analysis;33910;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the IDS gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3096;HUNY;Honey, IgE;HUNY;Honey, IgE;7412-0;Honey Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3097;HURLK;Hurler Syndrome, Known Mutation;33905;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Amplification/DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3098;HURLK;Hurler Syndrome, Known Mutation;33902;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3099;HURLK;Hurler Syndrome, Known Mutation;33901;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3100;HURLK;Hurler Syndrome, Known Mutation;33899;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3101;HURLS;Hurler Syndrome, Full Gene Analysis;33894;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3102;HURLS;Hurler Syndrome, Full Gene Analysis;33888;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3103;HURLS;Hurler Syndrome, Full Gene Analysis;33890;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3104;HURLS;Hurler Syndrome, Full Gene Analysis;33889;Result;57983-9;IDUA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-08-07;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3105;HURLS;Hurler Syndrome, Full Gene Analysis;33891;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3106;HV1CD;HIV-1 and HIV-2 Antibodies for Cadaveric or Hemolyzed Specimens, Serum;83628;HIV-1/-2 Cadaver/Hemolyzed, S;31201-7;HIV 1+2 Ab:ACnc:Pt:Ser:Ord:EIA;2009-11-13;Enzyme Immunoassay (EIA)-Screening Procedure
3107;HV1CM;HIV-1 and HIV-2 Antibody Screen for Hemolyzed Specimens, Serum;60357;HIV-1/-2 Ab Screen Hemolyzed, S;31201-7;HIV 1+2 Ab:ACnc:Pt:Ser/Plas:Ord:EIA;2014-01-28;Enzyme Immunoassay (EIA)-Screening Procedure
3108;HV1WB;HIV-1 Antibody Confirmation by Western Blot, Serum;9190;HIV-1 Ab Confirm Western Blot, S;13499-9;HIV 1 Ab band pattern:Imp:Pt:Ser:Nom:IB;2014-08-07;Western Blot
3109;HVA;Homovanillic Acid (HVA), 24 Hour, Urine;TM39;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3110;HVA;Homovanillic Acid (HVA), 24 Hour, Urine;VL37;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3111;HVA;Homovanillic Acid (HVA), 24 Hour, Urine;3572;HVA, Adult;2436-4;Homovanillate:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3112;HVA;Homovanillic Acid (HVA), 24 Hour, Urine;3573;HVA, Child (<15 yr);13760-4;Homovanillate/Creatinine:MRto:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3113;HVAR;Homovanillic Acid (HVA), Random, Urine;60275;Homovanillic Acid (HVA), Random, U;11146-8;Homovanillate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-24;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3114;HYD17;17-Hydroxyprogesterone, Serum;500050;17-Hydroxyprogesterone, S;1668-3;17-Hydroxyprogesterone:MCnc:Pt:Ser/Plas:Qn:;2011-06-27;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3115;HYD18;Hydroxycorticosterone, 18;Z0252;18-Hydroxycorticosterone, Serum;1674-1;;2012-03-12;HPLC Tandem, Mass Spectrometry
3116;HYOX;Hyperoxaluria Panel, Urine;29982;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS)
3117;HYOX;Hyperoxaluria Panel, Urine;50594;Oxalate;13483-3;Oxalate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-23;Gas Chromatography-Mass Spectrometry (GC-MS)
3118;HYOX;Hyperoxaluria Panel, Urine;50593;Glycerate;13749-7;Glycerate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-23;Gas Chromatography-Mass Spectrometry (GC-MS)
3119;HYOX;Hyperoxaluria Panel, Urine;50595;Glyoxylate;13752-1;Glyoxylate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-23;Gas Chromatography-Mass Spectrometry (GC-MS)
3120;HYOX;Hyperoxaluria Panel, Urine;50592;Glycolate;13751-3;Glycolate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-23;Gas Chromatography-Mass Spectrometry (GC-MS)
3121;HYPOG;Hypoglycemic Agent Screen, Serum;21301;Repaglinide;38542-7;Repaglinide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3122;HYPOG;Hypoglycemic Agent Screen, Serum;21298;Glimepiride;40465-7;Glimepiride:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3123;HYPOG;Hypoglycemic Agent Screen, Serum;21300;Glyburide;10540-3;Glyburide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3124;HYPOG;Hypoglycemic Agent Screen, Serum;21299;Glipizide;10539-5;Glipizide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3125;HYPOG;Hypoglycemic Agent Screen, Serum;21296;Tolazamide;9629-7;Tolazamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3126;HYPOG;Hypoglycemic Agent Screen, Serum;21297;Tolbutamide;4061-8;Tolbutamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3127;HYPOG;Hypoglycemic Agent Screen, Serum;21295;Chlorpropamide;3474-4;Chlorpropamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3128;HYPOG;Hypoglycemic Agent Screen, Serum;21294;Acetohexamide;27007-4;Acetohexamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3129;HYPOG;Hypoglycemic Agent Screen, Serum;21308;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3130;IDENT;Organism Referred for Identification, Aerobic Bacteria;IDENT;Organism Refer for ID, Aerobic Bact;32367-5;Bacteria identified:Prid:Pt:Isolate:Nom:Aerobic culture;2013-09-17;Dependent on organism submitted, 1 or more of the following methods will be used: conventional biochemical testing, commercial identification strips or panels, MALDI-TOF mass spectrometry, and 16S RNA gene sequencing.
3131;IDOAU;Drug Abuse Survey, Urine;21651;Amphetamines;19261-7;Amphetamines:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3132;IDOAU;Drug Abuse Survey, Urine;2574;Barbiturates;19270-8;Barbiturates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3133;IDOAU;Drug Abuse Survey, Urine;23591;Benzodiazepines;14316-4;Benzodiazepines:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3134;IDOAU;Drug Abuse Survey, Urine;2576;Cocaine;19359-9;Cocaine:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3135;IDOAU;Drug Abuse Survey, Urine;2577;Opiates;19295-5;Opiates:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3136;IDOAU;Drug Abuse Survey, Urine;2578;Phencyclidine;19659-2;Phencyclidine:ACnc:Pt:Urine:Ord:Screen;2013-08-28;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3137;IDOAU;Drug Abuse Survey, Urine;2579;Tetrahydrocannabinol;19415-9;Tetrahydrocannabinol:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3138;IDOAU;Drug Abuse Survey, Urine;30909;Alcohol;42242-8;Ethanol:Threshold:Pt:Urine:Ord:Screen;2013-08-26;Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay
3139;IDSBS;Alpha-L-Iduronidase, Blood Spot;32352;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Fluorometric Enzyme Assay
3140;IDSBS;Alpha-L-Iduronidase, Blood Spot;32353;Alpha-L-Iduronidase;55909-6;Alpha-L-iduronidase:CCnc:Pt:Bld.dot:Qn:;2011-06-23;Fluorometric Enzyme Assay
3141;IDSBS;Alpha-L-Iduronidase, Blood Spot;32354;Interpretation;59462-2;;2012-04-09;Fluorometric Enzyme Assay
3142;IDST;Alpha-L-Iduronidase, Fibroblasts;29879;Alpha-L-Iduronidase, Fibroblasts;24056-4;Alpha-L-iduronidase:CCnt:Pt:Fibroblasts:Qn:;2009-11-13;IDST: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3143;IDST;Alpha-L-Iduronidase, Fibroblasts;29766;Interpretation (IDST);59462-2;;2012-04-02;IDST: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3144;IDSWB;Alpha-L-Iduronidase, Blood;32357;Interpretation;59462-2;;2012-04-09;Fluorometric Enzyme Assay
3145;IDSWB;Alpha-L-Iduronidase, Blood;32356;Alpha-L-Iduronidase;24057-2;Alpha-L-iduronidase:CCnt:Pt:WBC:Qn:;2011-06-23;Fluorometric Enzyme Assay
3146;IDSWB;Alpha-L-Iduronidase, Blood;32355;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Fluorometric Enzyme Assay
3147;IFBA;Intrinsic Factor Blocking Antibody, Serum;IFBLA;Intrinsic Factor Blocking Ab, S;31444-3;Intrinsic factor blocking Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Immunoenzymatic Assay
3148;IFBA;Intrinsic Factor Blocking Antibody, Serum;CMT31;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Immunoenzymatic Assay
3149;IGA;Immunoglobulin A (IgA), Serum;IGA;Immunoglobulin A (IgA), S;2458-8;IgA:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3150;IGAS;IgA Subclasses, Serum;IGA2_;IgA2;6939-3;IgA subclass 2:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry for Total IgA, IgA1, and IgA2
3151;IGAS;IgA Subclasses, Serum;IGA1_;IgA1;6886-6;IgA subclass 1:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry for Total IgA, IgA1, and IgA2
3152;IGAS;IgA Subclasses, Serum;IGA_;IgA;2458-8;IgA:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry for Total IgA, IgA1, and IgA2
3153;IGD;Immunoglobulin D (IgD), Serum;IGD;Immunoglobulin D (IgD), S;2460-4;IgD:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3154;IGE;Immunoglobulin E (IgE), Serum;IGE;Immunoglobulin E (IgE), S;19113-0;IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3155;IGF1I;Insulin-Like Growth Factor 1, Serum;IGF1I;Insulin-Like Growth Factor 1, S;2484-4;Insulin-like growth factor-I:MCnc:Pt:Ser/Plas:Qn:;2013-04-11;Chemiluminescence
3156;IGFB3;Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3), Serum;IGFB3;IGFBP-3, S;2483-6;Insulin-Like growth factor binding protein 3:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Enzyme-Labeled Chemiluminescent Immunometric Assay
3157;IGG;Immunoglobulin G (IgG), Serum;IGG;Immunoglobulin G (IgG), S;2465-3;IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3158;IGGS;IgG Subclasses, Serum;IGG4;IgG 4;2469-5;IgG subclass 4:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3159;IGGS;IgG Subclasses, Serum;IGG2;IgG 2;2467-9;IgG subclass 2:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3160;IGGS;IgG Subclasses, Serum;IGG3;IgG 3;2468-7;IgG subclass 3:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3161;IGGS;IgG Subclasses, Serum;T_IGG;Total IgG;2465-3;IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3162;IGGS;IgG Subclasses, Serum;IGG1;IgG 1;2466-1;IgG subclass 1:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3163;IGGS;IgG Subclasses, Serum;IGG4;IgG 4;2469-5;IgG subclass 4:MCnc:Pt:Ser:Qn:;2012-03-15;NephelometryIncludes total immunoglobulin G.
3164;IGGS;IgG Subclasses, Serum;T_IGG;Total IgG;2465-3;IgG:MCnc:Pt:Ser:Qn:;2012-03-15;NephelometryIncludes total immunoglobulin G.
3165;IGGS;IgG Subclasses, Serum;IGG1;IgG 1;2466-1;IgG subclass 1:MCnc:Pt:Ser:Qn:;2012-03-15;NephelometryIncludes total immunoglobulin G.
3166;IGGS;IgG Subclasses, Serum;IGG2;IgG 2;2467-9;IgG subclass 2:MCnc:Pt:Ser:Qn:;2012-03-15;NephelometryIncludes total immunoglobulin G.
3167;IGGS;IgG Subclasses, Serum;IGG3;IgG 3;2468-7;IgG subclass 3:MCnc:Pt:Ser:Qn:;2012-03-15;NephelometryIncludes total immunoglobulin G.
3168;IGGS4;Immunoglobulin Subclass IgG4, Serum;IGGS4;Immunoglobulin Subclass IgG4, S;2469-5;IgG subclass 4:MCnc:Pt:Ser:Qn:;2013-04-11;Nephelometry
3169;IGM;Immunoglobulin M (IgM), Serum;IGM;Immunoglobulin M (IgM), S;2472-9;IgM:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3170;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29694;PMS2 IHC;50328-4;PMS-2 Ag:ACnc:Pt:Tiss:Ord:Immune stain;2011-10-05;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3171;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29696;Interpretation;59465-5;;2012-04-02;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3172;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29689;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3173;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29690;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3174;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29687;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3175;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29693;MSH6 IHC;50324-3;MSH-6 Ag:ACnc:Pt:Tiss:Ord:Immune stain;2011-10-05;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3176;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29692;MSH2 IHC;50323-5;MSH-2 Ag:ACnc:Pt:Tiss:Ord:Immune stain;2011-10-05;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3177;IHCO;Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor;29691;MLH1 IHC;50322-7;MLH-1 Ag:ACnc:Pt:Tiss:Ord:Immune stain;2011-10-05;Immunohistochemical Staining for MLH1, MSH2, MSH6, and PMS2
3178;IHDI;Isocyanate HDI, IgE;IHDI;Isocyanate HDI, IgE;7429-4;Hexamethylene diisocyanate (HDI) Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3179;IMDI;Isocyanate MDI, IgE;IMDI;Isocyanate MDI, IgE;7430-2;Diphenylmethane diisocyanate (MDI) Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3180;IMMG;Immunoglobulins (IgG, IgA, and IgM), Serum;IGM;Immunoglobulin M (IgM), S;2472-9;IgM:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3181;IMMG;Immunoglobulins (IgG, IgA, and IgM), Serum;IGG;Immunoglobulin G (IgG), S;2465-3;IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3182;IMMG;Immunoglobulins (IgG, IgA, and IgM), Serum;IGA;Immunoglobulin A (IgA), S;2458-8;IgA:MCnc:Pt:Ser:Qn:;2012-03-15;Nephelometry
3183;IMPR;Imipramine and Desipramine, Serum;2453;Imipramine and Desipramine;9627-1;Imipramine+Desipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3184;IMPR;Imipramine and Desipramine, Serum;8126;Imipramine;3690-5;Imipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3185;IMPR;Imipramine and Desipramine, Serum;2452;Desipramine;3531-1;Desipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3186;INAB;Insulin Antibodies, Serum;8666;Insulin Abs, S;60463-7;;2013-08-15;Radioimmunoassay (RIA)
3187;INHA;Inhibin A, Tumor Marker, Serum;INHA;Inhibin A, Tumor Marker, S;23883-2;Inhibin A:MCnc:Pt:Ser:Qn:;2012-03-15;Sequential 2-Step Immunoenzymatic Assay
3188;INHB;Inhibin B, Serum;88722;Inhibin B, S;56940-0;Inhibin B:MCnc:Pt:Ser/Plas:Qn:EIA;2011-06-24;Enzyme-Linked Immunosorbent Assay (ELISA)
3189;INHP;Isoniazid, Serum/Plasma;Z1310;Isoniazid;3697-0;Isoniazid:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-,MS/MS)
3190;INHU;Insulin (Human), IgE;INHU;Insulin (Human), IgE;6148-1;Insulin human Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3191;INS;Insulin, Serum;INS;Insulin, S;20448-7;Insulin:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
3192;IOD;Iodine, Serum;81574;Iodine, S;2494-3;Iodine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3193;IODU;Iodine, Random, Urine;8639;Iodine, Random, U;2495-0;Iodine:MCnc:Pt:Urine:Qn:;2011-06-21;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3194;IONCG;Calcium, Ionized, Serum;11304;Calcium, Ionized, S;17863-2;Calcium.ionized:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Ion-Selective Electrode (ISE)
3195;ISPG;Ispaghula, IgE;ISPG;Ispaghula, IgE;6150-7;Ispaghula laxative Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3196;ITCON;Itraconazole, Serum;5122;Hydroxyitraconazole;18337-6;Hydroxyitraconazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3197;ITCON;Itraconazole, Serum;81247;Itraconazole, S;10989-2;Itraconazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3198;ITDT;Isocyanate TDI, IgE;ITDT;Isocyanate TDI, IgE;7431-0;Toluene diisocyante (TDI) Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3199;IVD;Isovaleryl-CoA Dehydrogenase (IVD) Mutation Analysis (A282V);22628;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)-based assay (restriction enzyme digest) is used to detect the A282V mutation within exon 9 of the IVD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3200;IVD;Isovaleryl-CoA Dehydrogenase (IVD) Mutation Analysis (A282V);22631;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)-based assay (restriction enzyme digest) is used to detect the A282V mutation within exon 9 of the IVD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3201;IVD;Isovaleryl-CoA Dehydrogenase (IVD) Mutation Analysis (A282V);22629;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)-based assay (restriction enzyme digest) is used to detect the A282V mutation within exon 9 of the IVD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3202;IVD;Isovaleryl-CoA Dehydrogenase (IVD) Mutation Analysis (A282V);22626;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)-based assay (restriction enzyme digest) is used to detect the A282V mutation within exon 9 of the IVD gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3203;JACK;Jack Fruit, IgE;JACK;Jack Fruit, IgE;19744-2;Artocarpus heterophyllus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3204;JAK2B;JAK2 V617F Mutation Detection, Blood;29590;JAK2 V617F Mutation Detection, B;43399-5;JAK2 gene.p.V617F:Arb:Pt:Bld/Tiss:Ord:Molgen;2011-06-22;Point Mutation Detection in DNA Using Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3205;JAK2M;JAK2 V617F Mutation Detection, Bone Marrow;31157;JAK2 V617F Mutation Detection, BM;43399-5;JAK2 gene.p.V617F:Arb:Pt:Bld/Tiss:Ord:Molgen;2011-06-22;Point Mutation Detection in DNA Using Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3206;JAK2V;JAK2 V617F Mutation Detection, Varies;31160;JAK2 V617F Mutation Detection, V;43399-5;JAK2 gene.p.V617F:Arb:Pt:Bld/Tiss:Ord:Molgen;2011-06-16;Point Mutation Detection in DNA Using Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3207;JAKXB;JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood;20194;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;Mutation Detection in cDNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3208;JAKXM;JAK2 Exon 12 and Other Non-V617F Mutation Detection, Bone Marrow;20250;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;Mutation Detection in cDNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3209;JCEDR;Japanese Cedar, IgE;JCEDR;Japanese Cedar, IgE;14035-0;Cryptomeria japonica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3210;JMACK;Jack Mackerel, IgE;JMACK;Jack Mackerel, IgE;11184-9;Trachurus japonicus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3211;JMIL;Japanese Millet, IgE;JMIL;Japanese Millet, IgE;10942-1;Echinochloa crus-galli Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3212;JO1;Jo 1 Antibodies, IgG, Serum;JO1;Jo 1 Ab, IgG, S;33571-1;Jo-1 extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
3213;JOHN;Johnson Grass, IgE;JOHN;Johnson Grass, IgE;6152-3;Sorghum halepense Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3214;JUNE;June Grass, IgE;JUNE;June Grass, IgE;6153-1;Poa pratensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3215;KBF;Potassium, Body Fluid;FLD18;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Indirect Ion-Selective Electrode (ISE)
3216;KBF;Potassium, Body Fluid;K_BF;Potassium, BF;2821-7;Potassium:SCnc:Pt:Body fld:Qn:;2012-03-15;Indirect Ion-Selective Electrode (ISE)
3217;KCCL;Potassium, Serum;KCCL;Potassium, S;2823-3;Potassium:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode. Also available as part of an Electrolyte Panel. 
3218;KETAU;Ketamine and Metabolite Confirmation, Urine;89443;Ketamine Confirmation, U;20537-7;Ketamine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3219;KETAU;Ketamine and Metabolite Confirmation, Urine;31128;Norketamine;18322-8;Norketamine:MCnc:Pt:Urine:Qn:;2011-06-22;Gas Chromatography-Mass Spectrometry (GC-MS)
3220;KIDBN;Kidney Bean (Red), IgE;KIDBN;Kidney Bean (Red), IgE;7129-0;Bean kidney red Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3221;KITAS;KIT Asp816Val Mutation Analysis, Qualitative PCR;MP010;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Allele-Specific Oligonucleotide Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3222;KITAS;KIT Asp816Val Mutation Analysis, Qualitative PCR;19507;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Allele-Specific Oligonucleotide Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3223;KITB;KIT Asp816Val Mutation Analysis, Blood;34851;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2013-08-07;Allele-Specific Oligonucleotide Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3224;KITBM;KIT Asp816Val Mutation Analysis, Qualitative PCR, Bone Marrow;34852;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2013-08-07;Allele-Specific Oligonucleotide Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3225;KIWI;Kiwi Fruit, IgE;KIWI;Kiwi Fruit, IgE;6154-9;Actinidia chinensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3226;KNSRP;KPC (blaKPC) and NDM (blaNDM) Surveillance PCR;35166;NDM PCR;73982-1;Bacterial carbapenemase resistance (bla(NDM)) gene:Pr:Pt:Isolate:Ord:Probe.Amp.Tar;2013-07-30;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3227;KNSRP;KPC (blaKPC) and NDM (blaNDM) Surveillance PCR;SRCKP;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-30;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3228;KNSRP;KPC (blaKPC) and NDM (blaNDM) Surveillance PCR;35165;KPC PCR;49617-4;Bacterial carbapenemase resistance (bla(KPC)) gene:ACnc:Pt:Isolate:Ord:Prob.amp.tar;2013-07-30;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3229;KPNRP;KPC (blaKPC) and NDM (blaNDM) in Gram-Negative Bacilli, Molecular Detection, PCR;35168;KPC PCR;49617-4;Bacterial carbapenemase resistance (bla(KPC)) gene:ACnc:Pt:Isolate:Ord:Prob.amp.tar;2013-07-30;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3230;KPNRP;KPC (blaKPC) and NDM (blaNDM) in Gram-Negative Bacilli, Molecular Detection, PCR;35169;NDM PCR;73982-1;Bacterial carbapenemase resistance (bla(NDM)) gene:Pr:Pt:Isolate:Ord:Probe.Amp.Tar;2013-07-24;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3231;KPNRP;KPC (blaKPC) and NDM (blaNDM) in Gram-Negative Bacilli, Molecular Detection, PCR;SRC53;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3232;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51435;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3233;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51430;Result;21702-6;KRAS gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3234;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51433;Amendment;21702-6;KRAS gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3235;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51432;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3236;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51431;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3237;KRAS7;KRAS Mutation Analysis, 7 Mutation Panel, Colorectal;51429;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3238;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51443;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3239;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51446;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3240;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51440;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3241;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51444;Amendment;21702-6;KRAS gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3242;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51442;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3243;KRASA;KRAS Mutation Analysis, 7 Mutation Panel, Other (Non-Colorectal);51441;Result;21702-6;KRAS gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-04-11;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3244;KUR;Potassium, 24 Hour, Urine;K_CN;Potassium Concentration;21476-7;Potassium:SCnc:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode
3245;KUR;Potassium, 24 Hour, Urine;TM28;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode
3246;KUR;Potassium, 24 Hour, Urine;VL26;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode
3247;KUR;Potassium, 24 Hour, Urine;KURU;Potassium, 24 Hr, U;51720-1;Potassium:MRat:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode
3248;L3AFP;Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum;L3;%L3;42332-7;Alpha-1-Fetoprotein.L3/Alpha-1-Fetoprotein.total:MFr:Pt:Ser/Plas:Qn:;2012-03-15;Isotachophoresis with Laser-Induced Fluorescence
3249;L3AFP;Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum;TAFP;Total AFP, S;1834-1;Alpha-1-Fetoprotein:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Isotachophoresis with Laser-Induced Fluorescence
3250;LAA;Lactate, Plasma;LAA;Lactate, P;2524-7;Lactate:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Lactate Oxidase/Peroxidase (VITROS Dry Slide)
3251;LADV;Adenovirus, Molecular Detection, PCR;29295;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3252;LADV;Adenovirus, Molecular Detection, PCR;89074;Result;21055-9;Adenovirus DNA:ACnc:Pt:Ser/Plas:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3253;LADV;Adenovirus, Molecular Detection, PCR;SRC65;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3254;LAGU;Legionella Antigen, Urine;81268;Legionella Ag, U;32781-7;Legionella sp Ag:ACnc:Pt:Urine:Ord:;2009-11-13;Immunochromatographic Membrane Assay
3255;LAMB;Lamb, IgE;LAMB;Lamb, IgE;6155-6;Lamb Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3256;LAMO;Lamotrigine, Serum;80999;Lamotrigine, S;6948-4;Lamotrigine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3257;LAMO;Lamotrigine, Serum;80999;Lamotrigine, S;6948-4;Lamotrigine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High Turbulence Liquid Chromatography-Tandem Mass Spectrometry (HTLC-MS/MS)
3258;LAMQ;Lamb's Quarter, IgE;LAMQ;Lambs Quarter, IgE;6156-4;Chenopodium album Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3259;LANG;Langust (Lobster), IgE;LANG;Langust(Lobster), IgE;6249-7;Palinurus spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3260;LATX;Latex, IgE;LATX;Latex, IgE;6158-0;Latex Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3261;LBAB;Babesia species, Molecular Detection, PCR, Blood;36115;Babesia duncani;42641-1;Babesia sp:DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-05-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3262;LBAB;Babesia species, Molecular Detection, PCR, Blood;36116;Babesia divergens/MO-1;42641-1;Babesia sp:DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2014-05-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3263;LBAB;Babesia species, Molecular Detection, PCR, Blood;36114;Babesia microti;21089-8;Babesia microti:DNA:ACnc :Pt:Bld:Ord:Probe.amp.tar;2014-05-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3264;LCADP;Adenovirus, Molecular Detection, PCR, Plasma;56088;Adenovirus PCR, P;21055-9;Adenovirus DNA:ACnc:Pt:Ser/Plas:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3265;LCBK;BK Virus, Molecular Detection, PCR, Urine;88910;BK Virus PCR, U;47251-4;BK virus DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3266;LCBKP;BK Virus, Molecular Detection, PCR, Plasma;56084;BK Virus PCR, P;32362-6;BK virus DNA:ACnc:Pt:Ser/Plas:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3267;LCCMV;Cytomegalovirus (CMV), Molecular Detection, PCR;SS011;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3268;LCCMV;Cytomegalovirus (CMV), Molecular Detection, PCR;600000;Cytomegalovirus PCR;5000-5;Cytomegalovirus DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3269;LCEBV;Epstein-Barr Virus (EBV), Molecular Detection, PCR;SS015;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3270;LCEBV;Epstein-Barr Virus (EBV), Molecular Detection, PCR;600002;Epstein-Barr Virus PCR;23858-4;Epstein Barr virus DNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3271;LCHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34640;HSV type Indeterminate, PCR;5014-6;Herpes simplex virus DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3272;LCHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34638;HSV 1, PCR;16130-7;Herpes simplex virus 1 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3273;LCHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34639;HSV 2, PCR;16131-5;Herpes simplex virus 2 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-08-07;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3274;LCHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;SS010;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3275;LCJC;JC Virus, Molecular Detection, PCR, Spinal Fluid;88909;JC Virus PCR, CSF;33295-7;JC virus DNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3276;LCMAL;Malaria, Molecular Detection, PCR;26651;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3277;LCMAL;Malaria, Molecular Detection, PCR;87860;Result;47085-6;Plasmodium sp DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2014-04-28;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3278;LCMAL;Malaria, Molecular Detection, PCR;SRC96;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3279;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18262;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;Immunophenotyping
3280;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18263;Addendum Pathologist:;19139-5;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
3281;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18252;Biopsy;52121-1;Biopsy:Imp:Pt:XXX:Nar:;2009-11-13;Immunophenotyping
3282;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;19191;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
3283;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18528;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Immunophenotyping
3284;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18258;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
3285;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18256;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Immunophenotyping
3286;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18255;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Immunophenotyping
3287;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18247;Ref. Path Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunophenotyping
3288;LCMS;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry;18246;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
3289;LCMV;Cytomegalovirus (CMV), Molecular Detection, PCR;81240;Cytomegalovirus PCR;5000-5;Cytomegalovirus DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3290;LCMV;Cytomegalovirus (CMV), Molecular Detection, PCR;SRC66;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3291;LCVZV;Varicella-Zoster Virus, Molecular Detection, PCR;SS012;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3292;LCWNV;West Nile Virus, Molecular Detection, PCR;24292;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3293;LCWNV;West Nile Virus, Molecular Detection, PCR;86197;Result;34461-4;West Nile virus RNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2014-08-20;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3294;LCWNV;West Nile Virus, Molecular Detection, PCR;SS013;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3295;LD;Lactate Dehydrogenase (LD), Serum;LD;Lactate Dehydrogenase (LD), S;2532-0;Lactate dehydrogenase:CCnc:Pt:Ser/Plas:Qn:;2012-10-31;Photometric Rate
3296;LDBF;Lactate Dehydrogenase (LD), Body Fluid;FLD11;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric
3297;LDBF;Lactate Dehydrogenase (LD), Body Fluid;LD_BF;Lactate Dehydrogenase (LD), BF;2529-6;Lactate dehydrogenase:CCnc:Pt:Body fld:Qn:;2012-03-15;Photometric
3298;LDLD;LDL Cholesterol (Beta-Quantification), Serum;LDLC;LDL Chol (Beta-Quantification), S;2089-1;Cholesterol.in LDL:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Ultracentrifugation/Selective Precipitation/Enzymatic Colorimetry (Beta-Quantification)
3299;LDLM;Familial Hypercholesterolemia, LDLR Large Deletion/Duplication, Molecular Analysis;31629;Result;69485-1;;2012-04-10;Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)
3300;LDLM;Familial Hypercholesterolemia, LDLR Large Deletion/Duplication, Molecular Analysis;28486;Interp;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)
3301;LDLM;Familial Hypercholesterolemia, LDLR Large Deletion/Duplication, Molecular Analysis;15598;Comment;8251-1;Service comment:Imp:Pt:XXX:Nom;2014-04-29;Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)
3302;LEBV;Epstein-Barr Virus (EBV), Molecular Detection, PCR;SRC67;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3303;LEBV;Epstein-Barr Virus (EBV), Molecular Detection, PCR;81239;Epstein-Barr Virus PCR;23858-4;Epstein Barr virus DNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3304;LEBVB;Epstein-Barr Virus (EBV), Molecular Detection, PCR, Blood;600007;Epstein-Barr Virus PCR, B;5002-1;Epstein Barr virus DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-27;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3305;LEGRP;Legionella species, Molecular Detection, PCR;SRC57;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3306;LEGRP;Legionella species, Molecular Detection, PCR;29515;Result;49616-6;Legionella sp DNA:Prid:Pt:XXX:Nom:Probe.amp.tar;2009-11-13;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3307;LEIS;Leishmaniasis (Visceral) Antibody, Serum;86219;Leishmaniasis (Visceral) Ab, S;7958-2;Leishmania sp Ab:ACnc:Pt:Ser:Ord:;2009-11-13;Immunochromatographic Strip Assay
3308;LEM;Lemon, IgE;LEM;Lemon, IgE;6159-8;Citrus limon Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3309;LEN;Lentil, IgE;LEN;Lentil, IgE;7458-3;Lens esculenta Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3310;LENT;Enterovirus, Molecular Detection, PCR;80066;Enterovirus PCR;29591-5;Enterovirus RNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3311;LENT;Enterovirus, Molecular Detection, PCR;SRC68;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3312;LEPD;Lepidoglyphus destructor, IgE;LEPD;Lepidoglyphus Destructor, IgE;6160-6;Lepidoglyphus destructor Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3313;LEPTO;Leptospira Antibody, Serum;9697;Leptospira Ab, S;23198-5;Leptospira sp Ab:Titr:Pt:Ser:Qn:Aggl;2014-04-09;Indirect Hemagglutination
3314;LETT;Lettuce, IgE;LETT;Lettuce, IgE;6161-4;Lactuca sativa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3315;LEUC;Leucine Aminopeptidase;Z1542;Leucine Aminopeptidase;2187-3;Cytosol aminopeptidase:CCnc:Pt:Ser/Plas:Qn:;2013-11-01;Colorimetry
3316;LEVE;Levetiracetam, Serum;83140;Levetiracetam, S;30471-7;Levetiracetam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
3317;LEVET;Levetiracetam, Serum;500160;Levetiracetam, S;30471-7;Levetiracetam:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3318;LH;Luteinizing Hormone (LH), Serum;LH;Luteinizing Hormone (LH), S;10501-5;Lutropin:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
3319;LHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;SS001;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3320;LHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34797;HSV 1, PCR;16130-7;Herpes simplex virus 1 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-07-29;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3321;LHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34798;HSV 2, PCR;16131-5;Herpes simplex virus 2 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-07-29;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3322;LHSV;Herpes Simplex Virus (HSV), Molecular Detection, PCR;34799;HSV type Indeterminate, PCR;20444-6;Herpes simplex virus 1+2 DNA:ACnc:Pt:XXX:Ord:Prob.amp.tar;2013-09-17;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3323;LID;Lidocaine, Serum;8382;Lidocaine, S;3714-3;Lidocaine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
3324;LIME;Lime, IgE;LIME;Lime, IgE;7464-1;Citrus aurantifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3325;LIND;Linden, IgE;LIND;Linden, IgE;11179-9;Tilia cordata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3326;LINS;Linseed, IgE;LINS;Linseed, IgE;7312-2;Linum usitatissimum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3327;LIPA;Lipoprotein (a), Serum;LIPA;Lipoprotein (a), S;10835-7;Lipoprotein (little a):MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Turbidimetric Immunoassay
3328;LIS;Lithium, Serum;8384;Lithium, S;14334-7;Lithium:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Spectrophotometric
3329;LKM;Liver/Kidney Microsome Type 1 Antibodies, Serum;LKM;Liver/Kidney Microsome Type 1 Ab, S;32220-6;Liver kidney microsomal 1 Ab:ACnc:Pt:Ser:Qn:;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3330;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19570;Tissue Discription:;22634-0;Path report.gross observation:Find:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
3331;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19583;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Immunophenotyping
3332;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19582;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
3333;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19581;Addendum:;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
3334;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19577;Signing Pathologist:;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2013-08-08;Immunophenotyping
3335;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19575;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Immunophenotyping
3336;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19574;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Immunophenotyping
3337;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19573;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Immunophenotyping
3338;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19568;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Immunophenotyping
3339;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19566;Date and Time of Death:;31211-6;Date of death:TmStp:Pt:^Patient:Qn:;2011-10-05;Immunophenotyping
3340;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19564;Ref Path/Phys Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunophenotyping
3341;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19565;Place of Death:;21987-3;Geographic place of death:Type:Pt:^Patient:Nom:;2009-11-13;Immunophenotyping
3342;LLPT;Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Tissue;19563;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
3343;LLTOF;Leukemia and Lymphoma Phenotyping, Technical Only;CK072;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2013-12-05;Immunophenotyping
3344;LN;Chromosome Analysis, Lymphoid Tissue;16116;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3345;LN;Chromosome Analysis, Lymphoid Tissue;16115;Interpretation;69965-2;;2012-04-05;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3346;LN;Chromosome Analysis, Lymphoid Tissue;16114;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3347;LN;Chromosome Analysis, Lymphoid Tissue;G_527;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3348;LN;Chromosome Analysis, Lymphoid Tissue;50468;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3349;LN;Chromosome Analysis, Lymphoid Tissue;16112;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-07-29;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3350;LN;Chromosome Analysis, Lymphoid Tissue;16787;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3351;LOB;Lobster, IgE;LOB;Lobster, IgE;6165-5;Homarus gammarus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3352;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32331;Antigen Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-10-05;Flow Cytometry
3353;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32330;Max Prolif of TT as % CD3;69016-4;Lymphocyte proliferation.tetanus toxoid.maximum/CD45:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3354;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32329;Max Prolif of TT as % CD45;69029-7;Lymphocyte proliferation.tetanus toxoid.maximum/CD3:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3355;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32328;Max Prolif of CA as % CD3;69015-6;Lymphocyte proliferation.Candida albicans.maximum/CD3:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3356;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32327;Max Prolif of CA as % CD45;69014-9;Lymphocyte proliferation.Candida albicans.maximum/CD45:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3357;LPAGF;Lymphocyte Proliferation to Antigens, Blood;32325;Interpretation;69052-9;;2012-04-09;Flow Cytometry
3358;LPAWS;Lipoprotein (a) Cholesterol, Serum;23937;Interpretation;59462-2;;2012-04-09;Electrophoresis, Enzyme Staining, and Densitometry
3359;LPAWS;Lipoprotein (a) Cholesterol, Serum;2849;Lp(a) Cholesterol;10835-7;Lipoprotein (little a):MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Electrophoresis, Enzyme Staining, and Densitometry
3360;LPAWS;Lipoprotein (a) Cholesterol, Serum;23924;LpX;42178-4;Lipoprotein.X:ACnc:Pt:Ser/Plas:Ord:;2009-11-13;Electrophoresis, Enzyme Staining, and Densitometry
3361;LPC;Lysophosphatidylcholine, Plasma;23859;Interpretation;59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3362;LPCBS;Lysophosphatidylcholines by Liquid Chromatography Tandem Mass Spectrometry (Reflex), Blood Spot;34865;Interpretation (LPCBS);59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2013-08-07;Only orderable as a reflex. For further information see PLSD/89678 Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot.Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3363;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32324;Mitogen Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-10-05;Flow Cytometry
3364;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32320;Max Prolif of PHA as % CD3;57741-1;Lymphocyte proliferation.OKT3 stimulation:NRat:Pt:Bld:Qn:;2011-06-23;Flow Cytometry
3365;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32319;Max Prolif of PHA as % CD45;69038-8;Lymphocyte proliferation.phytohemagglutinin.maximum/CD45:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3366;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32323;Max Prolif of PWM as % CD19;69037-0;Lymphocyte proliferation.pokeweed mitogen.maximum/CD19:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3367;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32322;Max Prolif of PWM as % CD3;69020-6;Lymphocyte proliferation.pokeweed mitogen stimulation/CD3:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3368;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32317;Interpretation;69052-9;;2012-04-09;Flow Cytometry
3369;LPMGF;Lymphocyte Proliferation to Mitogens, Blood;32321;Max Prolif of PWM as % CD45;69019-8;Lymphocyte proliferation.pokeweed mitogen stimulation/CD45:NFr:Pt:Bld:Qn:Flow cytometry;2013-12-05;Flow Cytometry
3370;LPS;Lipase, Serum;LPS;Lipase, S;3040-3;Triacylglycerol lipase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Colorimetric Rate Reaction
3371;LPSBF;Lipase, Body Fluid;FLD7;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Colorimetric Rate Reaction
3372;LPSBF;Lipase, Body Fluid;LPBF;Lipase, BF;15212-4;Triacylglycerol lipase:CCnc:Pt:Body fld:Qn:;2012-03-15;Colorimetric Rate Reaction
3373;LSDU;Lysergic Acid Diethylamide (LSD) Confirmation, Urine;20679;LSD Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Confirmation with Quantitation
3374;LSDU;Lysergic Acid Diethylamide (LSD) Confirmation, Urine;21328;2-oxo-3-hydroxy-LSD by LC/MS/MS;45185-6;2-Oxo-3-Hydroxy-Lysergate diethylamide:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Confirmation with Quantitation
3375;LSDU;Lysergic Acid Diethylamide (LSD) Confirmation, Urine;20668;LSD-by LC/MS/MS;20542-7;Lysergate diethylamide:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Confirmation with Quantitation
3376;LSDX;Lysergic Acid Diethylamide (LSD) Confirmation, Chain of Custody, Urine;5851;LSD Immunoassay Screen;19528-9;Lysergate diethylamide:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Confirmation with Quantitation
3377;LUPN;Lupin, IgE;LUPN;Lupin, IgE;11180-7;Lupinus spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3378;LVZV;Varicella-Zoster Virus, Molecular Detection, PCR;SRC70;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3379;LY27B;HLA-B27, Blood;LY27;HLA-B27 Result;4821-5;HLA-B27:ACnc:Pt:Bld:Ord:;2012-03-15;Flow Cytometry
3380;LYME;Lyme Disease Serology, Serum;LYME;Lyme Disease Serology, S;20449-5;Borrelia burgdorferi Ab:ACnc:Pt:Ser:Ord:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3381;LYME;Lyme Disease Serology, Serum;LYME;Lyme Disease Serology, S;20449-5;Borrelia burgdorferi Ab:ACnc:Pt:Ser:Ord:EIA;2012-03-15;LYME: Enzyme-Linked Immunosorbent Assay (ELISA)LYWB: Western Blot
3382;LYSO;Lysozyme, IgE;LYSO;Lysozyme, IgE;11182-3;Lysozyme Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3383;LYWB;Lyme Disease Antibody, Immunoblot, Serum;23931;IgM Immunoblot;6321-4;Borrelia burgdorferi Ab.IgM:ACnc:Pt:Ser:Ord:IB;2009-11-13;Immunoblot
3384;LYWB;Lyme Disease Antibody, Immunoblot, Serum;2992;IgG Band(s);13502-0;Borrelia burgdorferi Ab.IgG band pattern:Imp:Pt:Ser:Nom:IB;2013-06-27;Immunoblot
3385;LYWB;Lyme Disease Antibody, Immunoblot, Serum;5744;IgG Immunoblot;6320-6;Borrelia burgdorferi Ab.IgG:ACnc:Pt:Ser:Ord:IB;2009-11-13;Immunoblot
3386;LYWB;Lyme Disease Antibody, Immunoblot, Serum;23932;IgM Band(s);13503-8;Borrelia burgdorferi Ab.IgM band pattern:Imp:Pt:Ser:Nom:IB;2013-06-27;Immunoblot
3387;LYWB;Lyme Disease Antibody, Immunoblot, Serum;6241;Interpretation;12781-1;Borrelia burgdorferi Ab band pattern:Imp:Pt:Ser:Nom:IB;2013-09-17;Immunoblot
3388;LYZKM;Lysozyme (LYZ) Gene, Known Mutation;33442;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3389;LYZKM;Lysozyme (LYZ) Gene, Known Mutation;33439;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3390;LYZKM;Lysozyme (LYZ) Gene, Known Mutation;33444;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3391;LYZKM;Lysozyme (LYZ) Gene, Known Mutation;33441;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3392;LYZMS;Lysozyme (LYZ) Gene, Full Gene Analysis;33431;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3393;LYZMS;Lysozyme (LYZ) Gene, Full Gene Analysis;33430;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3394;LYZMS;Lysozyme (LYZ) Gene, Full Gene Analysis;33428;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3395;LYZMS;Lysozyme (LYZ) Gene, Full Gene Analysis;33433;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3396;MA24;Microalbuminuria, 24 Hour, Urine;VL41;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Immunoturbidity
3397;MA24;Microalbuminuria, 24 Hour, Urine;RATE2;Excretion Rate;14956-7;Albumin:MRat:24H:Urine:Qn:Detection limit = 20 mg/L;2012-03-15;Immunoturbidity
3398;MA24;Microalbuminuria, 24 Hour, Urine;CONC3;Concentration;30003-8;Albumin:MCnc:24H:Urine:Qn:Detection limit <= 20 mg/L;2012-10-31;Immunoturbidity
3399;MA24;Microalbuminuria, 24 Hour, Urine;TM43;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Immunoturbidity
3400;MA24;Microalbuminuria, 24 Hour, Urine;24HEX;24 Hour Excretion;14956-7;Albumin:MRat:24H:Urine:Qn:Detection limit = 20 mg/L;2012-03-12;Immunoturbidity
3401;MA24;Microalbuminuria, 24 Hour, Urine;MI24H;Microalbuminuria, 24 Hr, U;14956-7;Albumin:MRat:24H:Urine:Qn:Detection limit = 20 mg/L;2012-03-15;Immunoturbidity
3402;MAAN;Maleic Anhydride, IgE;MAAN;Maleic Anhydride, IgE;19746-7;Maleic anhydride Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3403;MACE;Mace, IgE;MACE;Mace, IgE;15280-1;Mace Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3404;MACK;Mackerel, IgE;MACK;Mackerel, IgE;7474-0;Scomber scombrus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3405;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;10248;Additional comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;Two-Site Immunoenzymatic (Sandwich) Assay
3406;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7823;Birthdate;21112-8;Birth date:TmStp:Pt:^Patient:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3407;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;2907;Last Menstrual Period (LMP);8665-2;Date last menstrual period:TmStp:Pt:^Patient:Qn:Reported;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3408;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7206;Gestation (GA) by dates;11885-1;Gestational age:Time:Pt:^Fetus:Qn:Estimated from last menstrual period;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3409;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;MULTF;Number of Fetuses;55281-0;Fetuses:Num:Pt:^Patient:Qn:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
3410;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7203;GA on collection by U/S scan;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3411;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7204;GA on collection by dates;11885-1;Gestational age:Time:Pt:^Fetus:Qn:Estimated from last menstrual period;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3412;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7205;GA on collection by physical exam;11884-4;Gestational age:Time:Pt:^Fetus:Qn:Clinical.estimated;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3413;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7830;GA used in risk estimate;21299-3;Gestational age method:Prid:Pt:^Fetus:Nom:*;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3414;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;10351;AFP;31993-9;Alpha-1-Fetoprotein:ACnc:Pt:Ser/Plas:Ord:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3415;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;10356;INTERPRETATION;59462-2;;2012-04-05;Two-Site Immunoenzymatic (Sandwich) Assay
3416;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;10358;GENERAL TEST INFORMATION;62364-5;Test performance information:Find:Pt:XXX:Nar:;2013-12-05;Two-Site Immunoenzymatic (Sandwich) Assay
3417;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;10054;EDD by U/S scan;11781-2;Delivery date:TmStp:Pt:^Patient:Qn:US.composite.estimated;2014-04-29;Two-Site Immunoenzymatic (Sandwich) Assay
3418;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7201;Gestation (GA) by physical exam;11884-4;Gestational age:Time:Pt:^Fetus:Qn:Clinical.estimated;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3419;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7753;EDD by LMP;11779-6;Delivery date:TmStp:Pt:^Patient:Qn:Estimated from last menstrual period;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3420;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7817;Date of U/S;34970-4;Date ultrasound:TmStp:Pt:^Patient:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3421;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7816;Gestation (GA) by U/S;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3422;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;IVFP;IVF pregnancy;47224-1;In vitro fertilization pregnancy:Acnc:Pt:^Patient:Ord:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
3423;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;RACE;Black race;32624-9;Race:Type:Pt:^Patient:Nom:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
3424;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;IDD;Insulin dependent diabetes;33248-6;Diabetes status:Prid:Pt:^Patient:Nom:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
3425;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7834;Calculated age at EDD;43993-5;Age.at delivery:Time:Pt:^Patient:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3426;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;26717;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3427;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;26718;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3428;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;7058;Recalculated Maternal Serum Screen;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3429;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;32284;Other Information;52535-2;Other useful information:-:Pt:^Patient:-:;2013-12-05;Two-Site Immunoenzymatic (Sandwich) Assay
3430;MAFP;Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum;3009;Collection Date;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2009-11-13;Two-Site Immunoenzymatic (Sandwich) Assay
3431;MAHKM;Methylmalonic Aciduria and Homocystinuria, cblC Type, Known Mutation;50518;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3432;MAHKM;Methylmalonic Aciduria and Homocystinuria, cblC Type, Known Mutation;50520;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3433;MAHKM;Methylmalonic Aciduria and Homocystinuria, cblC Type, Known Mutation;50523;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3434;MAHKM;Methylmalonic Aciduria and Homocystinuria, cblC Type, Known Mutation;50521;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3435;MAHMS;Methylmalonic Aciduria and Homocystinuria, cblC Type, Full Gene Analysis;50511;Interpretation;69047-9; ;2012-04-05;MAHMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3436;MAHMS;Methylmalonic Aciduria and Homocystinuria, cblC Type, Full Gene Analysis;50509;Method;49549-9; ;2013-07-26;MAHMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3437;MAHMS;Methylmalonic Aciduria and Homocystinuria, cblC Type, Full Gene Analysis;50508;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;MAHMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3438;MAHMS;Methylmalonic Aciduria and Homocystinuria, cblC Type, Full Gene Analysis;50506;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;MAHMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3439;MAL;Malaria/Babesia Smear;MAL;Malaria/Babesia Smear;51714-4;Microscopic observation:Prid:Pt:Bld:Nom:Giemsa stain;2013-09-17;Giemsa Stain
3440;MALT;Malt, IgE;MALT;Malt, IgE;6166-3;Malt Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3441;MAND;Mandarin, IgE;MAND;Mandarin, IgE;7731-3;Citrus reticulata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3442;MANGO;Mango, IgE;MANGO;Mango, IgE;6167-1;Mangifera indica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3443;MANN;Alpha-Mannosidase, Leukocytes;35639;Alpha-Mannosidase, Leukocytes;24053-1;Alpha mannosidase:CCnt:Pt:WBC:Qn:;2013-12-05;Fluorometric
3444;MANT;Alpha-Mannosidase, Fibroblasts;29925;Alpha-Mannosidase, Fibroblasts;1819-2;Alpha mannosidase:CCnt:Pt:Tiss:Qn:;2009-11-13;MANT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3445;MANT;Alpha-Mannosidase, Fibroblasts;29836;Interpretation (MANT);59462-2;;2012-04-02;MANT: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3446;MAPTK;MAPT Gene, Sequence Analysis, Known Mutation;23460;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3447;MAPTK;MAPT Gene, Sequence Analysis, Known Mutation;23458;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3448;MAPTK;MAPT Gene, Sequence Analysis, Known Mutation;23455;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3449;MAPTK;MAPT Gene, Sequence Analysis, Known Mutation;23453;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3450;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23471;Result;40478-0;MAPT gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3451;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23472;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3452;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23473;Amendment;40478-0;MAPT gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3453;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23470;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3454;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23469;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3455;MAPTM;MAPT Gene, Sequence Analysis, 7 Exon Screening Panel;23467;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3456;MARE;Mare's Milk, IgE;MARE;Mare's Milk, IgE;10936-3;Mare milk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3457;MARJ;Marjoram, IgE;MARJ;Marjoram, IgE;10937-1;Origanum majorana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3458;MARS;Rough Marsh Elder, IgE;MARS;Rough Marsh Elder, IgE;6232-3;Iva ciliata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3459;MB2GP;Beta-2 Glycoprotein 1 Antibodies, IgM, Serum;MB2GP;Beta 2 GP1 Ab IgM, S;44449-7;Beta 2 glycoprotein 1 Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3460;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);16204;Results;51867-0;BCR-ABL:Prid:Pt:Bld/Tiss:Nar:FISH;2009-11-13;Fluorescence In Situ Hybridization (FISH)
3461;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);16206;Amendment;51867-0;BCR-ABL:Prid:Pt:Bld/Tiss:Nar:FISH;2013-08-09;Fluorescence In Situ Hybridization (FISH)
3462;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);G_514;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
3463;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);16205;Interpretation;69965-2;;2012-04-05;Fluorescence In Situ Hybridization (FISH)
3464;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);16202;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
3465;MBCR;BCR/ABL, Translocation 9;22, FISH (D-FISH);G_511;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
3466;MBL;Mannose-Binding Lectin, Serum;MANBL;Mannose-Binding Lectin, S;30152-3;Mannose-binding protein:MCnc:Pt:Ser:Qn:;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3467;MCA;Myocardial Antibodies, Serum;9746;Myocardial Abs, S;42181-8;Myocardium Ab:ACnc:Pt:Ser:Ord:IF;2009-11-13;Indirect Immunofluorescence
3468;MCADK;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, Known Mutation;22956;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3469;MCADK;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, Known Mutation;22958;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3470;MCADK;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, Known Mutation;22955;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3471;MCADK;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, Known Mutation;22953;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3472;MCADS;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Mutation Screen;51183;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in all 12 exons of the MCAD gene (ACADM).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3473;MCADS;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Mutation Screen;51182;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in all 12 exons of the MCAD gene (ACADM).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3474;MCADS;Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Mutation Screen;51180;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in all 12 exons of the MCAD gene (ACADM).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3475;MCC;Maternal Cell Contamination, Molecular Analysis;23337;Amendment;40704-9;Maternal cell contamination:Prid:Pt:Bld:Nom:;2013-07-30;Polymerase Chain Reaction (PCR)-Based Comparison of Microsatellite Markers(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3476;MCC;Maternal Cell Contamination, Molecular Analysis;23338;Result;40704-9;Maternal cell contamination:Prid:Pt:Bld:Nom:;2009-11-13;Polymerase Chain Reaction (PCR)-Based Comparison of Microsatellite Markers(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3477;MCC;Maternal Cell Contamination, Molecular Analysis;23334;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Polymerase Chain Reaction (PCR)-Based Comparison of Microsatellite Markers(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3478;MCDKM;MLYCD Gene, Known Mutation;50918;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3479;MCDKM;MLYCD Gene, Known Mutation;50917;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3480;MCDKM;MLYCD Gene, Known Mutation;50915;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by Site-Specific DNA Sequence Analysis and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3481;MCDMS;MLYCD Gene, Full Gene Analysis;50907;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3482;MCDMS;MLYCD Gene, Full Gene Analysis;50909;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3483;MCDMS;MLYCD Gene, Full Gene Analysis;50906;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3484;MCDMS;MLYCD Gene, Full Gene Analysis;50904;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3485;MCHZ;Cheese, Mold, IgE;MCHZ;Cheese, Mold, IgE;6068-1;Cheese mold type Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3486;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23009;Result;34658-5;MCOLN1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3487;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23007;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3488;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23005;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3489;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23011;Amendment;34658-5;MCOLN1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3490;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23008;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3491;MCIV;Mucolipidosis IV, Mutation Analysis, IVS3(-2)A->G and del6.4kb;23010;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with mucolipidosis type IV: IVS3(-2)A->G and delta 6.4kb.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3492;MCLIP;Phospholipid (Cardiolipin) Antibodies, IgM, Serum;MCLIP;Phospholipid Ab IgM, S;3287-0;Phospholipid Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Enzyme-Linked Immunosorbant Assay (ELISA)
3493;MCRNA;Chlamydia trachomatis, Miscellaneous Sites, by Nucleic Acid Amplification (GEN-PROBE);34507;C. trach, Misc, Amplified RNA;43304-5;Chlamydia trachomatis rRNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-12-05;Transcription Mediated Amplification
3494;MCRNA;Chlamydia trachomatis, Miscellaneous Sites, by Nucleic Acid Amplification (GEN-PROBE);SRC11;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Transcription Mediated Amplification
3495;MDCC3;Monospecific Direct Coombs C3, Blood;MDCC3;Monospecific Direct Coombs C3, B;54410-6;Direct antiglobulin test.complement C3 specific reagent:ACnc:Pt:RBC:Ord:;2012-03-15;Direct Antiglobulin Test Using Standard AABB Techniques
3496;MDCG;Monospecific Direct Coombs IgG, Blood;MDCG;Monospecific Direct Coombs IgG, B;1006-6;Direct antiglobulin test.IgG specific reagent:Imp:Pt:RBC:Nom:;2012-03-15;Direct Antiglobulin Test Using Standard AABB Techniques
3497;ME2KM;MECP2 Gene, Known Mutation;50176;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescent DNA Sequencing/Gene Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3498;ME2KM;MECP2 Gene, Known Mutation;50179;Method;49549-9; ;2013-07-26;Fluorescent DNA Sequencing/Gene Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3499;ME2KM;MECP2 Gene, Known Mutation;50178;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Fluorescent DNA Sequencing/Gene Dosage Analysis (Multiplex Ligation-Dependent Probe Amplification [MLPA])(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3500;ME2MS;MECP2 Gene, Full Gene Analysis;50204;Amendment;35137-9;MECP2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3501;ME2MS;MECP2 Gene, Full Gene Analysis;50200;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3502;ME2MS;MECP2 Gene, Full Gene Analysis;50202;Result;35137-9;MECP2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3503;ME2MS;MECP2 Gene, Full Gene Analysis;50198;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3504;ME2MS;MECP2 Gene, Full Gene Analysis;50201;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3505;MEAD;Meadow Fescue, IgE;MEAD;Meadow Fescue, IgE;6169-7;Festuca elatior Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3506;MEGR;Megrim, IgE;MEGR;Megrim, IgE;10939-7;Lepidorhombus whiffiagonis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3507;MELAI;Melaleuca leucadendron, IgE;MELAI;Melaleuca Leucadendron, IgE;6171-3;Melaleuca leucadendron Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3508;MELN;Melons, IgE;MELN;Melons, IgE;57884-9;Cucumis melo spp Ab.IgE:ACnc:Pt:Ser:Qn:;2013-09-27;Fluorescence Enzyme Immunoassay (FEIA)
3509;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22337;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3510;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22343;Amendment;21734-9;RET gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3511;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22342;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3512;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22341;Result;21734-9;RET gene mutations tested for:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3513;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22340;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3514;MENKM;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Known Mutation;22339;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3515;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16597;Amendment;40693-4;RET gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3516;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16595;Result;40693-4;RET gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3517;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16594;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3518;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16591;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3519;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16593;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3520;MENMS;Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen;16596;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3521;MESQ;Mesquite, IgE;MESQ;Mesquite, IgE;6173-9;Prosopis juliflora Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3522;METAF;Metanephrines, Fractionated, 24 Hour, Urine;2434;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2013-05-16;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3523;METAF;Metanephrines, Fractionated, 24 Hour, Urine;VL48;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3524;METAF;Metanephrines, Fractionated, 24 Hour, Urine;83006;Total Metanephrines, U;2609-6;Metanephrines:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3525;METAF;Metanephrines, Fractionated, 24 Hour, Urine;21545;Normetanephrine, U;2671-6;Normetanephrine:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3526;METAF;Metanephrines, Fractionated, 24 Hour, Urine;8552;Metanephrine, U;19049-6;Metanephrine:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3527;METAF;Metanephrines, Fractionated, 24 Hour, Urine;TM50;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3528;METR;Methemoglobin Reductase, Blood;9322;Methemoglobin Reductase, B;32703-1;NADH methemoglobin reductase:CCnt:Pt:RBC:Qn:;2009-11-13;Kinetic Spectrophotometry (KS)
3529;MEX;Mexiletine, Serum;9245;Mexiletine, S;3819-0;Mexiletine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3530;MFOX;Meadow Foxtail, IgE;MFOX;Meadow Foxtail, IgE;6170-5;Alopercurus pratensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3531;MGRNA;Neisseria gonorrhoea, Miscellaneous Sites, by Nucleic Acid Amplification (GEN-PROBE);34508;N. gonorr, Misc, Amplified RNA;43305-2;Neisseria gonorrhoeae rRNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-12-05;Transcription Mediated Amplification
3532;MGRNA;Neisseria gonorrhoea, Miscellaneous Sites, by Nucleic Acid Amplification (GEN-PROBE);SRC22;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Transcription Mediated Amplification
3533;MGRP;Mycoplasma genitalium, Molecular Detection, PCR;SRC88;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3534;MGRU;Magnesium, Random, Urine;60245;Magnesium, Random, U;19124-7;Magnesium:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
3535;MGS;Magnesium, Serum;MGS;Magnesium, S;19123-9;Magnesium:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Colorimetric Assay
3536;MGU;Magnesium, 24 Hour, Urine;VL50;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
3537;MGU;Magnesium, 24 Hour, Urine;857;Mg Concentration;32024-2;Magnesium:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
3538;MGU;Magnesium, 24 Hour, Urine;TM52;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
3539;MGU;Magnesium, 24 Hour, Urine;8595;Magnesium, 24 Hr, U;24447-5;Magnesium:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
3540;MHDKM;Methylmalonic Aciduria and Homocystinuria, cblD Type, Known Mutation;33378;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;
3541;MHDKM;Methylmalonic Aciduria and Homocystinuria, cblD Type, Known Mutation;33376;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;
3542;MHDKM;Methylmalonic Aciduria and Homocystinuria, cblD Type, Known Mutation;33375;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;
3543;MHDKM;Methylmalonic Aciduria and Homocystinuria, cblD Type, Known Mutation;33373;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;
3544;MHDMS;Methylmalonic Aciduria and Homocystinuria, cblD Type, Full Gene Analysis;33364;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;MHDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3545;MHDMS;Methylmalonic Aciduria and Homocystinuria, cblD Type, Full Gene Analysis;33365;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;MHDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3546;MHDMS;Methylmalonic Aciduria and Homocystinuria, cblD Type, Full Gene Analysis;33367;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;MHDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3547;MHDMS;Methylmalonic Aciduria and Homocystinuria, cblD Type, Full Gene Analysis;33362;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;MHDMS: Polymerase Chain Reaction (PCR) Followed by DNA Sequence AnalysisFBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3548;MHRP;Mycoplasma hominis, Molecular Detection, PCR;32536;Mycoplasma hominis PCR;68546-1;Mycoplasma hominis DNA :ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-07-10;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3549;MHRP;Mycoplasma hominis, Molecular Detection, PCR;SRC86;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3550;MHSV;Herpes Simplex Virus (HSV) Antibody Screen, IgM, by EIA, Serum;MHSV;HSV Ab Screen, IgM, S by EIA;40729-6;Herpes simplex virus Ab.IgM:ACnc:Pt:Ser:Ord:EIA;2012-03-15;MHSV: Enzyme Immunoassay (EIA)HSMR: Immunofluorescence Assay (IFA)
3551;MILK;Milk, IgE;MILK;Milk, IgE;7258-7;Cow milk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3552;MINT;Molecular Interpretation;34648;Molecular Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Only orderable as part of a profile. For further information see HEMP / Hereditary Erythrocytosis Mutations.This is a consultative interpretation for the Hereditary Erythrocytosis Mutations test.
3553;ML23K;GNPTAB Gene, Known Mutation;54988;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB is used to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3554;ML23K;GNPTAB Gene, Known Mutation;54989;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB is used to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3555;ML23K;GNPTAB Gene, Known Mutation;54992;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB is used to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3556;ML23K;GNPTAB Gene, Known Mutation;54986;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB is used to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3557;ML23S;GNPTAB Gene, Full Gene Analysis;54981;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB for all coding exons(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3558;ML23S;GNPTAB Gene, Full Gene Analysis;54978;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB for all coding exons(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3559;ML23S;GNPTAB Gene, Full Gene Analysis;54975;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/Universal primer sequencing of GNPTAB for all coding exons(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3560;MLH12;MLH1/MSH2 Mutation Screen;22802;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3561;MLH12;MLH1/MSH2 Mutation Screen;22807;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3562;MLH12;MLH1/MSH2 Mutation Screen;22805;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3563;MLH12;MLH1/MSH2 Mutation Screen;22808;Amendment;32630-6;MSH2 gene+MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3564;MLH12;MLH1/MSH2 Mutation Screen;22804;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3565;MLH12;MLH1/MSH2 Mutation Screen;22806;Result;32630-6;MSH2 gene+MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3566;MLH1H;MLH1 Hypermethylation Analysis, Tumor;26907;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3567;MLH1H;MLH1 Hypermethylation Analysis, Tumor;26908;Results;38536-9;MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3568;MLH1H;MLH1 Hypermethylation Analysis, Tumor;26906;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3569;MLH1H;MLH1 Hypermethylation Analysis, Tumor;26909;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3570;MLH1H;MLH1 Hypermethylation Analysis, Tumor;26904;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3571;MLH3K;MLH3 Gene, Known Mutation;34115;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-16;Polymerase Chain Reaction (PCR) amplification followed by DNA sequencing is utilized to test for the presence of a specific mutation in the MLH3 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3572;MLH3K;MLH3 Gene, Known Mutation;34111;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) amplification followed by DNA sequencing is utilized to test for the presence of a specific mutation in the MLH3 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3573;MLH3K;MLH3 Gene, Known Mutation;34112;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) amplification followed by DNA sequencing is utilized to test for the presence of a specific mutation in the MLH3 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3574;MLH3K;MLH3 Gene, Known Mutation;34109;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) amplification followed by DNA sequencing is utilized to test for the presence of a specific mutation in the MLH3 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3575;MLH3S;MLH3 Gene, Full Gene Analysis;34001;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH) are utilized to test for the presence of a mutation in the MLH3 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3576;MLH3S;MLH3 Gene, Full Gene Analysis;34000;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH) are utilized to test for the presence of a mutation in the MLH3 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3577;MLH3S;MLH3 Gene, Full Gene Analysis;34005;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-14;Polymerase Chain Reaction (PCR) Amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH) are utilized to test for the presence of a mutation in the MLH3 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3578;MLH3S;MLH3 Gene, Full Gene Analysis;33998;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification followed by DNA sequencing and gene dosage analysis by array comparative genomic hybridization (aCGH) are utilized to test for the presence of a mutation in the MLH3 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3579;MLHBL;MLH1 Hypermethylation Analysis, Blood;51369;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3580;MLHBL;MLH1 Hypermethylation Analysis, Blood;51367;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3581;MLHBL;MLH1 Hypermethylation Analysis, Blood;51370;Amendment;38536-9;MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2014-05-21;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3582;MLHBL;MLH1 Hypermethylation Analysis, Blood;51368;Result;38536-9;MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-08-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3583;MLHBL;MLH1 Hypermethylation Analysis, Blood;51364;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3584;MLHBL;MLH1 Hypermethylation Analysis, Blood;51366;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3585;MLHKM;MLH1 Known Mutation;17316;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3586;MLHKM;MLH1 Known Mutation;17319;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3587;MLHKM;MLH1 Known Mutation;17314;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3588;MLHKM;MLH1 Known Mutation;17317;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3589;MLHMS;MLH1 Mutation Screen;17330;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3590;MLHMS;MLH1 Mutation Screen;17325;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3591;MLHMS;MLH1 Mutation Screen;17328;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3592;MLHMS;MLH1 Mutation Screen;17331;Amendment;38536-9;MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3593;MLHMS;MLH1 Mutation Screen;17329;Result;38536-9;MLH1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3594;MLHMS;MLH1 Mutation Screen;17327;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3595;MMAAF;Methylmalonic Acid (MMA), Amniotic Fluid;21121;Interpretation;59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3596;MMAAF;Methylmalonic Acid (MMA), Amniotic Fluid;81921;Methylmalonic Acid, AF;34627-0;Methylmalonate:SCnc:Pt:Amnio fld:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3597;MMAP;Methylmalonic Acid (MMA), Quantitative, Plasma;31927;Methylmalonic Acid, QN, P;13964-2;Methylmalonate:SCnc:Pt:Ser/Plas:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3598;MMAS;Methylmalonic Acid (MMA), Quantitative, Serum;80289;Methylmalonic Acid, QN, S;13964-2;Methylmalonate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3599;MMAU;Methylmalonic Acid (MMA), Quantitative, Urine;80290;Methylmalonic Acid, QN, U;32287-5;Methylmalonate:SCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3600;MMPM;Mumps Virus Antibody, IgM, Serum;DEXM;Index Value;25419-3;Mumps virus Ab.IgM:ACnc:Pt:Ser:Qn:EIA;2012-03-12;Enzyme Immunoassay (EIA)
3601;MMPM;Mumps Virus Antibody, IgM, Serum;MUMP1;Mumps Ab, IgM, S;6478-2;Mumps virus Ab.IgM:ACnc:Pt:Ser:Ord:EIA;2012-03-15;Enzyme Immunoassay (EIA)
3602;MNB;Manganese, Blood;89120;Manganese, B;5681-2;Manganese:MCnc:Pt:Bld:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3603;MNRU;Manganese, Random, Urine;86154;Manganese, Random, U;5684-6;Manganese:MCnc:Pt:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3604;MNS;Manganese, Serum;8413;Manganese, S;5683-8;Manganese:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3605;MNU;Manganese, 24 Hour, Urine;8080;Manganese, 24 Hr, U;8203-2;Manganese:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3606;MNU;Manganese, 24 Hour, Urine;867;Mn Concentration;21382-7;Manganese:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3607;MNU;Manganese, 24 Hour, Urine;VL24;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3608;MNU;Manganese, 24 Hour, Urine;TM26;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
3609;MOLD1;Mold Panel;MOLD1;Mold Panel;30183-8;(Alternaria alternata+Aspergillus fumigatus+Candida albicans+Cladosporium herbarum+Helminthosporium halodes+Penicillium notatum) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3610;MOLPS;Molybdenum, Serum;89270;Molybdenum, S;5698-6;Molybdenum:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3611;MOLU;Molybdenum, 24 Hour, Urine;29343;Mo Conc;29974-3;Molybdenum:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3612;MOLU;Molybdenum, 24 Hour, Urine;89271;Molybdenum, U;29975-0;Molybdenum:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3613;MOLU;Molybdenum, 24 Hour, Urine;VL61;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3614;MOLU;Molybdenum, 24 Hour, Urine;TIME6;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3615;MOLUR;Molybdenum, Random, Urine;89473;Molybdenum, Random, U;5699-4;Molybdenum:MCnc:Pt:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3616;MONOS;Infectious Mononucleosis, Rapid Test, Serum;MONOS;Infectious Mono Test, S;31418-7;Heterophile Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Agglutination
3617;MORP;Morphine, Unconjugated, Serum;83132;Morphine, Unconjugated, S;3827-3;Morphine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry Using Selected Ion Monitoring (GC-MS SIM)
3618;MOSP;Mouse Serum Protein, IgE;MOSP;Mouse Serum Protein, IgE;6180-4;Mouse serum proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3619;MOTH;Moth, IgE;MOTH;Moth, IgE;7502-8;Moth Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3620;MOUP;Mouse Urine Protein, IgE;MOUP;Mouse Urine Protein, IgE;6181-2;Mouse urine proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3621;MOUS;Mouse Epithelium, IgE;MOUS;Mouse Epithelium, IgE;6179-6;Mouse epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3622;MP3AK;Mucopolysaccharidosis IIIA, Known Mutation;51681;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of specific mutations in the SGSH gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3623;MP3AK;Mucopolysaccharidosis IIIA, Known Mutation;51682;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of specific mutations in the SGSH gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3624;MP3AK;Mucopolysaccharidosis IIIA, Known Mutation;51685;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of specific mutations in the SGSH gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3625;MP3AK;Mucopolysaccharidosis IIIA, Known Mutation;51679;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of specific mutations in the SGSH gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3626;MP3AS;Mucopolysaccharidosis IIIA, Full Gene Analysis;51674;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in the SGSH gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3627;MP3AS;Mucopolysaccharidosis IIIA, Full Gene Analysis;51670;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in the SGSH gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3628;MP3AS;Mucopolysaccharidosis IIIA, Full Gene Analysis;51671;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in the SGSH gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3629;MP3AS;Mucopolysaccharidosis IIIA, Full Gene Analysis;51668;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA sequencing are utilized to test for the presence of a mutation in the SGSH gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3630;MP3BK;Mucopolysaccharidosis IIIB, Known Mutation;51597;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-19;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3631;MP3BK;Mucopolysaccharidosis IIIB, Known Mutation;51594;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3632;MP3BK;Mucopolysaccharidosis IIIB, Known Mutation;51593;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3633;MP3BK;Mucopolysaccharidosis IIIB, Known Mutation;51591;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3634;MP3BS;Mucopolysaccharidosis IIIB, Full Gene Analysis;51582;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3635;MP3BS;Mucopolysaccharidosis IIIB, Full Gene Analysis;51583;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3636;MP3BS;Mucopolysaccharidosis IIIB, Full Gene Analysis;51586;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-22;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3637;MP3BS;Mucopolysaccharidosis IIIB, Full Gene Analysis;51580;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3638;MPA;Mycophenolic Acid, Serum;15226;Mycophenolic Acid;23905-3;Mycophenolate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Tandem Mass Spectrometry (MS/MS)
3639;MPA;Mycophenolic Acid, Serum;15227;MPA Glucuronide;23906-1;Mycophenolate glucuronide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Tandem Mass Spectrometry (MS/MS)
3640;MPCR;DNA Analysis B;16508;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3641;MPCR;DNA Analysis B;16509;Result;62357-9;Chromosome analysis overall interpretation:Imp:Pt:Bld/Tiss:Ord:Molgen;2012-10-17;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3642;MPCR;DNA Analysis B;16510;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3643;MPCR;DNA Analysis B;16507;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3644;MPCR;DNA Analysis B;16505;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3645;MPCR;DNA Analysis B;16511;Amendment;62357-9;Chromosome analysis overall interpretation:Imp:Pt:Bld/Tiss:Ord:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3646;MPLB;MPL Exon 10 Mutation Detection, Blood;19997;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;Mutation Detection in DNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3647;MPLM;MPL Exon 10 Mutation Detection, Bone Marrow;20232;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;Mutation Detection in DNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3648;MPLVA;MPL Exon 10 Mutation Detection, Varies;34850;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2013-08-07;Mutation Detection in DNA Using Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3649;MPO;Myeloperoxidase Antibodies, IgG, Serum;MPO;Myeloperoxidase Ab, S;48404-8;Myeloperoxidase Ab.IgG:ACnc:Pt:Ser:Qn:;2014-02-28;Multiplex Flow Immunoassay
3650;MPPG;Mumps Virus Antibody, IgG, Serum;MUMG;Mumps Ab, IgG, S;6476-6;Mumps virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
3651;MPPG;Mumps Virus Antibody, IgG, Serum;DEXG5;Mumps IgG Antibody Index;25418-5;Mumps virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
3652;MPRP;Mycoplasma pneumoniae, Molecular Detection, PCR;SRCMP;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Rapid Polymerase Chain Reaction (PCR) Using Light Cycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3653;MPS6K;Mucopolysaccharidosis VI, Known Mutation;51709;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3654;MPS6K;Mucopolysaccharidosis VI, Known Mutation;51705;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3655;MPS6K;Mucopolysaccharidosis VI, Known Mutation;51706;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3656;MPS6K;Mucopolysaccharidosis VI, Known Mutation;51703;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3657;MPS6S;Mucopolysaccharidosis VI, Full Gene Analysis;51696;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a mutation in the ARSB gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3658;MPS6S;Mucopolysaccharidosis VI, Full Gene Analysis;51693;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a mutation in the ARSB gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3659;MPS6S;Mucopolysaccharidosis VI, Full Gene Analysis;51692;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a mutation in the ARSB gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3660;MPS6S;Mucopolysaccharidosis VI, Full Gene Analysis;51690;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing are utilized to test for the presence of a mutation in the ARSB gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3661;MPSF;Micropolyspora faeni, IgG Antibodies, Serum;MPSF;Micropolyspora faeni, IgG Ab, S;26948-0;Saccharopolyspora rectivirgula Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3662;MPSQN;Mucopolysaccharides (MPS), Quantitative, Urine;81473;Mucopolysaccharides (MPS), QN, U;46132-7;Glycosaminoglycans/Creatinine:Ratio:Pt:Urine:Qn:;2009-11-13;Spectrophotometry (SP)
3663;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501225;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
3664;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501230;Secobarbital;16238-8;Secobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3665;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501229;Phenobarbital;16241-2;Phenobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3666;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501228;Pentobarbital;16240-4;Pentobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3667;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501227;Butalbital;16237-0;Butalbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3668;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;501226;Amobarbital;16239-6;Amobarbital:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3669;MSBR;Drug of Abuse, Barbiturates GC-MS Confirmation, Urine;2837;GC/MS Confirmation - Barbiturate;20411-5;Barbiturates:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3670;MSCO;Drug of Abuse, Cocaine GC-MS Confirmation, Urine;BEUC;Benzoylecgonine;16226-3;Benzoylecgonine:MCnc:Pt:Urine:Qn:Confirm;2012-03-15;Gas Chromatography-Mass Spectrometry (GC-MS)
3671;MSCO;Drug of Abuse, Cocaine GC-MS Confirmation, Urine;COCAC;GC/MS Confirmation - Cocaine;20519-5;Cocaine:MCnc:Pt:Urine:Qn:Confirm;2012-03-15;Gas Chromatography-Mass Spectrometry (GC-MS)
3672;MSCO;Drug of Abuse, Cocaine GC-MS Confirmation, Urine;COCUC;Cocaine;20519-5;Cocaine:MCnc:Pt:Urine:Qn:Confirm;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
3673;MSH2K;MSH2 Known Mutation;17336;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3674;MSH2K;MSH2 Known Mutation;17341;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3675;MSH2K;MSH2 Known Mutation;17339;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3676;MSH2K;MSH2 Known Mutation;17338;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3677;MSH2M;MSH2 Mutation Screen;17352;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3678;MSH2M;MSH2 Mutation Screen;17349;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3679;MSH2M;MSH2 Mutation Screen;17347;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3680;MSH2M;MSH2 Mutation Screen;17350;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3681;MSH2M;MSH2 Mutation Screen;17353;Amendment;38550-0;MSH2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3682;MSH2M;MSH2 Mutation Screen;17351;Result;38550-0;MSH2 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3683;MSH6K;MSH6 Known Mutation;22757;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3684;MSH6K;MSH6 Known Mutation;22760;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3685;MSH6K;MSH6 Known Mutation;22762;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3686;MSH6K;MSH6 Known Mutation;22759;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing or Dosage Analysis (multiplex ligation-dependent probe amplification [MLPA] or Southern blot analysis) is utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3687;MSH6M;MSH6 Mutation Screen, Blood;22748;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3688;MSH6M;MSH6 Mutation Screen, Blood;22746;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3689;MSH6M;MSH6 Mutation Screen, Blood;22749;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3690;MSH6M;MSH6 Mutation Screen, Blood;22751;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3691;MSMT;Drug of Abuse, Methadone Confirmation, Urine;501240;Methadone;16246-1;Methadone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3692;MSMT;Drug of Abuse, Methadone Confirmation, Urine;11147;Confirmation - Methadone;16246-1;Methadone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3693;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200289;Oxymorphone;17395-5;Oxymorphone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3694;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200213;Oxycodone;16249-5;Oxycodone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3695;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200214;Morphine;16251-1;Morphine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3696;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200212;Hydromorphone;16998-7;Hydromorphone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3697;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200210;Codeine;16250-3;Codeine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3698;MSOP;Drug of Abuse, Opiates Confirmation, Urine;200211;Hydrocodone;16252-9;Hydrocodone:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3699;MSOP;Drug of Abuse, Opiates Confirmation, Urine;11141;Confirmation - Opiates;17384-9;Opiates:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3700;MSPCP;Drug of Abuse, Phencyclidine GC-MS Confirmation, Urine;501239;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
3701;MSPCP;Drug of Abuse, Phencyclidine GC-MS Confirmation, Urine;501238;Phencyclidine;16254-5;Phencyclidine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3702;MSPCP;Drug of Abuse, Phencyclidine GC-MS Confirmation, Urine;11146;GC/MS Confirmation - Phencyclidine;16254-5;Phencyclidine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3703;MSPP;Mosquito Species, IgE;MSPP;Mosquito Spp., IgE;6177-0;Aedes communis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3704;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;CMT56;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Kruger Criteria Strict Morphology
3705;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;HDZAB;Head Size Abnormal;10602-1;Spermatozoa.abnormal head/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3706;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;WBC6;WBC/mL;10579-1;Leukocytes:NCnc:Pt:Semen:Qn:;2012-03-12;Kruger Criteria Strict Morphology
3707;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;TAILD;Tail Defect;10604-7;Spermatozoa.abnormal tail/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-12;Kruger Criteria Strict Morphology
3708;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;DBLF;Double Forms;66497-9;;2012-11-13;Kruger Criteria Strict Morphology
3709;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;MD;Midpiece Defect;10603-9;Spermatozoa.abnormal midpiece/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3710;MSTC;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;HDSAB;Head Shape Abnormal;10602-1;Spermatozoa.abnormal head/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3711;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;HDZAB;Head Size Abnormal;10602-1;Spermatozoa.abnormal head/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3712;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;WBC6;WBC/mL;10579-1;Leukocytes:NCnc:Pt:Semen:Qn:;2012-03-12;Kruger Criteria Strict Morphology
3713;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;CMT56;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Kruger Criteria Strict Morphology
3714;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;DBLF;Double Forms;66497-9;;2012-11-13;Kruger Criteria Strict Morphology
3715;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;MD;Midpiece Defect;10603-9;Spermatozoa.abnormal midpiece/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3716;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;TAILD;Tail Defect;10604-7;Spermatozoa.abnormal tail/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-12;Kruger Criteria Strict Morphology
3717;MSTC1;Strict Criteria Sperm Morphology for Infertility Diagnosis and Treatment, Semen;HDSAB;Head Shape Abnormal;10602-1;Spermatozoa.abnormal head/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Kruger Criteria Strict Morphology
3718;MSTD;Mustard, IgE;MSTD;Mustard, IgE;6185-3;Mustard Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3719;MSTHC;Drug of Abuse, Tetrahydrocannabinol GC-MS Confirmation, Urine;501233;THC Carboxylic Acid;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3720;MSTHC;Drug of Abuse, Tetrahydrocannabinol GC-MS Confirmation, Urine;501234;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS)
3721;MSTHC;Drug of Abuse, Tetrahydrocannabinol GC-MS Confirmation, Urine;11145;GC/MS Confirmation - THC;20413-1;Cannabinoids:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3722;MTBRP;Mycobacterium tuberculosis Complex, Molecular Detection, PCR;56044;Result;38379-4;Mycobacterium tuberculosis complex DNA:Acnc:Pt:XXX:Ord:Probe.amp.tar;2014-04-09;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3723;MTBRP;Mycobacterium tuberculosis Complex, Molecular Detection, PCR;56045;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3724;MTBRP;Mycobacterium tuberculosis Complex, Molecular Detection, PCR;SRC62;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3725;MTDNS;Methadone, Serum;83131;Methadone, S;3772-1;Methadone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3726;MTDNU;Methadone Confirmation, Urine;21107;Methadone Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3727;MTDNU;Methadone Confirmation, Urine;83129;Methadone-by GC-MS;3774-7;Methadone:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3728;MTDNU;Methadone Confirmation, Urine;56028;EDDP-by GC-MS;50542-0;2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3729;MTDNX;Methadone Confirmation, Chain of Custody, Urine;21105;Methadone Immunoassay Screen;16199-2;Methadone:Threshold:Pt:Urine:Ord:Confirm;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3730;MTHAC;5,10-Methylenetetrahydrofolate Reductase A1298C, Mutation, Blood;34702;MTHAC Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Direct Mutation Analysis
3731;MTHAC;5,10-Methylenetetrahydrofolate Reductase A1298C, Mutation, Blood;34701;MTHFR A1298C Mutation Analysis, B;28060-2;MTHFR gene.c.1298A>C:Arb:Pt:Bld/Tiss:Ord:Molgen;2013-08-07;Direct Mutation Analysis
3732;MTHFR;5,10-Methylenetetrahydrofolate Reductase C677T, Mutation, Blood;21828;MTHFR Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Direct Mutation Analysis
3733;MTHFR;5,10-Methylenetetrahydrofolate Reductase C677T, Mutation, Blood;21827;Methylenetetrahydrofol Reduc Mut, B;21709-1;MTHFR gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Direct Mutation Analysis
3734;MTRNA;Trichomonas vaginalis, Miscellaneous Sites, by Nucleic Acid Amplification;SRC6;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-08-09;Transcription Mediated Amplification
3735;MTX;Methotrexate, Serum;8721;Methotrexate, S;14836-1;Methotrexate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
3736;MUG;Mugwort, IgE;MUG;Mugwort, IgE;6183-8;Artemisia vulgaris Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3737;MUGS;Hexosaminidase A (MUGS), Serum;80350;Hexosaminidase A (MUGS), S;16457-4;Beta-N-acetylhexosaminidase.A:CCnc:Pt:WBC:Qn:;2009-11-13;Fluorometric Manual Method Using 4-MUGS Substrate
3738;MULB;Mulberry, IgE;MULB;Mulberry, IgE;6281-0;Morus alba Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3739;MUR;Lysozyme (Muramidase), Plasma;MUR;Lysozyme (Muramidase), P;2589-0;Lysozyme:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Turbidimetric
3740;MUSH;Mushroom, IgE;MUSH;Mushroom, IgE;6848-6;Agaricus hortensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3741;MUSS;Blue Mussel, IgE;MUSS;Blue Mussel, IgE;6048-3;Mytilus edulis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3742;MYGLS;Myoglobin, Serum;MYGLS;Myoglobin, S;2639-3;Myoglobin:MCnc:Pt:Ser/Plas:Qn:;2013-12-05;Latex Particle-Enhanced Immunoturbidometric Assay
3743;MYGLS;Myoglobin, Serum;MYGLS;Myoglobin, S;2639-3;Myoglobin:MCnc:Pt:Ser/Plas:Qn:;2013-12-05;Immunoturbidimetric Assay
3744;MYGLU;Myoglobin, Urine;MYGLU;Myoglobin, U;2641-9;Myoglobin:MCnc:Pt:Urine:Qn:;2013-12-05;Latex Particle-Enhanced Immunoturbidometric Assay
3745;MYGLU;Myoglobin, Urine;MYGLU;Myoglobin, U;2641-9;Myoglobin:MCnc:Pt:Urine:Qn:;2013-12-05;Immunoturbidimetric Assay
3746;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22448;Amendment;40959-9;MUTYH gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3747;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22442;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3748;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22444;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3749;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22447;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3750;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22446;Result;40959-9;MUTYH gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3751;MYH;MYH Gene Analysis for Multiple Adenoma, Y165C and G382D;22445;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3752;NABF;Sodium, Body Fluid;FLD17;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Indirect Ion-Selective Electrode (ISE)
3753;NABF;Sodium, Body Fluid;NA_BF;Sodium, BF;2950-4;Sodium:SCnc:Pt:Body fld:Qn:;2012-03-15;Indirect Ion-Selective Electrode (ISE)
3754;NACCL;Sodium, Serum;NACCL;Sodium, S;2951-2;Sodium:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective ElectrodeAlso available as part of an Electrolyte Panel.
3755;NAD;Newborn Aneuploidy Detection, FISH;16298;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
3756;NAD;Newborn Aneuploidy Detection, FISH;16805;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Fluorescence In Situ Hybridization (FISH)
3757;NAD;Newborn Aneuploidy Detection, FISH;16295;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
3758;NAD;Newborn Aneuploidy Detection, FISH;G_491;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
3759;NAGR;Hexosaminidase A and Total, Leukocytes/Molecular Reflex;2284;Interpretation (NAGW);48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Heat Inactivation, Fluorometric, Semiautomated
3760;NAGR;Hexosaminidase A and Total, Leukocytes/Molecular Reflex;2294;Hexosaminidase Percent A, WBC;23825-3;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total:CFr:Pt:WBC:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Semiautomated
3761;NAGR;Hexosaminidase A and Total, Leukocytes/Molecular Reflex;8775;Hexosaminidase Total, WBC;24075-4;Beta-N-acetylhexosaminidase.A:CCnt:Pt:WBC:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Semiautomated
3762;NAGS;Hexosaminidase A and Total Hexosaminidase, Serum;27216;Interpretation (NAGS);59462-2;;2012-04-02;Heat Inactivation, Fluorometric, Automated
3763;NAGS;Hexosaminidase A and Total Hexosaminidase, Serum;27613;Hexosaminidase Percent A, S;12914-8;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total:CFr:Pt:Ser:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Automated
3764;NAGS;Hexosaminidase A and Total Hexosaminidase, Serum;27612;Hexosaminidase Total, S;1956-2;Beta-N-acetylhexosaminidase.A:CCnc:Pt:WBC:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Automated
3765;NAGW;Hexosaminidase A and Total Hexosaminidase, Leukocytes;8775;Hexosaminidase Total, WBC;24075-4;Beta-N-acetylhexosaminidase.A:CCnt:Pt:WBC:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Semiautomated
3766;NAGW;Hexosaminidase A and Total Hexosaminidase, Leukocytes;2284;Interpretation (NAGW);48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Heat Inactivation, Fluorometric, Semiautomated
3767;NAGW;Hexosaminidase A and Total Hexosaminidase, Leukocytes;2294;Hexosaminidase Percent A, WBC;23825-3;Beta-N-acetylhexosaminidase.A/Beta-N-acetylhexosaminidase.total:CFr:Pt:WBC:Qn:;2009-11-13;Heat Inactivation, Fluorometric, Semiautomated
3768;NARC;Narcolepsy-Associated Antigen, HLA-DQB1 Typing, Blood;NARC_;Narcolepsy Associated Ag Result;53938-7;Narcolepsy associated Ag:ACnc:Pt:Ser/Plas:Ord:;2012-03-15;Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probes (SSO)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3769;NAU;Sodium, 24 Hour, Urine;NACN;Sodium Concentration;21525-1;Sodium:SCnc:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode
3770;NAU;Sodium, 24 Hour, Urine;VL9;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode
3771;NAU;Sodium, 24 Hour, Urine;TM11;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Potentiometric, Indirect Ion-Selective Electrode
3772;NAU;Sodium, 24 Hour, Urine;NA_24;Sodium, 24 Hr, U;2956-1;Sodium:SRat:24H:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode
3773;NEFA;Free Fatty Acids, Total, Serum;NEFA;Free Fatty Acids, Total, S;15066-4;Fatty acids.nonesterified:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Enzymatic Colorimetric
3774;NETT;Nettle, IgE;NETT;Nettle, IgE;6186-1;Urtica dioica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3775;NEURF;Neuraminidase, Fibroblasts;32056;Interpretation (NEURF);59462-2;;2012-04-09;NEURF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3776;NEURF;Neuraminidase, Fibroblasts;35033;Neuraminidase Activity;24099-4;Sialidase:CCnt:Pt:Fibroblasts:Qn:;2013-04-11;NEURF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3777;NEZPP;Zinc Protoporphyrin, Blood;300009;Zinc Protoporphyrin, B;2893-6;Protoporphyrin.zinc:ACnc:Pt:Bld:Ord:;2009-11-13;Hematofluorometry
3778;NICOS;Nicotine and Metabolites, Serum;21314;Cotinine;10365-5;Cotinine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3779;NICOS;Nicotine and Metabolites, Serum;21313;Nicotine;3853-9;Nicotine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3780;NICOU;Nicotine and Metabolites, Urine;82510;Nicotine;3854-7;Nicotine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3781;NICOU;Nicotine and Metabolites, Urine;21323;Anabasine;33915-0;Anabasine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3782;NICOU;Nicotine and Metabolites, Urine;21321;Cotinine;10366-3;Cotinine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3783;NICOU;Nicotine and Metabolites, Urine;21324;Nornicotine;33917-6;Nornicotine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3784;NIEM;Niemann-Pick Type C Detection, Fibroblasts;29746;Interpretation (NIEM);59462-2;;2012-04-02;NIEM: Radiolabeled Lipid Extraction Using Thin Layer ChromatographyCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
3785;NIRU;Nickel, Random, Urine;60441;Nickel, Random, U;14099-6;Nickel:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3786;NIS;Nickel, Serum;8622;Nickel, S;5702-6;Nickel:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3787;NITF;Nitrogen, Total, Feces;17416;Total Weight;30078-0;Specimen weight:Mass:Pt:Stool:Qn:;2009-11-13;Dumas Combustion
3788;NITF;Nitrogen, Total, Feces;DUR9;Collection Duration;13363-7;Collection duration:Time:*:Stool:Qn:;2012-03-15;Dumas Combustion
3789;NITF;Nitrogen, Total, Feces;17417;Nitrogen, Total, F;16141-4;Nitrogen:MRat:24H:Stool:Qn:;2009-11-13;Dumas Combustion
3790;NITU;Nitrogen, Total, 24 Hour, Urine;DUR8;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Dumas Combustion
3791;NITU;Nitrogen, Total, 24 Hour, Urine;TOTV;Specimen Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Dumas Combustion
3792;NITU;Nitrogen, Total, 24 Hour, Urine;17418;Nitrogen, Total, U;2660-9;Nitrogen:MRat:24H:Urine:Qn:;2009-11-13;Dumas Combustion
3793;NIU;Nickel, 24 Hour, Urine;868;Ni Concentration;29936-2;Nickel:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3794;NIU;Nickel, 24 Hour, Urine;VL30;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3795;NIU;Nickel, 24 Hour, Urine;TM18;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3796;NIU;Nickel, 24 Hour, Urine;8626;Nickel, 24 Hr, U;5705-9;Nickel:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3797;NMEG;Nutmeg, IgE;NMEG;Nutmeg, IgE;6188-7;Nutmeg Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3798;NMRV;LDL and HDL Particle Concentration NMR, Plasma;LDLPV;Total LDL Particle Concentration;14815-5;Lipoprotein.beta:SCnc:Pt:Ser/Plas:Qn:Calculated;2013-08-07;Nuclear Magnetic Resonance (NMR)
3799;NORT;Nortriptyline, Serum;81858;Nortriptyline, S;3872-9;Nortriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3800;NPCKM;Niemann-Pick Type C Disease, Known Mutation;27495;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) followed by DNA Sequencing and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) of NPC1 and NPC2 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3801;NPCKM;Niemann-Pick Type C Disease, Known Mutation;27497;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) followed by DNA Sequencing and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) of NPC1 and NPC2 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3802;NPCKM;Niemann-Pick Type C Disease, Known Mutation;27492;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) followed by DNA Sequencing and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) of NPC1 and NPC2 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3803;NPCKM;Niemann-Pick Type C Disease, Known Mutation;27494;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) followed by DNA Sequencing and/or Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA) of NPC1 and NPC2 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3804;NPCMS;Niemann-Pick Type C, Full Gene Analysis;27475;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Amplification followed by DNA Sequencing is utilized to test for the presence of a mutation in the NPC1 and NPC2 genes and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)FBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3805;NPCMS;Niemann-Pick Type C, Full Gene Analysis;27476;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification followed by DNA Sequencing is utilized to test for the presence of a mutation in the NPC1 and NPC2 genes and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)FBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3806;NPCMS;Niemann-Pick Type C, Full Gene Analysis;27478;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification followed by DNA Sequencing is utilized to test for the presence of a mutation in the NPC1 and NPC2 genes and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)FBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3807;NPCMS;Niemann-Pick Type C, Full Gene Analysis;27473;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR) Amplification followed by DNA Sequencing is utilized to test for the presence of a mutation in the NPC1 and NPC2 genes and  Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)FBC: Cell Culture(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3808;NPD;Niemann-Pick Disease, Types A and B, Mutation Analysis;23021;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with Niemann-Pick disease types A and B: L302P, R496L, fsP330, and delta R608.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3809;NPD;Niemann-Pick Disease, Types A and B, Mutation Analysis;23019;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with Niemann-Pick disease types A and B: L302P, R496L, fsP330, and delta R608.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3810;NPD;Niemann-Pick Disease, Types A and B, Mutation Analysis;23018;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with Niemann-Pick disease types A and B: L302P, R496L, fsP330, and delta R608.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3811;NPD;Niemann-Pick Disease, Types A and B, Mutation Analysis;23016;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR) Analysis is used to test for mutations associated with Niemann-Pick disease types A and B: L302P, R496L, fsP330, and delta R608.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3812;NPDKM;Niemann-Pick Disease, Types A and B, Known Mutation;33706;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3813;NPDKM;Niemann-Pick Disease, Types A and B, Known Mutation;33701;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3814;NPDKM;Niemann-Pick Disease, Types A and B, Known Mutation;33704;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3815;NPDKM;Niemann-Pick Disease, Types A and B, Known Mutation;33703;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3816;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33692;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3817;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33693;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3818;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33694;Result;32641-3;SMPD1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3819;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33695;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3820;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33696;Amendment;32641-3;SMPD1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3821;NPDMS;Niemann-Pick Disease, Types A and B, Full Gene Analysis;33690;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-07-20;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3822;NPM1;Nucleophosmin (NPM1) Mutation Analysis;19729;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;DNA Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3823;NPM1;Nucleophosmin (NPM1) Mutation Analysis;MP011;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;DNA Polymerase Chain Reaction (PCR) with Fragment Analysis by Capillary Gel Electrophoresis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3824;NRDZ;Nordiazepam, Serum;501030;Nordiazepam, S;3537-8;Nordiazepam:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)
3825;NSE;Neuron-Specific Enolase (NSE), Serum;NSE;Neuron Specific Enolase, S;15060-7;Enolase.neuron specific:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Homogeneous Time-Resolved Fluorescence
3826;NSESF;Neuron-Specific Enolase (NSE), Spinal Fluid;NSESF;Neuron Specific Enolase, CSF;44802-7;Enolase.neuron specific:MCnc:Pt:CSF:Qn:;2012-03-15;Homogeneous Time-Resolved Fluorescence
3827;NUTH;Hazelnut-Food, IgE;NUTH;Hazelnut-Food, IgE;6136-6;Corylus avellana Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3828;OAK;Oak, IgE;OAK;Oak, IgE;6189-5;Quercus alba Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3829;OAP;Parasitic Examination;OAP;Parasitic Examination;10704-5;Ova & parasites identified:Prid:Pt:Stool:Nom:Mcroscopy.light;2013-09-17;MicroscopicIncludes concentrated wet preparation and permanent (trichrome) stained preparation. Also includes exam for fecal leukocytes.
3830;OATC;Cultivated Oat, IgE;OATC;Cultivated Oat, IgE;6093-9;Avena sativa cultivated Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3831;OATS;Oat, IgE;OATS;Oat, IgE;6190-3;Avena sativa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3832;OAU;Organic Acids Screen, Urine;80619;Organic Acids Scrn, U;2676-5;Organic acids:ACnc:Pt:Urine:Ord:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3833;OCTO;Octopus, IgE;OCTO;Octopus, IgE;10944-7;Octopus vulgaris Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3834;OH21;21-Hydroxylase Antibodies, Serum;81970;21-Hydroxylase Ab, S;17781-6;21-Hydroxylase Ab:ACnc:Pt:Ser:Qn:;2009-11-13;Immunoabsorption Assay
3835;OHPG;17-Hydroxyprogesterone, Serum;9231;17-Hydroxyprogesterone, S;1668-3;17-Hydroxyprogesterone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3836;OLIV;Olive Tree, IgE;OLIV;Olive-Tree, IgE;6192-9;Olea europaea pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3837;OLIVF;Olive-Food, IgE;OLIVF;Olive-Food, IgE;7545-7;Olive Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3838;OMHC;Oxcarbazepine Metabolite (MHC), Serum;81030;Oxcarbazepine Metabolite (MHC), S;31019-3;10-Hydroxycarbazepine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)
3839;ONIN;Onion, IgE;ONIN;Onion, IgE;6193-7;Allium cepa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3840;OPATM;Opiate Confirmation, Meconium;31852;Oxycodone;26869-8;Oxycodone:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3841;OPATM;Opiate Confirmation, Meconium;31850;Oxymorphone;69028-9;Oxymorphone:MCnt:Pt:Meconium:Qn:Confirm;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3842;OPATM;Opiate Confirmation, Meconium;31868;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3843;OPATM;Opiate Confirmation, Meconium;31851;Hydrocodone;26863-1;Hydrocodone:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3844;OPATM;Opiate Confirmation, Meconium;31847;Codeine;26865-6;Codeine:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3845;OPATM;Opiate Confirmation, Meconium;31849;Hydromorphone;26862-3;Hydromorphone:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3846;OPATM;Opiate Confirmation, Meconium;31848;Morphine;26860-7;Morphine:MCnt:Pt:Meconium:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3847;OPATU;Opiates Confirmation, Urine;6542;Morphine-by LC-MS/MS;3831-5;Morphine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3848;OPATU;Opiates Confirmation, Urine;21180;Opiates Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3849;OPATU;Opiates Confirmation, Urine;21178;Oxycodone-by LC-MS/MS;11246-6;Oxycodone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3850;OPATU;Opiates Confirmation, Urine;21179;Hydromorphone-by LC-MS/MS;9835-0;Hydromorphone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3851;OPATU;Opiates Confirmation, Urine;21177;Hydrocodone-by LC-MS/MS;3681-4;Hydrocodone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3852;OPATU;Opiates Confirmation, Urine;6543;Codeine-by LC-MS/MS;3508-9;Codeine:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3853;OPATX;Opiates Confirmation, Chain of Custody, Urine;6541;Opiates Immunoassay Screen;19295-5;Opiates:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay Followed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Confirmation with Quantitation
3854;OPRM1;Opioid Receptor, Mu 1 (OPRM1) Genotype for Naltrexone Efficacy;31913;OPRM1 Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) 5'-Nuclease End point Allelic Discrimination Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular System, Inc.)
3855;ORCH;Orchard Grass, IgE;ORCH;Orchard Grass, IgE;6195-2;Dactylis glomerata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3856;OREG;Oregano, IgE;OREG;Oregano, IgE;7552-3;Origanum vulgare Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3857;ORNG;Orange, IgE;ORNG;Orange, IgE;6194-5;Citrus sinensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3858;OROT;Orotic Acid, Urine;8905;Orotic Acid, U;30480-8;Orotate:ACnc:Pt:Urine:Ord:;2009-11-13;Colorimetric
3859;OSCAL;Osteocalcin, Serum;OSCAL;Osteocalcin, S;2697-1;Osteocalcin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
3860;OVAL;Ovalbumin, IgE;OVAL;Ovalbumin, IgE;7556-4;Ovalbumin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3861;OVMU;Ovomucoid, IgE;OVMU;Ovomucoid, IgE;7557-2;Ovomucoid Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3862;OXI;Ox-Eye Daisy, IgE;OXI;Ox-Eye Daisy, IgE;6196-0;Chrysanthemum leucanthemum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3863;OXU;Oxalate, 24 Hour, Urine;OXCN2;Oxalate Concentration;27222-9;Oxalate:MCnc:24H:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
3864;OXU;Oxalate, 24 Hour, Urine;OX_A;Ox Conc (mmol/L);34349-1;Oxalate:SCnc:24H:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
3865;OXU;Oxalate, 24 Hour, Urine;TM17;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Enzymatic Using Oxalate Oxidase
3866;OXU;Oxalate, 24 Hour, Urine;VL15;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Enzymatic Using Oxalate Oxidase
3867;OXU;Oxalate, 24 Hour, Urine;OXU1;Oxalate, U;2701-1;Oxalate:MRat:24H:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
3868;OXU;Oxalate, 24 Hour, Urine;OCATE;Oxalate, U;14862-7;Oxalate:SRat:24H:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
3869;OXYC;Oxycodone, Serum;500376;Oxycodone, S;3893-5;Oxycodone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry Using Selected Ion Monitoring (GC-MS SIM)
3870;OXYCS;Oxycodone, Serum;83654;Oxycodone, S;3893-5;Oxycodone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry Using Selected Ion Monitoring (GC-MS SIM)
3871;OYST;Oyster, IgE;OYST;Oyster, IgE;7558-0;Ostrea edulis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3872;P1433;14-3-3 Protein, Spinal Fluid;82528;14-3-3 Protein, CSF;36924-9;14-3-3 protein:MCnc:Pt:CSF:Qn:;2011-06-24;Immunochemiluminometric Assay (ICMA)
3873;P53CA;Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9;MP018;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Polymerase Chain Reaction (PCR) and Sanger Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3874;P53KM;TP53 Gene, Known Mutation;34203;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-31;Polymerase Chain Reaction (PCR) Amplification Followed by DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3875;P53KM;TP53 Gene, Known Mutation;34199;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification Followed by DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3876;P53KM;TP53 Gene, Known Mutation;34197;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification Followed by DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3877;P53KM;TP53 Gene, Known Mutation;34200;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification Followed by DNA(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3878;P53MS;TP53 Gene, Full Gene Analysis;34188;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3879;P53MS;TP53 Gene, Full Gene Analysis;34187;Result;21739-8;TP53 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-12-05;Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3880;P53MS;TP53 Gene, Full Gene Analysis;34186;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3881;P53MS;TP53 Gene, Full Gene Analysis;34189;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3882;P53MS;TP53 Gene, Full Gene Analysis;34193;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-31;Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3883;P5NT;Pyrimidine 5' Nucleotidase, Blood;2734;Pyrimidine 5' Nucleotidase, B;2902-5;Pyrimidine-5-Nucleotidase:ACnc:Pt:Bld:Ord:;2009-11-13;Kinetic Spectrophotometry (KS)
3884;PA;Procainamide, Serum;2462;Procainamide + NAPA;3983-4;Procainamide+N-acetylprocainamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;ImmunoassayIncludes a separate determination of N-acetylprocainamide (NAPA).
3885;PA;Procainamide, Serum;8683;Procainamide;3982-6;Procainamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;ImmunoassayIncludes a separate determination of N-acetylprocainamide (NAPA).
3886;PA;Procainamide, Serum;2461;N-Acetyl Procainamide;3834-9;N-acetylprocainamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;ImmunoassayIncludes a separate determination of N-acetylprocainamide (NAPA).
3887;PACP;Prostatic Acid Phosphatase (PAP), Serum;PACP;Prostatic Acid Phosphatase, S;20420-6;Acid phosphatase.prostatic:MCnc:Pt:Ser:Qn:;2012-03-15;Automated Chemiluminescent Immunometric Assay
3888;PAD;Prenatal Aneuploidy Detection, FISH;16304;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH)
3889;PAD;Prenatal Aneuploidy Detection, FISH;16307;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH)
3890;PAD;Prenatal Aneuploidy Detection, FISH;CG331;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH)
3891;PAD;Prenatal Aneuploidy Detection, FISH;CG334;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH)
3892;PAHD;Phthalic Anhydride, IgE;PAHD;Phthalic Anhydride, IgE;7601-8;Phthalic anhydride Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3893;PAI1;Plasminogen Activator Inhibitor Antigen, Plasma;86083;PAI-1 Ag, P;22758-7;Plasminogen activator inhibitor 1 Ag:MCnc:Pt:PPP:Qn:Imm;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
3894;PALB;Prealbumin (PAB), Serum;PALB;Prealbumin (PAB), S;46130-1;Prealbumin:MCnc:Pt:Ser/Plas:Qn:Nephelometry;2012-03-15;Nephelometry
3895;PAMY;Amylase, Pancreatic, Serum;PAMY;Amylase, Pancreatic, S;1805-1;Amylase.pancreatic:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Monoclonal Antibody Technique
3896;PAMYB;Amylase, Pancreatic, Body Fluid;FLD;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Monoclonal Antibody Technique
3897;PAMYB;Amylase, Pancreatic, Body Fluid;PAMBF;Amylase, Pancreatic, BF;48996-3;Amylase.pancreatic:CCnc:Pt:Body fld:Qn:;2012-03-15;Monoclonal Antibody Technique
3898;PAPN;Papain, IgE;PAPN;Papain, IgE;10945-4;Papain Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3899;PAPR;Paprika, IgE;PAPR;Paprika, IgE;7563-0;Capsicum annuum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3900;PAPY;Papaya, IgE;PAPY;Papaya, IgE;6850-2;Carica papaya Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3901;PARID;Parasite Identification;PARID;Parasite Identification;20932-0;Parasite identified:Prid:Pt:XXX:Nom:Inspection;2013-09-17;BUG: Arthropod and Artifact IdentificationWORMY: Gross and Microscopic Examination
3902;PARO;Paroxetine, Serum;83731;Paroxetine, S;9699-0;Paroxetine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3903;PARVO;Parvovirus B19, Molecular Detection, PCR;SRC73;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3904;PARVO;Parvovirus B19, Molecular Detection, PCR;83151;Parvovirus B19 By Rapid PCR;9571-1;Parvovirus B19 DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3905;PARVP;Parvovirus B19, Molecular Detection, PCR, Plasma;SS008;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3906;PARVP;Parvovirus B19, Molecular Detection, PCR, Plasma;56075;Parvovirus B19 By Rapid PCR;9572-9;Parvovirus B19 DNA:ACnc:Pt:Ser:Ord:Probe.amp.tar;2011-06-16;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3907;PBAR;Phenobarbital, Serum;8252;Phenobarbital, S;3948-7;Phenobarbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
3908;PBAR;Phenobarbital, Serum;8252;Phenobarbital, S;3948-7;Phenobarbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
3909;PBGDW;Porphobilinogen Deaminase (PBGD), Washed Erythrocytes;31945;Interpretation;59462-2;;2012-04-09;Enzymatic End point/Spectrofluorometric
3910;PBGDW;Porphobilinogen Deaminase (PBGD), Washed Erythrocytes;31944;PBG Deaminase, RBC;49228-0;Porphobilinogen deaminase:CCnt:Pt:RBC:Qn:;2011-06-22;Enzymatic End point/Spectrofluorometric
3911;PBGD_;Porphobilinogen Deaminase (PBGD), Whole Blood;28400;Interpretation;59462-2;;2012-04-09;Enzymatic End point/Spectrofluorometric
3912;PBGD_;Porphobilinogen Deaminase (PBGD), Whole Blood;4022;PBG Deaminase, WB;2812-6;Porphobilinogen deaminase:CCnc:Pt:RBC:Qn:;2009-11-13;Enzymatic End point/Spectrofluorometric
3913;PBGU;Porphobilinogen, Quantitative, Random, Urine;29366;Interpretation (PBGU);59462-2;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3914;PBGU;Porphobilinogen, Quantitative, Random, Urine;29365;Porphobilinogen, U;2811-8;Porphobilinogen:SCnc:Pt:Urine:Qn:;2011-06-22;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
3915;PBHA;Lead, Hair;PBHSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3916;PBHA;Lead, Hair;31898;Lead, Hair;5673-9;Lead:MCnt:Pt:Hair:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3917;PBLI;Plasma Cell Assessment, Blood;26839;PC Event Interpretation;69052-9;;2012-04-05;Six Color Flow Cytometry
3918;PBNA;Lead, Nails;2506;Lead, Nails;8202-4;Lead:MCnt:Pt:Nail:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3919;PBNA;Lead, Nails;PBNSC;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3920;PBNP;NT-Pro B-Type Natriuretic Peptide (BNP), Serum;PBNP;NT-Pro BNP, S;33762-6;Natriuretic peptide.B prohormone:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
3921;PBORB;Lyme Disease (Borrelia burgdorferi), Molecular Detection, PCR, Blood;56080;Lyme Disease PCR, B;32667-8;Borrelia burgdorferi DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3922;PBORR;Lyme Disease (Borrelia burgdorferi), Molecular Detection, PCR;23635;Lyme Disease PCR;4991-6;Borrelia burgdorferi DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3923;PBORR;Lyme Disease (Borrelia burgdorferi), Molecular Detection, PCR;SRC71;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3924;PBPO;Penicillin G, IgE;PBPO;Penicillin G, IgE;6851-0;Penicillin G Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3925;PBPR;Primidone and Phenobarbital, Serum;31153;Primidone, S;3978-4;Primidone:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Enzyme-Multiplied Immunoassay Technique (EMIT)
3926;PBPR;Primidone and Phenobarbital, Serum;31154;Phenobarbital, S;3948-7;Phenobarbital:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Enzyme-Multiplied Immunoassay Technique (EMIT)
3927;PBPR;Primidone and Phenobarbital, Serum;31154;Phenobarbital, S;3948-7;Phenobarbital:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Immunoassay
3928;PBPR;Primidone and Phenobarbital, Serum;31153;Primidone, S;3978-4;Primidone:MCnc:Pt:Ser/Plas:Qn:;2011-06-22;Immunoassay
3929;PBRU;Lead, Random, Urine;60246;Lead, Random, U;5676-2;Lead:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3930;PBU;Lead, 24 Hour, Urine;VL84;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3931;PBU;Lead, 24 Hour, Urine;866;Pb Concentration;20625-0;Lead:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3932;PBU;Lead, 24 Hour, Urine;31085;Lead, 24 Hr, U;5677-0;Lead:MRat:24H:Urine:Qn:;2011-06-22;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3933;PBU;Lead, 24 Hour, Urine;TM83;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
3934;PCAB;Parietal Cell Antibodies, IgG, Serum;PCAB;Parietal Cell Ab, IgG, S;40960-7;Parietal cell Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
3935;PCAG;Protein C Antigen, Plasma;9127;Protein C Ag, P;27820-0;Protein C Ag actual/Normal:RelMCnc:Pt:PPP:Qn:Imm;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
3936;PCHES;Pseudocholinesterase, Total, Serum;PCHES;Pseudocholinesterase, Total, S;2098-2;Cholinesterase:CCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Acetylthiocholine Substrate
3937;PCPMC;Phencyclidine Confirmation, Meconium;89069;PCP Confirmation, Meconium;26859-9;Phencyclidine:MCnt:Pt:Meconium:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3938;PCPMC;Phencyclidine Confirmation, Meconium;29905;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
3939;PCPU;Phencyclidine Confirmation, Urine;21192;Phencyclidine Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3940;PCPU;Phencyclidine Confirmation, Urine;6673;Phencyclidine-by GC/MS;16254-5;Phencyclidine:MCnc:Pt:Urine:Qn:Confirm;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3941;PCPX;Phencyclidine Confirmation, Chain of Custody, Urine;6672;Phencyclidine Immunoassay Screen;19659-2;Phencyclidine:ACnc:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
3942;PCT;Procalcitonin, Serum;PCT;Procalcitonin, S;33959-8;Procalcitonin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Homogeneous Time-Resolved Fluorescence
3943;PDRP;Pigeon Droppings, IgE;PDRP;Pigeon Droppings, IgE;6217-4;Pigeon droppings Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3944;PDSU;Drug Screen, Prescription/OTC, Urine;31260;Drugs detected:;41270-0;Drugs identified:Prid:Pt:Urine:Nom:;2011-06-22;Gas Chromatography-Mass Spectrometry (GC-MS) Qualitative results will be reported.
3945;PEAN;Peanut, IgE;PEAN;Peanut, IgE;6206-7;Arachis hypogaea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3946;PEAR;Pear, IgE;PEAR;Pear, IgE;6207-5;Pyrus communis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3947;PEC;Pecan-Food, IgE;PEC;Pecan-Food, IgE;6208-3;Carya illinoinensis nut Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3948;PECH;Peach, IgE;PECH;Peach, IgE;6205-9;Prunus persica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3949;PEE;Porphyrins Evaluation, Whole Blood;29356;Interpretation;59462-2;;2012-04-09;PEE: SpectrofluorometricPFR: High-Performance Liquid Chromatography (HPLC)
3950;PEE;Porphyrins Evaluation, Whole Blood;88886;Total Porphyrins, WB;2814-2;Porphyrins:MCnc:Pt:RBC:Qn:;2009-11-13;PEE: SpectrofluorometricPFR: High-Performance Liquid Chromatography (HPLC)
3951;PENG;Penicillin G, Serum;80134;Penicillin G, S;3913-1;Penicillin G:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3952;PENIV;Penicillin V, IgE;PENIV;Penicillin V, IgE;6210-9;Penicillin V Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3953;PENTS;Pentobarbital, Serum;8239;Pentobarbital, S;3924-8;Pentobarbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometery (GC-MS)
3954;PERS;Persimmon, IgE;PERS;Persimmon, IgE;10947-0;Diospyros kaki Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3955;PEWE;Porphyrins Evaluation, Washed Erythrocytes;31942;Total Porphyrins, RBC;2814-2;Porphyrins:MCnc:Pt:RBC:Qn:;2011-06-22;PEWE: SpectrofluorometricPFR: High-Performance Liquid Chromatography (HPLC)
3956;PEWE;Porphyrins Evaluation, Washed Erythrocytes;31943;Interpretation;59462-2;;2012-04-09;PEWE: SpectrofluorometricPFR: High-Performance Liquid Chromatography (HPLC)
3957;PF;Chromosomes, Body Fluid;16126;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3958;PF;Chromosomes, Body Fluid;16127;Interpretation;69965-2;;2012-04-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3959;PF;Chromosomes, Body Fluid;16128;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3960;PF;Chromosomes, Body Fluid;50470;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3961;PF;Chromosomes, Body Fluid;16124;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3962;PF;Chromosomes, Body Fluid;CG345;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3963;PF;Chromosomes, Body Fluid;16788;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-10-31;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
3964;PF199;Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid;SITE8;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-04-11;Immunoenzymatic Assay
3965;PF199;Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid;P199;CA 19-9, Pleural Fluid;19163-5;Cancer Ag 19-9:ACnc:Pt:Plr fld:Qn:;2013-04-11;Immunoenzymatic Assay
3966;PFCEA;Carcinoembryonic Antigen (CEA), Pleural Fluid;PCEA;CEA, Pleural Fluid;19168-4;Carcinoembryonic Ag:ACnc:Pt:Plr fld:Qn:;2013-12-05;Immunoenzymatic Assay
3967;PFCEA;Carcinoembryonic Antigen (CEA), Pleural Fluid;SITE9;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Immunoenzymatic Assay
3968;PFN;Propafenone, Serum;80295;Propafenone, S;6905-4;Propafenone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
3969;PFR;Porphyrins, Fractionation, Reflex;29355;Interpretation;59462-2;;2012-04-09;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3970;PFR;Porphyrins, Fractionation, Reflex;2328;Protoporphyrin;2896-9;Protoporphyrin:MCnc:Pt:Bld:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3971;PFR;Porphyrins, Fractionation, Reflex;2329;Coproporphyrin;18257-6;Coproporphyrin:MCnc:Pt:Bld:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3972;PFR;Porphyrins, Fractionation, Reflex;2347;Pentacarboxyl Porphyrins;18250-1;Pentacarboxylporphyrins:MCnc:Pt:Bld:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3973;PFR;Porphyrins, Fractionation, Reflex;2346;Hexacarboxyl Porphyrins;16963-1;Hexacarboxylporphyrin:MCnc:Pt:Bld:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3974;PFR;Porphyrins, Fractionation, Reflex;2341;Heptacarboxyl Porphyrins;9446-6;Heptacarboxylporphyrin:MCnc:Pt:RBC:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3975;PFR;Porphyrins, Fractionation, Reflex;2340;Uroporphyrin;14180-4;Uroporphyrin:MCnc:Pt:RBC:Qn:;2009-11-13;Only orderable as part of a reflex test. For further information see PEE / Porphyrins Evaluation, Whole Blood.
3976;PFRUT;Passion Fruit, IgE;PFRUT;Passion Fruit, IgE;10946-2;Passiflora edulis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3977;PGSN;Progesterone, Serum;PGSN;Progesterone, S;2839-9;Progesterone:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
3978;PHBF;Phosphorus, Body Fluid;FLD20;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric, Ammonium Molybdate
3979;PHBF;Phosphorus, Body Fluid;PHOBF;Phosphorus, BF;12242-4;Phosphate:MCnc:Pt:Body fld:Qn:;2012-03-15;Photometric, Ammonium Molybdate
3980;PHIV;HIV-1 Proviral DNA Qualitative Detection by PCR, Blood;88635;HIV-1 Proviral DNA, B;48023-6;HIV 1 proviral DNA:ACnc:Pt:Ser/Plas:Ord:Probe.amp.tar;2009-11-13;Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
3981;PHMA;Phoma betae, IgE;PHMA;Phoma Betae, IgE;6216-6;Phoma betae Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3982;PHOS;Phosphorus (Inorganic), Serum;PHOS;Phosphorus (Inorganic), S;2777-1;Phosphate:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Photometric, Ammonium Molybdate
3983;PHU_;pH, Urine;PHU_;pH, U;2756-5;pH:LsCnc:Pt:Urine:Qn:;2012-03-15;pH meter
3984;PHYF;Phenytoin, Free, Serum;9993;Phenytoin, Free, S;3969-3;Phenytoin.free:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
3985;PHYF;Phenytoin, Free, Serum;9993;Phenytoin, Free, S;3969-3;Phenytoin.free:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Membrane Separation/Immunoassay
3986;PIGE;Pig Epithelium, IgE;PIGE;Pig Epithelium, IgE;6262-0;Swine epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3987;PIGF;Pigeon Feathers, IgE;PIGF;Pigeon Feathers, IgE;10948-8;Pigeon feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3988;PINE;Pine Nut, IgE;PINE;Pine Nut, IgE;10954-6;Pinus edulis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3989;PINP;Procollagen I Intact N-Terminal, Serum;61695;Procollagen I Intact N-Terminal, S;47255-5;Procollagen peptide.type 1 N-Terminal:MCnc:Pt:Ser:Qn:;2013-12-05;
3990;PINS;Proinsulin, Plasma;80908;Proinsulin, P;27882-0;Proinsulin:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunochemiluminescent Assay
3991;PIOR;Pityrosporum orbiculare, IgE;PIOR;Pityrosporum Orbiculare, IgE;10949-6;Malassezia furfur Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3992;PIPA;Pipecolic Acid, Serum;29962;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS)
3993;PIPA;Pipecolic Acid, Serum;81326;Pipecolic Acid, S;32334-5;Pipecolate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3994;PIPU;Pipecolic Acid, Urine;29952;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS)
3995;PIPU;Pipecolic Acid, Urine;81248;Pipecolic Acid, U;47727-3;Pipecolate/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
3996;PISTA;Pistachio, IgE;PISTA;Pistachio, IgE;7613-3;Pistacia vera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3997;PJUD;Parietaria judaica, IgE;PJUD;Parietaria Judaica, IgE;6199-4;Parietaria judaica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
3998;PK;Pyruvate Kinase, Erythrocytes;PK_;Pyruvate Kinase, RBC;32552-2;Pyruvate kinase:CCnt:Pt:RBC:Qn:;2012-03-15;Kinetic Spectrophotometry (KS)
3999;PKU;Phenylalanine and Tyrosine, Plasma;8627;Tyrosine, P;20660-7;Tyrosine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4000;PKU;Phenylalanine and Tyrosine, Plasma;8380;Phenylalanine, P;14875-9;Phenylalanine:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4001;PLAB;Platelet Antibody, Serum;CMT34;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-03-15;Enzyme-Linked Immunoabsorbent Assay (ELISA)
4002;PLAB;Platelet Antibody, Serum;PL_AB;Platelet Ab, S;24375-8;Platelet Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Enzyme-Linked Immunoabsorbent Assay (ELISA)
4003;PLAI;Plaice, IgE;PLAI;Plaice, IgE;10959-5;Pleuronectes platessa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4004;PLHBB;Plasma Hemoglobin, Plasma;31970;Total Hemoglobin;721-1;Hemoglobin.free:MCnc:Pt:Plas:Qn:;2011-06-22;Spectrophotometry (SP)
4005;PLINK;PNH, PI-Linked Antigen, Blood;CK079;Interpretation;69052-9;Flow cytometry specialist review:Imp:Pt:XXX:Nar:;2013-08-07;Immunophenotyping
4006;PLP;Pyridoxal 5-Phosphate (PLP), Plasma;4047;Pyridoxal 5-Phosphate (PLP), P;30552-4;Pyridoxal phosphate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4007;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34814;Galactocerebrosidase;62310-8;Galactocerebrosidase:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4008;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34821;Interpretation (PLSD);62301-7;Lysosomal storage disorders:Imp:Pt:Bld.dot:Nom:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4009;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34815;Alpha-Galactosidase;55908-8;Alpha galactosidase A:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4010;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34816;Alpha-L-Iduronidase;55909-6;Alpha-L-iduronidase:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4011;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34813;Acid Alpha-Glucosidase;55827-0;Acid alpha glucosidase:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4012;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34812;Sphingomyelinase;62316-5;Acid sphingomyelinase:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4013;PLSD;Lysosomal and Peroxisomal Storage Disorders Screen, Blood Spot;34811;Acid Beta-Glucosidase;55917-9;Acid beta glucosidase:CCnc:Pt:Bld.dot:Qn:;2013-08-07;Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
4014;PLUM;Plum, IgE;PLUM;Plum, IgE;6853-6;Prunus domestica Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4015;PMET;Metanephrines, Fractionated, Free, Plasma;10139;Metanephrine, Free;49700-8;Metanephrine.free:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4016;PMET;Metanephrines, Fractionated, Free, Plasma;10140;Normetanephrine, Free;40851-8;Normetanephrine.free:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4017;PMLK;Milk, Processed, IgE;PMLK;Milk, Processed, IgE;6174-7;Milk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4018;PMLR;PML/RARA Quantitative, PCR;19449;Final Diagnosis;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Quantitative, Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4019;PMLR;PML/RARA Quantitative, PCR;MP012;Specimen Type;66746-9;Specimen type:Type:Pt:Specimen:Nom:;2014-05-21;Quantitative, Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4020;PMMIF;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Fibroblasts;50832;Interpretation;59462-2;;2012-04-02;PMMIF: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4021;PMMIF;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Fibroblasts;50829;Method;49549-9; ;2013-07-26;PMMIF: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4022;PMMIF;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Fibroblasts;50828;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;PMMIF: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4023;PMMIF;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Fibroblasts;50826;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;PMMIF: Colorimetric Enzyme AssayFIBR: Cultivated from Biopsy as MonolayerCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4024;PMMIL;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Leukocytes;50844;Interpretation;59462-2;;2012-04-02;Colorimetric
4025;PMMIL;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Leukocytes;50841;Method;49549-9; ;2013-07-26;Colorimetric
4026;PMMIL;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Leukocytes;50840;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Colorimetric
4027;PMMIL;Phosphomannomutase (PMM) and Phosphomannose Isomerase (PMI), Leukocytes;50838;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Colorimetric
4028;PMS2K;PMS2 Gene, Known Mutation;33627;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase chain reaction (PCR) followed by DNA sequencing or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of the PMS2 gene is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4029;PMS2K;PMS2 Gene, Known Mutation;33628;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase chain reaction (PCR) followed by DNA sequencing or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of the PMS2 gene is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4030;PMS2K;PMS2 Gene, Known Mutation;33625;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase chain reaction (PCR) followed by DNA sequencing or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of the PMS2 gene is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4031;PMS2K;PMS2 Gene, Known Mutation;33631;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase chain reaction (PCR) followed by DNA sequencing or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of the PMS2 gene is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4032;PMS2S;PMS2 Gene, Full Gene Analysis;33619;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4033;PMS2S;PMS2 Gene, Full Gene Analysis;33615;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-07-29;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4034;PMS2S;PMS2 Gene, Full Gene Analysis;33616;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4035;PMS2S;PMS2 Gene, Full Gene Analysis;33613;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4036;PMSBB;Postmortem Screening, Bile and Blood Spots;81931;Interpretation;59462-2; ;2014-05-21;Electrospray Tandem Mass Spectrometry (MS/MS)
4037;PMSBB;Postmortem Screening, Bile and Blood Spots;22680;Method;49549-9; ;2013-07-26;Electrospray Tandem Mass Spectrometry (MS/MS)
4038;PMSBB;Postmortem Screening, Bile and Blood Spots;22677;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Electrospray Tandem Mass Spectrometry (MS/MS)
4039;PMSBB;Postmortem Screening, Bile and Blood Spots;22679;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Electrospray Tandem Mass Spectrometry (MS/MS)
4040;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23965;Serotype 7F (51);25296-5;Streptococcus pneumoniae 51 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4041;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23970;Serotype 33F (70);40969-8;Streptococcus pneumoniae 70 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4042;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23950;Serotype 3 (3);27096-7;Streptococcus pneumoniae 3 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4043;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23949;Serotype 2(2);40964-9;Streptococcus pneumoniae 2 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4044;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23962;Serotype 6B (26);27118-9;Streptococcus pneumoniae 26 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4045;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23969;Serotype 9V (68);30153-1;Streptococcus pneumoniae 68 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4046;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23963;Serotype 10A (34);40967-2;Streptococcus pneumoniae 34 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4047;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23964;Serotype 11A (43);40968-0;Streptococcus pneumoniae 43 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4048;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23966;Serotype 15B (54);40973-0;Streptococcus pneumoniae 54 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4049;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23961;Serotype 23F (23);27389-6;Streptococcus pneumoniae 23 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4050;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23959;Serotype 20 (20);40965-6;Streptococcus pneumoniae 20 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4051;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23967;Serotype 18C (56);27395-3;Streptococcus pneumoniae 56 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4052;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23958;Serotype 19F (19);27390-4;Streptococcus pneumoniae 19 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4053;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23960;Serotype 22F (22);40966-4;Streptococcus pneumoniae 22 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4054;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23968;Serotype 19A (57);40974-8;Streptococcus pneumoniae 57 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4055;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23953;Serotype 8 (8);27113-0;Streptococcus pneumoniae 8 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4056;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23954;Serotype 9N (9);27392-0;Streptococcus pneumoniae 9 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4057;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23955;Serotype 12F (12);27374-8;Streptococcus pneumoniae 12 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4058;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23956;Serotype 14 (14);27387-0;Streptococcus pneumoniae 14 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4059;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23951;Serotype 4 (4);27094-2;Streptococcus pneumoniae 4 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4060;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23952;Serotype 5 (5);31183-7;Streptococcus pneumoniae 5 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4061;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23979;Serotype 1 (1);27092-6;Streptococcus pneumoniae 1 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4062;PN23;Streptococcus pneumoniae IgG Antibodies, 23 Serotypes, Serum;23957;Serotype 17F (17);40963-1;Streptococcus pneumoniae 17 Ab.IgG:MCnc:Pt:Ser:Qn:;2009-11-13;Microsphere Photometry
4063;PNAP;Pineapple, IgE;PNAP;Pineapple, IgE;6218-2;Ananas comosus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4064;PNRP;Pneumocystis jiroveci, Molecular Detection, PCR;24188;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-07-06;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4065;PNRP;Pneumocystis jiroveci, Molecular Detection, PCR;81698;Result;49441-9;Pneumocystis jiroveci DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4066;PNRP;Pneumocystis jiroveci, Molecular Detection, PCR;SRC63;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4067;PNY;Phenytoin, Total, Serum;8604;Phenytoin, Total, S;3968-5;Phenytoin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
4068;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;16103;Interpretation;69965-2;;2012-04-05;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4069;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;G_767;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4070;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;G_773;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4071;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;16100;Method;49549-9; ;2013-07-26;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4072;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;50471;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4073;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;16102;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4074;POC;Chromosome Analysis, Autopsy, Products of Conception, or Stillbirth;16104;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;POC: Includes 2 banded karyograms analysis of 20 or more metaphases, and other techniques when required.FPOCR: Fluorescence In Situ Hybridization (FISH) with DNA Probes
4075;POFF;Parietaria officinalis, IgE;POFF;Parietaria Officinalis, IgE;6200-0;Parietaria officinalis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4076;POPSD;Poppy Seed, IgE;POPSD;Poppy Seed, IgE;7623-2;Papaver somniferum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4077;PORK;Pork, IgE;PORK;Pork, IgE;6219-0;Pork Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4078;POSA;Posaconazole, Serum;89591;Posaconazole, S;53731-6;Posaconazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4079;POSV;Post Vasectomy Check, Semen;MOTIL;Motility;6800-7;Spermatozoa.motile/100 spermatozoa:NFr:Pt:Semen:Qn:;2012-03-15;Manual
4080;POSV;Post Vasectomy Check, Semen;SPML1;Sperm/mL;9780-8;Spermatozoa:NCnc:Pt:Semen:Qn:;2012-03-15;Manual
4081;POSV;Post Vasectomy Check, Semen;VL53;Semen Volume;3160-9;Specimen volume:Vol:Pt:Semen:Qn:;2012-03-12;Manual
4082;POSV;Post Vasectomy Check, Semen;ABSTN;Abstinence;10587-4;Sexual abstinence duration:Time:Pt:^Patient:Qn:;2012-03-12;Manual
4083;POTA;White Potato, IgE;POTA;White Potato, IgE;6220-8;Solanum tuberosum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4084;POU;Phosphorus, 24 Hour, Urine;PHOCN;P Concentration;21458-5;Phosphate:MCnc:24H:Urine:Qn:;2012-03-15;Molybdic Acid
4085;POU;Phosphorus, 24 Hour, Urine;VL10;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Molybdic Acid
4086;POU;Phosphorus, 24 Hour, Urine;POUU;Phosphorus, U;2779-7;Phosphate:MRat:24H:Urine:Qn:;2012-03-15;Molybdic Acid
4087;POU;Phosphorus, 24 Hour, Urine;TM12;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Molybdic Acid
4088;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7139;C26:0/C22:0;30198-6;Fatty acids.very long chain.C26:0/C22:0:SRto:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4089;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;81369;C22:0;30194-5;Fatty acids.very long chain.C22:0:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4090;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7144;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4091;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7142;Pristanic/Phytanic;30550-8;Pristanate/Phytanate:SRto:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4092;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7141;Phytanic Acid;22671-2;Phytanate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4093;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7140;Pristanic Acid;22761-1;Pristanate:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4094;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7137;C26:0;30197-8;Fatty acids.very long chain.C26:0:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4095;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7138;C24:0/C22:0;30196-0;Fatty acids.very long chain.C24:0/C22:0:SRto:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4096;POX;Fatty Acid Profile, Peroxisomal (C22-C26), Serum;7143;C24:0;30195-2;Fatty acids.very long chain.C24:0:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Stable Isotope Dilution Analysis
4097;POXA;Oxalate, Plasma;POXA;Oxalate, P;15085-4;Oxalate:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Spectrophotometry (SP)
4098;PPAN;Acute Porphyria, Multi-Gene Panel;51491;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4099;PPAN;Acute Porphyria, Multi-Gene Panel;51495;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4100;PPAN;Acute Porphyria, Multi-Gene Panel;51489;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4101;PPAN;Acute Porphyria, Multi-Gene Panel;51492;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4102;PPAPT;Parental Sample Prep for Prenatal Microarray Testing;53377;Interpretation;69965-2;Clinical cytogeneticist review:Imp:Pt:XXX:Nar:;2014-05-21;DNA Extraction and Cell Culture
4103;PPAPT;Parental Sample Prep for Prenatal Microarray Testing;53375;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;DNA Extraction and Cell Culture
4104;PPAPT;Parental Sample Prep for Prenatal Microarray Testing;CG913;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;DNA Extraction and Cell Culture
4105;PPAPT;Parental Sample Prep for Prenatal Microarray Testing;CG912;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;DNA Extraction and Cell Culture
4106;PPFE;Protoporphyrins, Fractionation, Whole Blood;29511;Interpretation;59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC) with Fluorescence DetectionIncludes separate quantitation of zinc protoporphyrins and free protoporphyrins.
4107;PPFE;Protoporphyrins, Fractionation, Whole Blood;2326;Free Protoporphyrin;2892-8;Protoporphyrin.free:MCnc:Pt:Bld:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC) with Fluorescence DetectionIncludes separate quantitation of zinc protoporphyrins and free protoporphyrins.
4108;PPFE;Protoporphyrins, Fractionation, Whole Blood;2327;Zinc-Complexed Protoporphyrin;33007-6;Protoporphyrin.zinc:MCnc:Pt:Bld:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC) with Fluorescence DetectionIncludes separate quantitation of zinc protoporphyrins and free protoporphyrins.
4109;PPFWE;Protoporphyrins, Fractionation, Washed Erythrocytes;31932;Zinc-Complexed Protoporphyrin;2895-1;Protoporphyrin.zinc:MCnc:Pt:RBC:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorescence DetectionIncludes separate quantitation of zinc protoporphyrins and free protoporphyrins.
4110;PPL;Phospholipids, Serum;PPL;Phospholipids, S;2568-4;Phospholipid:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Enzymatic Colorimetric
4111;PPOXK;PPOX Gene, Known Mutation;33805;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the PPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4112;PPOXK;PPOX Gene, Known Mutation;33808;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the PPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4113;PPOXK;PPOX Gene, Known Mutation;33811;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the PPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4114;PPOXK;PPOX Gene, Known Mutation;33807;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing is used to detect the presence of a specific mutation in the PPOX gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4115;PPOXS;PPOX Gene, Full Gene Analysis;33797;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4116;PPOXS;PPOX Gene, Full Gene Analysis;33800;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4117;PPOXS;PPOX Gene, Full Gene Analysis;33796;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4118;PPOXS;PPOX Gene, Full Gene Analysis;33794;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4119;PQNRU;Porphyrins, Quantitative, Random, Urine;32338;Interpretation;59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4120;PQNRU;Porphyrins, Quantitative, Random, Urine;32337;Porphobilinogen;2811-8;Porphobilinogen:SCnc:Pt:Urine:Qn:;2011-06-23;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4121;PQNRU;Porphyrins, Quantitative, Random, Urine;32333;Heptacarboxylporphyrins;34314-5;Heptacarboxylporphyrin:SCnc:Pt:Urine:Qn:;2011-06-23;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4122;PQNRU;Porphyrins, Quantitative, Random, Urine;32335;Pentacarboxylporphyrins;34352-5;Pentacarboxylporphyrins:SCnc:Pt:Urine:Qn:;2011-06-23;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4123;PQNRU;Porphyrins, Quantitative, Random, Urine;32332;Uroporphyrin, Octa;25166-0;Uroporphyrin:SCnc:Pt:Urine:Qn:;2011-06-23;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4124;PQNRU;Porphyrins, Quantitative, Random, Urine;32336;Coproporphyrin, Tetra;25167-8;Coproporphyrin:SCnc:Pt:Urine:Qn:;2011-06-23;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl). Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4125;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;TM3;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4126;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29360;Pentacarboxylporphyrins;25494-6;Pentacarboxylporphyrins:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4127;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;23403;Interpretation;59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4128;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29362;Porphobilinogen;14882-5;Porphobilinogen:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4129;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29359;Hexacarboxylporphyrins;25438-3;Hexacarboxylporphyrin:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4130;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29358;Heptacarboxylporphyrins;25434-2;Heptacarboxylporphyrin:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4131;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;VL1;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4132;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29357;Uroporphyrin, Octa;15096-1;Uroporphyrin:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4133;PQNU;Porphyrins, Quantitative, 24 Hour, Urine;29361;Coproporphyrin, Tetra;15041-7;Coproporphyrin:SRat:24H:Urine:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC) with Fluorometric DetectionIncludes quantitation of coproporphyrins, uroporphyrins, and intermediate porphyrins (heptacarboxyl, hexacarboxyl, and pentacarboxyl).Includes liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of porphobilinogen.
4134;PR3;Proteinase 3 Antibodies, IgG, Serum;PR3;Proteinase 3 Ab (PR3), S;48408-9;Proteinase 3 Ab.IgG:ACnc:Pt:Ser:Qn:;2014-02-28;Multiplex Flow Immunoassay
4135;PRA;Renin Activity, Plasma;8060;Renin Activity, P;2915-7;Renin:CCnc:Pt:Plas:Qn:;2009-11-13;Radioimmunoassay (RIA)
4136;PREGI;Pork Neutral-Regular Insulin, IgE;PREGI;Pork Neutral-Regular Insulin, IgE;6149-9;Insulin porcine Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4137;PREGN;Pregnenolone, Serum;88645;Pregnenolone, S;2837-3;Pregnenolone:MCnc:Pt:Ser/Plas:Qn:;2011-06-24;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4138;PRL;Prolactin, Serum;PRL;Prolactin, S;2842-3;Prolactin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
4139;PSA;Prostate-Specific Antigen (PSA) Diagnostic, Serum;PSA;Prostate-Specific Ag Diagnostic, S;2857-1;Prostate specific Ag:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay (ECLIA)
4140;PSAFT;Prostate-Specific Antigen (PSA), Total and Free, Serum;FPSA;Free PSA;10886-0;Prostate specific Ag.free:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay (ECLIA)
4141;PSAFT;Prostate-Specific Antigen (PSA), Total and Free, Serum;PSA_R;Free PSA/PSA Ratio;12841-3;Prostate specific Ag.free/Prostate specific Ag.total:MFr:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay (ECLIA)
4142;PSAFT;Prostate-Specific Antigen (PSA), Total and Free, Serum;TPSA;Total PSA;2857-1;Prostate specific Ag:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Electrochemiluminescent Immunoassay (ECLIA)
4143;PSGN;Plasminogen Activity, Plasma;PSGN;Plasminogen Activity, P;28660-9;Plasminogen actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-15;Amidolysis of Chromoginic Substrate
4144;PSLY;Parsley, IgE;PSLY;Parsley, IgE;6203-4;Petroselinum crispum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4145;PT;Prothrombin Time, Plasma;INRC;INR;6301-6;Coagulation tissue factor induced.INR:RelTime:Pt:PPP:Qn:Coag;2012-03-15;Electromagnetic Viscosity Detection System
4146;PT;Prothrombin Time, Plasma;PTTIC;Prothrombin Time, P;5902-2;Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag;2012-03-15;Electromagnetic Viscosity Detection System
4147;PTENK;PTEN Gene, Known Mutation;34243;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4148;PTENK;PTEN Gene, Known Mutation;34247;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-16;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4149;PTENK;PTEN Gene, Known Mutation;34244;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4150;PTENK;PTEN Gene, Known Mutation;34241;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4151;PTENS;PTEN Gene, Full Gene Analysis;34237;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-06-04;Polymerase chain reaction (PCR) amplification/DNA sequencing array (aCGH) is used to test for the presence of large deletions and duplications.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4152;PTENS;PTEN Gene, Full Gene Analysis;34232;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase chain reaction (PCR) amplification/DNA sequencing array (aCGH) is used to test for the presence of large deletions and duplications.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4153;PTENS;PTEN Gene, Full Gene Analysis;34233;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing array (aCGH) is used to test for the presence of large deletions and duplications.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4154;PTENS;PTEN Gene, Full Gene Analysis;34230;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing array (aCGH) is used to test for the presence of large deletions and duplications.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4155;PTENS;PTEN Gene, Full Gene Analysis;34231;Result;47969-1;PTEN gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-12-05;Polymerase chain reaction (PCR) amplification/DNA sequencing array (aCGH) is used to test for the presence of large deletions and duplications.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4156;PTHFN;Parathyroid Hormone, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash;SITEA;Site;39111-0;Body site:Anat:Pt:^Patient:Nom:;2013-08-08;Electrochemiluminescence Immunoassay
4157;PTHRP;Parathyroid Hormone-Related Peptide (PTHrP), Plasma;81774;PTH-Related Peptide;15087-0;Parathyrin related protein:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunochemiluminometric Assay (ICMA)
4158;PTNT;Prothrombin G20210A Mutation, Blood;21804;PTNT Interpretation;69049-5;;2012-04-05;Direct Mutation Analysis
4159;PTNT;Prothrombin G20210A Mutation, Blood;21803;Prothrombin G20210A Mutation, B;24475-6;F2 gene.c.20210G>A:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Direct Mutation Analysis
4160;PTOX;Toxoplasma gondii, Molecular Detection, PCR;SRC74;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4161;PTOX;Toxoplasma gondii, Molecular Detection, PCR;81795;Toxoplasma gondii PCR;42626-2;Toxoplasma gondii DNA:ACnc:Pt:CSF:Ord:Probe.amp.tar;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4162;PTP;Porphyrins, Total, Plasma;8731;Porphyrins, Total, P;2815-9;Porphyrins:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;PTP: Extraction and Scanning SpectrofluorometryPFP: High-Performance Liquid Chromatography (HPLC)
4163;PTP;Porphyrins, Total, Plasma;33869;Interpretation;59462-2;;2012-04-09;PTP: Extraction and Scanning SpectrofluorometryPFP: High-Performance Liquid Chromatography (HPLC)
4164;PTRE;Privet Tree, IgE;PTRE;Privet Tree, IgE;7632-3;Ligustrum vulgare Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4165;PTSE;Platinum, Serum;61749;Platinum, S;5714-1;Platinum:MCnc:Pt:Ser/Plas:Qn:;2013-04-11;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4166;PTU;Protein, Total, 24 Hour, Urine;VL21;Urine Volume;19153-6;Specimen volume:Vol:XXX:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
4167;PTU;Protein, Total, 24 Hour, Urine;CONC1;Concentration;35663-4;Protein:MCnc:XXX:Urine:Qn:;2012-03-15;Dye Binding (Pyrogallol Red)
4168;PTU;Protein, Total, 24 Hour, Urine;TM23;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
4169;PTU;Protein, Total, 24 Hour, Urine;TP2;Total Protein;2889-4;Protein:MRat:24H:Urine:Qn:;2012-03-12;Dye Binding (Pyrogallol Red)
4170;PUPY;Purine and Pyrimidine Panel, Urine;6816;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4171;PUPY;Purine and Pyrimidine Panel, Urine;6815;Xanthine;38371-1;Xanthine/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4172;PUPY;Purine and Pyrimidine Panel, Urine;6813;Uric Acid;34385-5;Urate/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4173;PUPY;Purine and Pyrimidine Panel, Urine;6814;Hypoxanthine;38366-1;Hypoxanthine/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4174;PUPY;Purine and Pyrimidine Panel, Urine;81420;Uracil;25140-5;Uracil/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4175;PUSE;Pumpkin Seed, IgE;PUSE;Pumpkin Seed, IgE;11193-0;Cucurbita pepo seed Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4176;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16654;Result;38907-2;NIPA1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4177;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16656;Amendment;38907-2;NIPA1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4178;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16652;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4179;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16653;Method;49549-9; ;2013-07-26;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4180;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16650;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4181;PWDNA;Prader-Willi/Angelman Syndrome, Molecular Analysis;16655;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Methylation-Sensitive Multiple Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Diagnostic Systems, Inc.)
4182;PYR;Pyruvic Acid, Blood;7729;Pyruvic Acid, B;2905-8;Pyruvate:MCnc:Pt:Bld:Qn:;2009-11-13;Spectrophotometry (SP)
4183;PYR;Pyruvic Acid, Blood;8657;Pyruvic Acid, B;14121-8;Pyruvate:SCnc:Pt:Bld:Qn:;2009-11-13;Spectrophotometry (SP)
4184;PYRC;Pyruvate, Spinal Fluid;83356;Pyruvic Acid, CSF;14122-6;Pyruvate:SCnc:Pt:CSF:Qn:;2009-11-13;Spectrophotometry (SP)
4185;Q10;Coenzyme Q10, Reduced and Total, Plasma;30159;Interpretation;59462-2;;2012-04-09;High-Performance Liquid Chromatography (HPLC) with Electrochemical Detection
4186;Q10;Coenzyme Q10, Reduced and Total, Plasma;30091;CoQ10 Total;27923-2;Ubiquinone 10:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC) with Electrochemical Detection
4187;QBK;BK Virus, Molecular Detection, Quantitative, PCR, Plasma;31060;Copies/ml;41479-7;BK virus DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2011-06-22;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4188;QBK;BK Virus, Molecular Detection, Quantitative, PCR, Plasma;83187;BK Virus PCR, Quant, P;41479-7;BK virus DNA:NCnc:Pt:Ser/Plas:Qn:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4189;QBKU;BK Virus, Molecular Detection, Quantitative, PCR, Urine;30058;Copies/mL;48309-9;BK virus DNA:NCnc:Pt:XXX:Qn:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4190;QBKU;BK Virus, Molecular Detection, Quantitative, PCR, Urine;87859;BK Virus PCR, Quant, U;41480-5;BK virus DNA:NCnc:Pt:Urine:Qn:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4191;QEBV;Epstein-Barr Virus (EBV), Molecular Detection, Quantitative PCR, Blood;21862;Copies/mL;36923-1;Epstein Barr virus DNA:NCnc:Pt:Bld:Qn:Probe.amp.tar;2009-11-13;LightCycler Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems Inc.)
4192;QFP;Q Fever Antibody, IgG and IgM, Serum;24009;Q Fever Phase II Ab, IgM;9711-3;Coxiella burnetii phase 2 Ab.IgM:Titr:Pt:Ser:Qn:IF;2013-09-17;Indirect Immunofluorescence
4193;QFP;Q Fever Antibody, IgG and IgM, Serum;24010;Interpretation;59464-8;;2012-04-09;Indirect Immunofluorescence
4194;QFP;Q Fever Antibody, IgG and IgM, Serum;24011;Q Fever Phase II Ab, IgG;34717-9;;2013-08-15;Indirect Immunofluorescence
4195;QFP;Q Fever Antibody, IgG and IgM, Serum;81115;Q Fever Phase I Ab, IgM;9710-5;Coxiella burnetii phase 1 Ab.IgM:Titr:Pt:Ser:Qn:IF;2013-09-17;Indirect Immunofluorescence
4196;QFP;Q Fever Antibody, IgG and IgM, Serum;80965;Q Fever Phase I Ab, IgG;34716-1;;2013-08-15;Indirect Immunofluorescence
4197;QPALM;Queen Palm, IgE;QPALM;Queen Palm, IgE;6222-4;Syagrus romanzoffianum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4198;QTBG;Mycobacterium tuberculosis Infection Determination by QuantiFERON-TB Gold, Blood;32272;Tuberculosis Antigen Value;64084-7;Mycobacterium tuberculosis stimulated gamma interferon^^corrected for background :ACnc:Pt:Bld:Qn:;2014-01-02;Enzyme-Linked Immunosorbent Assay (ELISA)
4199;QTBG;Mycobacterium tuberculosis Infection Determination by QuantiFERON-TB Gold, Blood;83896;M. tuberculosis by QuantiFERON, B;71773-6;Mycobacterium tuberculosis tuberculin stimulated gamma interferon:Threshold:Pt:Bld:Ord:;2014-01-02;Enzyme-Linked Immunosorbent Assay (ELISA)
4200;QUAD;Quad Screen (Second Trimester) Maternal, Serum;32284;Other Information;52535-2;Other useful information:-:Pt:^Patient:-:;2013-12-05;Immunoenzymatic Assay
4201;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10354;INHIBIN;2478-6;Inhibin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoenzymatic Assay
4202;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7816;Gestation (GA) by U/S;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;Immunoenzymatic Assay
4203;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10358;GENERAL TEST INFORMATION;62364-5;Test performance information:Find:Pt:XXX:Nar:;2013-12-05;Immunoenzymatic Assay
4204;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10248;Additional comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;Immunoenzymatic Assay
4205;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10334;Down syndrome screen risk estimate;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
4206;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10335;Down syndrome maternal age risk;49090-4;Trisomy 21 risk based on maternal age:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
4207;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7201;Gestation (GA) by physical exam;11884-4;Gestational age:Time:Pt:^Fetus:Qn:Clinical.estimated;2009-11-13;Immunoenzymatic Assay
4208;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10351;AFP;31993-9;Alpha-1-Fetoprotein:ACnc:Pt:Ser/Plas:Ord:;2009-11-13;Immunoenzymatic Assay
4209;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10353;hCG, TOTAL;2116-2;Choriogonadotropin.intact:ACnc:Pt:Ser/Plas:Ord:;2009-11-13;Immunoenzymatic Assay
4210;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10337;Trisomy 18 screen risk estimate;43994-3;Trisomy 18 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
4211;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7205;GA on collection by physical exam;11884-4;Gestational age:Time:Pt:^Fetus:Qn:Clinical.estimated;2009-11-13;Immunoenzymatic Assay
4212;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7830;GA used in risk estimate;21299-3;Gestational age method:Prid:Pt:^Fetus:Nom:*;2009-11-13;Immunoenzymatic Assay
4213;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7204;GA on collection by dates;11885-1;Gestational age:Time:Pt:^Fetus:Qn:Estimated from last menstrual period;2009-11-13;Immunoenzymatic Assay
4214;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7203;GA on collection by U/S scan;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2009-11-13;Immunoenzymatic Assay
4215;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7753;EDD by LMP;11779-6;Delivery date:TmStp:Pt:^Patient:Qn:Estimated from last menstrual period;2009-11-13;Immunoenzymatic Assay
4216;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7206;Gestation (GA) by dates;11885-1;Gestational age:Time:Pt:^Fetus:Qn:Estimated from last menstrual period;2009-11-13;Immunoenzymatic Assay
4217;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10054;EDD by U/S scan;11781-2;Delivery date:TmStp:Pt:^Patient:Qn:US.composite.estimated;2014-04-29;Immunoenzymatic Assay
4218;QUAD;Quad Screen (Second Trimester) Maternal, Serum;2907;Last Menstrual Period (LMP);8665-2;Date last menstrual period:TmStp:Pt:^Patient:Qn:Reported;2009-11-13;Immunoenzymatic Assay
4219;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7817;Date of U/S;34970-4;Date ultrasound:TmStp:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
4220;QUAD;Quad Screen (Second Trimester) Maternal, Serum;IVFP;IVF pregnancy;47224-1;In vitro fertilization pregnancy:Acnc:Pt:^Patient:Ord:;2012-03-15;Immunoenzymatic Assay
4221;QUAD;Quad Screen (Second Trimester) Maternal, Serum;MULTF;Number of Fetuses;55281-0;Fetuses:Num:Pt:^Patient:Qn:;2012-03-15;Immunoenzymatic Assay
4222;QUAD;Quad Screen (Second Trimester) Maternal, Serum;RACE;Black race;32624-9;Race:Type:Pt:^Patient:Nom:;2012-03-15;Immunoenzymatic Assay
4223;QUAD;Quad Screen (Second Trimester) Maternal, Serum;IDD;Insulin dependent diabetes;33248-6;Diabetes status:Prid:Pt:^Patient:Nom:;2012-03-15;Immunoenzymatic Assay
4224;QUAD;Quad Screen (Second Trimester) Maternal, Serum;26718;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
4225;QUAD;Quad Screen (Second Trimester) Maternal, Serum;26717;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
4226;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7823;Birthdate;21112-8;Birth date:TmStp:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
4227;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7058;Recalculated Maternal Serum Screen;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2009-11-13;Immunoenzymatic Assay
4228;QUAD;Quad Screen (Second Trimester) Maternal, Serum;3009;Collection Date;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2009-11-13;Immunoenzymatic Assay
4229;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10356;INTERPRETATION;59462-2;;2012-04-05;Immunoenzymatic Assay
4230;QUAD;Quad Screen (Second Trimester) Maternal, Serum;7834;Calculated age at EDD;43993-5;Age.at delivery:Time:Pt:^Patient:Qn:;2009-11-13;Immunoenzymatic Assay
4231;QUAD;Quad Screen (Second Trimester) Maternal, Serum;10352;uE3;27259-1;Estriol.unconjugated:ACnc:Pt:Ser/Plas:Ord:;2009-11-13;Immunoenzymatic Assay
4232;QUIN;Quinidine, Serum;8302;Quinidine, S;6694-4;Quinidine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
4233;RACTH;Adrenocorticotrophic Hormone, ACTH, IgE;RACTH;Adrenocorticotropic Horm, ACTH, IgE;6016-0;Corticotropin Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4234;RAMB;Rabbit Meat, IgE;RAMB;Rabbit Meat, IgE;7642-2;Rabbit meat Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4235;RAMSU;Amylase, Random, Urine;RAMSU;Amylase, Random, U;1799-6;Amylase:CCnc:Pt:Urine:Qn:;2012-03-15;Enzymatic Rate
4236;RASE;Rape Seed, IgE;RASE;Rape Seed, IgE;11195-5;Brassica rapa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4237;RASP;Raspberry, IgE;RASP;Raspberry, IgE;7656-2;Rubus idaeus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4238;RAT;Rat Epithelium, IgE;RAT;Rat Epithelium, IgE;6224-0;Rat epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4239;RBP24;Retinol-Binding Protein, 24 Hour, Urine;RBP1;Retinol-Binding Protein, 24-Hour, U;18362-4;Alpha-2-Retinol binding protein:MRat:24H:Urine:Qn:;2012-03-15;Immunonephelometry
4240;RBP24;Retinol-Binding Protein, 24 Hour, Urine;CRCN;Creatinine Concentration;20624-3;Creatinine:MCnc:24H:Urine:Qn:;2012-03-15;Immunonephelometry
4241;RBP24;Retinol-Binding Protein, 24 Hour, Urine;DUR6;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Immunonephelometry
4242;RBP24;Retinol-Binding Protein, 24 Hour, Urine;VL59;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Immunonephelometry
4243;RBPG;Rubella Antibodies, IgG, Serum;DEXG2;Rubella IgG Antibody Index;5334-8;Rubella virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4244;RBPG;Rubella Antibodies, IgG, Serum;RBG;Rubella Ab, IgG, S;40667-8;Rubella virus Ab.IgG:ACnc:Pt:Ser/Plas:Ord:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4245;RCCOC;Coccidioides Antibody, Complement Fixation and Immunodiffusion, Spinal Fluid;35792;Cocci ID-IgG (CSF );30207-5;Coccidioides immitis Ab.IgG:ACnc:Pt:CSF:Ord;2014-06-19;Complement Fixation (CF)/Immunodiffusion (ID)
4246;RCCOC;Coccidioides Antibody, Complement Fixation and Immunodiffusion, Spinal Fluid;35941;Cocci ID-IgM (CSF );30208-3;Coccidioides immitis Ab.IgM:ACnc:Pt:CSF:Ord;2014-06-19;Complement Fixation (CF)/Immunodiffusion (ID)
4247;RCCOC;Coccidioides Antibody, Complement Fixation and Immunodiffusion, Spinal Fluid;35791;Cocci Ab, CF (CSF );13197-0;Coccidioides immitis Ab:Titr:Pt:CSF:Qn:Comp fix;2014-06-19;Complement Fixation (CF)/Immunodiffusion (ID)
4248;RCHLU;Chloride, Random, Urine;RCHLU;Chloride, Random, U;2078-4;Chloride:SCnc:Pt:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode (ISE)
4249;RCITR;Citrate Excretion, Pediatric, Random, Urine;CREA9;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Enzymatic
4250;RCITR;Citrate Excretion, Pediatric, Random, Urine;CITR1;Citrate Concentration, Peds, Random, U;2128-7;Citrate:MCnc:Pt:Urine:Qn:;2012-03-15;Enzymatic
4251;RCITR;Citrate Excretion, Pediatric, Random, Urine;RATO8;Citrate/Creatinine Ratio;13722-4;Citrate/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-15;Enzymatic
4252;RCTUR;Creatinine, Random, Urine;RCTUR;Creatinine, Random, U;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Enzymatic Colorimetric Assay
4253;RECR;Red Currant, IgE;RECR;Red Currant, IgE;19754-1;Ribes sylvestre Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4254;REDT;Red Top, IgE;REDT;Red Top, IgE;6228-1;Agrostis stolonifera Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4255;REED;Common Reed, IgE;REED;Common Reed, IgE;6855-1;Phragmites communis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4256;REPII;Rabbit Epithelium, IgE;REPII;Rabbit Epithelium, IgE;6223-2;Rabbit epithelium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4257;RGLUR;Glucose, Random, Urine;RGLUR;Glucose, Random, U;2350-7;Glucose:MCnc:Pt:Urine:Qn:;2012-03-15;Glucose Hexokinase
4258;RHNI;Rhizopus nigricans, IgE;RHNI;Rhizopus Nigricans, IgE;6229-9;Rhizopus nigricans Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4259;RHUT;Rheumatoid Factor, Serum;RHUT;Rheumatoid Factor, S;11572-5;Rheumatoid factor:ACnc:Pt:Ser:Qn:;2012-03-15;Turbidimetry
4260;RHUT;Rheumatoid Factor, Serum;RHUT;Rheumatoid Factor, S;11572-5;Rheumatoid factor:ACnc:Pt:Ser:Qn:;2012-03-15;Turbidometry
4261;RIB;Ribosome P Antibodies, IgG, Serum;RIB;Ribosome P Ab, IgG, S;53892-6;Ribosomal P Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
4262;RICE;Rice, IgE;RICE;Rice, IgE;6230-7;Oryza sativa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4263;RKUR;Potassium, Random, Urine;RKUR;Potassium, Random, U;2828-2;Potassium:SCnc:Pt:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode (ISE)
4264;RMA;Microalbumin, Random, Urine;MALB1;Microalbumin;14957-5;Albumin:MCnc:Pt:Urine:Qn:Detection limit = 20 mg/L;2012-03-15;Immunoturbidity/Enzymatic Colorimetric Assay
4265;RMA;Microalbumin, Random, Urine;A_CR;Albumin/Creatinine Ratio;9318-7;Albumin/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-12;Immunoturbidity/Enzymatic Colorimetric Assay
4266;RMA;Microalbumin, Random, Urine;CRE2;Creatinine;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Immunoturbidity/Enzymatic Colorimetric Assay
4267;RMA;Microalbumin, Random, Urine;RMALB;Microalbumin-Random, U;14957-5;Albumin:MCnc:Pt:Urine:Qn:Detection limit = 20 mg/L;2012-03-15;Immunoturbidity/Enzymatic Colorimetric Assay
4268;RNAUR;Sodium, Random, Urine;RNAUR;Sodium, Random, U;2955-3;Sodium:SCnc:Pt:Urine:Qn:;2012-03-15;Potentiometric, Indirect Ion-Selective Electrode
4269;RNP;RNP Antibodies, IgG, Serum;RNP;RNP Ab, IgG, S;31588-7;Ribonucleoprotein extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
4270;ROC;Rubeola (Measles) Antibodies, IgG and IgM (Separate Determinations), Spinal Fluid;5742;Rubeola (Measles) Ab, IgM;22505-2;Measles virus Ab.IgM:Titr:Pt:CSF:Qn:;2009-11-13;Immunofluorescence Assay (IFA)
4271;ROC;Rubeola (Measles) Antibodies, IgG and IgM (Separate Determinations), Spinal Fluid;5741;Rubeola (Measles) Ab, IgG;22501-1;Measles virus Ab.IgG:Titr:Pt:CSF:Qn:;2009-11-13;Immunofluorescence Assay (IFA)
4272;ROM;Measles (Rubeola) Antibodies, IgM, Serum;80979;Measles (Rubeola) Ab, IgM, S;21503-8;Measles virus Ab.IgM:ACnc:Pt:Ser:Ord:;2009-11-13;Immunofluorescence Assay (IFA)
4273;ROPG;Measles (Rubeola) Antibodies, IgG, Serum;DEXG3;Measles IgG Antibody Index;5244-9;Measles virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4274;ROPG;Measles (Rubeola) Antibodies, IgG, Serum;ROG;Measles (Rubeola) Ab, IgG, S;35275-7;Measles virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4275;ROTA;Rotavirus Antigen, Feces;24082;Rotavirus Ag, F;5880-0;Rotavirus Ag:ACnc:Pt:Stool:Ord:EIA;2009-11-13;Enzyme Immunoassay (EIA)
4276;ROXU;Oxalate, Pediatric, Random, Urine;RATO7;Oxalate/Creatinine Ratio;13483-3;Oxalate/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
4277;ROXU;Oxalate, Pediatric, Random, Urine;CREA8;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Enzymatic Using Oxalate Oxidase
4278;ROXU;Oxalate, Pediatric, Random, Urine;OXCON;Oxalate, Pediatric, Random, U;15086-2;Oxalate:SCnc:Pt:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
4279;ROXU;Oxalate, Pediatric, Random, Urine;OXCO2;Oxalate Concentration;2700-3;Oxalate:MCnc:Pt:Urine:Qn:;2012-03-15;Enzymatic Using Oxalate Oxidase
4280;RPOU;Phosphorus, Pediatric, Random, Urine;POCON;Phosphorus, Pediatric, Random, U;2778-9;Phosphate:MCnc:Pt:Urine:Qn:;2012-03-15;Molybdic Acid
4281;RPOU;Phosphorus, Pediatric, Random, Urine;CREA6;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Molybdic Acid
4282;RPOU;Phosphorus, Pediatric, Random, Urine;RATO5;Phosphorus/Creatinine Ratio;11141-9;Phosphate/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-15;Molybdic Acid
4283;RPRT;Rapid Plasma Reagin (RPR), Response to Therapy, Serum;31696;RPR, Response to Therapy, S;31147-2;Reagin Ab:ACnc:Pt:Ser:Qn:RPR;2013-09-17;Flocculation
4284;RPTL;Reptilase Time, Plasma;RPTL;Reptilase Time, P;6683-7;Coagulation reptilase induced:Time:Pt:PPP:Qn:Coag;2012-03-15;Clot-Based AssayMeasures conversion of fibrinogen to fibrin clot after addition of reptilase.
4285;RPTU;Protein, Total, Random, Urine;RATO3;Protein/Creatinine Ratio;2890-2;Protein/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-15;Dye Binding (Pyrogallol Red)
4286;RPTU;Protein, Total, Random, Urine;PTCON;Protein, Total, Random, U;2888-6;Protein:MCnc:Pt:Urine:Qn:;2012-03-15;Dye Binding (Pyrogallol Red)
4287;RPTU;Protein, Total, Random, Urine;CREA4;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Dye Binding (Pyrogallol Red)
4288;RRRP;Rough Pigweed, IgE;RRRP;Rough Pigweed, IgE;6233-1;Pigweed rough Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4289;RSER;Rabbit Serum Proteins, IgE;RSER;Rabbit Serum Proteins, IgE;10960-3;Rabbit serum proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4290;RTA;Reticulin Antibodies, Serum;9275;Reticulin Abs, S;17521-6;Reticulin Ab:ACnc:Pt:Ser:Ord:;2009-11-13;Indirect Immunofluorescence
4291;RTIC;Reticulocytes, Blood;ARTIC;Absolute Reticulocyte;14196-0;Reticulocytes:NCnc:Pt:Bld:Qn:;2012-03-12;Flow Cytometry
4292;RTIC;Reticulocytes, Blood;PRTIC;Reticulocytes, B;17849-1;Reticulocytes/100 erythrocytes:NFr:Pt:Bld:Qn:Automated count;2012-03-15;Flow Cytometry
4293;RTSP;Rat Serum Protein, IgE;RTSP;Rat Serum Protein, IgE;6225-7;Rat serum proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4294;RTUP;Rat Urine Protein, IgE;RTUP;Rat Urine Protein, IgE;6226-5;Rat urine proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4295;RUPR;Rabbit Urine Proteins, IgE;RUPR;Rabbit Urine Proteins, IgE;10961-1;Rabbit urine proteins Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4296;RURAU;Urea, Random, Urine;RATO4;Urea/Creatinine Ratio;56997-0;Urea/Creatinine:MCrto:Pt:Ser/Plas:Qn:;2012-03-15;Kinetic Ultraviolet Assay
4297;RURAU;Urea, Random, Urine;URCON;Urea, Random, U;3092-4;Urea:MCnc:Pt:Urine:Qn:;2012-03-15;Kinetic Ultraviolet Assay
4298;RURAU;Urea, Random, Urine;CREA5;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Kinetic Ultraviolet Assay
4299;RURCU;Uric Acid, Random, Urine;URCO2;Uric Acid, Random, U;3086-6;Urate:MCnc:Pt:Urine:Qn:;2012-03-12;Uricase
4300;RURCU;Uric Acid, Random, Urine;RATO6;Uric Acid/Creatinine Ratio;3089-0;Urate/Creatinine:MCrto:Pt:Urine:Qn:;2012-03-15;Uricase
4301;RURCU;Uric Acid, Random, Urine;CREA7;Creatinine Concentration;2161-8;Creatinine:MCnc:Pt:Urine:Qn:;2012-10-31;Uricase
4302;RUSS;Russian Thistle, IgE;RUSS;Russian Thistle, IgE;6234-9;Salsola kali Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4303;RWEED;Rape Weed, IgE;RWEED;Rape Weed, IgE;11194-8;Brassica napus pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4304;RYE;Rye, IgE;RYE;Rye, IgE;7674-5;Secale cereale Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4305;RYEG;Rye Grass, IgE;RYEG;Rye Grass, IgE;7369-2;Lolium perenne Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4306;SAFB;Acid-Fast Smear for Mycobacterium;SAFB;Acid Fast Smear For Mycobacterium;676-7;Microscopic observation:Prid:Pt:XXX:Nom:Rhodamine-auramine fluorohrome ;2014-08-29;Auramine-Rhodamine Stain
4307;SAGR;Salt Grass, IgE;SAGR;Salt Grass, IgE;6238-0;Distichlis spicata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4308;SAL;Hypersensitivity Pneumonitis IgG Antibodies, Serum;TAMV;Thermoactinomyces vulgaris, IgG Ab;34190-9;Thermoactinomyces vulgaris Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4309;SAL;Hypersensitivity Pneumonitis IgG Antibodies, Serum;MPSF;Micropolyspora faeni, IgG Ab, S;26948-0;Saccharopolyspora rectivirgula Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4310;SAL;Hypersensitivity Pneumonitis IgG Antibodies, Serum;SASP;Aspergillus fumigatus, IgG Ab, S;26954-8;Aspergillus fumigatus Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4311;SALC;Salicylate, Serum;8480;Salicylate, S;4024-6;Salicylates:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
4312;SALCT;Cortisol, Saliva;23614;Midnight Cortisol;58642-0;Cortisol^12 AM specimen:MCnc:Pt:Saliva:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4313;SALCT;Cortisol, Saliva;84225;Cortisol, Saliva;2142-8;Cortisol:MCnc:Pt:Saliva:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4314;SALCT;Cortisol, Saliva;23613;PM Cortisol;58676-8;Cortisol^8 PM specimen:MCnc:Pt:Saliva:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4315;SALCT;Cortisol, Saliva;23612;AM Cortisol;58674-3;Cortisol^8 AM specimen:MCnc:Pt:Saliva:Qn:;2013-11-19;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4316;SALM;Salmon, IgE;SALM;Salmon, IgE;6237-2;Salmo salar Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4317;SAM;Entamoeba histolytica Antibody, Serum;9049;E. Histolytica Ab, S;22285-1;Entamoeba histolytica Ab:ACnc:Pt:Ser:Ord;2014-04-18;Enzyme-Linked Immunosorbent Assay (ELISA)
4318;SARD;Sardine (Pilchard), IgE;SARD;Sardine (Pilchard), IgE;30989-8;Sardinops melanostictus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4319;SASP;Aspergillus fumigatus, IgG Antibodies, Serum;SASP;Aspergillus fumigatus, IgG Ab, S;26954-8;Aspergillus fumigatus Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4320;SBK;Chromosome Analysis, Spontaneous Breakage Analysis, Blood;50473;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;72-Hour Culture with Phytohemagglutinin 
4321;SBK;Chromosome Analysis, Spontaneous Breakage Analysis, Blood;30010;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2009-11-13;72-Hour Culture with Phytohemagglutinin 
4322;SBK;Chromosome Analysis, Spontaneous Breakage Analysis, Blood;CG370;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;72-Hour Culture with Phytohemagglutinin 
4323;SBK;Chromosome Analysis, Spontaneous Breakage Analysis, Blood;29998;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-02-15;72-Hour Culture with Phytohemagglutinin 
4324;SBL;Blastomyces Antibody by Immunodiffusion, Serum;15125;Blastomyces Immunodiffusion;5058-3;Blastomyces dermatitidis Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2013-09-17;Immunodiffusion
4325;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16666;Result;35359-9;AR gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4326;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16668;Amendment;35359-9;AR gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4327;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16667;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4328;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16665;Method;49549-9; ;2013-07-26;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4329;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16664;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4330;SBMA;Spinobulbar Muscular Atrophy (Kennedy's Disease), Molecular Analysis;16662;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;A polymerase chain reaction (PCR)-based assay is utilized to detect expansion-type mutations (CAG repeats) within the androgen receptor gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4331;SBSE;Sugarbeet Seed, IgE;SBSE;Sugarbeet Seed, IgE;24165-3;Beta vulgaris seed Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4332;SBWE;Sugarbeet Weed, IgE;SBWE;Sugarbeet Weed, IgE;7147-2;Beta vulgaris Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4333;SCADK;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Known Mutation;23171;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4334;SCADK;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Known Mutation;23170;Results;73736-1;ACADVL gene mutation analysis limited to known familial mutations:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-12-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4335;SCADK;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Known Mutation;23169;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4336;SCADK;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Known Mutation;23166;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4337;SCADK;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Known Mutation;23168;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4338;SCADM;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Mutation Screen;23182;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4339;SCADM;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Mutation Screen;23180;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4340;SCADM;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Mutation Screen;23179;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4341;SCADM;Short-Chain Acyl-CoA Dehydrogenase (SCAD) Deficiency, Mutation Screen;23177;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4342;SCALS;Scallop, IgE;SCALS;Scallop, IgE;7691-9;Pecten spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4343;SCE;Chromosome Analysis, Sister Chromatid Exchange (SCE) for Bloom Syndrome, Blood;16778;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Cell Culture with Exposure to BrdU Prior to HarvestAnalysis of metaphases for statistical analysis of spontaneous sister chromatid exchange.
4344;SCE;Chromosome Analysis, Sister Chromatid Exchange (SCE) for Bloom Syndrome, Blood;15971;Interpretation;69965-2; ;2014-04-29;Cell Culture with Exposure to BrdU Prior to HarvestAnalysis of metaphases for statistical analysis of spontaneous sister chromatid exchange.
4345;SCE;Chromosome Analysis, Sister Chromatid Exchange (SCE) for Bloom Syndrome, Blood;50474;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Cell Culture with Exposure to BrdU Prior to HarvestAnalysis of metaphases for statistical analysis of spontaneous sister chromatid exchange.
4346;SCE;Chromosome Analysis, Sister Chromatid Exchange (SCE) for Bloom Syndrome, Blood;CG382;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Cell Culture with Exposure to BrdU Prior to HarvestAnalysis of metaphases for statistical analysis of spontaneous sister chromatid exchange.
4347;SCE;Chromosome Analysis, Sister Chromatid Exchange (SCE) for Bloom Syndrome, Blood;15968;Method;49549-9; ;2013-07-26;Cell Culture with Exposure to BrdU Prior to HarvestAnalysis of metaphases for statistical analysis of spontaneous sister chromatid exchange.
4348;SCL70;Scl 70 Antibodies, IgG, Serum;SCL70;Scl 70 Ab, IgG, S;47322-3;SCL-70 extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-15;Multiplex Flow Immunoassay
4349;SCLAM;Chlamydia Serology, Serum;188;C. psittaci IgM;6917-9;Chlamydophila psittaci Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4350;SCLAM;Chlamydia Serology, Serum;191;C. trachomatis IgM;6920-3;Chlamydia trachomatis Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4351;SCLAM;Chlamydia Serology, Serum;190;C. trachomatis IgG;6919-5;Chlamydia trachomatis Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4352;SCLAM;Chlamydia Serology, Serum;185;C. pneumoniae IgG;6913-8;Chlamydophila pneumoniae Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4353;SCLAM;Chlamydia Serology, Serum;187;C. psittaci IgG;6916-1;Chlamydophila psittaci Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4354;SCLAM;Chlamydia Serology, Serum;186;C. pneumoniae IgM;6914-6;Chlamydophila pneumoniae Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Micro-Immunofluorescent Antibody (MIF) AssayIncludes Chlamydophila pneumoniae, Chlamydophila psittaci, and Chlamydia trachomatis.
4355;SCLE;Scale, IgE;SCLE;Scale, IgE;6239-8;Atriplex lentiformis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4356;SCOC;Coccidioides Antibody, Serum;21649;Cocci Immunodiffusion-IgG;22209-1;Coccidioides immitis Ab.IgG:ACnc:Pt:Ser:Ord:;2013-09-17;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
4357;SCOC;Coccidioides Antibody, Serum;21648;Cocci Immunodiffusion-IgM;22210-9;Coccidioides immitis Ab.IgM:ACnc:Pt:Ser:Ord:;2013-09-17;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
4358;SCOC;Coccidioides Antibody, Serum;8295;Cocci Complement F;5096-3;Coccidioides immitis Ab:ACnc:Pt:Ser:Ord:Comp fix;2012-03-05;Complement Fixation (CF) Using Coccidioidin: IgG Immunodiffusion: IgG and IgM
4359;SDEL;Single-Gene Large Deletion and Duplication Analysis;51414;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-07-10;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)
4360;SDEL;Single-Gene Large Deletion and Duplication Analysis;51407;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)
4361;SDEL;Single-Gene Large Deletion and Duplication Analysis;51411;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)
4362;SDEL;Single-Gene Large Deletion and Duplication Analysis;51409;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2013-08-07;Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH)
4363;SDEX;Hemoglobin S, Screen, Blood;9180;Hemoglobin S, Scrn, B;4621-9;Hemoglobin S:ACnc:Pt:Bld:Ord:;2009-11-13;Hemoglobin S Solubility
4364;SDHDD;Succinate Dehydrogenase (SDH) Gene, Deletion Detection;57099;Comment;8251-1;Service comment 01:Imp:Pt:XXX:Nom:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4365;SDHDD;Succinate Dehydrogenase (SDH) Gene, Deletion Detection;57098;Interpretation;69053-7;Endocrinologist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4366;SDHDD;Succinate Dehydrogenase (SDH) Gene, Deletion Detection;57095;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-24;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4367;SDHDD;Succinate Dehydrogenase (SDH) Gene, Deletion Detection;57096;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4368;SECOS;Secobarbital, Serum;8243;Secobarbital, S;4028-7;Secobarbital:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
4369;SEPTK;SEPT9 Gene, Known Mutation;33746;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase chain reaction (PCR) followed by DNA sequencing and/or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of SEPT9 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4370;SEPTK;SEPT9 Gene, Known Mutation;33748;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) followed by DNA sequencing and/or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of SEPT9 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4371;SEPTK;SEPT9 Gene, Known Mutation;33751;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase chain reaction (PCR) followed by DNA sequencing and/or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of SEPT9 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4372;SEPTK;SEPT9 Gene, Known Mutation;33749;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) followed by DNA sequencing and/or gene dosage analysis by multiplex ligation-dependent probe amplification (MLPA) of SEPT9 genes is utilized to test for the presence of mutations previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4373;SEPTS;SEPT9 Gene, Mutation Screen;33739;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4374;SEPTS;SEPT9 Gene, Mutation Screen;33737;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4375;SEPTS;SEPT9 Gene, Mutation Screen;33736;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4376;SEPTS;SEPT9 Gene, Mutation Screen;33734;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4377;SEQF;Sequential Maternal Screening, Part 2, Serum;29485;Scan Date;34970-4;Date ultrasound:TmStp:Pt:^Patient:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4378;SEQF;Sequential Maternal Screening, Part 2, Serum;29504;Additional Comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;Two-Site Immunoenzymatic (Sandwich) Assay
4379;SEQF;Sequential Maternal Screening, Part 2, Serum;29505;Recommended Follow Up;49544-0;Newborn screening recommended follow-up:Imp:Pt:^Patient:Nom:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4380;SEQF;Sequential Maternal Screening, Part 2, Serum;29506;General Test Information;62364-5;Test performance information:Find:Pt:XXX:Nar:;2013-12-05;Two-Site Immunoenzymatic (Sandwich) Assay
4381;SEQF;Sequential Maternal Screening, Part 2, Serum;29503;Interpretation;59462-2;;2012-04-09;Two-Site Immunoenzymatic (Sandwich) Assay
4382;SEQF;Sequential Maternal Screening, Part 2, Serum;29502;Trisomy 18 Screen Risk Estimate;43994-3;Trisomy 18 risk:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4383;SEQF;Sequential Maternal Screening, Part 2, Serum;29500;Down Syndrome Screen Risk Estimate;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4384;SEQF;Sequential Maternal Screening, Part 2, Serum;29501;Down Syndrome Maternal Age Risk;49090-4;Trisomy 21 risk based on maternal age:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4385;SEQF;Sequential Maternal Screening, Part 2, Serum;29497;Inhibin;35738-4;Inhibin A:MoM:Pt:Ser/Plas:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4386;SEQF;Sequential Maternal Screening, Part 2, Serum;29482;Black Race;32624-9;Race:Type:Pt:^Patient:Nom:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4387;SEQF;Sequential Maternal Screening, Part 2, Serum;29496;hCG, Total;20465-1;Choriogonadotropin:MoM:Pt:Ser/Plas:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4388;SEQF;Sequential Maternal Screening, Part 2, Serum;29887;PAPP-A;32123-2;Pregnancy associated plasma protein A:MoM:Pt:Ser/Plas:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4389;SEQF;Sequential Maternal Screening, Part 2, Serum;29892;Calculated age at EDD;43993-5;Age.at delivery:Time:Pt:^Patient:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4390;SEQF;Sequential Maternal Screening, Part 2, Serum;29479;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4391;SEQF;Sequential Maternal Screening, Part 2, Serum;29481;Insulin Dependent Diabetes;33248-6;Diabetes status:Prid:Pt:^Patient:Nom:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4392;SEQF;Sequential Maternal Screening, Part 2, Serum;29495;uE3;20466-9;Estriol.unconjugated:MoM:Pt:Ser/Plas:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4393;SEQF;Sequential Maternal Screening, Part 2, Serum;29491;NT;33069-6;Width.translucency:Len:Pt:Neck.soft tissue^fetus:Qn:US.measured;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4394;SEQF;Sequential Maternal Screening, Part 2, Serum;29494;AFP;20450-3;Alpha-1-Fetoprotein:MoM:Pt:Ser/Plas:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4395;SEQF;Sequential Maternal Screening, Part 2, Serum;29489;CRL Measure 2;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2011-07-07;Two-Site Immunoenzymatic (Sandwich) Assay
4396;SEQF;Sequential Maternal Screening, Part 2, Serum;29886;Number of Fetuses;11878-6;Fetuses:Num:Pt:^Patient:Qn:US;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4397;SEQF;Sequential Maternal Screening, Part 2, Serum;29488;CRL Measure 1;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4398;SEQF;Sequential Maternal Screening, Part 2, Serum;29493;Collection Date 2;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2013-08-14;Two-Site Immunoenzymatic (Sandwich) Assay
4399;SEQF;Sequential Maternal Screening, Part 2, Serum;29480;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4400;SEQF;Sequential Maternal Screening, Part 2, Serum;29888;IVF;47224-1;In vitro fertilization pregnancy:ACnc:Pt:^Patient:Ord:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4401;SEQF;Sequential Maternal Screening, Part 2, Serum;29477;Collection Date 1;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4402;SEQF;Sequential Maternal Screening, Part 2, Serum;29478;Maternal Birthdate;21112-8;Birth date:TmStp:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4403;SEQF;Sequential Maternal Screening, Part 2, Serum;29893;GA on Collection by U/S Scan 1;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4404;SEQU;Sequential Maternal Screening, Part 1, Serum;29470;Down Syndrome Maternal Age Risk;49090-4;Trisomy 21 risk based on maternal age:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4405;SEQU;Sequential Maternal Screening, Part 1, Serum;29454;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4406;SEQU;Sequential Maternal Screening, Part 1, Serum;29891;GA on Collection by U/S Scan;11888-5;Gestational age:Time:Pt:^Fetus:Qn:US.composite.estimated;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4407;SEQU;Sequential Maternal Screening, Part 1, Serum;NT1;NT;33069-6;Width.translucency:Len:Pt:Neck.soft tissue^fetus:Qn:US.measured;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4408;SEQU;Sequential Maternal Screening, Part 1, Serum;29473;Additional Comments;55107-7;Addendum:Find:Pt:^Patient:Doc:;2012-01-27;Two-Site Immunoenzymatic (Sandwich) Assay
4409;SEQU;Sequential Maternal Screening, Part 1, Serum;29474;Recommended Follow Up;49544-0;Newborn screening recommended follow-up:Imp:Pt:^Patient:Nom:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4410;SEQU;Sequential Maternal Screening, Part 1, Serum;29472;Interpretation;49586-1;First & Second trimester integrated maternal screen:Imp:Pt:^Patient:Nom:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4411;SEQU;Sequential Maternal Screening, Part 1, Serum;29469;Down Syndrome Screen Risk Estimate;43995-0;Trisomy 21 risk:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4412;SEQU;Sequential Maternal Screening, Part 1, Serum;29468;PAPP-A;32123-2;Pregnancy associated plasma protein A:MoM:Pt:Ser/Plas:Qn:;2013-12-05;Two-Site Immunoenzymatic (Sandwich) Assay
4413;SEQU;Sequential Maternal Screening, Part 1, Serum;RACE_;Black Race;32624-9;Race:Type:Pt:^Patient:Nom:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4414;SEQU;Sequential Maternal Screening, Part 1, Serum;IVF1;IVF;47224-1;In vitro fertilization pregnancy:Acnc:Pt:^Patient:Ord:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4415;SEQU;Sequential Maternal Screening, Part 1, Serum;SNDT1;Scan Date;34970-4;Date ultrasound:TmStp:Pt:^Patient:Qn:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4416;SEQU;Sequential Maternal Screening, Part 1, Serum;29471;Trisomy 18 Screen Risk Estimate;43994-3;Trisomy 18 risk:Find:Pt:^Fetus:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4417;SEQU;Sequential Maternal Screening, Part 1, Serum;CRL2A;CRL Measure 2;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4418;SEQU;Sequential Maternal Screening, Part 1, Serum;CRL1A;CRL Measure 1;11957-8;Length.crown rump:Len:Pt:^Fetus:Qn:US.measured;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4419;SEQU;Sequential Maternal Screening, Part 1, Serum;FET1;Number of Fetuses;11878-6;Fetuses:Num:Pt:^Patient:Qn:US;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4420;SEQU;Sequential Maternal Screening, Part 1, Serum;DIAB1;Insulin Dependent Diabetes;33248-6;Diabetes status:Prid:Pt:^Patient:Nom:;2012-03-15;Two-Site Immunoenzymatic (Sandwich) Assay
4421;SEQU;Sequential Maternal Screening, Part 1, Serum;29890;Calculated Age at EDD;43993-5;Age.at delivery:Time:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4422;SEQU;Sequential Maternal Screening, Part 1, Serum;29455;Maternal Weight;29463-7;Body weight:Mass:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4423;SEQU;Sequential Maternal Screening, Part 1, Serum;29453;Maternal Birthdate;21112-8;Birth date:TmStp:Pt:^Patient:Qn:;2011-06-16;Two-Site Immunoenzymatic (Sandwich) Assay
4424;SEQU;Sequential Maternal Screening, Part 1, Serum;29452;Collection Date 1;51953-8;Collection date:TmStp:Pt:Bld:Qn:;2011-06-22;Two-Site Immunoenzymatic (Sandwich) Assay
4425;SEQU;Sequential Maternal Screening, Part 1, Serum;29487;General Test Information;62364-5;Test performance information:Find:Pt:XXX:Nar:;2013-12-05;Two-Site Immunoenzymatic (Sandwich) Assay
4426;SER;Serotonin, Serum;84395;Serotonin, S;27057-9;Serotonin:MCnc:Pt:Ser:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4427;SERU;Serotonin, 24 Hour, Urine;TM80;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4428;SERU;Serotonin, 24 Hour, Urine;26603;Serotonin, 24 Hr, U;18253-5;Serotonin:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4429;SERU;Serotonin, 24 Hour, Urine;VL67;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4430;SERWB;Serotonin, Blood;84373;Serotonin, B;2939-7;Serotonin:MCnc:Pt:Bld:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4431;SES;Selenium, Serum;9765;Selenium, S;5724-0;Selenium:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4432;SESA;Sesame Seed, IgE;SESA;Sesame Seed, IgE;6242-2;Sesamum indicum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4433;SEU;Selenium, 24 Hour, Urine;862;Se Concentration;47976-6;Selenium:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4434;SEU;Selenium, 24 Hour, Urine;TM19;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4435;SEU;Selenium, 24 Hour, Urine;9793;Selenium, 24 Hr, U;5727-3;Selenium:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4436;SEU;Selenium, 24 Hour, Urine;VL17;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4437;SEUR;Selenium, Random, Urine;60077;Selenium, Random, U;5726-5;Selenium:MCnc:Pt:Urine:Qn:;2011-06-24;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4438;SFC;Crystal Identification, Synovial Fluid;SFCID;Crystal ID, Synovial Fl;5781-0;Crystals:Prid:Pt:Synv fld:Nom:Microscopy.light;2012-03-15;Compensated Polarized Light Microscopy Includes cytospin prep.
4439;SFGP;Spotted Fever Group Antibody, IgG and IgM, Serum;84342;Spotted Fever Group Ab, IgG, S;5313-2;Rickettsia spotted fever group Ab.IgG:Titl:Pt:Ser:Qn:IF;2013-09-18;Immunofluorescence
4440;SFGP;Spotted Fever Group Antibody, IgG and IgM, Serum;84346;Spotted Fever Group Ab, IgM, S;5315-7;Rickettsia spotted fever group Ab.IgM:Titr:Pt:Ser:Qn:IF;2013-09-18;Immunofluorescence
4441;SFLA;Influenza Virus A Antibodies, IgG and IgM (Separate Determinations), Serum;5732;Influenza Virus A Ab, IgM;43838-2;Influenza virus A Ab.IgM:ACnc:Pt:Ser:Ord:;2009-11-13;Immunofluorescence
4442;SFLA;Influenza Virus A Antibodies, IgG and IgM (Separate Determinations), Serum;5731;Influenza Virus A Ab, IgG;43837-4;Influenza virus A Ab.IgG:ACnc:Pt:Ser:Ord:;2009-11-13;Immunofluorescence
4443;SFLB;Influenza Virus B Antibodies, IgG and IgM (Separate Determinations), Serum;5734;Influenza Virus B Ab, IgM;9536-4;Influenza virus B Ab.IgM:Titr:Pt:Ser:Qn:;2009-11-13;Immunofluorescence
4444;SFLB;Influenza Virus B Antibodies, IgG and IgM (Separate Determinations), Serum;5733;Influenza Virus B Ab, IgG;9535-6;Influenza virus B Ab.IgG:Titr:Pt:Ser:Qn:;2009-11-13;Immunofluorescence
4445;SFMON;Hemoglobin S and Hemoglobin F Quantitation for Therapeutic Monitoring, Blood;32245;Hemoglobin F;4576-5;Hemoglobin F/Hemoglobin.total:MFr:Pt:Bld:Qn:;2011-06-22;Cation Exchange/High-Performance Liquid Chromatography (HPLC)
4446;SFMON;Hemoglobin S and Hemoglobin F Quantitation for Therapeutic Monitoring, Blood;32246;Hemoglobin S;4625-0;Hemoglobin S/Hemoglobin.total:MFr:Pt:Bld:Qn:;2011-06-22;Cation Exchange/High-Performance Liquid Chromatography (HPLC)
4447;SFMON;Hemoglobin S and Hemoglobin F Quantitation for Therapeutic Monitoring, Blood;32247;Hb S/F Interpretation;59466-3;;2012-04-05;Cation Exchange/High-Performance Liquid Chromatography (HPLC)
4448;SFZ;Sulfamethoxazole, Serum;8238;Sulfamethoxazole, S;10342-4;Sulfamethoxazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4449;SGBF;Specific Gravity, Body Fluid;SG_BF;Specific Gravity, Body Fluid;2964-5;Specific gravity:Rden:Pt:Body fld:Qn:;2012-03-15;Refractometry
4450;SGBF;Specific Gravity, Body Fluid;FLD4;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Refractometry
4451;SGSS;Synthetic Glucocorticoid Screen, Serum;23604;Triamcinolone;41766-7;Triamcinolone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4452;SGSS;Synthetic Glucocorticoid Screen, Serum;23593;Betamethasone;41745-1;Betamethasone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4453;SGSS;Synthetic Glucocorticoid Screen, Serum;23602;Prednisolone;12727-4;Prednisolone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4454;SGSS;Synthetic Glucocorticoid Screen, Serum;23601;Methylprednisolone;14186-1;Methylprednisolone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4455;SGSS;Synthetic Glucocorticoid Screen, Serum;23600;Megestrol Acetate;41762-6;Megestrol acetate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4456;SGSS;Synthetic Glucocorticoid Screen, Serum;23599;Fluticasone Propionate;41757-6;Fluticasone propionate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4457;SGSS;Synthetic Glucocorticoid Screen, Serum;23605;Triamcinolone Acetonide;41767-5;Triamcinolone acetonide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4458;SGSS;Synthetic Glucocorticoid Screen, Serum;23603;Prednisone;12434-7;Prednisone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4459;SGSS;Synthetic Glucocorticoid Screen, Serum;23597;Flunisolide;41755-0;Flunisolide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4460;SGSS;Synthetic Glucocorticoid Screen, Serum;23596;Fludrocortisone;41754-3;Fludrocortisone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4461;SGSS;Synthetic Glucocorticoid Screen, Serum;23595;Dexamethasone;14062-4;Dexamethasone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4462;SGSS;Synthetic Glucocorticoid Screen, Serum;23594;Budesonide;41747-7;Budesonide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4463;SGSS;Synthetic Glucocorticoid Screen, Serum;23598;Fluorometholone;41756-8;Fluorometholone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4464;SGSU;Synthetic Glucocorticoid Screen, Urine;23571;Prednisolone;46955-1;Prednisolone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4465;SGSU;Synthetic Glucocorticoid Screen, Urine;23573;Triamcinolone;46957-7;Triamcinolone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4466;SGSU;Synthetic Glucocorticoid Screen, Urine;23572;Prednisone;46956-9;Prednisone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4467;SGSU;Synthetic Glucocorticoid Screen, Urine;23570;Methylprednisolone;46954-4;Methylprednisolone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4468;SGSU;Synthetic Glucocorticoid Screen, Urine;23569;Megestrol Acetate;46953-6;Megestrol acetate:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4469;SGSU;Synthetic Glucocorticoid Screen, Urine;23567;Fluorometholone;46951-0;Fluorometholone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4470;SGSU;Synthetic Glucocorticoid Screen, Urine;23574;Triamcinolone Acetonide;46958-5;Triamcinolone acetonide:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4471;SGSU;Synthetic Glucocorticoid Screen, Urine;23566;Flunisolide;46950-2;Flunisolide:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4472;SGSU;Synthetic Glucocorticoid Screen, Urine;23565;Fludrocortisone;46949-4;Fludrocortisone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4473;SGSU;Synthetic Glucocorticoid Screen, Urine;23564;Dexamethasone;46948-6;Dexamethasone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4474;SGSU;Synthetic Glucocorticoid Screen, Urine;23563;Budesonide;46947-8;Budesonide:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4475;SGSU;Synthetic Glucocorticoid Screen, Urine;23562;Betamethasone;46946-0;Betamethasone:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4476;SGSU;Synthetic Glucocorticoid Screen, Urine;23568;Fluticasone Propionate;46952-8;Fluticasone propionate:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4477;SGSU;Synthetic Glucocorticoid Screen, Urine;23561;Beclomethasone Dipropionate;46945-2;Beclomethasone dipropionate:MCnc:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Stable Isotope Dilution Analysis
4478;SGU;Specific Gravity, Urine;SGU;Specific Gravity;5811-5;Specific gravity:Rden:Pt:Urine:Qn:Test strip;2012-03-15;Refractometer
4479;SGUM;Sweet Gum, IgE;SGUM;Sweet Gum, IgE;6260-4;Liquidambar styraciflua Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4480;SHBG;Sex Hormone-Binding Globulin (SHBG), Serum;SHBG;Sex Hormone Binding Globulin, S;13967-5;Sex hormone binding globulin:SCnc:Pt:Ser/Plas:Qn:;2012-03-15;Automated Chemiluminescent Immunometric Assay
4481;SHPV;Human Papillomavirus (HPV) DNA Detection with Genotyping, High Risk Types by PCR, SurePath;SS018;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4482;SHRI;Shrimp, IgE;SHRI;Shrimp, IgE;6246-3;Pandalus borealis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4483;SHSTO;Histoplasma Antibody, Serum;15123;Histoplasma Immunodiffusion;5218-3;Histoplasma capsulatum Ab:ACnc:Pt:Ser:Ord:Immune diffusion;2009-11-13;Complement Fixation (CF)/Immunodiffusion
4484;SHSTO;Histoplasma Antibody, Serum;15122;Histoplasma Yeast;20574-0;Histoplasma capsulatum yeast phase Ab:Titr:Pt:Ser:Qn:Comp Fix;2014-04-14;Complement Fixation (CF)/Immunodiffusion
4485;SHSTO;Histoplasma Antibody, Serum;15121;Histoplasma Mycelial;20573-2;Histoplasma capsulatum mycelial phase Ab:Titr:Pt:Ser:Qn:Comp Fix;2014-04-14;Complement Fixation (CF)/Immunodiffusion
4486;SHWL;Sheep Wool, IgE;SHWL;Sheep Wool, IgE;6245-5;Sheep wool Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4487;SIIRO;Sirolimus, Blood;35144;Sirolimus, B;29247-4;Sirolimus:MCnc:Pt:Bld:Qn:;2013-12-05;High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS)
4488;SILK;Silk, IgE;SILK;Silk, IgE;6247-1;Silk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4489;SLEG;Legionella pneumophila (Legionnaires Disease), Antibody, Serum;SLEG;Legionella Pneumophila Ab, S;7947-5;Legionella pneumophila Ab:ACnc:Pt:Ser:Ord:;2012-03-15;Enzyme-Linked Immunosorbent Assay (ELISA)
4490;SLO;Smith-Lemli-Opitz Screen, Plasma;29968;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Gas Chromatography-Mass Spectrometry (GC-MS)
4491;SLO;Smith-Lemli-Opitz Screen, Plasma;29972;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS)
4492;SLO;Smith-Lemli-Opitz Screen, Plasma;29970;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)
4493;SLO;Smith-Lemli-Opitz Screen, Plasma;29971;Method;49549-9; ;2013-07-26;Gas Chromatography-Mass Spectrometry (GC-MS)
4494;SM;Sm Antibodies, IgG, Serum;SM;Sm Ab, IgG, S;18323-6;Smith extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
4495;SMA;Smooth Muscle Antibodies, Serum;6284;Anti-Smooth Muscle Ab;26971-2;Smooth muscle Ab:ACnc:Pt:Ser:Ord:IF;2009-11-13;Indirect Immunofluorescence
4496;SMADK;SMAD4 Gene, Known Mutation;34159;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-22;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the SMAD4 gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4497;SMADK;SMAD4 Gene, Known Mutation;34155;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the SMAD4 gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4498;SMADK;SMAD4 Gene, Known Mutation;34156;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the SMAD4 gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4499;SMADK;SMAD4 Gene, Known Mutation;34153;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing is used to detect the presence of a specific mutation in the SMAD4 gene that was previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4500;SMADS;SMAD4 Gene, Full Gene Analysis;34149;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-22;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of all coding regions and intron/exon boundaries of the SMAD4 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc) Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4501;SMADS;SMAD4 Gene, Full Gene Analysis;34142;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of all coding regions and intron/exon boundaries of the SMAD4 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc) Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4502;SMADS;SMAD4 Gene, Full Gene Analysis;34145;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of all coding regions and intron/exon boundaries of the SMAD4 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc) Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4503;SMFL;Seminal Fluid, IgE;SMFL;Seminal Fluid, IgE;6240-6;Seminal fluid Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4504;SNAIL;Snail, IgE;SNAIL;Snail, IgE;11200-3;Helix aspersa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4505;SOLEF;Sole, IgE;SOLEF;Sole, IgE;7709-9;Solea solea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4506;SORR;Red Sorrel, IgE;SORR;Red Sorrel, IgE;6244-8;Rumex acetosella Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4507;SOY;Soybean, IgE;SOY;Soybean, IgE;6248-9;Glycine max Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4508;SPAG;Special Red Cell Antigen Typing;SPG_H;Special Red Cell Ag Typing;906-8;Blood group antigens present:Prid:Pt:Bld:Nom:;2012-03-15;
4509;SPB;Pigeon Breeders Disease Serology, Serum;SPB;Pigeon Breeders Disease Serology, S;38368-7;Pigeon droppings Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4510;SPCID;Specimen Source Identification;17287;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Microsatellite markers are used to compare the genotype for the specimen in question with that from DNA isolated from patient specimens of known identity.(Polymerase chain reaction [PCR] is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4511;SPCID;Specimen Source Identification;17285;Method;49549-9; ;2013-07-26;Microsatellite markers are used to compare the genotype for the specimen in question with that from DNA isolated from patient specimens of known identity.(Polymerase chain reaction [PCR] is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4512;SPCID;Specimen Source Identification;17284;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Microsatellite markers are used to compare the genotype for the specimen in question with that from DNA isolated from patient specimens of known identity.(Polymerase chain reaction [PCR] is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4513;SPCID;Specimen Source Identification;17282;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Microsatellite markers are used to compare the genotype for the specimen in question with that from DNA isolated from patient specimens of known identity.(Polymerase chain reaction [PCR] is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4514;SPHT;Sphingomyelinase, Fibroblasts;30045;Interpretation (SPHT);59462-2;;2012-04-02;SPHT: Colorimetric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4515;SPIN;Spinach, IgE;SPIN;Spinach, IgE;6856-9;Spinacia oleracea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4516;SPN;Pneumocystis Smear;SPN;Pneumocystis smear;48055-8;Pneumocystis jiroveci:ACnc:Pt:XXX:Ord:Calcoflour white preparation;2013-09-18;Calcofluor White Fluorochrome Stain
4517;SPNC;Streptococcus pneumoniae Antigen, Spinal Fluid;31667;Streptococcus pneumoniae Ag, CSF;20489-1;Streptococcus pneumoniae Ag:ACnc:Pt:CSF:Ord:;2011-06-22;Immunochromatographic Membrane Assay
4518;SPNEU;Streptococcus pneumoniae Antigen, Urine;83150;Streptococcus pneumoniae Ag, U;24027-5;Streptococcus pneumoniae Ag:ACnc:Pt:Urine:Ord:;2009-11-13;Immunochromatographic Membrane Assay
4519;SPOT;Sweet Potato, IgE;SPOT;Sweet Potato, IgE;7627-3;Ipomoea batatas Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4520;SPRU;Spruce, IgE;SPRU;Spruce, IgE;6857-7;Picea excelsa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4521;SPSA;Prostate-Specific Antigen (PSA) Screen, Serum;SPSA;Prostate-Specific Ag Screen, S;2857-1;Prostate specific Ag:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescent Immunoassay (ECLIA)
4522;SPUT;Bacterial Culture, Aerobic, Respiratory;SPUT;Bacterial Culture, Aerobic, Resp;634-6;Bacteria identified:Prid:Pt:XXX:Nom:Aerobic culture;2013-09-18;Conventional Culture Technique
4523;SQUA;Squash, IgE;SQUA;Squash, IgE;7713-1;Squash Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4524;SQUI;Pacific Squid, IgE;SQUI;Pacific Squid, IgE;14038-4;Todarodes pacificus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4525;SQUID;Squid, IgE;SQUID;Squid, IgE;6858-5;Loligo sp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4526;SRSV;Respiratory Syncytial Virus (RSV) Antibodies, IgG and IgM (Separate Determinations), Serum;5737;Respiratory Syncytial Virus, IgG;9573-7;Respiratory syncytial virus Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence
4527;SRSV;Respiratory Syncytial Virus (RSV) Antibodies, IgG and IgM (Separate Determinations), Serum;5738;Respiratory Syncytial Virus, IgM;9574-5;Respiratory syncytial virus Ab.IgM:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence
4528;SRW;Short Ragweed, IgE;SRW;Short Ragweed, IgE;6085-5;Ambrosia elatior Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4529;SSA;SS-A/Ro Antibodies, IgG, Serum;SSA;SS-A/Ro Ab, IgG, S;33610-7;Sjogrens syndrome-A extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
4530;SSB;SS-B/La Antibodies, IgG, Serum;SSB;SS-B/La Ab, IgG, S;33613-1;Sjogrens syndrome-B extractable nuclear Ab.IgG:ACnc:Pt:Ser:Qn:;2012-03-15;Multiplex Flow Immunoassay
4531;SSP;Sporothrix Antibody, Serum;9673;Sporothrix Ab, S;13273-8;Sporothrix schenckii Ab:ACnc:Pt:Ser:Ord:;2009-11-13;Latex Agglutination
4532;SSPC;Sporothrix Antibody, Spinal Fluid;81532;Sporothrix Ab, CSF;49860-0;Sporothrix schenckii Ab:ACnc:Pt:CSF:Ord:LA;2009-11-13;Latex Agglutination
4533;STBY;Strawberry, IgE;STBY;Strawberry, IgE;6257-0;Fragaria vesca Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4534;STCH;Strychnine,  Serum/Plasma;Z1312;Strychnine;5738-0;Strychnine:MCnc:Pt:XXX:Qn:;2012-03-12;Gas Chromatography (GC)
4535;STEM;Stemphyllium, IgE;STEM;Stemphyllium, IgE;6252-1;Stemphylium botryosum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4536;STER;Sterols, Plasma;29942;Interpretation;59462-2;;2012-04-02;Gas Chromatography-Mass Spectrometry (GC-MS)/Gas Chromatography-Flame Ionization Detection (GC-FID)
4537;STER;Sterols, Plasma;29940;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS)/Gas Chromatography-Flame Ionization Detection (GC-FID)
4538;STER;Sterols, Plasma;29941;Method;49549-9; ;2013-07-26;Gas Chromatography-Mass Spectrometry (GC-MS)/Gas Chromatography-Flame Ionization Detection (GC-FID)
4539;STER;Sterols, Plasma;29938;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Gas Chromatography-Mass Spectrometry (GC-MS)/Gas Chromatography-Flame Ionization Detection (GC-FID)
4540;STFR;Soluble Transferrin Receptor (sTfR), Serum;STFR;Soluble Transferrin Receptor (sTfR);30248-9;Transferrin receptor.soluble:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoturbidimetric Assay
4541;STFRP;Shiga Toxin, Molecular Detection, PCR, Feces;56052;Result;33764-2;STX gene:Prid:Pt:XXX:Nom:Probe.amp.tar;2009-11-13;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4542;STFRP;Shiga Toxin, Molecular Detection, PCR, Feces;SRC59;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4543;STKKM;STK11 Gene, Known Mutation;34181;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-22;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4544;STKKM;STK11 Gene, Known Mutation;34177;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4545;STKKM;STK11 Gene, Known Mutation;34178;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4546;STKKM;STK11 Gene, Known Mutation;34175;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4547;STKMS;STK11 Gene, Full Gene Analysis;34171;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-05-22;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4548;STKMS;STK11 Gene, Full Gene Analysis;34164;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4549;STKMS;STK11 Gene, Full Gene Analysis;34167;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4550;STKMS;STK11 Gene, Full Gene Analysis;34166;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-07;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4551;STKMS;STK11 Gene, Full Gene Analysis;34165;Result;53795-1;STK11 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-12-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)Array comparative genomic hybridization (aCGH) is used to test for the presence of large deletions and duplications.
4552;STL;Enteric Pathogens Culture, Stool;STL;Enteric Pathogens Culture, Stool;625-4;Bacteria identified:Prid:Pt:Stool:Nom:Culture;2013-09-18;Conventional Culture Technique Includes Aeromonas, Campylobacter, Salmonella, Shigella, and Yersinia.Note: Does not include culture for Escherichia coli O157:H7.
4553;STLP;St. Louis Encephalitis Antibody, IgG and IgM, Serum;87268;St. Louis Enceph Ab, IgM, S;10907-4;Saint Louis encephalitis virus Ab.IgM:Titr:Pt:Ser:Qn:IF;2014-04-09;Immunofluorescence Assay (IFA)
4554;STLP;St. Louis Encephalitis Antibody, IgG and IgM, Serum;8182;St. Louis Enceph Ab, IgG, S;10906-6;Saint Louis encephalitis virus Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4555;STLPC;St. Louis Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26368;St. Louis Enceph Ab, IgM, CSF;21510-3;Saint Louis encephalitis virus Ab.IgM:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4556;STLPC;St. Louis Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26367;St. Louis Enceph Ab, IgG, CSF;21509-5;Saint Louis encephalitis virus Ab.IgG:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4557;STR;Striational (Striated Muscle) Antibodies, Serum;8746;Striational (Striated Muscle) Ab, S;8097-8;Striated muscle Ab:Titr:Pt:Ser:Qn:;2009-11-13;Enzyme Immunoassay (EIA)
4558;STRIC;Trichinella Antibody, Serum;9017;Trichinella Ab, S;19253-4;Trichinella spiralis Ab:ACnc:Pt:Ser:Ord:EIA;2009-11-13;Enzyme-Linked Immunosorbent Assay (ELISA)
4559;STSH;Thyroid-Stimulating Hormone-Sensitive (s-TSH), Serum;STSH;TSH, Sensitive, S;11579-0;Thyrotropin:ACnc:Pt:Ser/Plas:Qn:Detection limit = 0.01 mu/L;2012-03-15;Electrochemiluminescent Immunoassay
4560;SUAC;Succinylacetone, Blood Spot;22714;Interpretation;59462-2;;2012-04-02;Tandem Mass Spectrometry (MS/MS)
4561;SUAC;Succinylacetone, Blood Spot;22712;Method;49549-9; ;2013-07-26;Tandem Mass Spectrometry (MS/MS)
4562;SUAC;Succinylacetone, Blood Spot;22711;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Tandem Mass Spectrometry (MS/MS)
4563;SUAC;Succinylacetone, Blood Spot;22713;Results;53231-7;Succinylacetone:SCnc:Pt:Bld.dot:Qn:;2009-11-13;Tandem Mass Spectrometry (MS/MS)
4564;SUAC;Succinylacetone, Blood Spot;22709;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Tandem Mass Spectrometry (MS/MS)
4565;SULFU;Sulfate, 24 Hour, Urine;SLF_U;Sulfate, U;39576-4;Sulfate:MRat:24H:Urine:Qn:;2012-03-15;High-Performance Liquid Chromatography (HPLC)
4566;SULFU;Sulfate, 24 Hour, Urine;VL71;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;High-Performance Liquid Chromatography (HPLC)
4567;SULFU;Sulfate, 24 Hour, Urine;TM89;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;High-Performance Liquid Chromatography (HPLC)
4568;SULFU;Sulfate, 24 Hour, Urine;SUL_C;Sulfate Concentration;12920-5;Sulfate:MCnc:24H:Urine:Qn:;2012-03-15;High-Performance Liquid Chromatography (HPLC)
4569;SUMFK;Multiple Sulfatase Deficiency, Known Mutation;51663;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4570;SUMFK;Multiple Sulfatase Deficiency, Known Mutation;51657;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4571;SUMFK;Multiple Sulfatase Deficiency, Known Mutation;51659;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4572;SUMFK;Multiple Sulfatase Deficiency, Known Mutation;51660;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) Amplification/DNA Sequencing (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4573;SUMFS;Multiple Sulfatase Deficiency, Full Gene Analysis;51648;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the SUMF1 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4574;SUMFS;Multiple Sulfatase Deficiency, Full Gene Analysis;51649;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the SUMF1 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4575;SUMFS;Multiple Sulfatase Deficiency, Full Gene Analysis;51652;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the SUMF1 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4576;SUMFS;Multiple Sulfatase Deficiency, Full Gene Analysis;51646;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2014-04-28;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of a mutation in the SUMF1 gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4577;SUNF;Sunflower, IgE;SUNF;Sunflower, IgE;7726-3;Helianthus annuus pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4578;SUNFS;Sunflower Seed, IgE;SUNFS;Sunflower Seed, IgE;6258-8;Helianthus annuus seed Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4579;SWORD;Swordfish, IgE;SWORD;Swordfish, IgE;7728-9;Xiphias gladius Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4580;SYPGN;Syphilis Antibody, IgG, Serum;SYPGN;Syphilis IgG Ab, S;6561-5;Treponema pallidum Ab.IgG:ACnc:Pt:Ser:Ord:;2012-03-15;Multiplex Flow Immunoassay
4581;SYPGR;Syphilis IgG Antibody with Reflex, Serum;SYPGR;Syphilis IgG Ab w/Reflex, S;47238-1;Treponema pallidum Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-09-18;SYPGR: Multiplex Flow ImmunoassayRRPR: FlocculationRTPPA: Particle Agglutination
4582;S_FX;Protein S Activity, Plasma;S_FX;Protein S Activity, P;31102-7;Protein S actual/Normal:RelCCnc:Pt:PPP:Qn:Chromo;2012-03-15;Clot-Based End point
4583;T3;T3 (Triiodothyronine), Total, Serum;T3;T3 (Triiodothyronine), Total, S;3053-6;Triiodothyronine:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
4584;T4;T4 (Thyroxine), Total Only, Serum;T4;T4 (Thyroxine), Total Only, S;3026-2;Thyroxine:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Immunoenzymatic Assay
4585;TAE;Therapeutic Antibody by Flow Cytometry;19986;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
4586;TAE;Therapeutic Antibody by Flow Cytometry;19975;Biopsy;52121-1;Biopsy:Imp:Pt:XXX:Nar:;2009-11-13;Immunophenotyping
4587;TAE;Therapeutic Antibody by Flow Cytometry;19968;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
4588;TAE;Therapeutic Antibody by Flow Cytometry;19985;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;Immunophenotyping
4589;TAE;Therapeutic Antibody by Flow Cytometry;19987;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Immunophenotyping
4590;TAE;Therapeutic Antibody by Flow Cytometry;19981;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
4591;TAE;Therapeutic Antibody by Flow Cytometry;19979;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Immunophenotyping
4592;TAE;Therapeutic Antibody by Flow Cytometry;19978;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;Immunophenotyping
4593;TAE;Therapeutic Antibody by Flow Cytometry;19969;Ref. Path Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunophenotyping
4594;TAE;Therapeutic Antibody by Flow Cytometry;19971;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Immunophenotyping
4595;TAE;Therapeutic Antibody by Flow Cytometry;19972;Bone Marrow Differential;47286-0;Differential panel:-:Pt:Bone Mar:Qn:;2009-11-13;Immunophenotyping
4596;TAKRO;Tacrolimus, Blood;35145;Tacrolimus, B;11253-2;Tacrolimus:MCnc:Pt:Bld:Qn:;2013-12-05;High-Performance Liquid Chromatography/Tandem Mass Spectrometry (HPLC-MS/MS)
4597;TAMV;Thermoactinomyces vulgaris, IgG Antibodies, Serum;TAMV;Thermoactinomyces vulgaris, IgG Ab;34190-9;Thermoactinomyces vulgaris Ab.IgG:MCnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4598;TARR;Tarragon, IgE;TARR;Tarragon, IgE;11202-9;Artemisia dracunculus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4599;TBBS;T- and B-Cell Quantitation by Flow Cytometry;6657;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-11-13;Flow Cytometry
4600;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3326;CD8 (Supp'r Cells);14135-8;Cells.CD3+CD8+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4601;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3320;% CD8 (Supp'r Cells);8101-8;Cells.CD3+CD8+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4602;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3327;H/S Ratio;54218-3;Cells.CD3+CD4+/Cells.CD3+CD8+:NRto:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4603;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3325;CD4 (Helper Cells);24467-3;Cells.CD3+CD4+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4604;TBBS;T- and B-Cell Quantitation by Flow Cytometry;4055;CD16+CD56 (NK cells);20402-4;Cells.CD16+CD56+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4605;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3324;CD19 (B Cells);8116-6;Cells.CD19:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4606;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3322;CD3 (T Cells);8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4607;TBBS;T- and B-Cell Quantitation by Flow Cytometry;4054;% CD16+CD56 (NK cells);18267-5;Cells.CD16+CD56+/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4608;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3319;% CD4 (Helper Cells);8123-2;Cells.CD3+CD4+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry
4609;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3318;% CD19 (B Cells);8117-4;Cells.CD19/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4610;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3316;% CD3 (T Cells);8124-0;Cells.CD3/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4611;TBBS;T- and B-Cell Quantitation by Flow Cytometry;3321;CD45 Lymph Count, Flow;27071-0;Cells.CD45:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4612;TBGI;Thyroxine-Binding Globulin (TBG), Serum;TBGI;Thyroxine Binding Globulin, S;3021-3;Thyroxine binding globulin:MCnc:Pt:Ser/Plas:Qn:;2012-03-15;Solid-Phase Chemiluminescent Assay
4613;TBNY;T and B Quantitation, New York;3318;% CD19 (B Cells);8117-4;Cells.CD19/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4614;TBNY;T and B Quantitation, New York;3326;CD8 (Supp'r Cells);14135-8;Cells.CD3+CD8+:NCnc:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4615;TBNY;T and B Quantitation, New York;3327;H/S Ratio;54218-3;Cells.CD3+CD4+/Cells.CD3+CD8+:NRto:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4616;TBNY;T and B Quantitation, New York;3324;CD19 (B Cells);8116-6;Cells.CD19:NCnc:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4617;TBNY;T and B Quantitation, New York;4055;CD16+CD56 (NK cells);20402-4;Cells.CD16+CD56+:NCnc:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4618;TBNY;T and B Quantitation, New York;6657;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-11-13;Fluorescent Flow Cytometry
4619;TBNY;T and B Quantitation, New York;3320;% CD8 (Supp'r Cells);8101-8;Cells.CD3+CD8+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4620;TBNY;T and B Quantitation, New York;3325;CD4 (Helper Cells);24467-3;Cells.CD3+CD4+:NCnc:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4621;TBNY;T and B Quantitation, New York;3322;CD3 (T Cells);8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4622;TBNY;T and B Quantitation, New York;21151;Physician Review;14869-2;Pathologist review:Imp:Pt:Bld:Nom:Pathologist comment;2009-11-13;Fluorescent Flow Cytometry
4623;TBNY;T and B Quantitation, New York;3319;% CD4 (Helper Cells);8123-2;Cells.CD3+CD4+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Fluorescent Flow Cytometry
4624;TBNY;T and B Quantitation, New York;4054;% CD16+CD56 (NK cells);18267-5;Cells.CD16+CD56+/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4625;TBNY;T and B Quantitation, New York;3316;% CD3 (T Cells);8124-0;Cells.CD3/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4626;TBNY;T and B Quantitation, New York;3321;CD45 Lymph Count, Flow;27071-0;Cells.CD45:NCnc:Pt:Bld:Qn:;2009-11-13;Fluorescent Flow Cytometry
4627;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;3101;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Electrophoretic Determination of the Major Binding Proteins of T4
4628;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;3345;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Electrophoretic Determination of the Major Binding Proteins of T4
4629;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;8838;Thyroxine-Binding Protein Electro;50681-6;Thyroxine binding protein pattern:Imp:Pt:Ser/Plas:Nom:Electrophoresis;2009-11-13;Electrophoretic Determination of the Major Binding Proteins of T4
4630;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;2860;TBG;14016-0;Thyroxine.thyroxine binding globulin bound:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Electrophoretic Determination of the Major Binding Proteins of T4
4631;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;2899;T4 (Thyroxine), Total Only, S;3026-2;Thyroxine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Electrophoretic Determination of the Major Binding Proteins of T4
4632;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;2862;Pre-Albumin;14014-5;Thyroxine.prealbumin bound:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Electrophoretic Determination of the Major Binding Proteins of T4
4633;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;3102;Comment;69053-7;Endocrinologist review:Imp:Pt:XXX:Nar:;2013-07-29;Electrophoretic Determination of the Major Binding Proteins of T4
4634;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;3103;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Electrophoretic Determination of the Major Binding Proteins of T4
4635;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;3104;Comment;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Electrophoretic Determination of the Major Binding Proteins of T4
4636;TBPE;Thyroxine-Binding Protein Electrophoresis, Serum;2861;Albumin;11062-7;Thyroxine.albumin bound:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Electrophoretic Determination of the Major Binding Proteins of T4
4637;TCD4;CD4 Count for Immune Monitoring, Blood;3316;% CD3 (T Cells);8124-0;Cells.CD3/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4638;TCD4;CD4 Count for Immune Monitoring, Blood;3327;H/S Ratio;54218-3;Cells.CD3+CD4+/Cells.CD3+CD8+:NRto:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4639;TCD4;CD4 Count for Immune Monitoring, Blood;3326;CD8 (Supp'r Cells);14135-8;Cells.CD3+CD8+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4640;TCD4;CD4 Count for Immune Monitoring, Blood;3322;CD3 (T Cells);8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4641;TCD4;CD4 Count for Immune Monitoring, Blood;3325;CD4 (Helper Cells);24467-3;Cells.CD3+CD4+:NCnc:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4642;TCD4;CD4 Count for Immune Monitoring, Blood;3321;CD45 Lymph Count, Flow;27071-0;Cells.CD45:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4643;TCD4;CD4 Count for Immune Monitoring, Blood;3320;% CD8 (Supp'r Cells);8101-8;Cells.CD3+CD8+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4644;TCD4;CD4 Count for Immune Monitoring, Blood;3319;% CD4 (Helper Cells);8123-2;Cells.CD3+CD4+/100 cells:NFr:Pt:Bld:Qn:;2013-06-20;Flow Cytometry, Single Platform (CD3, CD4, CD8, CD45)
4645;TCGBM;T-Cell Receptor Gene Rearrangement, PCR, Bone Marrow;19957;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;DNA Extracted for Analysis/Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc. and InVivoScribe Technologies.)
4646;TCGR;T-Cell Receptor Gene Rearrangement, PCR, Blood;18210;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2009-11-13;DNA Extracted for Analysis/Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc. and InVivoScribe Technologies)
4647;TCGRV;T-Cell Receptor Gene Rearrangement, PCR, Varies;19936;Final Diagnosis:;34574-4;Path report.final diagnosis:Imp:Pt:Specimen:Nom:;2011-06-21;DNA Extracted for Analysis/Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc. and InVivoScribe Technologies)
4648;TCGRV;T-Cell Receptor Gene Rearrangement, PCR, Varies;MP016;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;DNA Extracted for Analysis/Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc. and InVivoScribe Technologies)
4649;TCP;T-Cell Subsets, Naive, Memory and Activated;29178;Interpretation;69052-9; ;2013-08-22;Flow Cytometry
4650;TCP;T-Cell Subsets, Naive, Memory and Activated;29174;Activated CD4 T cells (4+CD25+);26982-9;Cells.CD4+CD25+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4651;TCP;T-Cell Subsets, Naive, Memory and Activated;29168;CD4+CD45RO+ memory T cells;34475-4;Cells.CD4+CD45RO+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4652;TCP;T-Cell Subsets, Naive, Memory and Activated;29164;CD4+CD45RA+ naive T cells;26759-1;Cells.CD4+CD45RA+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4653;TCP;T-Cell Subsets, Naive, Memory and Activated;29155;%CD4+CD45RO+ memory T cells;41994-5;Cells.CD4+CD45RO+/100 cells:NFr:Pt:Bld:Qn:;2011-10-03;Flow Cytometry
4654;TCP;T-Cell Subsets, Naive, Memory and Activated;29161;%Activated CD4 T cells (4+CD25+);13332-2;Cells.CD4+CD25+/100 cells:NFr:Pt:Bld:Qn:;2013-12-05;Flow Cytometry
4655;TCP;T-Cell Subsets, Naive, Memory and Activated;29151;%CD4+CD45RA+ naive T cells;13336-3;Cells.CD4+CD45RA+/100 cells:NFr:Pt:Bld:Qn:;2011-10-03;Flow Cytometry
4656;TCPT;Trichophyton rubrum, IgE;TCPT;Trichophyton Rubrum, IgE;6860-1;Trichophyton rubrum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4657;TEA;Tea, IgE;TEA;Tea, IgE;6264-6;Camellia sinensis Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4658;TFE3;Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue;34292;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Fluorescence In Situ Hybridization (FISH)
4659;TFE3;Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue;34294;Interpretations;69965-2; ;2014-05-07;Fluorescence In Situ Hybridization (FISH)
4660;TFE3;Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue;CG600;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-04-11;Fluorescence In Situ Hybridization (FISH)
4661;TFE3;Alveolar Soft Part Sarcoma (ASPS)/Renal Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue;34289;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-06-20;Fluorescence In Situ Hybridization (FISH)
4662;TGAB;Thyroglobulin Antibody, Serum;TGAB;Thyroglobulin Antibody, S;8098-6;Thyroglobulin Ab:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemilumescence Immunoassay
4663;TGAB;Thyroglobulin Antibody, Serum;TGAB;Thyroglobulin Antibody, S;8098-6;Thyroglobulin Ab:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Electrochemiluminescence Immunoassay
4664;THCG;Human Chorionic Gonadotropin (hCG), Quantitative, Pregnancy, Serum;THCG;HCG, Quantitative, Pregnancy, S;21198-7;Choriogonadotropin.beta subunit:ACnc:Pt:Ser/Plas:Qn:;2012-03-12;Electrochemiluminescent Immunoassay
4665;THCM;11-nor-Delta-9-Tetrahydrocannabinol-9-Carboxylic Acid (Carboxy-THC), Confirmation, Meconium;31876;Interpretation;69050-3;;2012-04-09;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4666;THCM;11-nor-Delta-9-Tetrahydrocannabinol-9-Carboxylic Acid (Carboxy-THC), Confirmation, Meconium;31863;THC;69007-3;Carboxy tetrahydrocannabinol:MCnt:Pt:Meconium:Qn:Confirm;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4667;THCU;Carboxy-Tetrahydrocannabinol (THC) Confirmation, Urine;2497;Carboxy-THC- by GC/MS;3530-3;Tetrahydrocannabinol:MCnc:Pt:Urine:Qn:;2009-11-13;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
4668;THCU;Carboxy-Tetrahydrocannabinol (THC) Confirmation, Urine;21186;Carboxy-THC Interpretation;69050-3;;2012-04-09;Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
4669;THCX;Carboxy-Tetrahydrocannabinol (THC) Confirmation, Chain of Custody, Urine;2449;Carboxy-THC Immunoassay Screen;19415-9;Tetrahydrocannabinol:Threshold:Pt:Urine:Ord:Screen;2009-11-13;Immunoassay/Gas Chromatography-Mass Spectrometry (GC-MS) Confirmation with Quantitation
4670;THCY;Thiocyanate, Serum;8619;Thiocyanate, S;3002-3;Thiocyanate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Colorimetric
4671;THEO;Theophylline, Serum;8661;Theophylline, S;4049-3;Theophylline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
4672;THYM;Thyme, IgE;THYM;Thyme, IgE;7737-0;Thymus vulgaris Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4673;THYRO;Thyrotropin Receptor Antibody, Serum;THYRO;Thyrotropin Receptor Ab, S;5385-0;Thyrotropin receptor Ab:ACnc:Pt:Ser:Qn:;2012-03-12;Electrochemiluminescence Immunoassay
4674;TIAG;Tiagabine Concentration, Serum;82524;Tiagabine, S;21565-7;Tiagabine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4675;TIMG;Timothy Grass, IgE;TIMG;Timothy Grass, IgE;6265-3;Phleum pratense Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4676;TIU;Titanium, 24 Hour, Urine;TM108;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2013-08-14;Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES)
4677;TLB;Thallium, Blood;8149;Thallium, B;5744-8;Thallium:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4678;TLDLP;LDL Particle Concentration NMR, Plasma;LDLPV;Total LDL Particle Concentration;14815-5;Lipoprotein.beta:SCnc:Pt:Ser/Plas:Qn:Calculated;2013-08-07;Nuclear Magnetic Resonance (NMR)
4679;TLDLP;LDL Particle Concentration NMR, Plasma;NMRIT;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2013-08-07;Nuclear Magnetic Resonance (NMR)
4680;TLRU;Thallium, Random, Urine;60324;Thallium, Random, U;5745-5;Thallium:MCnc:Pt:Urine:Qn:;2011-06-24;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4681;TLU;Thallium, 24 Hour, Urine;864;Tl Concentration;21558-2;Thallium:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4682;TLU;Thallium, 24 Hour, Urine;VL12;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4683;TLU;Thallium, 24 Hour, Urine;8603;Thallium, 24 Hr, U;5746-3;Thallium:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4684;TLU;Thallium, 24 Hour, Urine;TIME2;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4685;TMA;Trimellitic Anhydride, TMA, IgE;TMA;Trimellitic Anhydride, TMA, IgE;7746-1;Trimellitic anhydride Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4686;TMP;Trimethoprim, Serum;80146;Trimethoprim, S;11005-6;Trimethoprim:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4687;TOBAC;Tobacco, IgE;TOBAC;Tobacco, IgE;6859-3;Nicotiana tabacum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4688;TOBP;Tobramycin, Peak, Serum;500694;Tobramycin, Peak, S;4057-6;Tobramycin^peak:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Enzyme-Multiplied Immunoassay Technique (EMIT)
4689;TOBPK;Tobramycin, Peak, Serum;6799;Tobramycin, Peak, S;4057-6;Tobramycin^peak:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
4690;TOBR;Tobramycin, Random, Serum;81751;Tobramycin, Random, S;35670-9;Tobramycin^random:MCnc:Pt:Ser/Plas:Qn:;2011-04-28;Enzyme-Multiplied Immunoassay Technique (EMIT)
4691;TOMA;Tomato, IgE;TOMA;Tomato, IgE;6266-1;Lycopersicon lycopersicum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4692;TOPI;Topiramate, Serum;81546;Topiramate, S;17713-9;Topiramate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
4693;TOXGP;Toxoplasma gondii Antibody, IgG, Serum;TOXG;Toxoplasma Ab, IgG, S;40677-7;Toxoplasma gondii Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2014-01-29;Multiplex Flow Immunoassay (MFI)
4694;TOXGP;Toxoplasma gondii Antibody, IgG, Serum;DEXG6;Toxoplasma IgG Value;56991-3;Toxoplasma gondii Ab.IgG avidity:Threshold:Pt:Ser:Ord:EIA;2014-01-29;Multiplex Flow Immunoassay (MFI)
4695;TOXMP;Toxoplasma gondii Antibody, IgM, Serum;TOXM;Toxoplasma Ab, IgM, S;35282-3;Toxoplasma gondii Ab.IgM:ACnc:Pt:Ser/Plas:Ord:IF;2014-01-29;Enzyme-Linked Fluorescence Assay (ELFA)
4696;TOXMP;Toxoplasma gondii Antibody, IgM, Serum;DEXM7;Toxoplasma IgM Value;5390-0;Toxoplasma gondii Ab.IgM index:ACnc:Pt:Ser:QN:EIA;2014-04-18;Enzyme-Linked Fluorescence Assay (ELFA)
4697;TP;Protein, Total, Serum;TP;Protein, Total, S;2885-2;Protein:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Colorimetric, Biuret
4698;TPBF;Protein, Total, Body Fluid;TPBF1;Protein, Total, BF;2881-1;Protein:MCnc:Pt:Body fld:Qn:;2012-03-12;Photometric, Biuret
4699;TPBF;Protein, Total, Body Fluid;FLD23;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric, Biuret
4700;TPMT;Thiopurine Methyltransferase (TPMT), Erythrocytes;80291;Thiopurine Methyltransferase, RBC;21563-2;Thiopurine methyltransferase:CCnc:Pt:RBC:Qn:;2009-11-13;Enzymatic End point/Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4701;TPNI;Troponin I, Serum;TPNI;Troponin I, S;10839-9;Troponin I.cardiac:MCnc:Pt:Ser/Plas:Qn:;2013-08-07;Chemiluminometric Immunoassay
4702;TPNT;Troponin T, Serum;TPNT;Troponin T, S;6598-7;Troponin T.cardiac:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Electrochemiluminescent Immunoassay
4703;TPO;Thyroperoxidase (TPO) Antibodies, Serum;TPO;Thyroperoxidase Ab, S;8099-4;Thyroperoxidase Ab:ACnc:Pt:Ser:Qn:;2012-03-12;Immunoenzymatic Assay
4704;TPPA;Syphilis Antibody by TP-PA, Serum;61480;Syphilis Ab by TP-PA, S;24312-1;Treponema pallidum Ab:ACnc:Pt:Ser:Ord:Aggl;2013-07-24;Particle Agglutination
4705;TPPTF;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Fibroblasts;50796;Method;49549-9; ;2013-07-26;TPPTF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4706;TPPTF;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Fibroblasts;50798;PPT1, F;34647-8;PPT1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2012-01-26;TPPTF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4707;TPPTF;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Fibroblasts;50799;Interpretation;59462-2;;2012-04-02;TPPTF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4708;TPPTF;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Fibroblasts;50795;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;TPPTF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4709;TPPTF;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Fibroblasts;50793;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;TPPTF: Fluorometric Enzyme AssayCRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
4710;TPPTL;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Leukocytes;50696;Interpretation;59462-2;;2012-04-02;Fluorometric
4711;TPPTL;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Leukocytes;50692;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Fluorometric
4712;TPPTL;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Leukocytes;50693;Method;49549-9; ;2013-07-26;Fluorometric
4713;TPPTL;Tripeptidyl Peptidase 1 (TPP1) and Palmitoyl-Protein Thioesterase 1 (PPT1), Leukocytes;50690;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Fluorometric
4714;TPSF;Protein, Total, Spinal Fluid;TPSF;Protein, Total, CSF;2880-3;Protein:MCnc:Pt:CSF:Qn:;2012-03-12;Reflectance Spectrophotometry
4715;TRAG;Tragacanth, IgE;TRAG;Tragacanth, IgE;7743-8;Astragalus spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4716;TREC;T-Cell Receptor Excision Circles (TREC) Analysis, Blood;30292;Interpretation;69048-7;;2012-04-09;Real-Time Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4717;TREC;T-Cell Receptor Excision Circles (TREC) Analysis, Blood;28308;CD8 T Cells;14135-8;Cells.CD8:NCnc:Pt:Bld:Qn:;2014-07-23;Real-Time Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4718;TREC;T-Cell Receptor Excision Circles (TREC) Analysis, Blood;28307;CD4 T Cells;24467-3;Cells.CD4:NCnc:Pt:Bld:Qn:;2014-07-23;Real-Time Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4719;TREC;T-Cell Receptor Excision Circles (TREC) Analysis, Blood;28306;CD3 T Cells;8122-4;Cells.CD3:NCnc:Pt:Bld:Qn:;2009-11-13;Real-Time Quantitative Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4720;TREE1;Tree Panel # 1;TREE1;Tree Panel # 1;30184-6;(Acer negundo+Betula verrucosa+Quercus alba+Ulmus americana+Juglans californica) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4721;TREE4;Tree Panel # 4;TREE4;Tree Panel # 4;30182-0;(Olea europaea+Salix caprea+Pinus strobus+Eucalyptus spp+Acacia longifolia+Melaleuca leucadendron) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4722;TREGS;T-Cell Subsets, Regulatory (Tregs);29143;% Activated CD4+ T cells (4+CD25+);13332-2;Cells.CD4+CD25+/100 cells:NFr:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4723;TREGS;T-Cell Subsets, Regulatory (Tregs);29147;Activated CD4+ T cells (4+CD25+);26982-9;Cells.CD4+CD25+:NCnc:Pt:Bld:Qn:;2009-11-13;Flow Cytometry
4724;TREGS;T-Cell Subsets, Regulatory (Tregs);29177;Interpretation;69052-9; ;2013-08-22;Flow Cytometry
4725;TRICY;Tricyclic Antidepressant Screen, Serum;7931;Doxepin;3579-0;Doxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4726;TRICY;Tricyclic Antidepressant Screen, Serum;7927;Amitriptyline and Nortriptyline;3335-7;Amitriptyline+Nortriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4727;TRICY;Tricyclic Antidepressant Screen, Serum;7933;Doxepin and Nordoxepin;3582-4;Doxepin+Nordoxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4728;TRICY;Tricyclic Antidepressant Screen, Serum;7930;Imipramine and Desipramine;9627-1;Imipramine+Desipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4729;TRICY;Tricyclic Antidepressant Screen, Serum;7932;Nordoxepin;3862-0;Nordoxepin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4730;TRICY;Tricyclic Antidepressant Screen, Serum;7929;Desipramine;3531-1;Desipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4731;TRICY;Tricyclic Antidepressant Screen, Serum;7928;Imipramine;3690-5;Imipramine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4732;TRICY;Tricyclic Antidepressant Screen, Serum;7926;Nortriptyline;3872-9;Nortriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4733;TRICY;Tricyclic Antidepressant Screen, Serum;7925;Amitriptyline;3333-2;Amitriptyline:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4734;TRIG;Triglycerides, Serum;TRIG;Triglycerides, S;2571-8;Triglyceride:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Enzymatic Colorimetric
4735;TRIGC;Triglycerides, CDC, S;TRIGC;Triglycerides, CDC, S;2571-8;Triglyceride:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Only orderable as part of ECRMP / Novel Cardiovascular Risk Panel.
4736;TROT;Trout, IgE;TROT;Trout, IgE;6268-7;Oncorhynchus mykiss Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4737;TRPU;Trichosporon pullulans, IgE;TRPU;Trichosporon Pullulans, IgE;11203-7;Trichosporon pullulans Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4738;TRVI;Trichoderma viride, IgE;TRVI;Trichoderma Viride, IgE;6267-9;Trichoderma viride Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4739;TRYPI;Tyrophagus putrescentiae, IgE;TRYPI;Tyrophagus Putrescentiae, IgE;6256-2;Tyrophagus putrescentiae Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4740;TRYPP;Tryptophan, Plasma;82955;Tryptophan;20659-9;Tryptophan:SCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4741;TRYPT;Tryptase, Serum;TRYPT;Tryptase, S;21582-2;Tryptase:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4742;TRYPU;Tryptophan, Urine;83823;Tryptophan, U;25139-7;Tryptophan/Creatinine:SRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4743;TRZ;Trazodone, Serum;9624;Trazodone, S;4064-2;Trazodone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4744;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17381;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4745;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17386;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4746;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17387;Amendment;32632-2;HEXA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4747;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17384;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4748;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17385;Result;32632-2;HEXA gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4749;TSD;Tay-Sachs Disease, Mutation Analysis, HEXA;17383;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR) analysis is used to test for the following mutations associated with Tay-Sachs disease: 1278insTATC, G269S, IVS12(+1)G->C, IVS9(+1) G->A, delta 7.6kb, R247W, R249W.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4750;TSI;Thyroid-Stimulating Immunoglobulin (TSI), Serum;8634;Thyroid-Stimulating Immunoglob, S;30567-2;Thyroid stimulating immunoglobulins:ACnc:Pt:Ser:Qn:;2009-11-13;Recombinant Bioassay
4751;TT;Thrombin Time (Bovine), Plasma;TT;Thrombin Time (Bovine), P;46717-5;Coagulation thrombin induced.factor substitution^immediately after addition of bovine thrombin:Time:Pt:PPP:Qn:Coag;2012-03-12;Clot-Based AssayMeasures time of fibrinogen to fibrin conversion after adding bovine thrombin
4752;TTGA;Tissue Transglutaminase (tTG) Antibody, IgA, Serum;TTGA;Tissue Transglutaminase Ab, IgA, S;46128-5;Tissue transglutaminase Ab.IgA:ACnc:Pt:Ser:Qn:EIA;2012-03-07;Enzyme-Linked Immunosorbent Assay (ELISA)
4753;TTGG;Tissue Transglutaminase (tTG) Antibody, IgG, Serum;TTGG;Tissue Transglutaminase Ab, IgG, S;56537-4;Tissue transglutaminase Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2012-03-07;Enzyme-Linked Immunosorbent Assay (ELISA)
4754;TTIG;Tetanus Toxoid IgG Antibody Assay, Serum;TTIG;Tetanus Toxoid IgG Ab, S;53935-3;Clostridium tetani toxin Ab.IgG:ACnc:Pt:Ser/Plas:Qn:EIA;2012-03-12;Enzyme Immunoassay (EIA)
4755;TTOX;Tetanus Toxoid, IgE;TTOX;Tetanus Toxoid, IgE;19760-8;Clostridium tetani toxoid Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4756;TTRX;Amyloidosis, Transthyretin-Associated Familial, Reflex, Blood;50944;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Liquid Chromatography-Mass Spectrometry (LC-MS)
4757;TTST;Testosterone, Total, Serum;8533;Testosterone, Total, S;2986-8;Testosterone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4758;TUMOR;Chromosome Analysis, Solid Tumors;16164;Amendment;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2013-08-09;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4759;TUMOR;Chromosome Analysis, Solid Tumors;16162;Results;35129-6;Karyotype:Prid:Pt:XXX:Nom:;2009-11-13;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4760;TUMOR;Chromosome Analysis, Solid Tumors;16163;Interpretation;69965-2;;2012-04-05;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4761;TUMOR;Chromosome Analysis, Solid Tumors;16160;Method;49549-9; ;2013-07-26;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4762;TUMOR;Chromosome Analysis, Solid Tumors;50476;Banding Methods;62359-5;Chromosome banding method:Type:Pt:Bld/Tiss:Nom:Molgen;2011-03-23;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4763;TUMOR;Chromosome Analysis, Solid Tumors;G_471;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4764;TUMOR;Chromosome Analysis, Solid Tumors;16791;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Includes 2 banded karyograms, analysis of 20 or more metaphases, and other techniques when required.
4765;TUNA;Tuna, IgE;TUNA;Tuna, IgE;6270-3;Thunnus albacares Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4766;TUP;T3 (Triiodothyronine), Uptake, Serum;TUP;T3 (Triiodothyronine), Uptake, S;3050-2;Triiodothyronine resin uptake (T3RU):NFr:Pt:Ser/Plas:Qn:;2012-03-12;Chemiluminometric Immunoassay
4767;TURK;Turkey, IgE;TURK;Turkey, IgE;6271-1;Turkey meat Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4768;TURKF;Turkey Feathers, IgE;TURKF;Turkey Feathers, IgE;7753-7;Turkey feather Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4769;TVRNA;Trichomonas vaginalis by Nucleic Acid Amplification;SRC29;SOURCE:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2014-04-28;Transcription Mediated Amplification
4770;TWRP;Tropheryma whipplei, Molecular Detection, PCR;22302;Result;42602-3;Tropheryma whippelii DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2013-08-27;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4771;TWRP;Tropheryma whipplei, Molecular Detection, PCR;SRC56;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4772;TXBU;11-Dehydro-Thromboxane B2, Urine;83335;11-Dehydro-Thromboxane B2, U;50686-5;11-Dehydro thromboxane beta 2/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;TXBU: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)AACT: Enzymatic Colorimetric Assay
4773;UBEKM;UBE3A Gene, Known Mutation;33726;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis   (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4774;UBEKM;UBE3A Gene, Known Mutation;33725;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis   (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4775;UBEKM;UBE3A Gene, Known Mutation;33723;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis   (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4776;UBEKM;UBE3A Gene, Known Mutation;33728;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequencing Analysis   (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4777;UBEMS;UBE3A Gene, Full Gene Analysis;33714;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4778;UBEMS;UBE3A Gene, Full Gene Analysis;33715;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4779;UBEMS;UBE3A Gene, Full Gene Analysis;33716;Result;35291-4;UBE3A gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4780;UBEMS;UBE3A Gene, Full Gene Analysis;33717;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nom:;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4781;UBEMS;UBE3A Gene, Full Gene Analysis;33718;Amendment;35291-4;UBE3A gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2014-05-01;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4782;UBEMS;UBE3A Gene, Full Gene Analysis;33712;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-09-05;Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4783;UBT;Helicobacter pylori Breath Test;81590;H. pylori C Urea Breath Test;29891-9;Carbon dioxide^post dose urea:ACnc:Pt:Exhl gas:Ord:;2009-11-13;Infrared Spectrophotometry (SP)
4784;UE3;Estriol, Unconjugated, Serum;UE3;Estriol, Unconjugated, S;2250-9;Estriol.unconjugated:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Immunoenzymatic Assay
4785;UEA1;Ulex Europeaus I Lectin Immunop ST;UEA1;Ulex Europeaus I Lectin Immunop ST;10518-9;Ulex europaeus I lectin Ag:ACnc:Pt:Tiss:Ord:Immune stain;2012-03-12;
4786;UEBF;Blood Urea Nitrogen, Body Fluid;FLD15;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Photometric, Urease
4787;UEBF;Blood Urea Nitrogen, Body Fluid;UE_BF;Bld Urea Nitrog, BF;3093-2;Urea nitrogen:MCnc:Pt:Body fld:Qn:;2012-03-12;Photometric, Urease
4788;UHIST;Histoplasma Antigen, Urine;HISTQ;Histoplasma Ag Result;44524-7;Histoplasma capsulatum Ag:ACnc:Pt:Urine:Ord:EIA;2014-08-21;Enzyme Immunoassay (EIA)
4789;UHIST;Histoplasma Antigen, Urine;DEXHU;Histoplasma Ag Value;13971-7;Histoplasma capsulatum Ag:ACnc:Pt:Urine:Qn:EIA;2014-08-21;Enzyme Immunoassay (EIA)
4790;UHSD;Hemosiderin, Urine;RBC3;RBC;13945-1;Erythrocytes:Naric:Pt:Urine sed:Qn:Microscopy.light.HPF;2012-03-15;Rous Method
4791;UHSD;Hemosiderin, Urine;HGB7;Hemoglobin;725-2;Hemoglobin:ACnc:Pt:Urine:Ord:;2012-03-15;Rous Method
4792;UHSD;Hemosiderin, Urine;US_HD;Hemosiderin, U;4644-1;Hemosiderin:ACnc:Pt:Urine:Ord:;2012-03-12;Rous Method
4793;UIOD;Iodine, 24 Hour, Urine;3346;Iodine Concentration;26842-5;Iodine:MCnc:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4794;UIOD;Iodine, 24 Hour, Urine;TIME5;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4795;UIOD;Iodine, 24 Hour, Urine;VL23;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4796;UIOD;Iodine, 24 Hour, Urine;9549;Iodine, 24 Hr, U;2492-7;Iodine:MRat:24H:Urine:Qn:;2009-11-13;Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
4797;ULCH;Ulocladium chartarum, IgE;ULCH;Ulocladium Chartarum, IgE;11204-5;Ulocladium chartarum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4798;UNHB;Unstable Hemoglobin, Blood;9095;Hemoglobin, Unstable, B;4639-1;Hemoglobin.unstable:ACnc:Pt:RBC:Ord:;2009-11-13;Isopropanol Stability
4799;UOSMB;Osmolality, Body Fluid;FLD6;Fluid Type;14725-6;Fluid:Type:Pt:Body fld:Nom:;2012-03-15;Freezing Point Depression
4800;UOSMB;Osmolality, Body Fluid;OSBF;Osmolality, BF;15200-9;Osmolality:Osmol:Pt:Body fld:Qn:;2012-03-15;Freezing Point Depression
4801;UOSMS;Osmolality, Serum;UOSMS;Osmolality, S;2692-2;Osmolality:Osmol:Pt:Ser/Plas:Qn:;2012-03-12;Freezing Point Depression
4802;UOSMU;Osmolality, Urine;UOSMU;Osmolality, U;2695-5;Osmolality:Osmol:Pt:Urine:Qn:;2012-03-12;Freezing Point Depression
4803;UPD;Uniparental Disomy;17277;Amendment;36917-3;Chromosome uniparental disomy:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-07-30;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4804;UPD;Uniparental Disomy;17273;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4805;UPD;Uniparental Disomy;17274;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4806;UPD;Uniparental Disomy;17271;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4807;UPD;Uniparental Disomy;17275;Result;36917-3;Chromosome uniparental disomy:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4808;UPD;Uniparental Disomy;17276;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR)/Microsatellite markers on the chromosome of interest are used to test DNA from parents and child for the presence of uniparental disomy.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4809;UPGC;Uroporphyrinogen III Synthase (Co-Synthase) (UPG III S), Erythrocytes;80288;Uroporphyrinogen III Synthase, RBC;11066-8;Uroporphyrinogen III synthase:CCnc:Pt:RBC:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4810;UPGD;Uroporphyrinogen Decarboxylase (UPG D), Whole Blood;8599;UPG Decarboxylase, WB;49596-0;Uroporphyrinogen decarboxylase:ACnc:Pt:RBC:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)/Incubation of Lysed Erythrocytes
4811;UPGDW;Uroporphyrinogen Decarboxylase (UPG D), Washed Erythrocytes;31892;UPG Decarboxylase, RBC;49596-0;Uroporphyrinogen decarboxylase:ACnc:Pt:RBC:Qn:;2011-06-22;High-Performance Liquid Chromatography (HPLC)/Incubation of Lysed Erythrocytes
4812;UPH24;pH, 24 Hour, Urine;VL72;Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;pH Meter
4813;UPH24;pH, 24 Hour, Urine;TM90;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;pH Meter
4814;UPH24;pH, 24 Hour, Urine;PH24;pH, Urine 24 Hour;27378-9;pH:LsCnc:24H:Urine:Qn:;2012-03-15;pH Meter
4815;UPHB;pH, Body Fluid;SRC18;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;pH Meter
4816;UPHB;pH, Body Fluid;U_PHB;pH, BF;2748-2;pH:LsCnc:Pt:Body fld:Qn:;2012-03-12;pH Meter
4817;UR;Bacterial Culture, Aerobic, Urine;UR;Bacterial Culture, Aerobic, Urine;630-4;Bacteria identified:Prid:Pt:Urine:Nom:Culture;2013-09-18;Conventional Quantitative Culture Technique; Identification of Pathogens Greater Than or Equal to 10,000 cfu/mL
4818;URAU;Urea, 24 Hour, Urine;URECN;Urea Concentration;63481-6;Urea:MCnc:24H:Urine:Qn:;2012-03-12;Kinetic UV Assay 
4819;URAU;Urea, 24 Hour, Urine;TM33;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Kinetic UV Assay 
4820;URAU;Urea, 24 Hour, Urine;VL31;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Kinetic UV Assay 
4821;URAU;Urea, 24 Hour, Urine;UREA;Urea, U;48999-7;Urea:MRat:24H:Urine:Qn:;2012-03-12;Kinetic UV Assay 
4822;URCU;Uric Acid, 24 Hour, Urine;UACID;Uric Acid, U;3087-4;Urate:MRat:24H:Urine:Qn:;2012-03-12;Uricase
4823;URCU;Uric Acid, 24 Hour, Urine;VL27;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Uricase
4824;URCU;Uric Acid, 24 Hour, Urine;UACN1;Uric Acid Concentration;21587-1;Urate:MCnc:24H:Urine:Qn:;2012-03-12;Uricase
4825;URCU;Uric Acid, 24 Hour, Urine;TM29;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Uricase
4826;UREDF;Reducing Substance, Feces;6215;Reducing Substance, F;11060-1;Reducing substances:ACnc:Pt:Stool:Ord:;2009-11-13;Clinitest Reagent Tablets
4827;URIC;Uric Acid, Serum;URIC;Uric Acid, S;3084-1;Urate:MCnc:Pt:Ser/Plas:Qn:;2012-03-12;Photometric, Uricase/Quinone-Imine Dye Formation
4828;URRP;Ureaplasma species, Molecular Detection, PCR;SRC80;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4829;URRP;Ureaplasma species, Molecular Detection, PCR;35128;Ureaplasma urealyticum PCR;51988-4;Ureaplasma urealyticum DNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2013-04-11;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4830;URRP;Ureaplasma species, Molecular Detection, PCR;35129;Ureaplasma parvum PCR;69933-0;Ureaplasma parvum DNA:Threshold:Pt:XXX:Ord:Probe.amp.tar;2013-04-11;Real-Time Polymerase Chain Reaction (PCR) Using LightCycler and Fluorescent Resonance Energy Transfer (FRET)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4831;USNU;Ustilago nuda, Mold Grain Rust, IgE;USNU;Ustilago Nuda, Mold Grain Rust, IgE;46721-7;Ustilago nuda Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4832;VANCR;Vancomycin, Random, Serum;81749;Vancomycin, Random, S;20578-1;Vancomycin:MCnc:Pt:Ser/Plas:Qn:;2011-04-18;Immunoassay
4833;VANCT;Vancomycin, Trough, Serum;6802;Vancomycin, Trough, S;4092-3;Vancomycin^trough:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
4834;VANIL;Vanilla, IgE;VANIL;Vanilla, IgE;7756-0;Vanilla planifolia Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4835;VANPK;Vancomycin, Peak, Serum;6801;Vancomycin, Peak, S;4090-7;Vancomycin^peak:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
4836;VDSF;VDRL, Spinal Fluid;9028;VDRL, CSF;31146-4;Reagin Ab:Titr:Pt:CSF:Qn:VDRL;2013-09-18;Floculation/Agglutination
4837;VELV;Velvet Leaf, IgE;VELV;Velvet Leaf, IgE;6272-9;Holcus lanatus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4838;VENLA;Venlafaxine, Serum;30195;O-desmethyl Venlafaxine;9630-5;Venlafaxine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4839;VENLA;Venlafaxine, Serum;32182;Venlafaxine+O-Desmethylvenlafaxine;62849-5;Venlafaxine+Norvenlafaxine:MCnc:Pt:Ser/Plas:Qn:;2013-12-05;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4840;VENLA;Venlafaxine, Serum;83732;Venlafaxine;9630-5;Venlafaxine:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4841;VERG;Sweet Vernal Grass, IgE;VERG;Sweet Vernal Grass, IgE;6261-2;Anthoxanthum odoratum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4842;VH;Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Pediatric, Urine;2144;Child HVA;11146-8;Homovanillate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4843;VH;Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA), Pediatric, Urine;2143;Child VMA;3124-5;Vanillylmandelate/Creatinine:MRto:Pt:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4844;VHLD;Von Hippel-Lindau (VHL) Deletion Detection;31724;Result;34502-5;VHL gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2011-06-22;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4845;VHLD;Von Hippel-Lindau (VHL) Deletion Detection;31725;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4846;VHLD;Von Hippel-Lindau (VHL) Deletion Detection;31722;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-22;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4847;VHLD;Von Hippel-Lindau (VHL) Deletion Detection;31723;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR) Amplification/Deletion Detection by Multiplex Ligation-Dependent Probe Amplification (MLPA)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4848;VIBC;Vibrio Culture, Stool;VIBC;Vibrio Culture, Stool;6581-3;Vibrio sp identified:Prid:Pt:XXX:Organism specific culture;2013-09-18;Conventional Culture Technique
4849;VIP;Vasoactive Intestinal Polypeptide (VIP), Plasma;8150;Vasoactive Intestinal Polypeptide,P;3125-2;Vasoactive intestinal peptide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Radioimmunoassay (RIA)
4850;VIRNR;Viral Culture, Non-Respiratory;VIRNR;Viral Culture, Non Respiratory;6584-7;Virus identified:Prid:Pt:XXX:Nom:Culture;2013-09-18;Cell Culture Shell Vial Assay for Herpes Simplex Virus or Cytomegalovirus
4851;VISCS;Viscosity, Serum;8168;Viscosity, S;3128-6;Viscosity:Visc:Pt:Ser:Qn:;2009-11-13;Sonoclot Coagulation Analyzer
4852;VITA;Vitamin A, Serum;7597;Free Retinol(Vit A);17527-3;Retinol.free:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)Specific quantitation of retinol.
4853;VITB2;Riboflavin (Vitamin B2), Plasma;61637;Riboflavin (Vitamin B2), P;2924-9;Riboflavin:MCnc:Pt:Ser/Plas:Qn:;2013-08-07;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4854;VITC;Ascorbic Acid (Vitamin C), Plasma;8312;Ascorbic Acid, P;1903-4;Ascorbate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4855;VITE;Vitamin E, Serum;2350;A-Tocopherol, Vitamin E;1823-4;Alpha tocopherol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Specific quantitation of alpha-tocopherol.
4856;VITK1;Vitamin K1, Serum;62167;Vitamin K1, S;9622-2;Phytonadione:MCnc:Pt:Ser/Plas:Qn:;2013-08-07;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4857;VLCKM;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Known Mutation;51030;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4858;VLCKM;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Known Mutation;51031;Result;73736-1;ACADVL gene mutation analysis limited to known familial mutations:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-12-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4859;VLCKM;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Known Mutation;51032;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4860;VLCKM;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Known Mutation;51029;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4861;VLCKM;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Known Mutation;51027;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-21;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4862;VLCMS;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Full Gene Analysis;51044;Interpretation;59462-2;Clinical biochemist review:Imp:Pt:XXX:Nar:;2012-04-05;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4863;VLCMS;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Full Gene Analysis;51039;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4864;VLCMS;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Full Gene Analysis;51042;Method;49549-9; ;2013-07-26;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4865;VLCMS;Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Full Gene Analysis;51041;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2011-06-23;Polymerase Chain Reaction (PCR)/DNA Sequencing Analysis(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4866;VLTB;Volatile Screen, Blood;30922;Ethanol, B;5640-8;Ethanol:MCnc:Pt:Bld:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4867;VLTB;Volatile Screen, Blood;30924;Isopropanol, B;5667-1;Isopropanol:MCnc:Pt:Bld:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4868;VLTB;Volatile Screen, Blood;30923;Acetone, B;9425-0;Acetone:MCnc:Pt:Bld:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4869;VLTB;Volatile Screen, Blood;89190;Volatile Scrn, B;41266-8;Volatiles:Prid:Pt:Bld:Nom:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4870;VLTB;Volatile Screen, Blood;30921;Methanol, B;9334-4;Methanol:MCnc:Pt:Bld:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4871;VLTS;Volatile Screen, Serum;30920;Isopropanol, S;5669-7;Isopropanol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4872;VLTS;Volatile Screen, Serum;30918;Ethanol, S;5643-2;Ethanol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4873;VLTS;Volatile Screen, Serum;30919;Acetone, S;5568-1;Acetone:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4874;VLTS;Volatile Screen, Serum;30917;Methanol, S;5693-7;Methanol:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4875;VLTS;Volatile Screen, Serum;8632;Volatile Scrn, S;32044-0;Volatiles:Prid:Pt:Ser/Plas:Nom:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4876;VLTU;Volatile Screen, Urine;30905;Ethanol, U;5645-7;Ethanol:MCnc:Pt:Urine:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4877;VLTU;Volatile Screen, Urine;30907;Isopropanol, U;9434-2;Isopropanol:MCnc:Pt:Urine:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4878;VLTU;Volatile Screen, Urine;30906;Acetone, U;5570-7;Acetone:MCnc:Pt:Urine:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4879;VLTU;Volatile Screen, Urine;30904;Methanol, U;5695-2;Methanol:MCnc:Pt:Urine:Qn:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4880;VLTU;Volatile Screen, Urine;8826;Volatile Scrn, U;12983-3;Volatiles:Prid:Pt:Urine:Nom:;2009-11-13;Headspace Gas Chromatography-Flame Ionization Detector (HSGC-FID)Includes methanol, ethanol, isopropanol, and acetone.
4881;VMA;Vanillylmandelic Acid (VMA), 24 Hour, Urine;VL39;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4882;VMA;Vanillylmandelic Acid (VMA), 24 Hour, Urine;TM41;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4883;VMA;Vanillylmandelic Acid (VMA), 24 Hour, Urine;3581;VMA, Child (<15yr);30571-4;Vanillylmandelate/Creatinine:MRto:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4884;VMA;Vanillylmandelic Acid (VMA), 24 Hour, Urine;3580;VMA, Adult;3122-9;Vanillylmandelate:MRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4885;VMAR;Vanillylmandelic Acid (VMA), Random, Urine;60274;Vanillylmandelic Acid, Random, U;3124-5;Vanillylmandelate/Creatinine:MRto:Pt:Urine:Qn:;2011-06-24;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4886;VORI;Voriconazole, Serum;88698;Voriconazole, S;38370-3;Voriconazole:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4887;VPA;Valproic Acid, Total, Serum;8707;Valproic Acid, Tot, S;4086-5;Valproate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Enzyme-Multiplied Immunoassay Technique (EMIT)
4888;VPA;Valproic Acid, Total, Serum;8707;Valproic Acid, Tot, S;4086-5;Valproate:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Immunoassay
4889;VRERP;Vancomycin-Resistant Enterococcus, Molecular Detection, PCR;84406;VRE PCR;71718-1;Enterococcus sp DNA:Threshold:Pt:XXX:Ord:Probe.amp.tar;2013-10-03;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4890;VRERP;Vancomycin-Resistant Enterococcus, Molecular Detection, PCR;SRC60;Specimen source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4891;VRESP;Viral Culture, Respiratory;VRESP;Viral Culture, Respiratory;6584-7;Virus identified:Prid:Pt:XXX:Nom:Culture;2013-09-18;Cell Culture Shell Vial Assay for Herpes Simplex Virus or Cytomegalovirus
4892;VRID2;Culture Referred for Identification, Virus;VRID2;Culture Referred for ID, Virus;6584-7;Virus identified:Prid:Pt:XXX:Nom:Culture;2013-12-05;Shell Vial Assay for Appropriate Virus and/or Tube Cell Culture
4893;VS;Vanadium, Serum;83396;Vanadium, S;5756-2;Vanadium:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4894;VU;Vanadium, 24 Hour, Urine;21903;Vanadium Concentration;29931-3;Vanadium:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4895;VU;Vanadium, 24 Hour, Urine;TM76;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4896;VU;Vanadium, 24 Hour, Urine;83395;Vanadium, 24 Hour, U;29932-1;Vanadium:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4897;VU;Vanadium, 24 Hour, Urine;VL65;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4898;VUR;Vanadium, Random, Urine;89680;Vanadium, Random, U;5757-0;Vanadium:MCnc:Pt:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4899;VWAG;von Willebrand Factor Antigen, Plasma;VWAG;von Willebrand Factor Ag, P;27816-8;von Willebrand factor Ag actual/Normal:RelMCnc:Pt:PPP:Qn:Imm;2012-03-12;Automated Latex Immunoassay (LIA)
4900;VWD2N;von Willebrand Disease 2N (Subtype Normandy), Blood;21817;VWD2N Interpretation;69049-5;;2012-04-05;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4901;VWD2N;von Willebrand Disease 2N (Subtype Normandy), Blood;15231;Arg854Gln;41209-8;VWF gene.p.A91G:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4902;VWD2N;von Willebrand Disease 2N (Subtype Normandy), Blood;15230;Arg816Trp;41210-6;VWF gene.p.A53W:Arb:Pt:Bld/Tiss:Ord:Molgen;2009-11-13;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4903;VWD2N;von Willebrand Disease 2N (Subtype Normandy), Blood;81662;Thr791Met;41268-4;VWF gene.p.T791M:Arb:Pt:Bld:Ord:Molgen;2013-08-28;Direct Mutation Analysis by Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4904;VWFM2;von Willebrand Factor Multimer Analysis, Plasma;8844;von Willebrand Factor Multimer, P;32217-2;von Willebrand factor multimers:ACnc:Pt:PPP:Ord:;2009-11-13;Agarose Gel Electrophoresis/Infrared Dye-Labeled Antibody Detection
4905;VWFX;von Willebrand Factor Activity, Plasma;VWFX;von Willebrand Factor Activity, P;68324-3;von Willebrand factor Ag actual/Normal:RelMCnc:Pt:PPP:Qn:Imm;2012-03-05;Latex Particle Enhanced Immunoassay
4906;VZM;Varicella-Zoster Virus (VZV) Antibody, IgM, Serum;80964;Varicella-Zoster Ab, IgM, S;43588-3;Varicella zoster virus Ab.IgM:ACnc:Pt:Ser:Ord:IF;2012-03-12;Immunofluorescence Assay (IFA)
4907;VZPG;Varicella-Zoster Antibody, IgG, Serum;VZG;Varicella-Zoster Ab, IgG, S;15410-4;Varicella zoster virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4908;VZPG;Varicella-Zoster Antibody, IgG, Serum;DEXG4;Varicella IgG Antibody Index;5403-1;Varicella zoster virus Ab.IgG:ACnc:Pt:Ser:Qn:EIA;2013-12-18;Multiplex Flow Immunoassay (MFI)
4909;WALN;Walnut Tree, IgE;WALN;Walnut Tree, IgE;6274-5;Juglans california Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4910;WBAPS;HIV-1 Antibody Confirmation Western Blot Patient Source, Serum;13013;HIV-1 Ab Confirm Western Blot PS, S;5221-7;HIV 1 Ab:ACnc:Pt:Ser:Ord:IB;2009-11-13;Only orderable as part of BBFPS / Blood and Body Fluid Source Profile II, HVCPS / HIV-1 and HIV-2 Antigen and Antibody Screen Patient Source, Serum, or BBFSR / Blood and Body Fluid Source Profile Rapid
4911;WDKM;Wilson Disease Known Mutation, ATP7B DNA Sequencing;22703;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4912;WDKM;Wilson Disease Known Mutation, ATP7B DNA Sequencing;22701;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4913;WDKM;Wilson Disease Known Mutation, ATP7B DNA Sequencing;22700;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4914;WDKM;Wilson Disease Known Mutation, ATP7B DNA Sequencing;22698;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of a specific mutation previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4915;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22689;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4916;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22693;Amendment;21626-7;ATP7B gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2013-07-30;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4917;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22691;Result;21626-7;ATP7B gene mutation analysis:Prid:Pt:Bld/Tiss:Nom:Molgen;2009-11-13;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4918;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22690;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4919;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22692;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4920;WDMS;Wilson Disease Mutation Screen, ATP7B DNA Sequencing;22687;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR)/DNA sequencing are utilized to test for the presence of mutations in all 21 exons and a portion of the promoter of the ATP7B gene.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4921;WEED1;Weed Panel # 1;WEED1;Weed Panel # 1;24480-6;(Ambrosia elatior+Artemisia vulgaris+Chenopodium album+Plantago lanceolata+Salsola kali) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4922;WEED2;Weed Panel # 2;WEED2;Weed Panel # 2;24493-9;(Ambrosia psilostachya+Artemisia vulgaris+Atriplex lentiformis+Chenopodium album+Plantago lanceolata) Ab.IgE:ACnc:Pt:Ser:Qn:Multidisk;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4923;WEEP;Western Equine Encephalitis Antibody, IgG and IgM, Serum;87279;West Equine Enceph Ab, IgM, S;6958-3;Western equine encephalitis virus Ab.IgM:Titr:Pt:Ser:Qn:IF;2014-03-21;Immunofluorescence Assay (IFA)
4924;WEEP;Western Equine Encephalitis Antibody, IgG and IgM, Serum;8193;West Equine Enceph Ab, IgG, S;6957-5;Western equine encephalitis virus Ab.IgG:Titr:Pt:Ser:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4925;WEEPC;Western Equine Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26372;West Equine Enceph Ab, IgM, CSF;9316-1;Western equine encephalitis virus Ab.IgM:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4926;WEEPC;Western Equine Encephalitis Antibody Panel, IgG and IgM, Spinal Fluid;26371;West Equine Enceph Ab, IgG, CSF;9315-3;Western equine encephalitis virus Ab.IgG:Titr:Pt:CSF:Qn:IF;2009-11-13;Immunofluorescence Assay (IFA)
4927;WFHV;White Faced Hornet Venom, IgE;WFHV;White Faced Hornet Venom, IgE;6280-2;Dolichovespula maculata Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4928;WHEY;Whey, IgE;WHEY;Whey, IgE;7774-3;Cow whey Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4929;WHIC;White Hickory, IgE;WHIC;White Hickory, IgE;7407-0;Carya tomentosa Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4930;WHIPB;Tropheryma whipplei, Molecular Detection, PCR, Blood;56064;Result;42602-3;Tropheryma whippelii DNA:ACnc:Pt:Bld:Ord:Probe.amp.tar;2011-06-23;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4931;WHIPB;Tropheryma whipplei, Molecular Detection, PCR, Blood;SRC89;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Rapid Polymerase Chain Reaction (PCR)(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4932;WHT;Wheat, IgE;WHT;Wheat, IgE;6276-0;Triticum aestivum Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4933;WHTC;Cultivated Wheat, IgE;WHTC;Cultivated Wheat, IgE;6277-8;Triticum aestivum pollen Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4934;WILL;Willow, IgE;WILL;Willow, IgE;6285-1;Salix caprea Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4935;WMEL;Watermelon, IgE;WMEL;Watermelon, IgE;7770-1;Citrullus lanatus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4936;WNV;West Nile Virus (WNV) Antibody, IgG and IgM, Serum;WNVGS;West Nile Virus Ab, IgG, S;29566-7;West Nile virus Ab.IgG:ACnc:Pt:Ser:Ord:EIA;2013-09-18;Enzyme-Linked Immunosorbent Assay (ELISA)
4937;WNV;West Nile Virus (WNV) Antibody, IgG and IgM, Serum;WNVMS;West Nile Virus Ab, IgM, S;29567-5;West Nile virus Ab.IgM:ACnc:Pt:Ser:Ord:EIA;2013-09-18;Enzyme-Linked Immunosorbent Assay (ELISA)
4938;WNVC;West Nile Virus (WNV) Antibody, IgG and IgM, Spinal Fluid;WNVGC;West Nile Virus Ab, IgG, CSF;41236-1;West Nile virus Ab.IgG:ACnc:Pt:CSF:Ord:;2012-03-12;Enzyme-Linked Immunosorbent Assay (ELISA)
4939;WNVC;West Nile Virus (WNV) Antibody, IgG and IgM, Spinal Fluid;WNVMC;West Nile Virus Ab, IgM, CSF;29569-1;West Nile virus Ab.IgM:ACnc:Pt:CSF:Ord:EIA;2013-09-18;Enzyme-Linked Immunosorbent Assay (ELISA)
4940;WNVP;West Nile Virus (WNV), Molecular Detection, PCR, Plasma;56073;Special Information;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4941;WNVP;West Nile Virus (WNV), Molecular Detection, PCR, Plasma;56072;Result;34892-0;West Nile virus RNA:ACnc:Pt:XXX:Ord:Probe.amp.tar;2011-06-23;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4942;WNVP;West Nile Virus (WNV), Molecular Detection, PCR, Plasma;SRC97;Specimen Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-03-15;Real-Time Polymerase Chain Reaction (PCR)/RNA Probe Hybridization(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4943;WORM;Wormwood, IgE;WORM;Wormwood, IgE;6286-9;Artemisia absinthium Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4944;WPIN;White Pine, IgE;WPIN;White Pine, IgE;6282-8;Pinus strobus Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4945;WRF;Warfarin, Serum;8760;Warfarin, S;4098-0;Warfarin:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4946;WRGR;Wild Rye Grass, IgE;WRGR;Wild Rye Grass, IgE;16922-7;Elymus triticoides Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4947;WRW;Western Ragweed, IgE;WRW;Western Ragweed, IgE;6275-2;Ambrosia psilostachya Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4948;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;16265;Method;49549-9; ;2013-07-26;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4949;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;16268;Interpretation;69965-2;;2012-04-09;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4950;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;16269;Amendment;48970-8;ELN gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-08-09;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4951;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;16267;Results;48970-8;ELN gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2009-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4952;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;CG392;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2012-03-15;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4953;WSCR;Williams Syndrome, 7q11.23 Deletion, FISH;CG389;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-11-13;Fluorescence In Situ Hybridization (FISH) with DNA Probes
4954;WSLK;Wild Silk, IgE;WSLK;Wild Silk, IgE;6284-4;Silk wild Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4955;WSPV;Wasp Venom, IgE;WSPV;Wasp Venom, IgE;13176-3;Wasp venom Ab.IgE:ACnc:Pt:Ser/Plas:Qn:;2012-03-15;Fluorescence Enzyme Immunoassay (FEIA)
4956;XALDK;X-Linked Adrenoleukodystrophy, Known Mutation;51641;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-06-04;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the ABCD1 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4957;XALDK;X-Linked Adrenoleukodystrophy, Known Mutation;51637;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the ABCD1 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4958;XALDK;X-Linked Adrenoleukodystrophy, Known Mutation;51638;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the ABCD1 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4959;XALDK;X-Linked Adrenoleukodystrophy, Known Mutation;51635;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase chain reaction (PCR) amplification/DNA sequencing are utilized to test for the presence of specific mutations in the ABCD1 gene previously identified in an affected family member.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4960;XALDS;X-Linked Adrenoleukodystrophy, Full Gene Analysis;51624;Reason for Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2013-08-08;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4961;XALDS;X-Linked Adrenoleukodystrophy, Full Gene Analysis;51625;Result;53836-3;ABCD1 gene mutation analysis:Prid:Pt:Bld/Tiss:Nar:Molgen;2013-12-05;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4962;XALDS;X-Linked Adrenoleukodystrophy, Full Gene Analysis;51626;Interpretation;69047-9;Geneticist review:Imp:Pt:XXX:Nar:;2014-05-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4963;XALDS;X-Linked Adrenoleukodystrophy, Full Gene Analysis;51627;Method;49549-9;Reference lab test method:Type:XXX:Reference lab test:Nar:;2013-08-21;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4964;XALDS;X-Linked Adrenoleukodystrophy, Full Gene Analysis;51630;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2013-06-04;Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc)
4965;XAN;Xanthine and Hypoxanthine, 24 Hour, Urine;VL68;Urine Volume;3167-4;Specimen volume:Vol:24H:Urine:Qn:;2012-03-12;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4966;XAN;Xanthine and Hypoxanthine, 24 Hour, Urine;DUR3;Urine Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-15;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4967;XAN;Xanthine and Hypoxanthine, 24 Hour, Urine;80313;Xanthine;41227-0;Xanthine:SRat:24H:Urine:Qn:;2009-11-13;Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
4968;XHIM;X-Linked Hyper IgM Syndrome, Blood;23901;Interpretation;69052-9;;2012-04-09;Flow Cytometry
4969;YFHV;Yellow Faced Hornet Venom, IgE;YFHV;Yellow Faced Hornet Venom, IgE;6288-5;Dolichovespula arenaria Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4970;YJV;Yellow Jacket Venom, IgE;YJV;Yellow Jacket Venom, IgE;6740-5;Vespula spp Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4971;YMICR;Y Chromosome Microdeletions, Molecular Detection;17304;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-14;Polymerase chain reaction (PCR) is used to test DNA for the presence of microdeletions of the Y chromosome (region AZFa, AZFb, and AZFc).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4972;YMICR;Y Chromosome Microdeletions, Molecular Detection;17306;Result;35456-3;Y chromosome deletion:Prid:Pt:Bld/Tiss:Nom:;2009-11-13;Polymerase chain reaction (PCR) is used to test DNA for the presence of microdeletions of the Y chromosome (region AZFa, AZFb, and AZFc).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4973;YMICR;Y Chromosome Microdeletions, Molecular Detection;17305;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR) is used to test DNA for the presence of microdeletions of the Y chromosome (region AZFa, AZFb, and AZFc).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4974;YMICR;Y Chromosome Microdeletions, Molecular Detection;17307;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR) is used to test DNA for the presence of microdeletions of the Y chromosome (region AZFa, AZFb, and AZFc).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4975;YMICR;Y Chromosome Microdeletions, Molecular Detection;17308;Amendment;35456-3;Y chromosome deletion:Prid:Pt:Bld/Tiss:Nom:;2013-07-30;Polymerase chain reaction (PCR) is used to test DNA for the presence of microdeletions of the Y chromosome (region AZFa, AZFb, and AZFc).(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4976;YOLK;Egg Yolk, IgE;YOLK;Egg Yolk, IgE;6107-7;Egg yolk Ab.IgE:ACnc:Pt:Ser:Qn:;2012-03-12;Fluorescence Enzyme Immunoassay (FEIA)
4977;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19536;Addendum;35265-8;Path report.addendum:Find:Pt:Specimen:Nar:;2011-07-07;Immunophenotyping
4978;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19537;Addendum Comment:;22638-1;Path report.comments:Imp:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
4979;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19538;Addendum Pathologist:;19139-5;Pathologist name:PN:Pt:Provider:Nom:;2009-11-13;Immunophenotyping
4980;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19532;Signing Pathologist;19139-5;Pathologist name:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
4981;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19529;Final Diagnosis;22637-3;Path report.final diagnosis:Imp:Pt:Specimen:Nar:;2009-11-13;Immunophenotyping
4982;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19530;Comment:;48767-8;Annotation comment:Imp:Pt:{system}:Nar:;2012-10-31;Immunophenotyping
4983;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19520;Ref. Path Address;74221-3;Referring physician address:Addr:Pt:Provider:Nom;2014-01-27;Immunophenotyping
4984;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19522;Specimen:;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2009-11-13;Immunophenotyping
4985;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19523;Bone Marrow Differential;47286-0;Differential panel:-:Pt:Bone Mar:Qn:;2009-11-13;Immunophenotyping
4986;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19526;Biopsy;52121-1;Biopsy:Imp:Pt:XXX:Nar:;2009-11-13;Immunophenotyping
4987;ZAP70;ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis;19519;Referring Pathologist/Physician;46608-6;Primary referring physician ID:ID:Pt:Provider:Nom:;2011-06-29;Immunophenotyping
4988;ZMMLS;Antimicrobial Susceptibility, Aerobic Bacteria, MIC;ZMMLS;Susceptibility, Aerobic, MIC;29576-6;Bacterial susceptibility panel;2013-09-18;Minimum Inhibitory Concentration (MIC) by Agar Dilution
4989;ZNRU;Zinc, Random, Urine;60526;Zinc, Random, U;5764-6;Zinc:MCnc:Pt:Urine:Qn:;2011-06-24;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4990;ZNS;Zinc, Serum;8620;Zinc, S;5763-8;Zinc:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4991;ZNU;Zinc, 24 Hour, Urine;865;Zn Concentration;21610-1;Zinc:MCnc:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4992;ZNU;Zinc, 24 Hour, Urine;VL5;Urine Volume;28009-9;Specimen volume:Vol:Pt:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4993;ZNU;Zinc, 24 Hour, Urine;TM8;Collection Duration;13362-9;Collection duration:Time:*:Urine:Qn:;2012-03-12;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4994;ZNU;Zinc, 24 Hour, Urine;8591;Zinc, 24 Hr, U;5765-3;Zinc:MRat:24H:Urine:Qn:;2009-11-13;Dynamic Reaction Cell-Inductively Coupled Plasma-Mass Spectrometry (DRC-ICP-MS)
4995;ZONI;Zonisamide, Serum;83685;Zonisamide, S;29620-2;Zonisamide:MCnc:Pt:Ser/Plas:Qn:;2009-11-13;High-Performance Liquid Chromatography (HPLC)
4996;ZYG;Zygosity Testing (Multiple Births);16686;Source;31208-2;Specimen source:Prid:Pt:XXX:Nom:;2012-05-18;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4997;ZYG;Zygosity Testing (Multiple Births);16688;Reason For Referral;42349-1;Reason for referral:Find:Pt:^Patient:Nar:;2009-11-13;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4998;ZYG;Zygosity Testing (Multiple Births);16689;Method;49549-9; ;2013-07-26;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
4999;ZYG;Zygosity Testing (Multiple Births);16690;Result;55198-6;Twin zygosity:Prid:Pt:Buccal:Nom:;2013-07-30;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
5000;ZYG;Zygosity Testing (Multiple Births);16691;Interpretation;69047-9;Service comment 01:Imp:Pt:XXX:Nom:;2012-04-05;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
5001;ZYG;Zygosity Testing (Multiple Births);16692;Amendment;55198-6;Twin zygosity:Prid:Pt:Buccal:Nom:;2013-07-30;Polymerase chain reaction (PCR)/microsatellite markers are used to provide a genotype for multiples and their parents to determine if siblings are monozygotic twins.(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
